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EPIGRAPH 
 
A peels an apple, while B kneels to God, 
C telephones to D, who has a hand 
On E's knee, F coughs, G turns up the sod 
For H's grave, I do not understand 
But J is bringing one clay pigeon down 
While K brings down a nightstick on L's head, 
And M takes mustard, N drives into town, 
O goes to bed with P, and Q drops dead, 
R lies to S, but happens to be heard 
By T, who tells U not to fire V 
For having to give W the word 
That X is now deceiving Y with Z, 
Who happens just now to remember A 
Peeling an apple somewhere far away. 
 
(Howard Nemerov) 
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ABSTRACT 
Chronic Obstructive Pulmonary Disease (COPD) is a neutrophil-associated pulmonary 
condition that is accompanied by chronic inflammation. Neutrophil lifespan is typically 
controlled by constitutive apoptosis, but their prolonged persistence at inflammatory sites is 
implicated in COPD pathology. However, current COPD therapies are inadequate at targeting 
neutrophilia. 
Prostaglandin E2 (PGE2) is a potent pro-survival mediator in neutrophils that is increased in 
COPD. Therefore, PGE2 may contribute to neutrophilic accumulation in COPD lungs and the 
resolution of inflammation may be achieved by decreasing neutrophil lifespan. Specifically, it 
was hypothesised that PGE2 modulates protein kinase A (PKA)-dependent neutrophil lifespan 
through a specific prostaglandin (EP) receptor subtype, and that the nuclear receptors NR4A2 or 
NR4A3 are downstream effectors of PKA-mediated neutrophil survival. 
Human polymorphonuclear neutrophils (PMN) were isolated from the blood of healthy 
volunteers and COPD patients. Cellular apoptosis was assessed by light microscopy and 
phosphatidyl serine exposure. Gene expression of PGE2 and NR4A receptors was measured by 
RT-PCR and qPCR. Additionally, a novel approach uses murine neutrophils (mNØ) derived 
from cultures of bone-marrow progenitors, conditionally immortalised by expression of a 
chimeric Hoxb8 protein. RNAi strategies to knock down NR4A2 and NR4A3 in mNØ were 
undertaken. 
PGE2 and a pharmacological EP2 receptor agonist induced PKA-dependent PMN survival and 
NR4A2 expression by qPCR. Likewise, PGE2-induced PKA survival was blocked by EP2 
receptor antagonism. Interestingly, the inflammatory mediator LPS increased EP2 and EP4 
expression by qPCR in healthy control and COPD PMN. Consistently, LPS induced early PKA-
dependent survival and enhanced late PGE2 survival. Additionally, RNAi-mediated knockdown 
of NR4A2 in mNØ decreased cell numbers during mNØ differentiation. 
In conclusion, EP2 is the dominant receptor subtype in PGE2/PKA survival in PMN. In the 
context of COPD, LPS further enhances PGE2 survival through increased prostaglandin 
receptor expression. Moreover, this study links the nuclear receptor NR4A2 to neutrophil 
survival induced by the PGE2/PKA signalling axis, potentially providing a novel, specific 
molecular target for neutrophilia in COPD. 
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CHAPTER 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE: 
IMPACT OF NEUTROPHILS ON DISEASE PATHOLOGY. 
Progressive lung-tissue destruction and remodelling in chronic inflammation are common 
characteristics of various otherwise distinct inflammatory lung diseases, such as chronic 
obstructive pulmonary syndrome (COPD), acute respiratory distress syndrome (ARDS), chronic 
asthma and cystic fibrosis. These conditions are estimated to cause 4.1 million deaths per year 
and will be the third most common cause of death in non-communicable diseases worldwide by 
2030 (Abegunde et al., 2007; WHO, 2007). Additionally, an estimated 210 & 300 million 
people suffer from COPD and asthma respectively (Masoli et al., 2004, WHO, 2007). Tobacco 
abuse is a major risk factor for COPD and sensitisation in asthmatic disease development 
(Alwan et al., 2010), but also exposure to second-hand smoke and air pollution can induce the 
disease (Abramson et al., 2015; Assad et al., 2015). Tobacco causes ~ 42 % of chronic 
respiratory diseases and tobacco-related deaths are estimated to increase to  
10 % of total worldwide deaths by 2020 (Horton, 2007; Alwan, 2011). However, the 
susceptibility to the development of the disease varies amongst smokers and a substantial 
portion of patients are non-smokers (20 %; Mannino et al., 2002; Lundback et al., 2003). The 
only known genetic factor in the predisposition for the development of COPD is the mutation of 
the gene coding for the protease inhibitor α-1 antitrypsin. α-1 antitrypsin deficiency results in 
the development of COPD characteristics, mediated by the inefficiency to cleave neutrophil 
elastase (NE; de Serres, Blanco, 2012). Overall, inflammatory lung diseases, such as COPD, 
present an immense economic burden and are of major clinical importance, for smokers and 
non-smokers alike. 
The severity and progression of the disease is categorized according to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stages (Rabe et al., 2007). Spirometric assessment 
of lung function forms the basis of the classification of patient into 4 stages from a mild disease 
with limited sputum production and a chronic cough to a very severe clinical manifestation with 
secondary effects such as severely disabling exercise incapacity and cardiovascular 
complications (King, 2015). Airflow limitation is measured as a ratio of forced expiratory 
volume (FEV) and forced vital capacity (FVC). The progressive airflow limitation and shortness 
of breath (decrease in FEV) in the different stages may be interrupted by a sudden drop in FEV, 
which is classified as a disease exacerbation that may be life-threatening in stage IV disease 
patients (Rabe et al., 2007). The processes leading to the decreased FEV values are well 
characterised: a destructive inflammatory process that ultimately results in peripheral airway 
narrowing and changes in the efficiency of gas exchange in emphysema and hypoxemia.  
The COPD-characteristic inflammatory response (Pauwels et al., 2001; MacNee, 2006) in the 
airways, pulmonary tissue and vasculature activated in response to the toxic xenobiotics and 
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free radicals contained in cigarette smoke (Yoshida, Tuder, 2007) is markedly different to the 
patterns of inflammation in other chronic inflammatory lung diseases, such as asthma (MacNee, 
2006; Barnes, 2004). It is believed that cigarette smoke exposure of the epithelium and resident 
macrophages induces the production of chemoattractants (i.e. CXCL8 and LTB4), pro-
inflammatory cytokines and chemokines (Barnes, 2004). In the course of the immune response, 
a large number of effector cells, such as CD8
+
 T-lymphocytes, neutrophils and monocytes are 
recruited from the circulation to the airways (Retamales et al., 2001), which contribute to the 
secretion of chemokines, cytokines and proteinases (MacNee, 2006). Recruited and activated 
neutrophils induce the secretion of NE and metalloproteinases, contributing to the excessive 
mucus secretion, ultimately leading to the progressive obstruction of the airways, chronic 
bronchitis and airtrapping in the alveoli (Fig. 1). In acute exacerbations, the lung function 
deteriorates quickly and it has been reported that 14% of patients released from hospital after 
exacerbations die within a 3 month period (Roberts et al., 2005). Exacerbations can be induced 
by bacterial, or viral respiratory infections, but also by environmental stimuli, such as air 
pollution and allergens. The number of neutrophils in the lung is even further increased during 
exacerbations (MacNee, 2006; Table 1), although the clearance of pathogens is impaired, 
leading to persistent or recurrent bacterial and viral infections and disease exacerbations. This 
may be caused by hypoxic stress, which can impair neutrophil apoptosis (Walmsley et al., 
2005), bacterial killing and has the potential to induce tissue damage due to increased 
degranulation (Hoenderdos et al., 2013). The chronic inflammation in the small airways and the 
parenchyma ultimately results in the destruction of lung tissue and the development of 
emphysema, as well as fibrosis.  
1.1. The Pathophysiology of COPD. 
1.1.1. Implication of Neutrophils in the Pathophysiology of COPD. 
The key inflammatory cells in COPD are thought to be neutrophils, which represent over 70 % 
of the cells found in the sputum of COPD patients (Peleman et al., 1999). Neutrophil numbers 
in the lung increase with disease progression (Vestbo et al., 2013; Table 1), and also during 
acute exacerbations (Qiu et al., 2003). The increases were correlated with disease severity 
according to GOLD stages (Sparrow et al., 1984; Keatings et al., 1996; Stanescu et al., 1996; Di 
Stefano et al., 1998; Moermans et al., 2011) and as such, neutrophil presence in the sputum was 
previously proposed to be included as a clinical marker of disease severity (Singh et al., 2010).  
Also increased are macrophages, which are often found in bronchoalveolar lavage 
(BAL) fluid or sputum and may represent over 20 % of cells found in COPD patient sputum 
(Peleman et al., 1999), due to their increased presence in the airway lumen. In contrast, the  
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Figure 1: Neutrophil Recruitment Cascade. The recruitment of neutrophils is a multi-step 
process, following tissue damage or infection. After the release of neutrophils into the blood 
stream, they will be tethered by endothelial cells. Then, they roll along the endothelium and 
become activated close to sites of infection. Eventually, neutrophils will firmly adhere and then 
traverse the endothelial barrier and basal lamina in diapedesis and extravasation. Ultimately, 
they will chemotactically migrate towards the source of the chemokine gradient, released at the 
site of infection. During this process, neutrophils and endothelial cells will display different 
expression profiles, of which the most important are summarized in the box at the left.  
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Table 1: Evidence for a Role of Neutrophils in the Pathogenesis of COPD. The involvement of 
neutrophils in COPD pathology (overview of selected references only).  
Cell types Steady-state Exacerbations Contra 
Increased 
Neutrophil 
Numbers 
• Peleman et al., 
1999# 
• Baraldo et al., 2004 
(airway SMC) 
• Rutgers et al. 2000# 
• Lacoste et al., 1993* 
• Keatings et al., 
1996# 
• DiStefano et al., 
1998†‡ (late-stage 
COPD) 
• Qiu et al., 2003†  
• Drost et al., 2005* 
• Riise et al., 1995* 
• Qiu et al., 2003† 
(stable/exacerbated) 
• Lacoste et al., 
1993‡ 
• Finkelstein et al., 
1995 (lung 
parenchyma) 
• Saetta et al., 1993‡ 
• O’Shaughnessy et 
al., 1997† 
Increased 
Neutrophil Elastase 
• Yoshioka et al., 1999 
• Panzner et al., 2003 
• Qiu et al., 2003† • Qiu et al., 2003† 
(steady state) 
NE Induces Mucus 
Hypersecretion or 
disease severity 
• Nadel, 1991 
• Hill et al., 1999 
  
Increased 
Chemoattractants 
(and inflammatory 
markers) 
• Keatings et al., 
1996# 
• Yamamoto et al., 
1997 
• Traves et al., 2002 
• Qiu et al., 2003† 
• Biernacki et al., 
2003 
• Aaron et al., 2001 
• Qiu et al., 2003† 
(steady state) 
Correlation of 
Neutrophil Presence 
with COPD 
severity/ airway 
dysfunction 
• O’Donnell et al., 
2004 
• Baraldo et al., 2004  
• Peleman et al., 1999 
• DiStefano et al., 
1998 
• O’Donnell et al., 
2004 
• Baraldo et al., 
2004 
• Drost et al., 2005* 
 
Neutrophils 
correlate with 
emphysema 
• Betsuyaka et al., 
1999* 
• Yoshioka et al., 
1995* 
 • O’Donnell et al., 
2004 
• Finkelstein et al., 
1995 
Delayed neutrophil 
apoptosis correlated 
with COPD severity 
• Zhang et al., 2012 • Zhang et al., 2012  
BAL (*) - Broncho-alveolar lavage; SMC - smooth muscle cells; sputum (#); subepithelium 
bronchi biopsy (†); bronchial mucosa (‡) 
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increased presence of CD8
+
 T-lymphocytes (Barnes, 2003) is not evidenced in BAL or sputum, 
as they commonly reside on the alveolar walls in the lung parenchyma. 
1.1.1.1. Neutrophilia in COPD. 
Neutrophils play a pivotal role in the pathogenesis of COPD. Neutrophil presence is increased 
by over 30 % in the induced sputum of COPD patients (Perng et al., 2004), and neutrophilia in 
both stable-state COPD and exacerbations are a well documented occurrence (see Table 1). 
Despite the compelling evidence for the detrimental effects of neutrophils in chronic 
inflammation of COPD in vivo (O’Donnell et al., 2004; Baraldo et al., 2004), neutrophilia 
remains a particularly neglected characteristic of COPD pathology. Firstly, neutrophil 
secretions, such as NE are increased (Damiano et al., 1986; Gottlieb et al., 1996) and have been 
linked to induction of mucus hypersecretion (Nadel, 1991) and emphysema (Galdston et al., 
1977; Yoshioka et al., 1995). Neutrophil presence (Perng et al., 2004) and activation (Caramori 
et al., 2005) was correlated with deteriorating lung function and the severity of the symptoms, 
respectively.  
1.1.1.2. Neutrophilic Inflammation 
Neutrophils are thought to perpetuate chronic inflammation in COPD, through the secretion of 
inflammatory cytokines or the co-incidental release of cytotoxic substances, such as of NE or 
reactive oxygen species (ROS), leading to tissue damage. (MacNee et al., 1989; Dubravec et al., 
1990; Tetley, 1993; Baines et al., 2011).  
Neutrophils became invariably linked to the inflammatory phenotype of COPD and its 
pathology, as the genetic disease α1-antitrypsin deficiency was shown to cause emphysema in a 
COPD patient cohort (Laurell et al., 1963). α1‐antitrypsin is the major protease inhibitor of NE 
and alterations in the balance of proteases and antiproteases in the lung are thought to facilitate 
neutrophil-induced tissue damage (Tetley, 1993). In this context, neutrophilic NE content and 
mucus hypersecretion (Nadel, 1991), as well as the severity of emphysema in COPD have long 
been linked (Galdston et al., 1977; Yoshioka et al., 1995). NE and other proteases, such as 
cathepsin G, matrix metalloproteinases (MMP) and proteinase 3 can thereby stimulate the 
general mucosal secretion by mucus glands and goblet cells in the pulmonary epithelium by 
direct and indirect mechanisms (Sommerhoff et al., 1990; Tetley et al., 1993; Witko-Sarsat et 
al., 1999; O’Donnell et al., 2006), resulting in progressive airway obstruction and lung damage 
in chronic bronchitis.  
The increased serine protease content in inflammatory neutrophils (Burnett et al., 1987; Nadel, 
1991) may thus contribute to the increased proteolytic capabilities of neutrophils from 
emphysema patients (Burnett et al., 1987; Betsuyaku et al., 1999). A prerequisite for the 
immune function of neutrophils is their functional activation.  
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Priming is required for the functional activation of neutrophils, and recruited neutrophils in the 
COPD lung are likely to be activated, as evidenced by the increased presence of neutrophil 
products in COPD BAL (Condliffe et al., 1998; Noguera et al., 2001; Keatings, Barnes, 1997; 
Peleman et al., 1999). Moreover, COPD neutrophils show increased responsiveness to 
inflammatory mediators, such as LPS and in the respiratory burst (Brown et al., 2009; Langereis 
et al., 2011; Blidberg et al., 2012; Richards et al., 1989).  
1.1.1.3. Mechanisms in the Modulation of Pulmonary Neutrophilia. 
As elaborated above, neutrophil presence in COPD is increased and their presence contributes to 
the development of all major disease characteristics and is has been described to perpetuate 
chronic inflammation. Neutrophil proteinase secretions induce mucus hypersecretion, bronchitis 
and fibrosis. Increased neutrophil numbers may be caused by four distinct variables that may 
contribute to the neutrophilic phenotype of COPD. Firstly, accelerated neutrophil maturation 
and increased release from the bone marrow; secondly, increased recruitment and neutrophil 
infiltration into the pulmonary vasculature, tissues and airways; thirdly, the prolongation of their 
lifespan in the inflammatory environment and lastly, a failure of apoptotic neutrophil clearance.  
Left-shifts, i.e. a rapid increase in the bone-marrow release of immature neutrophils into 
the bloodstream, are a highly specific indicator of infections (Seebach et al., 1997), being 
attributed to the increased need for neutrophils in an inflammatory setting. The level of 
neutrophil maturity relates to the expression of cell surface receptors, such as CXCR4, which 
can cooperate with inflammatory chemokines to orchestrate neutrophil release in inflammation 
(Suratt et al., 2004). Although the expression of cell surface receptors in COPD peripheral 
blood neutrophils, such as TLR2, cell adhesion molecules and chemokine receptors, has 
repeatedly been found to be altered (von Scheele et al., 2011; Kennedy, Kilpatrick, 2013), no 
potential alterations in neutrophil maturity have been investigated, or linked to this occurrence. 
However, it has been shown that smoking may induce the release of neutrophils from the bone 
marrow (Terashima et al., 1997), possibly mediated by the release of inflammatory mediators 
by alveolar macrophages upon phagocytosis of carbon particles.  
Evidence for increased neutrophil infiltration of the COPD lung tissue was indirectly provided 
by the massive presence of chemoattractants (further discussed in chapter 1.1.2) and by the 
increased expression of the adhesion molecule E-selectin on pulmonary endothelial cells (Di 
Stefano et al., 1994). However, neutrophil presence was predominantly found in the BAL or 
sputum of COPD smokers (Rytilä et al., 2006; Makris et al., 2009; Pace et al., 2011), whereas 
their increased presence in pulmonary tissue could not consistently be demonstrated by 
immunohistochemical methods (Finkelstein et al., 1995; Retamales et al., 2001). This may 
suggest that the main determinant for their accumulation in the lung appears to be subsequent to 
the recruitment step.  
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Neutrophil survival in the airways may become increased due to the presence of inflammatory 
survival factors, such as LPS and PGE2 (further discussed in chapters 1.1.2 and 1.3), which 
enables their accumulation in the lung. Moreover, it was proposed that the functionality of 
phagocytic macrophages is reduced due to noxious substances in cigarette smoke (Terashima et 
al., 1997; Lundborg et al., 2001; Lundborg et al., 2006), resulting in the defective clearance of 
neutrophils from the airways. Since compelling evidence for both scenarios exists, it is likely 
that both cooperate in the occurrence of neutrophilia in COPD.  
1.1.2. Inflammatory Mediators in the Pathophysiology of COPD 
Chronic Inflammation in COPD increases the pulmonary levels of various cytokines, 
chemokines and prostaglandins that have known immunomodulatory properties. While being a 
typical inflammatory response, the pulmonary microenvironment is unique in regards to the 
influences of oxygen, exposure to environmental pollutants and bacterial products, such as 
lipopolysaccharide (LPS). Airway inflammation increases the susceptibility to disease 
exacerbations and therefore, the events and modulators in chronic COPD inflammation are of 
major importance. This chapter will explore the influence of inflammatory mediators on COPD 
pathology and their role in interactions with other cells in the lung parenchyma. 
1.1.2.1. Chemoattractants & Cell Activators 
One of the first stages of injury following vasodilation is the influx of immune cells into the 
tissue via the release of chemotactic factors at the site of inflammation. Major migratory factors 
released in the context of inflammation are Leukotriene B4 (LTB4), CXC motif chemokine 8 
(CXCL8; formerly IL8) and the CXC3 subfamily of chemokines (Tecchio et al., 2014). Both 
LTB4 and CXCL8 are increased in COPD (Traves et al., 2002; Tanino et al., 2002) and 
cytokine levels correlate with neutrophil numbers (Profita et al., 2005; Perng et al., 2004). 
Further studies have confirmed the chemotactic effects of these mediators on neutrophils 
(Corhay et al., 2009; Beeh et al., 2003). The major sources of LTB4 are thought to be activated 
macrophages and neutrophils (Shamsuddin et al., 1997; Bazzoni et al., 1991). CXCL8 is 
thought to be released in the context of COPD by a variety of activated cell types, such as 
epithelial cells, macrophages, neutrophils and smooth muscle cells (de Boer et al., 2000; Zhang 
et al., 1995; Altstaedt et al., 1996; Oltmanns et al., 2005). In particular, neutrophilic cytokine 
release may in this context contribute to the self-perpetuating loop of inflammation in COPD. 
The CXCL cytokines CXCL9, CXCL10 and CXCL11 are major CD8
+
 T lymphocyte attractants 
that are elevated in COPD (Clark-Lewis et al., 2003; Panzner et al., 2003; Saetta et al., 2002; 
Porter et al., 2008). Moreover, the corresponding ligand receptor CXCR3 is overexpressed on  
T lymphocytes in COPD smokers (Saetta et al., 2002). However, while CXCL9 and CXCL10 
may contribute to the accumulation of T lymphocytes in the lung (Barnes, 2004), CXCL11 has 
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also been found to be involved in the resolution of inflammation as CXCL11 levels are 
decreased in the sputum of patients with fibrosis and emphysema (Zhao et al., 2012) and also by 
establishing a cytokine gradient in egression (Porter et al., 2008). Due to their potentially dual 
roles in cell recruitment and resolution of inflammation, the classification of cytokines as pro- 
or anti-inflammatory stimuli is complicated. Moreover, chemoattractants can possess additional 
functions, as cell activators and pro-survival mediators, as for platelet activating factor (PAF), 
which attracts and activates neutrophils, but is not expressed in COPD (Barnes, 2004). 
1.1.2.2. Pro-Survival Mediators 
As a second step in the inflammatory response, the lifespan of immune cells in the lung can be 
extended by the presence of inflammatory mediators with potent pro-survival properties in the 
respiratory tract. In this context, macrophage and even more so neutrophil survival are sensitive 
to pro-survival factors. Here, the influence of LPS and selected cytokines will be explored. 
LPS  
LPS is a membrane component of gram negative bacteria. In vivo, LPS causes a COPD-like 
phenotype, as LPS-challenge exacerbates elastase-induced emphysema in mice and induces the 
secretion of the COPD biomarkers C-reactive protein (CRP), NE and α1-antitrypsin (Kobayashi 
et al., 2013; Korsgren et al., 2012). LPS acts via TLR4 receptors, which are expressed on 
neutrophils, and are upregulated on T cells in COPD (Sabroe et al., 2002a; Sabroe et al., 2003; 
Freeman et al., 2013). In neutrophils, LPS is a potent activator and pro-survival molecule and 
causes MAPK activation, CD62L shedding, CD11b expression, respiratory burst and cytokine 
generation (Sabroe et al., 2002a; Sabroe et al., 2003; Dick et al., 2009). In COPD neutrophils, 
the LPS-induced secretion of CXCL8 and MMP, as well as mRNA expression of TLR2 and 
TLR4 is enhanced, suggesting that COPD neutrophils might be more susceptible to LPS 
challenge or bacterial infections (Baines et al., 2011). In macrophages, LPS induces the 
secretion of a variety of inflammatory mediators, such as IL-6, IL-10 and IFNβ (Strassmann et 
al., 1994; Yamane et al., 2000; Xu et al., 2008; Finney-Hayward et al., 2009; Rossol et al., 
2011), by which it may perpetuate chronic inflammation in the condition. LPS has also been 
shown to induce the secretion of the prostaglandin PGE2 by the engagement of cyclooxygenase-
2 (Cox2) in macrophages and endothelial cells (Ulcar et al., 2004; Amann et al., 2001; Ikegami 
et al., 2001; Hofer et al., 2004; Yamagata et al., 2001), potentially through the activation of 
nuclear factor NF–κB (Newton et al., 1997; Andreakos et al., 2004). This is thought to 
contribute to increased levels of PGE2 in inflammatory settings and the self-perpetuating 
characteristics of COPD.  
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Growth Factors 
Although interleukins and related cytokines may have some protective properties on cell 
survival, a central role for growth factors, such as granulocyte-macrophage colony stimulating 
factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) was found (Coxon et al., 
1999; Jun et al., 2015). In particular, GM-CSF was able to delay neutrophil apoptosis, induced 
by the cytokine-mediated activation of endothelial cells (Coxon et al., 1999) with NFκB being a 
major inducer of GM-CSF synthesis (O’Donnel et al., 2006). Macrophages are also able to 
secrete GM-CSF (Culpitt et al., 2003). In COPD, the levels of GM-CSF are increased (Balbi et 
al., 1997) and may thus potentially have a role in COPD inflammation. Moreover, the vascular 
endothelial growth factor (VEGF) had a role in alveolar cell survival, whereas its levels in 
COPD were not found to be increased (Kasahara et al., 2000). 
1.1.2.3. Oxidative Stress 
The balance of oxidants and antioxidants in the lung has also been found to be disturbed in 
COPD and that this is an important characteristic of the disease (Stanojkovic et al., 2011; 
MacNee, 2001). Major oxidants are the reactive oxygen species (ROS), which are contained in 
cigarette smoke and can also be released by neutrophils and macrophages in response to 
inflammatory stimuli, such as LPS (MacNee, 2001; Barnes, 2004; Bae et al., 2009). ROS alters 
the protease balance by the activation of proteases, such as NE and inhibition of the antiprotease 
A1AT. Coincidentally, ROS is linked to the secretion of the cytokines CXCL8 and TNFα 
(Zinovkin et al., 2014), which are potent pro-inflammatory agents in COPD. As ROS prevents 
macrophage phagocytosis, it was also previously linked to the efficient clearance of bacteria 
from the COPD lung (Thimmulappa et al., 2012; Yoshida et al., 2007). Moreover, it has been 
shown that ROS has the potential to induce direct tissue damage in the COPD lung (Neofytou et 
al., 2012). 
1.2. Investigating Neutrophil Biology in the Context of COPD. 
The importance of neutrophils in the immune response is clearly demonstrated by the effect of 
their dysregulation. Low neutrophil levels in neutropenia are correlated with increased persistent 
infection risk and high mortality, while neutrophilia is often observed in infection, where 
increased amounts of neutrophils are required to match the infection size. In this sense, tight 
regulation of neutrophil levels is necessary and this is reflected in their spontaneous death after 
a short lifespan. Increased amounts of bacterial and viral lung infections are observed during 
exacerbations in the advanced stages of COPD. Correlations between elevated neutrophils, 
bacterial or viral exacerbations and deteriorating lung function might support either 
physiological or pathogenic roles of neutrophils in this setting (Toews, 2005). These might 
account for neutrophil recruitment, but not necessarily for their persistence in the chronic 
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inflammatory response in the lung. Upon infection, neutrophil lifespan is prolonged and is often 
further modulated in chronic disease (Ertel et al., 1998; Jimenez et al., 1997). 
In the chronic inflammatory settings of chronic asthma, COPD and cystic fibrosis, increased 
chemokine expression and chemokine release through tissue damage is present (Drost and 
MacNee, 2002), acting as potential neutrophil chemoattractants. The main models of self-
amplifying neutrophil recruitment that fails to clear a persistent bacterial infection are twofold 
(Hartl et al, 2007). In cystic fibrosis, proteolytic CXCR1 cleavage inactivates neutrophils and 
triggers CXCL8 expression in epithelial cells (Hartl et al, 2007, Sabroe and Whyte, 2007). 
Mucus hypersecretion and resulting elastase-mediated lung injury may predispose for infections 
and thus increase neutrophil recruitment. Although progressive tissue damage in COPD is often 
attributed to the neutrophilic release of cytotoxic contents in the immune response (Coxon et al., 
1999; Savill et al., 2000; Parker et al., 2005), exaggerated neutrophil presence in COPD was 
also found in absence of bacterial colonisation of the lung (Makam et al, 2009).  
1.2.1. Neutrophil Maturation, Recruitment and Immune Roles in the Lung. 
In the course of the innate immune response, neutrophils are the first recruited immune cells at 
inflammatory sites. Their recruitment proceeds through a series of consecutive events, 
beginning with the margination, tethering, rolling, activation and firm adhesion of neutrophils 
on the blood vessel endothelium, followed by diapedesis, crossing of basal lamina and 
subsequent chemotactic migration towards the source of an inflammatory chemokine gradient. 
Margination occurs independently of infection, while rolling is more commonly associated with 
infection. Following their recruitment, neutrophils phagocytose pathogens and release 
extracellular traps (NETosis) to capture and destruct pathogens at the site of infection.  
1.2.1.1. Haematopoiesis 
Neutrophils are derived from multipotent myeloid, hematopoietic stem cells of the bone 
marrow, which differentiate in a multi-stage process termed granulopoiesis, upon stimulation 
with the survival sustaining cytokine granulocyte colony-stimulating factor (G-CSF; Basu et al, 
2002). Granulopoiesis is a continuous process taking up to 14 days, where cells remain mitotic 
until the myelocyte stage at approximately day 7 (Bainton et al, 1971) after which time the 
characteristic nuclear changes occur.  
Neutrophils mature in six stages, namely myeloblasts, promyelocytes, myelocytes, 
metamyelocytes, band neutrophils and finally mature neutrophils (Fig. 2). The presence of four 
granule types in neutrophils is essential for their immune function. Azurophilic granules 
develop during promyelocyte stages, followed by secondary granules in myelocytes (Bainton et 
al, 1971). In metamyelocytes, gelatinase granules and secretory vesicles develop (Jog et al, 
2007). During phagocytosis, azurophilic granules fuse with phagocytic vesicles, where granule   
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Figure 2: Neutrophil Lifetime and Development. Human neutrophil granulopoiesis takes place 
in the bone marrow. Initially, common myeloid progenitors develop into myeloblasts, 
promyelocytes and myelocytes during the first developmental week, where they can still divide 
(Panel A). During the second week, post-mitotic development to metamyelocytes, band and 
mature neutrophils takes place. Characteristic features of these stages are summarized in boxes. 
The boundary between pre- and post-mitotic development is highlighted as mitosis margin and a 
discontinued line. After their survival in the circulation (8-10 hours), neutrophils die through 
apoptosis. Common characteristics are membrane blebbing, chromatin cleavage and 
condensation and formation of apoptotic bodies (Panels A, B).  
Giemsa stained human PMN. Giemsa stained murine mNØ. 
A 
B 
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contents, consisting of defensins, lysozyme, azurocidin, bacterial permeability-increasing 
protein (BPI) and elastase, mediate the destruction of diverse kinds of pathogens. Secondary 
granules are secreted outside of the cell in exocytosis and notable contents are vitamin B12-
binding protein, lysozyme and collagenase. Gelatinase granules, as well as secretory vesicles 
secret their content to the neutrophilic cell-surface. While the former contain the movement-
facilitating gelatinase, acetyltransferase and lysozyme, the latters' most notable contents are 
fMLP-receptors, which are important in pathogen-derived signalling. Thereafter, nuclear 
chromatin condensation forms a band-like structure. Nuclei of mature human neutrophils form 
lobulated nuclei with 3-4 segmented lobes, connected through chromatin filaments. 
1.2.1.2. Neutrophil Recruitment 
Innate immune responses are initiated by tissue injury or infection. Thus damaged, epithelial 
cells activate local inflammatory cells, such as macrophages through chemokine release (as 
described in chapter 1.1.1.). This might increase vasodilation and enhance vascular 
permeabilisation, leading to the inflammatory side effects of swelling and pain. Further 
chemokine release (TNFα, IL-1/IL-6) of local macrophages activates neighbouring blood vessel 
EC, enabling capturing of blood neutrophils and facilitated recruitment through the 
permeabilised membranes towards the chemokine gradient (Feldmann et al, 1996, Janeway et 
al, 2001).  
The neutrophil recruitment cascade initiates with the margination of neutrophils along the blood 
vessel endothelium, as the forces of the blood stream will initially push them towards the vessel 
wall, where they will be tethered by endothelial cells (EC). Once captured neutrophils have 
formed an initial bond, they will migrate along the blood vessel wall in a rolling motion through 
consecutive release and readhesion to EC through strong, but transient ligand-receptor binding 
of the constitutive endothelial sialomucin sialylated Lewis-carbohydrate (s-Lex). This selectin 
ligand mainly binds to neutrophil L-selectin, which is expressed in higher levels, directly after 
release of neutrophils into the circulation (Matsuba et al, 1997). However, inhibition of  
L-selectin shedding does not only increase the amount of firm adhesion, but also of neutrophil 
extravasation in vivo (Hafezi-Moghadam et al, 2001), implicating L-selectin in neutrophilic 
transmigration. The specific role of L-selectin is still controversial, due to contradictory studies 
in vitro and in vivo (Allport et al, 1997, Hafezi-Moghadam et al, 2001). 
The capturing of rolling neutrophils and their firm binding to the endothelium is 
enabled through the activation of EC through local inflammatory cytokines, i.e. TNFα, CXCL1, 
leading to upregulation of P-/E-selectin expression and further chemoattractant chemokines in 
EC. The presented chemokines are specific to the immune cells they are recruiting. Neutrophils 
are specifically recruited by specific G-coupled protein receptors through the endothelial 
chemokines of the subgroup containing a CXC-motif close to an ELR-motif (i.e. CXCL1-3; 
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CXCL5-8; Murdoch and Finn, 2000; Laing and Secombes, 2004). Moreover, additional binding 
of endothelial CD54 (ICAM-1) to the adhesion molecules CD11b/CD18 (Smith et al, 1989) 
results in the arrest of rolling neutrophils. Thereafter, neutrophils migrate through EC, or 
intercellular junctions, to enter the tissue, where they migrate chemotactically towards the 
source of the released CXCL8 gradient. The major routes of migration for neutrophils into the 
pulmonary spaces are thought to be through the alveolar walls and postcapillary venules in the 
tracheobronchial tree (Hogg, Walker, 1995; Pettersen, Adler, 2002), whereas potential 
alterations in the cellular mechanisms of neutrophil recruitment through the pulmonary 
vasculature are not well established and subject to intensive research. The rearrangement of the 
neutrophil actin cytoskeleton and the polarisation of the cell play crucial roles in leading edge 
formation, required for the detachment of the cell from its former integrin bonds, chemotaxis 
and subsequent phagocytosis of pathogens (Moissoglu and Schwarz, 2006, Servant et al, 2000). 
Neutrophil activation coincides with their recruitment by EC following the rolling stage, 
which upregulates the integrins CD11b/CD18 and leads to L-selectin shedding. Activated 
neutrophils can potentiate neutrophil and monocyte recruitment through the release of the 
chemoattractants CXCL1, CXCL2, CXCL8, CCL2, CCL3 and CCL4, which have also pro-
inflammatory properties (Scapini et al, 2000; Hurst et al, 2001). In turn, recruited monocytes 
can prolong neutrophil lifespan through the release of the survival factors G-CSF, GM-CSF and 
low amounts of TNFα (Silva, 2010), additionally enhancing neutrophil presence. 
1.2.1.3. Pathogen Clearance 
Phagocytosis is an important mechanism of neutrophil-mediated pathogen destruction, where 
neutrophils engulf pathogens and enclose them in phagocytic vesicles. The phagocytic response 
to bacterial pathogens is primarily engaged due to the binding of TLR2, TLR4 and TLR5 to 
lipoproteins, LPS and flagellin, respectively (Parker et al., 2005). Azurophilic granules fuse 
with the phagocytic vacuole to form a phagolysosome. Additionally, activation of cells, e.g. via 
fMLP receptors, triggers a respiratory burst in response to pathogens. During this response, 
NADPH oxidase generates superoxide radicals, which are transformed to hydrogen peroxide 
and then ultimately to hydroxyl radicals under oxygen consumption. These reactive oxygen 
species (ROS) are then released into the phagocytic vesicles (Edwards, 1994). Interestingly, 
monocyte/macrophage and polymorphonuclear cell phagocytosis was impaired in COPD 
patients (Prieto et al., 2001; Taylor et al., 2010), mimicked by the exposure to first- and second-
hand cigarette smoke (Martí-Lliteras et al., 2009; Ni et al., 2015), carbon particles (Lundborg et 
al., 2001; Lundborg et al., 2006) or the modelling of an inflammatory environment in COPD 
(McPhillips et al., 2007). These factors may contribute to impaired macrophage efferocytosis of 
neutrophils, comparable to their reduced efferocytosis of eosinophils (Eltboli et al., 2014). 
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Moreover, neutrophil survival determines their inflammatory function (Whyte et al., 1993a; 
Watson et al., 1996; DeLeo et al., 2004). 
A second mechanism of neutrophilic immune responses upon stimulation with bacterial 
endotoxin LPS or the cytokine CXCL8, is the release of chromatin fibre nets, which act as 
extracellular traps and barriers for pathogens (Brinkmann et al, 2004). Neutrophil Extracellular 
Traps (NETs) are constituted of released DNA, histones, serine proteases and elastase – all of 
which are implicated in neutrophil-mediated inflammation and tissue damage. This is a broadly 
targeted process, but risks the release of tissue damaging factors (Lee and Grinstein, 2004). In 
particular, NE was shown to affect tissues in COPD, which directly relates presence of NETs 
with tissue damage. In cystic fibrosis, NETs have also been implicated in mucus build-up, as the 
treatment of cystic fibrosis lungs with the NET-destroying enzyme DNAse leads to considerable 
improvement in mucus clearance (Fuchs et al, 1994).  
1.2.2. Resolution of Inflammation: The Mechanisms of Neutrophil Lifespan 
Regulation.  
Apoptotic, but not necrotic neutrophil death prevents the release of tissue damaging compounds 
that are required by neutrophils for pathogen clearance. Apoptosis can be engaged by external 
stimuli, such as ligand binding to the Fas receptor, or through pathogen-mediated stimuli 
through the TNF receptor. The intrinsic pathway can be activated by irradiation, however also 
passive effects, such as the withdrawal of growth factors results in the development of an 
apoptotic phenotype. Neutrophils are unique, as they furthermore undergo constitutive apoptosis 
that predetermines their lifespan. However, a loss of functionality is observed in the course of 
neutrophil apoptosis. In particular, neutrophils may lose their ability to phagocytose, chemotax, 
degranulate and participate in cytokine secretion (Whyte et al., 1993a; Watson et al., 1996; 
DeLeo et al., 2004). Thus, upon fulfilment of their immune function, neutrophils are cleared 
from the infected site, as they may otherwise prolong inflammation (Savill et al., 2000). 
Apoptotic neutrophils can be cleared from the site of inflammation by macrophage efferocytosis 
through the exposure of the cell surface epitope phosphatidylserine (PS; Savill et al., 1989; 
Fadok et al., 1992), or through their reverse migration to the spleen (Mathias et al., 2006, 
Buckley et al., 2006), contributing to the maintenance of adequate amounts of neutrophils in 
inflammatory tissues.  
1.2.2.1. Regulation of Neutrophil Clearance 
Apoptosis 
Apoptosis was first described as an important phenomenon in the course of embryogenesis, 
where biochemical and morphological changes in the cell are actively engaged to remove cells, 
while necrosis is more often seen as a failure of cells to maintain homeostasis. Neutrophils were 
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long thought to only survive ~8-10 hours following their maturation and release from the bone 
marrow (Basu et al, 2002; Bicknell et al., 1994). However, a more recent re-evaluation of 
neutrophil lifespan showed that their lifespan in circulation might be up to 10 times longer than 
previously reported (Pillay et al, 2010). The lifespan of peripheral blood neutrophils is limited 
through constitutive apoptosis and thereby significantly shorter than that of other immune cells. 
The recruitment of neutrophils to inflammatory sites functionally activates them by 
inflammatory mediators, such as G-CSF and GM-CSF (Saba et al., 2002) to promote pathogen 
clearance. Thereby, their lifespan is prolonged to 1-4 days (Colotta et al., 1992; Brach et al., 
1992), preventing the resolution of inflammation. Inflammatory tissue damage may thus be 
caused by a neutrophilic failure to engage apoptosis (Savill et al., 2000), substantiated by 
delayed neutrophil apoptosis in various malignancies, such as inflammatory bowel disease 
(Dibbert et al, 1999, Brannigan et al, 2000). Therefore, upon clearance of pathogens from the 
site of infection, neutrophils have fulfilled their immune functions, are obsolete and need to be 
removed. This mainly occurs through spontaneous apoptosis, which facilitates their phagocytic 
removal through macrophages (Savill et al, 2002). In contrast to necrosis, apoptotic cell death 
can occur under normal physiological conditions, and requires the cell to actively participate in 
its own death by activation of cellular signalling chains and machinery. Additionally, a novel 
mechanism of neutrophil clearance has been proposed to be neutrophilic reverse migration. 
Morphologically, apoptotic neutrophils are characterised by cleavage of inter-lobular 
chromatin bridges leading to nucleus and chromatin condensation, cytoplasmic vacuolisation, 
membrane blebbing and eventually, formation of apoptotic bodies, which contain fragments of 
the nucleus (Fig. 2). In contrast to necrosis, DNA degradation in apoptosis is a coordinated 
process, as the DNA is cleaved into a distinctive pattern by endonucleases. Prior to the 
morphological changes, which ultimately allow the efferocytosis of neutrophils, surface receptor 
changes and alterations in the biochemistry take place. Furthermore, exposure of phospholipids 
such as phosphatidylserine (PS) on the cell surface, allows the selective recognition of apoptotic 
neutrophils for their clearance by macrophages (Fadok et al, 1992, Savill et al, 1989). While 
necrotic cells swell and rupture, apoptotic neutrophils maintain their membrane integrity with 
decreasing cell volume and do not elicit an inflammatory response, as they become 
phagocytosed before the release of cytotoxic intracellular contents. However, in part, this is also 
due to the activation of TGFβ, which decreases the inflammatory response through 
downregulated cytokine production in apoptotic neutrophils and anti-inflammatory cytokine 
expression by macrophages following neutrophil efferocytosis (McDonald et al, 1999). No pro-
inflammatory substances are released from the cell in apoptotic death, thereby circumventing 
potentially additional tissue damage to surrounding tissue by an inflammatory response.  
Neutrophil apoptosis can be inhibited by multiple factors to allow bacterial clearance in 
vivo (Coxon et al, 1996, Dibbert et al, 1999, Hotta et al, 2001). Pro-inflammatory cytokines, 
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such as GM-CSF and G-CSF (see chapter 1.1.2.2.) prolong the survival of neutrophils at sites of 
inflammation. However, even the anti-apoptotic effect of the most important survival factor, 
granulocyte-macrophage colony stimulating factor (GM-CSF) is only limited and cannot 
entirely reverse the fate of neutrophils.  
Apoptosis can be modulated through various molecular mechanisms, but is always accompanied 
by a downregulation of neutrophil function. This was shown by the inability of apoptotic 
neutrophils to initiate a respiratory burst upon stimulation and their degranulation (Savill, 
1997a; Whyte et al, 1993a). Lost chemotactic abilities were also observed and attributed to 
inhibited polarisation through the actin cytoskeleton, as well as inhibition of granule exocytosis 
(Jog et al, 2007). Apoptotic neutrophils shed various adhesion molecules and surface receptors 
(Jones and Morgan, 1995, Whyte et al, 1993a). Moreover, it was previously reported that the 
inflammatory environment may enhance PS cleavage (Vandivier et al., 2002; Huynh et al., 
2002) and therefore inhibit immune cell clearance from the lung (Fadok et al., 2000). 
Reverse Migration 
Reverse migration is a common and well-described process in various immune cells, such as 
monocytes and lymphocytes (Bradfield et al, 2007, McGettrick et al, 2009, Randolph et al, 
1998), all of which possess significantly longer lifespans than neutrophils, enabling them to be 
recirculated and potentially re-used in novel inflammatory responses. Despite their hypothesised 
potential for only a single respiratory burst, the underestimation of their lifespan challenges the 
general validity of apoptotic neutrophil clearance by macrophages (Pillay et al, 2010; Buckley 
et al, 2006). Neutrophil populations that are present in inflammatory conditions have been 
found to possess altered expression profiles, allowing for the detachment of neutrophils from 
EC and indicating that potential reverse migration mechanisms may occur (Bordon, 2011). The 
reverse chemotaxis of neutrophils from inflammatory sites was also demonstrated in vivo, 
(Mathias et al, 2006). However, it remains unclear whether neutrophils are still functional after 
reverse migration, or whether their migration is merely directed towards the place of final 
clearance. In this context, neutrophils with altered expression profiles were localised in the bone 
marrow, a potential location for final neutrophil clearance (Furze and Rankin, 2008, Suratt et al, 
2001).  
1.2.2.2. Alterations of Neutrophil Lifespan in COPD. 
A body of evidence supports a potential alteration in neutrophil apoptosis in COPD. Peripheral 
blood neutrophil apoptosis in COPD patients was significantly delayed in a temporal manner in 
stable-state (Zhang et al., 2012) and during exacerbations (Pletz et al., 2004; Schmidt-Ioanas et 
al., 2006; Juss et al., 2013). Likewise, sputum neutrophil apoptosis was significantly delayed in 
stable COPD patients by over 20 % (Brown et al., 2009). In a different study, no changes in 
constitutive apoptosis were detected in circulating neutrophils, but altered surface cytokine 
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expression in COPD patient neutrophils (increased CD11b and decreased CD62L expression), 
indicated that peripheral blood neutrophils from COPD patients were already activated before 
their recruitment to the inflammatory site (Noguera et al., 2004). This may be consistent with 
the reported systemic cytokine expression in COPD (Moermans et al., 2011; Biffl et al., 1996) 
that has the potential to contribute to cellular activation and survival. Moreover, inflammatory 
neutrophil activation may result in pro-inflammatory cytokine release, which can further 
prolong their lifespan in the lung. Although systemic cytokines expression (Moermans et al., 
2011; Biffl et al., 1996) may be present in steady state, it is well accepted that cytokine 
expression is increased during exacerbations (Wedzicha et al., 2000), and their effect on 
neutrophil survival may be greater in this scenario. Despite the influence of steroid therapy on 
inflammation and neutrophil apoptosis (Sin et al., 2004; Zhang et al., 2001), the delay in 
neutrophil apoptosis was not correlated with cytokine levels (i.e. IL-6, CXCL8 or TNFα levels), 
nor smoking habits, corticosteroid treatment or state of hypoxemia (Schmidt-Ioanas et al., 
2006). Of note, the authors concluded that most “non-smokers” involved in the study stopped 
smoking only days before the onset of the exacerbation, which may contribute to the lacking 
difference in neutrophil apoptosis between smokers and non-smokers in their study. It was 
previously found that alterations in gene expression in smokers took 8 weeks to return to normal 
(Morozumi et al., 2004), thus indicating that the influence of smoking habits on the outcome of 
the study (Schmidt-Ioanas et al., 2006) may have even been underestimated.  
Taken together, these studies may indicate that the apoptotic process in neutrophils in COPD is 
dysregulated, where circulating neutrophils have apoptosis levels comparable to healthy 
controls, but systemic inflammation may increase the susceptibility to neutrophil activation and 
prime recruited neutrophils. Pro-survival mediators in the inflammatory lung environment, i.e. 
PGE2, cigarette smoke, LPS and medications, such as PDE inhibitors may then extend 
neutrophil lifespan. Additional to the reported impairment of macrophage efferocytosis and PS 
cleavage in susceptible patients, neutrophilia may develop as a functional consequence of 
increased survival with likewise decreased recognition and clearance. 
1.2.2.3. Molecular Regulation of Neutrophil Survival by cAMP/PKA Signalling. 
A central intracellular mediator of survival in neutrophils is cyclic adenosine monophosphate 
(cAMP), which activates the serine threonine kinase PKA (Rossi et al., 1995). PKA is involved 
in cytoskeleton remodelling, ER to Golgi transport, glycogenolytic cascade, transmission of 
nerve impulses and muscle contraction. Moreover, PKA plays important roles in the regulation 
of the cell cycle through the anaphase promoting complex APC and apoptosis, through 
mitochondrial proteins such as Bad. Activation of gene transcription through CREB further 
expands its myriad of roles. 
  
     CHAPTER 1 
- 36 - 
cAMP 
In COPD, infection with Pseudomonas aeruginosa decreases intracellular cAMP and induces 
neutrophil apoptosis (Usher et al., 2002). Interestingly, extracellular ATP levels were previously 
proposed as biomarkers for neutrophil-mediated airway inflammation (Esther et al., 2008). 
cAMP is involved in a variety of pathways, ranging from the cell growth pathway mTOR 
signalling to exchange proteins activated by cAMP (Epac), cytokine producing p38 signalling, 
and cell survival in the p7086K pathway, with pro and antiapoptotic effects in neutrophils (Insel 
et al., 2012, Martin et al., 2001). However, the predominant downstream effectors of cAMP are 
PKA, Epac and cAMP nucleotide-gated (CNG) membrane channels. cAMP is transformed from 
ATP by adenylyl cyclase (AC; Sunahara et al., 1996), which in turn is known to be activated 
through the binding of dissociated subunits of guanosine triphosphate (GTP)-binding proteins, 
induced by extracellular binding to G protein coupled transmembrane receptors (Strathmann, 
Simon, 1991). Furthermore, cAMP catalyses the opening of CNG channels, enabling the influx 
of sodium or calcium ions into the cell, linking it to calmodulin-dependent signalling. 
Moreover, Epac undergo conformational changes upon binding to cAMP, and then in turn 
activate the GTPases Rap-1/-2, which can inhibit the MAPK pathway-related GTPase Ras 
(Bichet, 2006). 
PKA 
PKA is present in the form of a hetero-tetramer, which is comprised of a dimer of regulatory 
and catalytic subunits. Binding of cAMP to two distinct sites on the regulatory subunits 
(Chochung et al., 1989) activates PKA and releases the active catalytic subunits, which become 
further modulated by phosphorylation. The downstream effectors activated by PKA are as 
diverse, as its isoforms (regulatory subunits: RIα, RIβ, RIIα, RIIβ; catalytic: Cα, Cβ, Cγ) and are 
subject to extensive research (Insel et al., 2012). The distinct isoforms are thought to react to 
different stimuli and elicit diverse responses with distinct affinities to cAMP binding (Skalhegg, 
Tasken, 2000). Functions of PKA are cell type specific, as PKA mRNA is widely expressed, but 
its localisation and composition varies (Griffiths et al., 1990, Nigg et al., 1985), as well as its 
activation in distinct cellular compartments through the varying availability of cAMP (Zaccolo, 
Pozzan, 2002). PKA has profound antiapoptotic effects in neutrophils (Vaughan et al., 2007) 
and induction of apoptosis in neutrophils has been described to be mediated by a caspase-
dependent mechanism, inhibiting pro-survival PKA/PI3K/Akt pathways (Sousa et al., 2010), 
overall resulting in the resolution of inflammation. Pro-apoptotic effects are mediated through 
activation of transcription by phosphorylation of the cAMP-responsive element binding protein 
(CREB) in the nucleus, influencing gene-expression (Montminy et al., 1990), and 
phosphorylation of NF-κB. PKA also inhibits 14-3-3, linking it to Bcl-2 signalling, as it 
prevents the promotion of cell survival through phosphorylation of Bad. Interference with the 
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JNK pathway exerts pro-and anti- apoptotic effects, by inhibition of Rho phosphorylation (Liu, 
Lin, 2005), as well as its interaction with extracellular-regulated kinase (ERK) signalling by 
inhibition of phosphorylation of Rho and activation of ERK, which is important in the 
regulation of various proliferative effects (Juan et al., 2010). A molecular mechanism of the 
prosurvival effects of PKA has been shown by the Sabroe/Whyte groups, who found the ATP-
receptor P2Y11 to be implicated in translation of extracellular ATP to intracellular cAMP 
signals (unpublished data), which might then through PKA support neutrophil survival 
(Vaughan et al., 2007). Interestingly, ATP is often released by cells damaged in infection and 
inflammation (Vaughan et al., 2007), implicating this P2Y receptor in neutrophil survival in 
infection. Universally, PKA is highly susceptible to changes in the levels of the second 
messenger cAMP, which is its sole substrate.  
1.2.2.4. Therapeutical Strategies in COPD. 
COPD still remains a major cause of death and current treatments are inadequate, as they may 
alleviate some of the symptoms, such as bronchoconstriction but are unable to reverse the 
disease progression. Treatment failure can have various causes, such as a failure to recognise the 
most suitable therapeutic target or disease characteristic (Sabroe et al., 2007). Despite the 
cytotoxic potential of neutrophils in COPD, neutrophilia has been particularly neglected in 
COPD therapy, and commonly used therapeutic strategies, such as β adrenoreceptor agonists 
and corticosteroids may prolong neutrophil lifespan and thus aggravate their persistence in the 
lung. A broad view approach to COPD treatment thus requires taking the overall contribution of 
neutrophils to disease severity into account, additional to their role in inflammatory gene 
expression. As elaborated in the previous chapter, a number of factors can increase the presence 
of neutrophils in the COPD lung and here, the contribution of current therapeutic options in the 
context of neutrophilia will be explored.  
Current Treatments and Effect on Neutrophils. 
Combination treatment with β adrenoreceptor agonists and corticosteroids is a mainstay of the 
current therapeutic options in the treatment of COPD (Rabe et al., 2007; Singh et al., 2008). The 
use of both drugs in COPD is controversely discussed due to their partly limited efficacy and the 
induction of non-specific side-effects (Meijer et al., 2013; Salpeter et al., 2004; Cazzola et al., 
1998; Calverley et al., 2007). Additionally, muscarinic receptor antagonists are a common 
therapeutic option in COPD (Montuschi et al., 2013). Here, the effects of these drug classes on 
inflammation and neutrophil lifespan regulation will be briefly reviewed. 
β adrenoreceptor agonists 
β adrenoreceptor agonists are available in two forms: short-acting and long-acting. Clinically, 
they are used as bronchodilators that increase airflow by relaxing airway smooth muscle cells 
(Di Marco et al., 2003; O'Donnell et al., 2004). Bronchodilators may temporarily alleviate the 
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symptoms of CODP, in particular during exacerbations (Rossi et al., 2008; Appleton et al., 
2006). However, bronchodilators, including β adrenoreceptor are ineffective at the reversal of 
airflow obstruction and NE secretion, as bronchoconstriction is not a driver of the disease 
progression (Meijer et al., 2013; Sabroe et al., 2007; Barnett et al., 1997). Moreover, they have 
been associated with an increased risk of cardiovascular complications (Cazzola et al., 1998), 
and β adrenoreceptor agonists did not reduce the overall mortality in COPD (Kliber et al., 
2010). 
In fact, bronchodilators work by increasing the levels of cAMP (Barnes, 1993), which is a 
potent pro-survival mediator in neutrophils (Rossi et al., 1995). In fact, it was found that 
neutrophil survival was enhanced by treatment with corticosteroids and that this could be 
increased by simultaneous treatment with β adrenoreceptor agonists (Pertunnen et al., 2008), 
indicating that the current therapeutic options in COPD may further increase neutrophilia in the 
condition. 
Corticosteroids 
Corticosteroids are a strategy of choice in the treatment of asthma and are often prescribed to 
COPD patients (Meijer et al., 2013). However, their efficacy in the treatment of COPD is 
limited to a subset of COPD patients with increased eosinophilic infiltration (Fujimoto et al., 
1999; Barnes, 2006; Jen et al., 2012; Barnes, 2013) and may help to reduce the occurrence of 
exacerbations (Calverley et al., 2007; Sabroe et al., 2013). However, it was recently determined 
that glucocorticoid treatment may have immunomodulatory properties and may predispose 
patients to develop secondary lung infections (Sabroe et al., 2013). In particular, steroid-
treatment does not target neutrophilic inflammation (Bianchi et al., 2006; Haslett, 1997; Barnes, 
2013), nor considerably reduces neutrophil or macrophage numbers (Jen et al., 2012), whereas 
it greatly reduces T cell presence. Corticosteroids may reduce systemic inflammation (Sin et al., 
2004), but are ineffective at the suppression of inflammatory mediator secretion, as the 
expression of the metalloprotease MMP-9, NE and various cytokines, such as CXCL8 and 
TNFα is not altered by steroid treatment (Keatings et al., 1997; Culpitt et al., 1999; Loppow et 
al., 2001) with only GM-CSF secretion being suppressed (Barnes, 2004). The lack of 
responsiveness to corticosteroids may be a unique feature of COPD, as the responsiveness of 
alveolar macrophages in COPD patients to corticosteroids is reduced (Culpitt et al., 2003). 
Moreover, corticosteroids inhibit LPS-induced NE release only in neutrophils from non-
smokers (Barnes, 2003; Meijer et al., 2013).  
In fact, the use of corticosteroids may be contraindicated in COPD patients with neutrophilia, 
but no concomitant asthma, as steroid treatment was consistently shown to delay neutrophil 
apoptosis (Chang et al., 2004; Saffar et al., 2011; Marwick et al., 2013), potentially increasing 
the severity of disease progression through the augmentation of neutrophilia. Steroids inhibit 
apoptosis in vitro (Zhang et al., 2001; Balaban et al., 2005) and systemic steroid treatment 
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during exacerbations or pulmonary infections coinciding with increased PMN survival (Zhang 
et al., 2001; Pletz et al., 2004; Strassburg et al., 2010). The use of corticosteroids is 
controversely discussed due to the potential risks associated with this type of medication 
(Sabroe et al., 2013; Babu et al., 2014). Thus, alternative or complimentary therapeutic 
strategies are urgently required to combat neutrophilia in COPD.  
Muscarinic Receptor Antagonists 
Several antimuscarinic drugs, such as aclidinium bromide, ipratropium bromide, oxitropium 
bromide and tiotropium bromide are used in COPD therapy (Montuschi et al., 2013). The low 
efficacy of these compounds in COPD therapy and controversial clinical outcomes, novel 
antimuscarinic drugs are still under development to prolong the short action of these compounds 
in the lung (Moulton, Fryer, 2011). Muscarinic receptor antagonists block the activation of the 
muscarinic actetylcholine receptors M1, M2, M3 and M4 and the presence of M1, M2 and M3 
receptors on neutrophils in COPD was demonstrated by Profita et al. (2005). The authors found 
that muscarinic receptors were implicated in LTB4 release, which may potentially lead to 
decreased neutrophil activation in COPD therapy with muscarinic receptor antagonists.  
Although the role of muscarinic receptor antagonists in neutrophil survival is not clear, it has 
been shown that carbachol, an activator of M1 and M3 receptors, potently induces Cox-2 
expression in airway smooth muscle cells (Kanefsky et al., 2006). Potentially, this may 
indirectly increase neutrophil survival through the induction of PGE2 secretion. This may be 
consistent with the reported reduction in neutrophil numbers in BAL through treatment with the 
non-selective muscarinic receptor antagonist tiotropium (Wollin, Pieper, 2010). However, 
tiotropium also blocked M3-receptor mediated neutrophil chemotaxis (Kurai et al., 2012), 
indicating that the neutrophil reducing function of the compound may also rely on its 
interference with cell migration. This is further supported by the findings of Profita et al. 
(2005), who found increased M3-dependent chemotactic abilities in COPD neutrophils. 
Novel Therapies and Effect on Neutrophils. 
Various novel therapeutic strategies have been explored in the treatment of COPD 
experimentally and in drug trials, and the regulation of neutrophil lifespan is of major clinical 
interest (Bianchi et al., 2006). In fact, increasing neutrophil apoptosis and thus reducing their 
numbers in the lung has resulted in a potent anti-inflammatory response in in vitro and in vivo 
models of COPD (Sydlik et al., 2013). In particular, anti-neutrophilic strategies may be 
unfavourable in early, but highly valuable in advanced stages of the disease, where the cytoxic 
effects of neutrophils outweigh their efficacy in driving the immune response (Bianchi et al., 
2006). 
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Adenosine A2A receptor agonists 
The adenosine A2A receptor is involved in the cAMP-dependent activation of PKA signalling 
(Barletta et al., 2012), and is expressed on neutrophils (Pliyev et al., 2014). The expression of 
A2A in the COPD lung parenchyma is increased (Varani et al., 2006), implicating cAMP/PKA 
signalling in COPD disease pathology. Therapeutic targeting of A2A receptors showed 
encouraging effects on smooth muscle cell relaxation and inflammatory cell recruitment, but a 
mixed response on inflammation (Xu et al., 2011; Yang et al., 2014; Philis, 2004; Bonneau et 
al., 2006; Polosa, Blackburn, 2009). In neutrophils, activation of the pro-survival receptor A2A 
promotes the production of Cox-2 derived PGE2, potentially encouraging the self-sustained 
characteristics of the disease. A2A agonism also inhibits various cellular functions in 
neutrophils, such as the inflammatory cytokine release, NE and ROS production, as well as 
degranulation (Barletta et al., 2012). A therapeutic intervention with A2A receptor agonists 
would thus require combinational treatment with a second drug to effectively control the 
inflammatory response. As A2A receptor agonism promotes neutrophil survival, it may be 
hypothesized that such a drug may target neutrophil survival. Current clinical trials have 
revealed cardiovascular side-effects of the drugs and no significant effects on disease pathology 
(Polosa, Blackburn, 2009; Beeh, Beier, 2006) 
PDE4 inhibitors 
Phosphodiesterases (PDE) catalyse that degradation of cAMP (Chang et al., 2000) and PDE4 is 
the main subtype present in neutrophils (Bäumer et al., 2007). PDE inhibition was shown to be 
of value in the treatment of extensive airflow limitation in COPD, as it induces the relaxation of 
airway smooth muscle cells (Beghe et al., 2013; Mehats et al., 2003), and are thus considered to 
be a potential therapeutic strategy in COPD (Garnock-Jones, 2015). PDE4-induced termination 
of the cAMP/PKA signal induces the expression of pro-inflammatory mediators, such as TNFα, 
CXCL8 and IFNγ (Jimenez et al., 2001; Au et al., 1998; Sheibanie et al., 2004). PDE4 
inhibitors suppressed the CXCL8 generation in activated neutrophils (Au et al., 1998) and this 
was enhanced by PGE2 treatment, suggesting that some anti-inflammatory effects of PGE2 on 
cytokine expression may be mediated via PKA signalling. Evidence for a dual role of 
cAMP/PKA signalling in inflammation exists, as PDE4 inhibition also increases the anti-
inflammatory cytokine IL-10 (Oger et al., 2005).  
Cox inhibitors 
Cyclooxygenases (Cox) mediate prostaglandin secretion. Cox2 in particular, has been linked to 
the LPS-induced secretion of PGE2. Due to the role of PGE2 in inflammatory gene expression, 
extension of neutrophil survival and its effects on mucus secretion (Meja et al., 1997; Rossi et 
al., 1995; Borchers et al., 1999), inhibition of Cox was regarded as a potential therapeutic 
strategy. In fact, a non-selective Cox inhibitor reduced mucus hypersecretion in COPD 
(Tamaoki et al., 1992), and Cox2 inhibitors showed anti-inflammatory potential for the 
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treatment of COPD (Newton et al., 1997). Nevertheless, the LPS-induced expression of the 
inflammatory marker TNFα by monocytes was prevented by PGE2, but became even more 
pronounced upon treatment with a non-selective Cox inhibitor (Ulcar et al., 2004). Additionally, 
the development of peptic ulcers and severe cardiovascular side-effects with these drugs were 
reported (Mukherjee et al., 2001; Hippisley-Cox, Coupland, 2005) and thus their experimental 
development halted.  
Putative Strategies in COPD Therapy. 
To conclude, both inhibition, as well as activation of PKA in inflammation has been shown to 
have therapeutic potential, supporting a dual role of PKA signalling in COPD pathology. 
Activation of PKA may induce anti-inflammatory cytokine expression, but likewise prolong the 
lifespan of immune cells. Once activated, immune cells such as neutrophils may then contribute 
to tissue damage in the condition and further increase the susceptibility to infection, overall 
exacerbating the disease severity. The pro-survival molecules PGE2 and LPS can have both 
anti- and pro-inflammatory functions, which may cause the unsatisfactory outcomes of many 
novel therapeutical strategies. Thus, their role in the molecular control of survival signalling in 
neutrophils requires a further detailed examination, and a common survival-specific 
downstream target may prove to be a magic bullet in the treatment of COPD. 
1.2.3. Neutrophil Models 
The most prominent feature of neutrophil biology is their constitutive apoptosis, making them 
unique amongst most other cells. The short lifespan of neutrophils limits experimental potential. 
A comprehensive characterisation of pathways underlying constitutive death and survival is 
challenging, as neutrophils are not only short-lived, but also post-mitotic and hence poorly 
genetically modifiable. Modulating the immune system through the alteration of neutrophil 
lifespan has been long proposed to be a valuable target in diseases. Therefore, introducing 
genetic modifications in model organisms from which genetically modified neutrophils can be 
obtained, has been of major interest to immunological research. As apoptosis is highly 
conserved in morphology and pathway events throughout most species, (i.e. Mus Musculus, 
Danio rerio, Drosophila melanogaster, Caenorhabditis elegans), including plants, apoptosis 
pathways can be successfully researched in species different to our own, whilst being aware that 
differences might be present.  
Immunology in the last decades has greatly relied on the use of genetically modified mice. 
Mouse neutrophil models used in this study were thereby derived from BALB/c mice, which 
can be used as an in vivo model in immunology, as this inbred strain possesses an intact immune 
system in contrast to most other laboratory mice strains. However, only limited amounts of 
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neutrophils can be obtained from the blood, bone marrow or the peritoneal cavity of genetically 
modified mice. 
1.2.3.1. Murine Model. 
BALB/c is an established inbred immunocompetent laboratory strain, which displays good 
immune responses to most stimuli. However, neutrophils from BALB/c mice show immune 
responses to stimuli, such as killed bacteria and thioglycolate broth, which are consistently 
lower in comparison to immune responses of C57BL/10 mice (Marley et al., 1994). More 
recently, it has been proposed that laboratory strains, raised in disease-free conditions, might not 
hold a representable immune system in contrast to wild-living mice, as these are in contrast 
exposed to pathogens that function to prime immune cells (Boysen et al., 2011). 
However, there are also known differences between the immune system of humans and mice, 
which is not surprising, as evolutionary progenitors of the species (Lamkanfi et al., 2002), were 
more likely to be exposed to different immunological tasks in their respective ecological niches, 
which is further evidenced by the higher occurrence of differences in adaptive immunity 
between the two species. Therefore, it is crucial for the prevention of translational failures to be 
aware of existing differences. The most obvious difference between humans and mice is the 
distribution of neutrophils in the blood. While neutrophils are abundant in human blood, in 
comparison there are generally more lymphocytes present in wild type murine blood (Doeing et 
al., 2003). 
Moreover, haematopoietic stem cells differ in expression patterns (see chapter 1.2.1.1). Mice 
derive defensins from Paneth cells in the small intestine, while in humans, neutrophils are able 
to directly express defensins (Risso, 2000). However, mice possess more different kinds of 
defensins than humans, highlighting the diverse immunological challenges due to different 
ecological niches and the adaptation to these. This is evidenced by the differential TLR 
expression amongst the two species. While TLR10 is expressed in humans, the receptors 
TLR11, TLR12 and TLR13 are more predominantly expressed in mice (Mestas, Hughes, 2004). 
In Balb/c mice, lower expression of TLR4 receptors has been found in various immune cells, 
coinciding with a lower responsiveness to TLR4 stimulation (Oliveira et al., 2014a; Tsukamoto 
et al., 2013). Furthermore, the expression on granulocytes differs, as CD33 is for instance 
expressed on all murine granulocytes, but in humans expression is limited to monocytes 
(Brinkman-Vand der Linden et al., 2003). The response to fMLP has a higher affinity in 
humans, due to structural aberrations of the structural domains in mice (Gao, Murphy, 1993). 
Absent in mice and present in humans are furthermore Caspase 10 (Tibbetts et al., 2003), 
ICAM3 (Geijtenbeek et al., 2000). They also differ in chemokine expression, most notably, 
CXCL8 and its receptor CXCR1 is absent in mice (Zlotnik, Yoshie, 2000, Olson, Ley, 2002). 
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1.2.3.2. Estrogen-regulated Hoxb8 Neutrophil Progenitors (mCMP) and derived Neutrophils 
(mNØ) 
A recent approach to enable the generation of large quantities of genetically modified 
neutrophils from knockout mice has been described (Wang et al., 2006). This approach is based 
on the discovery that Class I Homeobox (Hox) Transcription Factors are highly expressed in 
CD34
-
 Haematopoietic stem cells (HSC) and myeloid lineage committed progenitors (LCP), 
while they become downregulated with ongoing differentiation, as marked by the expression of 
CD34 (Lawrence et al., 1997, Pineault et al., 2002). Moreover, expression of Hoxb8 has also 
been shown to directly arrest the differentiation of myeloid progenitors (Fujino et al., 2001, 
Knoepfler et al., 2001), and thereby allows the expansion of myeloid progenitors via expression 
of Hox oncoproteins. In this model, BALB/c lineage-negative progenitors are factor-
dependently immortalised through the expression of a conditional form of the Hoxb8 
transcription factor with an estrogen receptor (ER)-binding domain fusion. Upon inactivation of 
the conditional Hoxb8 and supplementation with neutrophil lineage specific growth factors, 
mCMP terminally differentiated into neutrophils (mNØ), which had exited the cell cycle after 
the third day of differentiation and displayed typical immune responses, as well as not becoming 
aneuploid due to differentiation, nor significantly in the time of long term culture (Wang et al., 
2006). 
To evaluate differences between peripheral blood neutrophils and neutrophils derived from 
mCMP, marker expression profiles were characterised by Wang et al. (2006). It was highlighted 
that neutrophils derived from mCMP showed upregulated NADPH oxidases. Neutrophil gene 
markers were upregulated (GR-1, CD177 neutrophil marker of unknown function, IL8rb, IL17r, 
CD73), as were myeloid differentiation markers (CD14, Itgam, TLR2, IL1β) and general 
myeloid gene markers (TLR2, CD14, CD11b, Csf2rα, Mac-1 and Mannose receptor). 
Downregulation of differentiation-related genes and transcription factors, stem cell receptor and 
transcription factor gene markers (CD34, Meis1; specific haematopoietic), as well as 
promyelocyte genes and gene markers responsible for cell division CycB1 (G2/M progression), 
nucleotide biosynthesis, DNA replication, RNA maturation, Ribosome biogenesis and cell cycle 
further supported a differentiation to functionally mature neutrophils (Wang et al., 2006). 
Marker expression profiles are comparable to the expected profiles for primary human 
neutrophils (Wang et al., 2006) and resemble morphologically mature murine neutrophils 
(McDonald et al., 2011). The functionality of mNØ in the research of apoptosis was previously 
shown (Kirschnek et al., 2011). 
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1.3. The Inflammatory Mediator PGE2 and Its Pro-Survival Signalling 
Pathways in Neutrophils. 
PGE2 is a central regulator of inflammation in the context of COPD that is thought to elicit both 
pro- and anti-inflammatory responses through the differential expression of prostaglandin 
receptor subtypes. The prostaglandin is most notably secreted by fibroblasts, epithelial cells and 
further immune cells, such as monocytes (Saalbach et al., 2015; Schmidt et al., 2011; Fogel-
Petrovic et al., 2004). PGE2 was previously noted to be a crucial mediator of airway 
inflammation in the presence of cigarette smoke (Lin et al., 2010). Moreover, its expression 
becomes significantly enhanced in LPS-activated monocytes and macrophages in the course of 
the immune response, where LPS induces a 300 fold increase in PGE2 release compared to a 
medium control (Ikegami et al., 2001). A correlation between neutrophil numbers, endothelial 
cell adhesion and PGE2 levels in COPD smokers exist, whereby PGE2 secretion is promoted by 
cigarette smoke extract treatment, potentially contributing to neutrophilia in COPD (Profita et 
al., 2010). The pleiotropic effects of PGE2 vary in different cell types and are thought to depend 
on differential receptor subtype expression and the amount of PGE2 present in the 
microenvironment of the cell, where the high-affinity receptors EP3 and EP4 may become 
activated by lower PGE2 concentrations (Konger et al., 2005). Moreover, the distinct receptor 
subtypes activate divergent signalling pathways.  
In neutrophils, PGE2 interferes with fMLP-induced signalling (Burelout et al., 2007; Kanamori 
et al., 1997; Talpain et al., 1995; Wheeldon, Vardey et al., 1993; Armstrong, 1995; Ham et al., 
1983) and prevents LTB4 release following phagocytosis (Wheeldon, Vardey, 1993). PGE2 
itself is a potent pro-survival molecule for neutrophils that is increased in COPD smokers (Rossi 
et al., 1995; Ottonello et al., 1998; Montuschi et al., 2003; Kato et al., 2006; Dick et al., 2009; 
Profita et al., 2010), and has been shown to increase intracellular cAMP (Rossi et al., 1995). 
However, it may also induce apoptosis in cytotoxic CD8
+
 T lymphocytes (Chen et al., 2015). In 
steady-state, alveolar macrophages express Cox2 (Jiang et al., 2003), the expression of which is 
increased in COPD and correlates with increased PGE2 levels (Taha et al., 2000; Profita et al., 
2010).  
PGE2 may have both pro- and anti-inflammatory roles in COPD. PGE2 is linked to the 
development of classical inflammatory hallmarks, such as redness, pain, swelling and also fever 
(Funk, 2001). Moreover, PGE2 acts as a vasodilator, which enables the increased flow of blood, 
and thus the influx of immune cells to the inflamed tissue (Funk, 2001) and is also involved in 
the induction of mucus secretion (Borchers et al., 1999). Further pro-inflammatory functions are 
exerted through the expression of cytokines in neutrophils and the inhibition of monocytic 
release of pro-inflammatory cytokines (Meja et al., 1997). Moreover, PGE2 has been shown to 
act as a bronchodilator (Pavord, Tattersfield, 1995), but its metabolic product PGF2α, which is 
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also increased in COPD, may have the opposite effect (Montuschi et al., 2003; Nichol et al., 
1990). As an instigator of inflammatory cytokine expression, the effect of PGE2 ranges from 
supporting TNFα-induced IL-6 secretion (Kunisch et al., 2009) to the inhibition of anti-
inflammatory IFNγ and IL-2 expression in PBMC (Pripp, Stanisic, 2014; Corrigan et al., 2012). 
It interferes with LPS-induced inflammatory cytokine secretion of the pro-inflammatory 
cytokines IL-6 and TNFα (Pripp, Stanisic, 2014). In particular, PGE2 augments LPS-mediated 
IL-6, but blocks TNFα secretion in murine peritoneal neutrophils (Yamane et al., 2000). 
Moreover, the increased secretion of PGE2 in COPD fibroblasts has been proven to halt 
proliferation, as well as increasing pro-inflammatory cytokine expression (Dagouassat et al., 
2013). PGE2 mediates the macrophage-induced inflammation in septic shock (Xiang et al., 
2013) and can also account for the promotion of TH17 cell differentiation (Boniface et al., 
2009; Chizzolini et al., 2008; Napolitani et al., 2009). 
The anti-inflammatory effects of PGE2 may be exerted by the inhibition of pro-inflammatory 
cytokine secretion, such as IFNγ, IL-2 and TNFα in macrophages (Pripp, Stanisic, 2004; 
Corrigan et al., 2012; Meja et al., 1997). LPS transcriptionally activated the expression of the 
pro-inflammatory cytokines IL-1, CXCL8 and cytokines with dual properties in inflammation, 
such as TNFα and IL-6 (Cohen, 2002) in COPD. Neutrophil treatment with PGE2 suppressed 
LPS induced TNFα and enhanced IL-6 secretion (Yamane et al., 2000). Immunosuppressive 
properties of PGE2 have so far been proposed by several groups (van der Pouw et al., 1995; 
Ferreri et al., 1992). 
The contrasting role of PGE2 in inflammation may also be exerted through the products of 
protein metabolism and the selective affinity of these products to the distinct protein receptors. 
So has, for example PGD2 been shown to have a dual effect on functional responses, such as the 
induction of the respiratory burst and apoptosis at nanomolar to micromolar concentrations 
respectively (Sandig et al., 2007). Moreover, PGE2 acts as a bronchodilator in human airways 
(Pavord and Tattersfield, 1995), whereas its degradation product PGF2α is a bronchoconstrictor 
that like PGE2 is increased in COPD patients (Nichol et al., 1990; Montuschi et al., 2003; 
Profita et al., 2010). The distinct PGE2 receptor subtypes have differential roles in this context. 
PGE2 mediated TNFα suppression was mediated by the EP4 receptor (and partially by the EP2 
receptor), while IL-6 enhancement was mediated by EP2 only. However, also interactions of 
LPS and PGE2 have been reported to play a role in pro-survival cytokine generation in COPD. 
LPS primes anti-inflammatory and pro-survival G-CSF production, and PGE2 augmented this 
(Sugimoto et al., 2005), as well as IL10 production. PGE2 suppresses LPS-stimulated IFNβ 
production (Xu et al., 2008) and there is also an inhibitory effect of PGE2 and cAMP on LPS-
induced release of TNFα, and IL-6 production. Moreover, autocrine feedback mechanisms of 
LPS signalling by LPS-induced PGE2 production were previously proposed (Strassmann et al., 
1994; Benninghoff et al., 1988). 
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Thus, PGE2 has roles in the promotion and resolution of inflammation in inflammation and 
COPD. As it has the potential to perpetuate its own synthesis, by increasing Cox-2 expression, it 
may contribute to the self-sustained characteristics of chronic inflammation in COPD. Due to 
the rapid effects of prostaglandin production that are largely independent of translation and 
transcription, they can readily increase the expression of early response genes in inflammation, 
such as nuclear receptors. Therefore, a selective target downstream target of PGE2 involved in 
the transmission of its pro-inflammatory effects, such as increasing neutrophil survival, would 
thus be an interesting therapeutical target in COPD. 
1.3.1. Biosynthesis and metabolism of PGE2 
1.3.1.1. PGE2 Biosynthesis. 
Arachidonic Acid (AA) is the metabolic precursor of prostaglandin synthesis, the enzymatic 
metabolism of which can lead to a rapid increase in prostaglandin levels, as it is largely 
independent of transcriptional and translational mechanisms. AA is oxidized by 
Cyclooxygenase 1 (Cox-1) or Cyclooxygenase 2 (Cox-2) to PGH2 (O’Neill et al., 1994; 
Marnett et al., 1999; Fig. 3). PGH2 synthesis can occur either directly or in a two-step process 
with PGG2 being an intermediate reaction product in a process termed cyclooxygenase and 
peroxidase reaction respectively (Garavito et al., 2002; Chubb et al., 2006). Subsequently, 
PGH2 is metabolically transformed to the major bioactive prostaglandins PGD2, PGE1; PGE2, 
PGF2α or PGI2 by their respective synthase (Hayashi et al., 1989; Thoren et al., 2003; 
Murakami et al., 2000; Murakami et al., 2003; Hayashi et al., 1989; Lim et al., 2000), such as 
PGES in PGE2 production (Jakobsson et al., 1999). The expression of these prostaglandins 
varies in different cell types. Interestingly, whereas Cox-1 is ubiquitously and constitutively 
expressed, Cox-2 expression is positively regulated by its main metabolite PGE2, thereby 
perpetuating PGE2 expression (Dubois et al., 1998; Brock et al., 1999).  
In the course of inflammation, the expression of prostaglandins increases in cells such 
as mast cells (Tilley et al., 2001), whereas the LPS-induced cell activation in cells such as  
macrophages, promotes a shift from TXA2 to PGE2 secretion, with an over 200 fold increase in 
PGE2 expression (Ikegami et al., 2001). Thus, prostaglandins have been proposed as 
inflammatory markers. Non-steroid anti-inflammatory drugs (NSAIDs), such as ibuprofen 
(Cryer et al., 1998) are known to non-selectively inhibit Cox enzymes and prostaglandin 
synthesis, whereas aspirin or diclofenac are more selective towards Cox-1 or Cox-2 
respectively. Their common action on inflammation despite the structural differences of these 
compounds has long supported the importance of prostaglandins in inflammation (Vane, 1971). 
As Cox-2 is primarily overexpressed in the context of inflammation (Cryer et al., 1998),  
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Figure 3: Metabolism and Receptor Engagement of PGE2 and its Degradation Products. 
Arachidonic Acid (AA) metabolism initiates by the NSAID-inhibitable oxidation of AA to 
PGH2 by the action of Cox-1 or Cox-2. Prostaglandin E synthase (PGES) then mediates the 
transformation of PGH2 to PGE2, which can activate cAMP/PKA/CREB signalling and 
modulate gene expression via NR4A receptors and through the engagement of the prostaglandin 
receptors EP2 and EP4. PGE2 itself can be reduced to the PPARγ agonist 15-keto PGE2 by 15-
hydroxyprostaglandin dehydrogenase (PGDH) or to the FP receptor agonist PGF2α by carbonyl 
reductases (CBR). 
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selective Cox-2 inhibitors, such as celecoxib, rofecoxib and etoricoxib were employed to control 
inflammation (Mardini, FitzGerald, 2001); however, these displayed additional risks for 
unexpected cardiovascular complications (Friedewald et al., 2010), as opposed to the increased 
gastrointestinal side-effects of Cox-1 inhibitors (Cryer et al., 1998). Thus, diverse studies now 
support an early role of Cox-1-derived prostaglandins, whereas a dual role of subsequent 
induction of Cox-2 expression has been reported (Smyth et al., 2009; Langenbach et al., 1999; 
Gilroy et al., 1999; Wallace et al., 2000; Gavett et al., 1999). 
1.3.1.2. Metabolic Products of PGE2. 
PGE2 is rapidly metabolized in vivo by the action of 15-PGDH (Tai et al., 2002; Watzer et al., 
2009; Förstermann, Neufang, 1983; Nishigaki et al., 1996), whereas the presence of albumin 
determines its stability in an in vitro setting (Fitzpatrick et al., 1980). The metabolic products of 
PGE2 are varied. PGE2 can be directly catalysed to PGF2α by the carbonyl reductases CBR1, 
CBR2 and CBR3 (Inazu et al., 1992; Nakayama et al., 1986; Nakanishi et al., 1996) or 
dehydrogenases (Cho et al., 2005). However, PGF2α synthesis can also occur through the 
formation of the intermediate product 15-oxo-PGE2, mediated by the dehydrogenase 15-PGDH 
(Cho et al., 2006). Another major metabolic product with functional activity is 15-keto PGE2 
(Lu et al., 2013), which is synthesized through the action of 15-PGDH (Schlegel, Greep, 1976). 
Although 15-keto PGE2 has a significantly lower affinity to EP4 than EP2, further metabolisms 
are required to reduce the affinity of catabolic products to EP2 (Nishigaki et al., 1996). Through 
several subsequent modifications, PGE2 can also be transformed to PGB2, which has 
significantly reduced functional activity at PGE2 receptors (Polet, Levine, 1975). 
1.3.2. Activation of PGE2 Signalling Pathways by EP Receptors. 
PGE2 mediates its autocrine and paracrine effects by the involvement of four receptor subtypes, 
namely EP1, EP2, EP3 and EP4 (Konger et al., 2005). EP receptors are G-protein coupled 
transmembrane protein receptors that are primarily located on the outer plasma membrane of 
various cell types of internal organs, such as the lung, and in the immune, secretory, muscle, 
reproductive and nervous systems (Belinsky et al., 2015). Apart from these classical PGE2-
related receptors, PGE2 is furthermore known to target the PGF2α receptor FP, albeit with a 
diminished efficacy. 
1.3.2.1. EP1 
EP1 receptors are expressed in the plasma membrane and EP1 mRNA is particularly abundant 
in the cerebellum and the skin. In the immune system, EP1 has been found in whole blood and 
lymph nodes, but there are no consistent results as to its expression on white blood cells. In 
particular, its mRNA expression was not detected in neutrophils (Yamane et al., 2000). The 
intracellular signalling pathways engaged by EP1 agonism target phospholipase C (PLC), 
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leading to both, the activation of protein kinase C (PKC) and calcium mobilisation through 
increases in inositol 1,4,5-trisphosphate (IP3; Konger et al., 2005; Rundhaug et al., 2011). 
However, EP1 receptors did not elicit functional responses in neutrophils in a variety of assays, 
such as fMLP-stimulated O2- generation and phagocytosis-induced LTB4 release (Kanamori et 
al., 1997; Talpain et al., 1995; Wheeldon, Vardey, 1993).  
1.3.2.2. EP2 
EP2 is mainly localised in the plasma membrane, but may also be present in the extracellular 
space (Belinsky et al., 2015), where its role remains to be elucidated. EP2 mRNA is widely 
distributed throughout the body, and consistently found to be increased by microarray, RNAseq 
and SAGE assays in the brain, lung, skin and prostate tissues. Basal presence of EP2 protein 
was particularly pronounced on CD4+ T cells and PBMC. EP2 activation induces a rise in 
intracellular cAMP levels and subsequent PKA activation through the induction of adenylyl 
cyclase (AC; Rundhaug et al., 2011). In neutrophils, EP2-mediated signalling prevented 
secondary effects induced by fMLP, such as calcium influx, O2- generation and PKA-
independent chemotaxis (Burelout et al., 2007; Kanamori et al., 1997; Talpain et al., 1995; 
Armstrong, 1995). EP2 receptor stimulation is functionally linked to neutrophil immune 
function by NETosis (Domingo-Gonzalez et al., 2015). EP2-mediated signalling induced the 
expression of IL-6, and downregulated TNFα expression in murine peritoneal neutrophils 
(Yamane et al., 2000). Moreover, phagocytosis-induced LTB4 release was inhibited (Wheeldon, 
Vardey, 1993). A functional loss of EP2 receptors through a mutation in the EP2 receptor gene 
PTGER2 has been linked to an increased sensitivity and susceptibility to the development of 
aspirin-mediated asthma (Jinnai et al., 2004), suggesting that EP2 signalling may be required to 
limit aspirin-induced side-effects, such as bronchoconstriction due to smooth muscle cell 
contraction, in the lung. In aspirin sensitive asthma patients, the presence of bronchial mucosal 
neutrophils was increased, but their gene expression for the EP2 receptor was decreased 
(Corrigan et al., 2012). Nevertheless, a reduction in cytokine production of IFNγ, IL-2, IL-4 and 
IL-5 was achieved through EP2 agonism, indicating that the specific impairment of PGE2 
signalling in neutrophils contributes to the pathology of the condition. 
1.3.2.3. EP3 
EP3 is primarily localised in the plasma membrane and the nucleus (Belinsky et al., 2015). EP3 
mRNA is often found in the cerebellum, spinal cord, skin and prostate tissues, and EP3 protein, 
but not mRNA was found in neutrophils (Belinsky et al., 2015; Yamane et al., 2001). EP3 
activation provides a counterbalance to EP2 and EP4 activation, as it blocks the activation of 
AC (Rundhaug et al., 2011) and prevents smooth muscle cell relaxation. In neutrophils, EP3 
may contribute to the fMLP-stimulated O2- generation (Kanamori et al., 1997; Talpain et al., 
1995). 
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1.3.2.4. EP4 
EP4 is widely distributed throughout the cell and can be found in the plasma membrane, nucleus 
and cytosol, but also the extracellular space (Belinsky et al., 2015). EP4 mRNA, like EP2 
mRNA can be found in various tissue types, amongst others the whole blood. Most 
interestingly, EP4 proteins are most abundantly secreted in the cardia, the lung and CD8+  
T cells (Belinsky et al., 2015). Much like EP2 receptors, EP4 receptor-initiated signalling 
pathways involve the stimulation of cAMP and PKA (Rundhaug et al., 2011; Mizuno et al., 
2014), and likewise result in the relaxation of smooth muscle cells. EP4 has also roles in the 
prevention of vascular permeability (Kampitsch et al., 2012). In this context, PGE2 is thought to 
mediate its effects on the promotion of endothelial barrier function through activation of the 
EP4 receptor subtype. The EP4 receptor subtype was not linked to fMLP-stimulated  
O2 generation (Kanamori et al., 1997; Talpain et al., 1995), but as EP2 increased IL-6 
generation, blocked TNFα secretion (Yamane et al., 2000) and was linked to NETosis 
(Domingo-Gonzalez et al., 2005).  
1.3.2.5. Congruencies and Dissimilarities of EP2 and EP4 Receptors 
EP2 and EP4 receptor signalling have often been linked to the inflammatory response. Cigarette 
smoke extract increased mRNA and protein levels of EP2 and EP4 receptors in peripheral blood 
neutrophils from healthy volunteers, but not EP1 and EP3, at 3 hours and 24 hours by western 
blotting and qPCR (Profita et al., 2010). Cigarette smoke extract treated neutrophils showed 
increased epithelial cell adhesion upon treatment with the EP2 agonist butaprost or PGE2, 
which was blocked by an EP4 antagonist (Profita et al., 2010). Moreover, EP4 knockout mice 
(PTGER4
-/-
) showed increased pulmonary inflammation in response to a range of stimuli, such 
as LPS and cigarette smoke (Birrell et al., 2014) that were mediated by a cAMP/PKA signalling 
pathway. A potential explanation may be in the requirement for EP2 and EP4 receptors in the 
inhibition of LPS-induced cytokine release (Poloso et al., 2013). In macrophages, LPS induced 
the expression of EP2 and EP4 receptors, potentially increasing the influence of PKA signalling 
in an inflammatory context (Katsuyama et al., 1998; Ikegami et al., 2001). However, prolonged 
exposure to PGE2 downregulated EP2 and EP4 expression in Chinese hamster ovary cells 
(Nishigaki et al., 1996), suggesting a self-regulatory mechanism. Moreover, the influence of 
PGE2 also depends on its concentration, as a low PGE2 concentration induces pro-
inflammatory IL-23 release via EP4, but higher abundance of PGE2 may block IL-23 release 
via EP2, which further supports the self-regulatory effect of PGE2 in resolution of inflammation 
through variations in receptor usage. This is further supported by the induction of Cox-2 during 
the resolution phase of inflammation, where the inhibition of Cox-2 may further sustain 
inflammation (Gilroy et al., 1999; Willoughby et al., 2000). Although EP2 and EP4 are highly 
similar in many functions and often display redundancy (Brock et al., 1999), they are 
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structurally distinct and their expression profiles differ in response to stimuli (Arosh et al., 
2003; Chandramouli et al., 2012; Kickler et al., 2012). Moreover, EP4 only is sufficient for the 
PGE2-induced secretion of MMPs (Miyaura et al., 2000).  
1.3.2.6. FP  
The FP receptor is present in the plasma membrane and the extracellular space (Belinsky et al., 
2015). FP mRNA is present in various tissue types, amongst others the lung and whole blood. 
Most interestingly, the FP receptor is abundantly expressed in white blood cells (Belinsky et al., 
2015). Activation of the FP receptor induces intracellular increases in Ca
2+
 and subsequent 
activation of PKC (Fortier et al., 2008). A potential involvement of the FP receptor subtype in 
inflammatory neutrophil function was demonstrated by Wallace et al. (2009), who showed that 
the FP receptor induces inflammatory gene expression of CXCL1. As this chemokine acts as a 
neutrophil attractant, neutrophil chemotaxis was stimulated. Moreover, LPS-induced 
tachycardia in mice was diminished (Takayama et al., 2005), while little is known about the 
influence of LPS/FP signalling interactions on other cellular functions in neutrophils, such as 
cell survival. 
1.3.3. Mediation of PGE2 Survival Signalling by Nuclear Receptors. 
Apoptosis in neutrophils can be engaged by different mechanisms, which all lead to the 
activation of an effector arm and characteristic apoptotic changes. Apoptosis can be engaged by 
external stimuli, such as ligand binding to the Fas receptor, or through pathogen-mediated 
stimuli through the TNF receptor. The intrinsic pathway can be activated by irradiation, 
however also passive effects, such as the withdrawal of growth factors results in apoptosis. 
Neutrophils are unique, as they furthermore undergo constitutive apoptosis that predetermines 
their lifespan, and no strategy has been found so far that would completely prevent apoptosis in 
neutrophils. It is known that neutrophil lifespan becomes prolonged through recruitment to sites 
of infection to promote pathogen clearance through release of pro-inflammatory cytokines. 
Also, it is well established that neutrophil survival signalling can become altered in the context 
of inflammation (Simon, 2003) and induced by cigarette smoke (Morozumi et al., 2004). In this 
context, more substantial knowledge on the modulation of neutrophil lifespan in inflammation is 
needed to determine novel therapeutic strategies.  
Nuclear receptors are a large and highly conserved family of transcription factors, which 
regulate gene transcription by binding to enhancers or insulators upstream of their target gene, 
thereby bringing remote regions of the DNA together to enable target gene transcription. 
Nuclear receptors possess a high structural homology, containing an AF-1 and isoform-specific 
domain, a DNA binding domain, a hinge domain and a ligand-binding domain. In the form of 
monomers, homodimers or heterodimers, nuclear receptors have well documented roles in the 
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regulation of cell proliferation and metabolism, the maintenance of homeostasis and in 
inflammatory signaling. However, the stimuli that induce their expression are highly dependent 
on the cell type, but require the induction of a cAMP/PKA/CREB-dependent signaling pathway 
(Hawk, Abel, 2011).  
There are three types of nuclear receptors: Type I are classical steroid receptors that are 
localized in the cytosol. They are bound to inhibitory proteins in their inactive state, and will 
only translocate to the nucleus following ligand binding with ligands such as estrogen or 
glucocorticoids. In the nucleus, homodimers of Type I nuclear receptors can bind to a response 
element and enable target gene transcription. Type II are non-steroid receptors that can be 
activated by ligands such as thyroid hormones. In their inactive state, type II receptors typically 
already reside in the nucleus and are already bound to DNA with a corepressor. They can 
heterodimerize with Retinoid X receptors (RXR). Paradoxically, the identity of a ligand for type 
III, or orphan receptors is unknown. Orphan receptors represent half of the nuclear receptors 
known in humans, being founded in their discovery by cDNA library screening with degenerate 
primers, owing to their high structural homology. In retrospect, ligands were discovered for  
70 % of the former orphan receptors (Shi, 2007) and include the endocrine receptor subfamily 
and several peroxisome proliferator-activated receptors, such as PPARγ. Interestingly, while all 
adopted orphans possess a relatively typical domain structure, the Nuclear family 4 subgroup A 
(NR4A) orphan receptors have bulky ligand-binding domains with a lack of binding pockets, 
which is thought to make those receptors incapable of classic ligand binding (Wang et al., 2003; 
Ohkura et al., 1994; Baker et al., 2003; Flaig et al., 2005). Nevertheless, site-specific agonists 
for the selective targeting of other modulatory sites, such as AF1 (Codina et al., 2004; 
Ordentlich et al., 2003) enable the current drug development for NR4A modulators, which are 
currently under development for NR4A2 (Dubois et al., 2006; Jankovic et al., 2005). 
The NR4A subfamily of nuclear receptors is comprised of three members, namely 
NR4A1 (formerly Nurr77), NR4A2 (formerly Nurr1) and NR4A3 (formerly Nor1; Safe et al., 
2014). Members of this subfamily are proposed to be constitutively active and work in a ligand-
independent manner by affecting gene transcription through changes in their expression levels. 
Signalling pathways that additively induce the expression of NR4A members are PKA and 
MAPK pathways (Hawk, Abel, 2011). In macrophages, but not fibroblasts, LPS-treatment 
induced the NF-κB-dependent expression of all three NR4A subfamily members (Pei et al., 
2005), suggesting that targeting NR4A family expression may a useful target in the treatment of 
COPD. NR4A upregulation induced by various environmental stimuli required a 
cAMP/PKA/CREB dependent mechanism (Kwok et al., 1994; Kovalovsky et al., 2002; Darragh 
et al., 2005; Pearen et al., 2006). Additionally to this, it has been shown, that nuclear receptor 
activity can also be altered through different posttranslational modifications via growth factor 
and cytokine signalling. They are primarily thought to bind to DNA as monomers. 
     CHAPTER 1 
- 53 - 
NR4As are involved in many cellular functions including apoptosis, proliferation and 
metabolism. Expression of NR4As is induced by a variety of stimuli via multiple cell-signalling 
pathways, including PKA, NF-κB, PI3 kinase, c-jun-NH2-kinase (JNK), and MAPK pathways. 
The same stimuli often additionally induce further inflammatory signalling. NR4A receptors can 
be present in the cytoplasm and nucleus and can contribute to apoptosis in both scenarios. Their 
mitochondrial localisation might be linked with prostaglandin signalling as mitochondrial 
Cyclooxygenase (Cox2) induces inflammatory PGE2 production. Moreover, PGE2 was shown 
to induce NR4A gene expression via CREB and NF-κB signalling, potentially caused by a 
PGE2-induced CREB phosphorylation, which in turn can bind to NR4A promoters and enhance 
gene transcription (Holla et al., 2006). The dual role of NR4A receptors on the induction and 
inhibition of apoptosis may be consistent with the reported dual effect of cAMP/PKA signalling 
on survival, and may be transmitted through the involvement of the distinct nuclear receptor 
family members. 
1.3.3.1. NR4A1 
NR4A1 is a 7946 bps gene on chromosome 15. Homozygous deletion of NR4A1 in mice does 
not alter the overall mouse viability and leads to typical responses in terms of development, cell 
death and differentiation. A potential anti-inflammatory role in macrophagic inflammation has 
been proposed to be exerted through the control of IL-I β and IL-6 secretion (Bonta et al., 
2006). However, in macrophages, induction of NR4A1 by LPS or NF-κB increases the gene 
expression of pro-apoptotic and pro-inflammatory genes, i.e. caspase-4 and TNFα (Pei et al., 
2006). NR4A1 induces apoptosis in colon cancer cells (Wilson et al., 2003). Furthermore, 
NR4A1 expression in T cells is also considered to be pro-apoptotic through the induction of 
CD30 and Fas ligand (Zhang et al., 1999; Wei et al., 1996), consistent with the lack of 
peripheral T cells in NR4A1
-/-
 mice.  
1.3.3.2. NR4A2 
NR4A2 is a 17916 bps gene on chromosome 2. The gene product shows a predominantly nuclear 
localisation, but NR4A2 may be exported to the cytoplasm in response to oxidative stress. 
Homozygous deletion of NR4A2 in mice induces early lethality and a failure in neuronal 
development. In inflammation, NR4A2 is often abnormally expressed in tissues with prolonged 
or inappropriate inflammation that contributes to disease pathogenesis (e.g. in synovial tissue; 
McEvoy et al., 2002). Moreover, inherent overexpression of NR4A2 has been associated with 
the development of the inflammatory phenotype in rheumatoid arthritis (Mix et al., 2012; 
McCoy et al., 2015). A large body of evidence supports a pro-survival role of NR4A2 
expression, as alterations induced changes in cell survival and apoptosis in various in vitro and 
in vivo cell types, such as HeLa cells, neurons, in the central nervous system and NR4A2 
knockdown was correlated with decreased lymphocyte counts (Ke et al., 2004; Jankovic et al., 
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2005; Li et al., 2006; Saucedo-Cardenas et al., 1998; Le et al., 2003). A further important role 
for NR4A2 can be found in the regulation of neuronal differentiation, where they are 
overexpressed in precursor cells (Saucedo-Cardenas et al., 1998; Kim et al., 2002).  
PGE2 and Adenosine/A2A signalling have been shown to increase the expression of NR4A2 in 
colorectal cancer and rheumatoid arthritis (Holla et al., 2006; Ralph et al., 2005). Independent 
of the initial stimulus, NR4A2 expression is universally induced through cAMP/PKA signalling 
and activation of CREB (Holla et al., 2006; Lee et al., 2004). It has been shown that the Cox2 
inhibitor Rofecoxib also downregulates NR4A2, and this might be a more desirable target for 
non-steroidal anti-inflammatory drugs, with fewer side-effects than Cox2 inhibitors, in 
combination with a targeted therapy of the lungs only.  
1.3.3.3. NR4A3 
NR4A3 is a 41294 bps gene on chromosome 4. Homozygous deletion of NR4A3 in mice was 
either lethal in embryos or induced minor behavioural defects depending on the splice variant. 
Nuclear NR4A3 may be linked to inflammation, as its expression is altered in the inflammation 
of synovial tissue (McEvoy et al., 2002) and it shows anti-inflammatory properties in 
macrophages through the control of IL-1β and IL-6 secretion (Bonta et al., 2006). NR4A3 
knockdown reduces mast cell inflammatory gene expression of TNFα and IL-6 (Garcia-Faroldi 
et al., 2014).  
In neutrophils, NR4A3 increased superoxide generation and activated ERK (Lee et al. in 2000). 
An increase in NR4A3 expression in the course of apoptosis has been found in several in vitro 
models, the breast cancer cell line MCF-7 (Ohkubo et al., 2000), primary neurons (Ohkura et 
al., 1994), thymocytes (Cheng et al., 1997) and chondrocytes (Laflamme et al., 2003). 
Moreover, its expression is connected to the induction of apoptosis by T cells in tumours 
(Woronicz et al., 1994; Liu et al., 1994) and the maintenance of typical cell proliferation 
(Mullican et al., 2007). Taken together, this may suggest a pro-apoptotic role of NR4A3 in these 
cell types. In support, NR4A3 is expressed in smooth muscle cells (SMC) in the context of 
arteriosclerosis (Nomiyama et al., 2006), where SMC apoptosis contributes to the formation of 
arteriosclerotic lesions (Mayr, Xu, 2001). The expression of NR4A3 has found to be regulated 
by diverse signalling pathways, including ERK, MAPK, PI-3K, PKC, AMPK and CREB 
signalling (Lammi, Aarnisalo, 2008; Nomiyama et al., 2006; Ohkubo et al., 2000; Zhang et al., 
2010), with a potential involvement in differentiation and proliferation. 
1.4. Aims and Objectives 
Neutrophilia is a common feature in the COPD lung that contributes to disease pathology. This 
aspect of the disease is poorly addressed by the available treatment options, which may even 
further contribute to the extension of neutrophil survival in COPD.  
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The levels of the prostaglandin PGE2 are increased in COPD and can elicit both pro- and anti-
inflammatory responses through the engagement of four different receptor subtypes. Of these, 
the receptor subtypes EP2 and EP4 activate the major neutrophilic pro-survival molecule PKA.  
Here, it was hypothesised that the deleterious effect of PGE2 on disease pathology in 
COPD stem from their enhancement of neutrophil survival and our working hypothesis is that 
the specific inhibition of PKA survival signalling in neutrophils, will be beneficial towards the 
resolution of chronic inflammation in COPD. 
 
Therefore, the specific aims of this research project are to: 
1)  Identify the EP receptor subtype involved in pro-survival effects of PGE2 in PMN 
(Chapter 3). 
2) To substantiate the importance of PKA in PGE2 and LPS-mediated PMN survival in the 
context of COPD (Chapters 3-4). 
3) To delineate the role of nuclear receptors NR4A2 and NR4A3 in PGE2-mediated PKA 
signalling in PMN and a murine neutrophil model (Chapters 4-5). 
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CHAPTER 2. METHODOLOGY 
All studies on human cells were approved by the South Yorkshire Research Ethics Committee 
and blood was taken with informed consent of volunteers according to the regulations outlined 
by the regional Research Ethics Committee.  
If not otherwise indicated, all protocols were undertaken at room temperature. 
2.1. Cell Culture and Sample Preparation 
Human peripheral blood neutrophils (PMN), murine estrogen-regulated Hoxb8 myeloid 
precursor cells (mCMP) and mCMP-derived neutrophils (mNØ) were cultured at 37 °C in a 5 % 
CO2 humidified atmosphere. 
2.1.1. Murine Estrogen-Regulated Hoxb8 Progenitor Cells (mCMP) 
Murine estrogen-regulated Hoxb8 progenitors (mCMP) are a conditionally immortalized 
neutrophil precursor cell line, which yield mature murine neutrophils following a 4 day 
differentiation process (Wang et al., 2006). Briefly, to generate mCMP, lineage-negative 
neutrophil precursors were obtained from the bone marrow of female BALB/c mice. The 
homeobox protein Hoxb8 was fused to the binding domain of an estrogen receptor and 
precursor cells were retrovirally transfected with estrogen-regulated Hoxb8 (ER-Hoxb8). Thus, 
an estrogen-regulated, chimeric variant of Hoxb8 could be expressed in mCMP, blocking the 
differentiation of the precursors due to the suppressive nature of Hoxb8 on myeloid cell 
differentiation (Knoepfler et al., 2001).  
mCMP (kind gift from Prof. Philip Taylor, Cardiff University) were cultured as previously 
described (Kirschneck et al., 2011). mCMP were routinely cultured at 0.1 – 1 x 106 cells/ml in 
base medium, supplemented with 10 ng/ml recombinant murine Stem Cell Factor (SCF) and 1 
μM β-estradiol to conditionally immortalise mCMP, which were typically passaged every  
2 – 3 days. The base medium for mCMP and mNØ culture was OptiMEM, supplemented with 
10 % HI-FCS, 1 % L-glutamine, 30 μM β-mercaptoethanol and antibiotics  
(1 % penicillin/streptomycin). For long term storage cells were frozen in HI-FCS with  
10 % DMSO and stored in liquid nitrogen. All experiments were performed with cells between 
passages 2 to 8. 
2.1.2. Murine mCMP derived Neutrophils (mNØ) 
mCMP were differentiated into mNØ by estrogen withdrawal and supplementation with growth-
factors in a 4 day differentiation protocol (Fig. 4; Wang et al., 2006; Rosas et al., 2011). Briefly,  
1 x 10
6
 mCMP were washed three times in 1x dPBS by centrifugation at 350g for 5 minutes to 
remove residual β-estradiol. Washed mCMP were resuspended in 10 ml differentiation medium, 
consisting of base medium (as described in chapter 2.1.1.) supplemented with 20 ng/ml of the  
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Figure 4: Differentiation of mCMP to mNØ and Transfection. mCMP are maintained in 
culture in presence of SCF and β-estradiol through an estrogen regulated Hoxb8 fusion strategy, 
which conditionally immortalises the cells. Upon estrogen withdrawal and daily 
supplementation with G-CSF and SCF, mCMP differentiate into mature mNØ in a 4 day-
protocol (Panel A). Representative images on cells on different days throughout the 
haematopoietic process and their respective names are displayed (Panel B). Transfection was 
undertaken at day 1 post estrogen-withdrawal. Representative images of cells in the distinct 
developmental stages (Panel B). Abbreviations: D0 – day 0, D1 – day 1, D2 – day 2, D3 – day 
3, D4 – day 4, CMP – Common myeloid progenitors, mNØ – murine ER-Hoxb8 progenitor-
derived neutrophils. 
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recombinant murine growth factors SCF and granulocyte colony-stimulating factor (G-CSF). 
Media and growth factors were replenished daily for 4 days, at which point >90 % of mNØ had 
reached maturity, as assessed on the basis of mNØ morphology by light microscopy. 
For all subsequent assays, mNØs were cultured in 96-well Flexiwell plates at  
0.5 x 106 cells/well with or without treatment of SCF (20 ng/ml), G-CSF (20 ng/ml), Q-VD-OPh 
(QVD; 0.1 μM), dibutyryl cAMP (dbcAMP; 100 μM), staurosporine (STS; 500 μM),  
N6-MB-cAMP (100 μM) and 8-AHA-cAMP (100 μM). Appendix 1 contains a comprehensive 
list of all reagents used in this study. All experiments were performed in triplicate and each n 
originated from mNØ generated from independent passages of mCMP. mNØ used in this study 
were derived from mCMP cultures that did not exceed passage 8. 
2.1.3. Human Peripheral Blood Polymorphonuclear Neutrophils (PMN) 
2.1.3.1. Isolation through Percoll Density Gradient Centrifugation 
PMN were isolated from peripheral blood of healthy volunteers (Table 2) through dextran 
sedimentation and Percoll density gradient centrifugation, as previously described (Sabroe et al., 
2003; Vaughan et al., 2007). Briefly, to avoid coagulation, 40 ml of freshly sampled blood from 
human subjects was collected in citrated tubes (5 ml 3.8 % tri-sodium citrate [w/v]), obtaining a 
final concentration of 0.48 % tri-sodium citrate (w/v). Great care was taken during the 
procedure to avoid all unnecessary turbulence in the liquid, to reduce cell activation. Moreover, 
saline and HBSS buffer used in the procedure were Ca
2+
/Mg
2+
 free to prevent cell activation. 
Citrated blood was centrifuged at 270 g for 20 minutes to separate the cellular 
component from plasma, yielding an upper and lower phase. The upper phase, containing 
platelet rich plasma, was removed and centrifuged at 1155 g for 20 minutes to obtain platelet 
poor plasma (PPP). To the lower phase, 6 ml of a 6 % (w/v) dextran/saline (Ca
2+
/Mg
2+
 free) 
solution was added to obtain a final concentration of 0.5 % (w/v) dextran. Bubbles were 
carefully removed with a Pasteur pipette to prevent neutrophil activation and the lid replaced 
loosely to avoid subsequent disruption of the interface. Thereafter, red blood cells were allowed 
to sediment for 20 - 30 minutes, until a clear interphase had formed. The supernatant was then 
carefully taken off and centrifuged at 185 g for 6 minutes to pellet the white cells. 
The cell pellet was resuspended in 1.5 ml PPP and layered onto a discontinuous plasma-Percoll 
density gradient, which was composed of two layers, as follows: The upper layer contained  
42 % Percoll and 58 % PPP and was carefully layered onto the lower layer, which contained  
51 % Percoll and 49 % PPP. The Percoll gradient was centrifuged at 225 g for 11 minutes 
(brake at 0). Based on their distinct densities, red blood cells accumulated at the bottom of the 
tube, PMN on top of the 51 % Percoll/PPP layer, and peripheral blood mononuclear cells 
(PBMC) on top of the 42 % Percoll/PPP layer (Fig. 5). PBMC and PMN populations were  
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Figure 5: Percoll Density Gradient Centrifugation and Abundance of Blood Cells in Whole 
Blood. A biphasic Percoll density with a lower layer containing 51 % Percoll and an upper layer 
containing 42 % Percoll was overlayed with 1.5 ml of a cell pellet/PPP suspension. Following 
the centrifugation at 225g for 11 minutes, cells accumulated in the layers according to their 
respective densities (as outlined in Table 2).  
 
 
          Table 2: Presence and density of blood cell types in human blood. 
Cell types White blood cells (%) 
present in whole blood 
Density (g/ml) 
Monocytes 3 % 1.05 - 1.07 
Neutrophils 70 % 1.08 – 1.10 
Lymphocytes 25 % 1.06 - 1.08 
Basophils 1 % 1.07 - 1.08 
Eosinophils 1 %  1.09 – 1.10 
Erythrocytes N.A. 1.11 – 1.12 
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carefully extracted, resuspended in 5 ml PPP and diluted with HBSS buffer (Ca
2+
/Mg
2+
 free) to 
a final volume of 40 ml. A haemocytometer count was performed and subsequently, the cell 
suspension was centrifuged at 420 g for 6 minutes. The cell pellet was resuspended at a density 
of 5 x 10
6
 cells/ml in standard culture medium. 
2.1.3.2. Negative Magnetic Selection of Percoll Purified PMN. 
In experiments, where highly pure PMN were required, neutrophil purity was increased by 
negative magnetic selection using a custom antibody cocktail. As described in Sabroe et al. 
(2003), negative magnetic selection with antibodies against CD2, CD3, CD9, CD19, CD36, 
CD56 and glycophorin A was used to increase the purity of the Percoll pure PMN preparation to 
yield neutrophils of a purity > 97%. For the remainder of this thesis negatively selected 
neutrophil populations will be referred to as highly purified PMN. In all experiments, highly 
purified PMN were cultured at 1.67 × 106/ml in RPMI, supplemented with 10 % HI-FCS,  
1 % L-glutamine and antibiotics (1 % penicillin/streptomycin; Invitrogen) in 96-well Flexiwell 
plates.  
2.1.3.3. Cell Culture 
For all assays, freshly isolated PMN were cultured in 96-well Flexiwell plates at  
0.25 x 106 cells/well and stimulated with different pro- and anti-apoptotic factors as indicated in 
the figure legends. Appendix 1 contains a comprehensive list of all reagents used in this study. 
The start of the incubation was designated as 0 hours.  
Where appropriate, antagonists were preincubated for 15 minutes before addition of agonists. 
All experiments (apart from the optimisation of mNØ nucleofection) were performed at least in 
triplicate with cell preparations obtained from independent donors. 
2.1.3.4. Supernatant Co-Culture Assays 
In PMN supernatant co-culture experiments, 100 μl stimulated media was incubated for 1 hour 
with or without 50 μl highly pure PMN (0.5 x 106 cells/ml plain media) at 37 °C in a humidified 
atmosphere. Cell-free supernatants were collected after centrifugation of the samples at 350 rcf 
for 2 minutes. Thereafter, 100 μl PMN (0.5 x 106 cells/ml plain media) from the same donor 
were incubated with 50 μl of collected media or PMN supernatants (1:3 dilution) and incubated 
for a further 3 hours, before neutrophil apoptosis was quantified. 
2.2. Quantification of Neutrophil Apoptosis 
Neutrophil apoptosis was assessed morphologically by modified Wright-Giemsa Staining. 
Additionally, flow cytometry was used to determine phosphatidylserine (PS) exposure by  
PE-annexin V staining and membrane integrity by ToPro-3 staining. 
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2.2.1. Light Microscopy 
Apoptosis was first defined on the basis of morphological features, with one of the most 
prominent being chromatin condensation and cell shrinkage (Kerr et al., 1972). Although it has 
been shown that the distinct cellular changes connected with apoptosis are in fact caused by 
independent mechanistic processes (Lu et al., 2005), it remains well accepted that the 
occurrence of several stereotypical morphological changes of the cells constitutes apoptotic cell 
death. Therefore, light microscopy is recommended as a standard procedure in apoptosis 
research, since apoptotic features can be accurately visualised and aid in the detection of 
neutrophil apoptosis. Chromatin condensation and cleavage, along with other morphological 
changes associated with apoptosis, such as cell shrinkage and cell blebbing were visualised and 
quantified by microscopic inspection of cytospins, stained by the Romanowsky method 
(Romanowsky, 1891).  
Briefly, cells were spun onto microscope slides assembled onto cytocentrifuge chambers in a 
Cytospin centrifuge (Shandon Inc.) for 3 minutes at 300 rpm. Subsequently, cells were fixed 
with 100 % methanol, until the alcohol had evaporated. Slides were then immerged in Pink 
Diff-Quik dye for 1 minute to stain cytoplasmic organelles, and then transferred to Blue Diff-
Quik dye for 3-5 mins for nuclear staining. Following the removal of excessive dye by a wash in 
water, slides were air dried and coverslips were mounted onto fully dry slides with DPX 
mounting medium. Apoptosis was assessed by microscopy with a 100x oil-immersion 
magnifying lens, where 300 cells were typically counted per slide. Cell purity was assessed by 
assessing 500 cells on each of two slides. Absolute cell numbers were counted by 
haemocytometer counts and tryphan blue exclusion. All experiments performed in this 
dissertation were performed with cells of purity > 90% or 97% for highly pure PMN. 
2.2.2. Flow Cytometry 
Early apoptotic cells expose phosphatidylserine (PS) on the outer leaflet of the plasma 
membrane, which is a critical event preparing them for removal by tissue macrophages (Fadok 
et al., 2001; Hampton et al., 2002). For this purpose, the PS probe Annexin V conjugated to the 
fluorochrome phycoerythrin (PE) was used to bind to the epitope PS on apoptotic neutrophil cell 
surfaces. Simultaneous staining with the viability dye ToPro-3, detecting cytolysis, is therefore 
used to discriminate between healthy, apoptotic and necrotic cells (Fig. 6). The addition of 
CountBright beads allows the estimation of the total number of viable cells present in the 
sample. 
Briefly, for PE-annexin V/ToPro-3 staining, cells were collected from cell culture plates and 
washed in 1x DPBS at 350 rcf for 2 minutes in a tabletop microcentrifuge. Thereafter, cells were 
resuspended in 50 μl 1x Annexin binding buffer. Upon addition of 2.5 μl PE-annexin V (1:40), 
samples were incubated for 20 minutes in the dark. Thereafter, 50 μl of a 1:5000 dilution of   
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Figure 6: Flow Cytometric Measurement of Cell Death in mNØ. Viable cells possess an intact 
cellular membrane, and do not expose PS on their cell surface. (Panel A). In early apoptotic 
stages, cells still maintain membrane stability, but expose PS, to which PE-annexin V binds. 
With increasing length of culture of apoptotic neutrophils, the cell membrane gradually starts 
degrading and allows the leakage of the membrane DNA intercalating dye ToPro-3 into the cell. 
Representative flow cytometric images of Gating controls for annexin V/ToPro-3 stained 
neutrophils (Panels B, C). Unstained controls show a high percentage of viable cells in a tight 
population of SSC/FSC scatter plots (Panel B) with a low level of autofluorescence for FL2/FL4 
(Panel C). Necrotic cell death was modelled by freezing the samples at – 80 °C for 2 minutes 
prior to the addition of antibodies, which induced the formation of substantial amounts of cells 
with decreased size and cellular debris on SSC/FSC scatter plots, while most cells were highly 
fluorescent for ToPro-3. EDTA controls were aimed to determine the levels of unspecific 
binding of PE-annexin V, as EDTA is a calcium chelator, which uses calcium in competition for 
the calcium dependence of the annexin V/PS binding.  
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ToPro-3 (total 1:10000) in annexin binding buffer, as well as 10 μl of well vortexed CountBright 
counting beads were added, before the sample was analysed on FL-2 and FL-4 (log-scale) with 
a FACSCalibur flow cytometer and CellQuest Software. The following served as controls for 
flow cytometry:  
 An unstained control for background FL-2 fluorescence. 
 A calcium chelated control through addition of 2 μl 0.5 M EDTA to inhibit the calcium-
dependent binding of Annexin V to phosphatidyl serine. 
 A freeze/thaw control, which was incubated for 2 minutes at -80°C before addition of 
fluorescent dyes, to create cell populations with permeabilised membranes. 
2.3. mRNA Transcript Modulation and Quantification 
2.3.1. Trizol RNA Extraction 
Total RNA was extracted from cells using TRI reagent. TRI reagent is a commercially available 
adaptation of the guanidinium isothiocyanate-phenol-chloroform extraction method 
(Chomczynski, 1989). According to this method, cells are initially lysed in TRI reagent, which 
acts as a denaturing solution. In this way, the protein denaturant guanidine thiocyanate denatures 
ribonucleases and eliminates remaining RNase activity. Centrifugation of the sample fractions it 
into a lower organic phase and an upper aqueous phase. In contrast to DNA and proteins, RNA 
remains water soluble in the acidic conditions in the sample, and can therefore be isolated and 
precipitated from the aqueous fraction. 
Briefly, cells in 150 μl culture media were homogenised in a 1:3 ratio of TRI reagent/cells. 
Addition of 5 % 1-bromo-3 chloropropane, incubation for 2 - 5 minutes and centrifugation at 
12,000 rcf for 15 minutes at 4 °C separated protein into a lower organic phase, DNA in an 
interphase and RNA in the top aqueous phase. RNA in the aqueous phase was precipitated with 
0.5 ml 100% isopropanol, incubated for 5-10 minutes and centrifuged at 12,000 rcf for  
10 minutes. Ultimately, RNA was washed twice in 75% ethanol. The resulting RNA was treated 
with a DNase free Kit as per manufacturer’s instructions, to eliminate contaminating DNA from 
the sample. To this end, 2 Units rDNase I were added to the DNA and the sample was incubated 
for 20-30 minutes at 37 °C. 
Following this, rDNase I was inactivated by DNase Inactivation Reagent and incubated for  
2 minutes. Sample concentration was determined by Nanodrop. The expected value for 
A260/A280 was < 1.9-2.0. 
2.3.2. Reverse Transcription PCR 
1 μg of DNAse-treated, total RNA was reverse transcribed with the High-Capacity cDNA 
Reverse Transcription Kit according to the manufacturer’s instructions. Briefly, random 
amplification primers were used to initiate the first-strand cDNA synthesis in a buffer 
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containing 5 mM dNTP, 100 U Multiscribe Reverse Transcriptase and 1 μl RNAse Inhibitor in a 
total volume of 40 μl. Samples were then incubated for 10 minutes at 25 °C, 2 hours at 37 °C, 
and 5 minutes at 85 °C for the reverse transcription reaction to occur.  
2.3.3. Conventional PCR 
1 μl of the synthesised cDNA reaction (as described in chapter 2.3.2.) was used for conventional 
PCR. Conventional PCR was conducted in GoTAQ Green Flexi Buffer in a final volume of 25 
μl, using GoTAQ Flexi DNA Polymerase with 1 mM MgCl2, 12.5 μg BSA and  
200 nM of each PCR primer. Primers were designed to include at least one exon-exon junction 
spanning using PrimerBlast (NCBI). Primer sequences can be found in appendix 5. The PCR 
cycling conditions for the amplification of the desired products were initiated by a 2 minute 
denaturation at 94 °C. PCR reaction was performed using 30-37 cycles of a denaturation of  
94 °C for 30 seconds, 1 minute annealing at the primer specific annealing temperature (see 
appendix 5), and 30 seconds of elongation at 72 °C. This was followed by a final elongation of 
2 minutes at 72 °C. PCR products were visualized on a 1.2 % TAE agarose gel, stained with 
ethidium bromide. PCR products were quantified by densitometry using ImageJ software and 
normalised to the expression of endogenous cyclophilin B (CypB) or Glyceraldehyde-3-
Phosphate (GAPDH), as well as an internal calibrator, such as the media or 0 hours control, as 
indicated. 
2.3.4. Quantitative RT-PCR (qPCR) 
Taqman qPCR is a PCR based amplification strategy, by which changes in gene expression 
(mRNA) can be analysed, and PCR product amplification tracked in real time. To this end, 
cDNA derived from a reverse transcribed mRNA (see chapter 2.3.2) is amplified by using a 
probe for the target sequence, tagged with the fluorophore 6-carboxylfluorescein (FAM) and the 
quencher tetramethylrhodamine (TAMRA). Product amplification degrades the primer and thus 
releases FAM, which is no longer quenched by TAMRA. Therefore, released FAM can be 
detected through Fluorescence Resonance Energy Transfer (FRET) in the qPCR cycler, and is 
directly proportional to the amount of cDNA present in the sample. 
qPCR was performed with 1 μl cDNA template on the ABI PRISM 7900HT Sequence 
Detection System (Life Technologies). In a reaction volume of 20 μl, 1x qPCR MasterMix Plus 
with hotstart enzyme HotGoldStar, 1x Taqman gene expression array (Applied Biosystems), 
sequence specific primer probes (FAM/TAMRA), 1 μl cDNA template and water were mixed. 
The qPCR reaction was recorded in real-time using an ABI 7900 automated TaqMan System 
(Applied Biosystems)  using the following cycles: 50 °C 2 minutes, 95 °C 10.25 minutes, 60 °C 
1 minute for 40 cycle repeats. Samples were run in duplicates and were quantified as indicated 
using the 2
-∆∆CT
 method, by Taqman standard curves against known plasmid copy numbers or 
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against an arbitrary standard (PBMC cDNA pooled from 5 samples) through the SDS software 
(Applied Biosystems). Data were normalised to expression of endogenous GAPDH. For 2
-∆∆CT
, 
statistical analysis was performed on values normalised against the endogenous control (∆CT), 
and displayed on the corresponding graphs for 2
-∆∆CT
. Hereby, ∆CT was the difference between 
CT(target gene) and CT(GAPDH), as defined by the formula:  
∆CT =  CT(target gene)  − CT(reference gene;  GAPDH) 
The ∆CT of all tested conditions were normalised to the internal control, or calibrator by using: 
∆∆CT =  ∆CT(test)  − ∆CT(calibrator;  media/0 hours) 
The relative change in gene expression can be expressed as  
𝑅𝑎𝑡𝑖𝑜: (
∆𝐶𝑇(𝑡𝑒𝑠𝑡)
∆𝐶𝑇 (𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟)
) = 𝐸∆𝐶𝑇(𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟)−∆𝐶𝑇 (𝑡𝑒𝑠𝑡) 
With the efficiency of the reaction being defined as 𝐸 =  10
−1
𝑠𝑙𝑜𝑝𝑒, and a perfect slope with 
𝑠𝑙𝑜𝑝𝑒 (𝑝𝑒𝑟𝑓𝑒𝑐𝑡) =  −𝜋, it follows that 𝐸 =  10
−1
−𝜋 = 2. Thus: 
𝑅𝑎𝑡𝑖𝑜: (
∆𝐶𝑇(𝑡𝑒𝑠𝑡)
∆𝐶𝑇 (𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟)
) = 2∆𝐶𝑇(𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟)−∆𝐶𝑇 (𝑡𝑒𝑠𝑡) = 2− ∆∆𝐶𝑇(𝑡𝑒𝑠𝑡/𝑐𝑎𝑙𝑖𝑏𝑟𝑎𝑡𝑜𝑟) 
 
2.3.5. Primer Sequences 
All oligonucleotides for conventional PCR used in this study (Appendix 5) were synthesised in 
solid-phase with a Silyl-phosphoramidite method by Sigma. Primer design was by PrimerBlast 
(NCBI), aiming at a GC content of ~60%, introduction of a GC clamp and avoiding secondary 
structures and repeats. Primers were designed to include at least one exon-exon junction 
spanning. For all qPCR reactions, the primer/probe sets in Table 3 were used.  
2.3.6. Nucleofection and RNAi mediated mRNA Knockdown 
The RNA interference pathway is an epigenetic modulation strategy, allowing the transient 
silencing of gene expression levels. The RNAse Dicer converts long double-stranded RNAs 
(dsRNA) into short double-stranded interference RNAs (siRNA). siRNA is catalytically 
unwound and the thus separated antisense strand is integrated into the RNA-induced silencing 
complex (RISC). Homologous mRNA is recognised and degraded by RISC-activated 
ribonucleases, depleting overall mRNA levels for the specific gene product.  
siRNA was introduced into the cell by Nucleofection, which is an electroporation strategy. For 
this, the many hydrophobic pore openings in the hydrophobic bilayer cell membrane are 
converted into hydrophilic pores through an electric pulse, leading to rearrangements of the 
lipids in the pore composition, so that highly charged RNA is enabled to pass through. 
Nucleofection (Fig. 7) was carried out according to the manufacturer’s protocol with lyophilised  
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Table 3: qPCR primer/probe sets by Applied Biosystems used in the study. 
qPCR Primer 
Probe Set 
RefSeq (Translated Protein) Exon 
Boundar
y 
Assay 
Locatio
n 
Amplicon 
Length 
GAPDH NM_001256799.1 (GAPDH isoform 2) 6-7 728 93 
NM_002046.4 (GAPDH isoform 1) 7-8 704 93 
NR4A2 NM_006186.3 (NR4A2) 5-6 1578 69 
NR4A3 NM_006981.3 (NR4A3 isoform a) 4-5 1816 68 
NM_173200.2 (NR4A3 isoform b) 5-6 1888 68 
NM_173199.2 (NR4A3 isoform c) 4-5 1816 68 
PTGER2 
(EP2) 
NM_000956.3 (EP2) 1-2 1089 92 
PTGER4 
(EP4) 
NM_000958.2 (EP4) 2-3 1457 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Mechanism of siRNA-mediated Gene Silencing. Electroporation or Lipid-based 
reagents can be employed to mediate the transfer of the coding sequence for specific siRNA into 
cells. While electroporation changes the composition of pores, lipids enclose the siRNA and are 
transferred into the cell by endocytosis, and the lipids degraded in the lysosome. The siRNA 
reaches the nucleus and integrates into host DNA sequences. Transcription and export of the 
resulting siRNA into the cytoplasm enables the formation of a siRNA/RISC complexes, 
resulting in the binding and recognition of the single stranded siRNA to its target sequence, 
ultimately resulting in depletion of siRNA products for the gene of interest.  
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siRNA (20 μM), with the Amaxa Nucleofector Kit V. 
Briefly, 1x10
6
 cells were washed 3x in PBS and resuspended for 2 minutes in 100 μl of 
supplemented Nucleofector Solution and 3 μg of a target-specific siRNA pool or a scrambled 
control. Suspensions were transferred into cuvettes, nucleofected with program D-023 and 
immediately recovered in 1 ml of fresh growth medium. For mCMPs, cells were then 
maintained in 10 ml media for 48 hours until their harvest. For mNØs, cells were transferred 
into 10 ml differentiation media and media was replenished daily until they were harvested 
following differentiation for 3 or 4 days. Knockdown efficiency was assessed by qPCR. 
2.4. Immunostaining 
2.4.1. Immunocytochemistry (ICC) & Confocal Microscopy 
PMN cytospins were prepared (as per section 2.3.1) and fixed using 100 % MeOH. A wax pen 
(Sigma) was used to define a (hydrophobic) boundary around the cells. Slides were blocked for 
1 hour using 20 % goat serum, and subsequently incubated with polyclonal PE-conjugated 
antibodies against EP2 (4 μg/ml, IMG-71915, Cayman Chemicals), EP4 (5 μg/ml,  
115-01, Cayman Chemicals) or IgG (5 μg/ml, Columbia Biosciences) for 1 hour at 4 °C in a 
humidified chamber. Cytospins were rinsed 3 times for 5 minutes in PBS before incubation for 
1 hour at 4 °C with 5 μg/ml DAPI. Subsequently, coverslips were mounted with Fluoromount 
mounting medium (Sigma) and stored at 4 °C in aluminium foil. Light exposure was avoided 
during incubation and storage of the stained cytospins to circumvent photobleaching. Slides 
were examined in triplicate for each condition by confocal microscopy on a Nikon A1 Confocal 
Microscope with the LIS Elements software.  
2.4.2. Western Blotting 
Western blotting is a well-established technique, used to separate proteins according to their size 
on SDS-PAGE gels, and fix proteins on membranes. For the analysis of protein expression in 
highly pure PMN, whole cell lysates were extracted, separated on 10 % SDS-PAGE gels and 
transferred to nitrocellulose membranes using semi-dry transfer. 
2.4.2.1. Whole Cell Lysate Preparation 
PMN were isolated through Percoll density gradient centrifugation, as described in chapter 
2.1.3. Total cell numbers were determined by haemocytometer counts. Neutrophils contain a 
high amount of diverse proteases in their granules (Pham, 2006). Therefore, the serine protease 
inhibitors phenylmethanesulfonylfluoride (PMSF) and diisopropyl fluorophosphate (DFP), 
which preferentially inhibit trypsin and esterases, respectively, were employed in addition to a 
cocktail of diverse protease inhibitors (PI) during the cell lysis procedure. 
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For every sample, 5 x 10
6
 PMN were pelleted by centrifugation at 350 g for 2 minutes and then 
washed once in PBS. Cells were lysed in 50 μl of cold lysis buffer, consisting of 0.5 μl DFP,  
0.5 μl PMSF, 0.5 μl PI and 48.5 μl water. Cells were incubated on ice for 1 minute to allow 
complete lysis to occur. After the addition of 50 μl 2x SDS loading dye, samples were boiled for 
10 minutes to degrade secondary structures, such as disulphide and hydrogen bonds, which 
might introduce alterations in their polarity or structure. Lysates were stored at – 20 ºC until 
required. All buffer recipes can be found in appendix 2. 
2.4.2.2. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE is a widely used method for the size-dependent separation of proteins. A  
10 % SDS-PAGE gel was cast by pouring a stacking gel onto a polymerised resolving gel 
(Table 4) in a gel casting frame, assembled according to the manufacturer’s instructions. 
Briefly, glass plates were cleaned with alcohol before use, and assembled in the gel casting 
frame. Reagents in black (Table 4) for the resolving and stacking gels were mixed in 
consecutive order, as indicated in Table 4. Addition of APS and TEMED was delayed until the 
respective gels were poured to prevent premature polymerization. Firstly, the resolving gel was 
poured into the casting frame, overlayed with isopropanol and allowed to polymerize. 
Isopropanol was poured off, and the plates rinsed with water. Thereafter, APS and TEMED 
were mixed with the prepared stacking gel reagents, mixed well, and pipetted onto the 
polymerised resolving gel. A comb was added, and the gel was allowed to solidify. Thereafter, 
combs were removed and the gel was placed into a gel tank with 1x running buffer  
(Appendix 1). After the wells were rinsed with running buffer, 20 μl of PMN lysate  
(~1 x 10
6
 PMN) was loaded into individual lanes of the 10% SDS-PAGE gel. An electric 
current of 100 V was introduced to the gel tank to stack proteins above the resolving gel layer, 
after which the current was increased to 150 V. The uniform charge imposed onto the proteins 
thereby allows for their size-dependent separation in the resolving gel. A molecular weight 
marker was used to estimate the respective band sizes. 
 
Table 4: Recipe for 10% SDS-PAGE gel, to obtain resolution of 30-200 kDa proteins.  
Reagent 10% Separating Gel (4 gels) 4% Stacking Gel (4 Gels) 
H20 6.3 ml 3.05 ml 
1.5M Tric-HCl, pH 8.8 4 ml  
0.5M Tric-HCl, pH 6.8  1.25 ml 
30% Acrylamide 5.4 ml 0.67 ml 
10% SDS 160 μl 50 μl 
10% APS 160 μl 50 μl 
TEMED 16 μl 12 μl 
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2.4.2.3. Semi-Dry Protein Transfer 
Proteins on SDS-PAGE gels were transferred to nitrocellulose membranes through semi-dry 
transfer with transfer buffer (as described in appendix 2) on a G2 Fast Blotter (Pierce). Briefly, 
an SDS-PAGE gel was removed from between the glass plates and placed into transfer buffer. 
Similarly, pre-cut blotting paper (Whatman) was likewise soaked in transfer buffer. The layers 
for semi-dry blotting were assembled on the blotter as follows: a piece of pre-wet nitrocellulose 
membrane was placed onto 3 pieces of soaked Whatman paper. The SDS-PAGE gel was 
carefully positioned onto the nitrocellulose membrane and covered by three pieces of soaked 
Whatman paper. Transfer buffer was used to moisten the stack, before air bubbles and excess 
liquid were removed by rolling the layers lightly. The G2 Fast Blotter was assembled, as per 
manufacturer’s instructions and proteins were transferred for 7 minutes at 25 V, for 1 single gel. 
2.4.3. Immunostaining of Western Blots 
Protein expression for the target proteins was determined through immunostaining with target-
specific antibodies, chemiluminescent exposure of the stained western blots and densitometric 
analysis. 
2.4.3.1. Immunostaining 
Membranes were blocked for 1 hour in 5 % milk/TBS-0.1 % Tween-20 at room temperature. 
Primary antibodies for EP2 (1:200) and EP4 (1:100) in 5 % milk/TBS-0.1% Tween-20 were 
incubated with the blots at 4 ºC overnight. Before incubation with appropriate HRP conjugated 
secondary antibodies in 5 % milk/TBS-0.1 % Tween-20 for 1 hour, blots were washed 4 times 
in TBS/0.1% Tween-20 for 10 minutes. Bands respective to the target (EP2 – 53 kDa;  
EP4 – 65 kDa/52 kDa) were visualised by chemiluminescence through the Clarity Western ECL 
Substrate Kit using the Chemidoc system. Western blots were incubated with Ponceau S 
solution and washed in TBS/0.1% Tween-20, before western blots were re-probed with 
antibodies for β-actin (1:10,000), as a loading control. Densitometry of the exposed blots was 
performed using the ImageJ software.  
2.4.3.2. Stripping and Reprobing 
To strip the membranes, 0.2 M NaOH was incubated on the membranes for 15 minutes, before 
it was diluted with 3 washes in dH20 and TBS/0.1 % Tween-20, before the membrane was 
blocked and reprobed. 
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2.5. Statistical Analysis 
Data were analysed using the Prism 6.04 software (GraphPad). Statistical tests were performed 
as appropriate and included the following: Two-way ANOVA, One-way ANOVA, Student’s t-
test and a post hoc test, as indicated. Comparisons between data sets with one or two variables 
were performed through One-Way or Two-Way ANOVA respectively. Student’s t test was used 
to compare the differences of two independently treated data points with a single variable. Bars 
show mean ± SEM. Differences to controls are indicated by asterisks (*), and differences 
between treatments are indicated by octothorpes (#). For cytospins 300 cells were typically 
counted per timepoint, while for flow cytometry 10,000 events were accumulated per sample. 
Statistically significant comparisons were illustrated as follows: p<0.05 (*), p<0.01 (**), 
p<0.001 (***), p<0.0001 (****). 
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CHAPTER 3. MECHANISMS OF PGE2 SURVIVAL IN LPS 
PRIMED PMN. 
LPS and PGE2 are both potent mediators of neutrophil survival in the context of COPD (Dick et 
al., 2009; Ottonello et al., 1998; Profita et al., 2010). Inhalation of LPS has been shown to 
mimic inflammatory characteristics of COPD and disease exacerbations (Korsgren et al., 2012; 
Kobayashi et al., 2013), potentially through the induction of inflammatory gene expression by 
TLR signalling (Sabroe et al., 2003). LPS and PGE2 can play a cooperative role in vivo. LPS 
induces monocyte PGE2 expression via Cyclooxygenase 2 (Cox2; Amann et al., 2001; Ikegami 
et al., 2001; Hofer et al., 2004). This increases the amount of free intracellular PGE2, and 
monocytes might thereby serve as a major source of prostaglandin in the lung (Fogel-Petrovic et 
al., 2004). PGE2 is also known to be highly increased in the induced sputum of smokers, 
corresponding with an elevation in Cox2 expression in COPD patients and smokers (Profita et 
al., 2010). However, there is contradictory evidence towards the impact of PGE2 on airway 
inflammation (as discussed in chapter 1.3.). Briefly, both pro- and anti-inflammatory functions 
have been reported for various prostaglandins, such as PGD2, its metabolites (Sandig et al., 
2007) and PGE2 (Akaogi et al., 2006; Frolov et al., 2013), potentially through the engagement 
of the EP4 receptor subtype (Birrell et al., 2015). Divergently, pro-inflammatory effects of 
PGE2 in various inflammatory conditions have likewise been reported (Sheibanie et al., 2007) 
and proposed (Ward et al., 2004). Furthermore, PGE2 induced PMN survival is implicated in 
the occurrence of neutrophilia, which can exacerbate inflammatory conditions.  
Stimulation of blood neutrophils with LPS transiently upregulated their TLR2 and TLR4 
receptor expression (Baines et al., 2011). Additionally, the Sabroe/Whyte research groups have 
previously shown that LPS-stimulation of neutrophils only transiently increased their survival 
via TLR4 and NF-κB activation with an observed loss of TLR4 responsiveness after the 
immediate immune responses (Sabroe et al., 2002a). Thus, TLR4 desensitization would be 
expected to abrogate LPS induced neutrophil survival. Surprisingly, neutrophil survival at a late 
timepoint was sustained following TLR4 desensitization, where LPS required the presence of 
monocytes to elicit a biological response (Sabroe et al., 2002a). This was attributed by the 
authors to indirect effects on PMN survival through secretion of survival factors by monocytes. 
Here, the effects and mechanisms of PGE2 in PMN survival were examined. It was 
hypothesized that LPS increases PKA-dependent survival responses in PMN through the 
modulation of prostaglandin receptor expression. This might increase the susceptibility of PMN 
to LPS-induced PGE2 secretion by monocytes. The first aim of this chapter was to determine 
the prostaglandin receptor responsible for mediating survival effects of PGE2 and secondly, to 
understand the role of LPS in priming PGE2 induced survival. 
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3.1. Identifying the Receptor Subtypes Involved in the Pro-Survival Effects 
of PGE2 in PMN. 
PGE2 is an important agonist at sites of inflammation, with physiological concentrations in the 
lung to be estimated in the micromolar range, and which can be further increased in the sputum 
of COPD smokers (Profita et al., 2010). In the same study, PGE2 concentrations correlated with 
increased neutrophil numbers, which is consistent with diverse studies, where PGE2 or its 
analogues inhibited apoptosis in PMN (Rossi et al., 1995; Ottonello et al., 1998; Walker et al., 
1997; Davern et al., 1999; Ward et al., 2002). 
PGE2 has four cell surface receptors: EP1, EP2, EP3 and EP4, by which it mediates its 
pleiotropic effects (Sugimoto, Narumiya, 2007). Cellular responses of EP1 and EP3 receptor 
engagement are thought to be mediated by the stimulation of calcium mobilisation or inhibition 
of adenylyl cyclase (AC) in Chinese hamster ovary cells, respectively (Sugimoto et al., 1992; 
Sugimoto, Narumiya, 2007). Both receptors have been shown to engage cell death in diverse 
cell types (Shimamura et al., 2013; Ikeda-Matsuo et al., 2011; Kovarova, Koller, 2014). In 
contrast, stimulation of EP2 and EP4 activates AC and thereby induces the formation of cAMP 
(Sugimoto, Narumiya, 2007), which is the main ligand of PKA. EP2 and EP4 are both thought 
to elicit pro-survival responses through the activation of AC and resulting increases in cAMP. 
However, EP2 and EP4 can differentially regulate cellular responses and a loss of one receptor 
can only partly be compensated for by the other receptor. 
In PMN, expression of PTGER2 (EP2), PTGER3 (EP3) and PTGER4 (EP4), but not PTGER1 
(EP1), have previously been detected (Yamane et al. 2000). The expression of EP receptors can 
be regulated by inflammatory stimuli, such as LPS (Arakawa et al., 1996; Pavlovic et al., 2006; 
Katsuyama et al., 1998; Ikegami et al., 2001). Cigarette smoke extract treatment increased EP2 
and EP4 levels at early and late timepoints in PMN, as determined by qPCR and western 
blotting (Profita et al., 2010). Moreover, neutrophilia correlated to increased neutrophilic 
expression of the EP2 receptor in asthma patients (Corrigan et al., 2012). Additionally, the EP4 
receptor is implicated in the PKA-dependent mediation of the anti-inflammatory PGE2 
responses for chronic inflammatory conditions of the airways (Birrell et al., 2015). However, 
the role of the distinct receptors on PGE2 induced neutrophil survival has so far not been 
examined in detail. Therefore, here the role of PGE2 and the specific involvement of receptor 
subtypes in PMN survival were examined. 
3.1.1. PGE2: Regulation of PMN Survival by Prostaglandin Signalling. 
The effect of PGE2 on PMN survival was initially confirmed using PMN isolated from the 
blood of healthy volunteers (see chapter 2.1.3.). Treatment of PMN with a range of PGE2 
concentrations (100 nM – 10 μM) extended PMN lifespan in a dose dependent manner at  
4 hours, reaching statistical significance at 0.3 μM (Fig. 8A). This is greater than 10-fold in  
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Demographical data of chronic obstructive pulmonary disease 
patients. Data are presented as mean ± SEM or total number. 
Subjects (n) 9 
Age (yrs) 66 ± 1.5 
M/F (n) 7/2 
Exacerbations in year before donation 1.8 ± 0.5 
FEV1 (litres) 1.6 ± 0.1 
FEV1 (%) 55.2 ± 4.2 
Smoking habits (SM/EX) 2/7 
Pack years 45.5 ± 6.8 
 
 
 
 
 
Figure 8: PGE2 is a Potent Stimulus of PMN Survival in Healthy Control and COPD 
Neutrophils. Percoll purified PMN (Panel B) were further refined by negative magnetic 
selection (Panel A) with a custom antibody cocktail (purity > 97 %). PMN were incubated with 
varying concentrations of PGE2 (0.01 - 10 μM), as indicated. PGE2 treatment dose-dependently 
decreased apoptosis (Panels A, B) at 4 hours post inoculation. 10 μM PGE2 exerted a greater 
effect on PMN from COPD patients than in healthy controls (Panel B). Ki values (nM) of PGE2 
at prostaglandin receptors are displayed (Panel C). Data shown (Panels A, B) are mean ± SEM 
of 3 independent experiments with cells isolated from distinct volunteers, as described in 
chapter 21.3. Cellular morphology was assessed by light microscopy based on chromatin 
cleavage and condensation. Representative images are displayed in Figure 2B. Statistical 
analysis was performed through One Way ANOVA with Dunnet’s posttest (Panel A) or Two 
Way RM ANOVA with Sidak’s posttest (Panel B). Asterisks (*) denote significant differences 
to untreated conditions. Results were considered to be statistically significant for p<0.05 (*/#), 
p<0.01 (**/##), p<0.001 (***/###) and p<0.0001 (****/####). Abbreviations: HC – healthy 
control.  
PGE2 [nM] 
C 
A B 
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excess of the Ki (0.85 – 20 nM) for PGE2 towards its receptors EP1, EP2, EP3 and EP4  
(Table 5). Additionally, PMN were isolated through Percoll density centrifugation from the 
blood of COPD patients and healthy control patients. PMN apoptosis was delayed in both 
COPD patients and healthy controls at 4 hours (Fig. 8B). In COPD patient PMN, 10 μM PGE2 
increased PMN survival with greater potency than in healthy control PMN. Consequently, 
potential influences that might cause the lower than expected efficacy of PGE2 in the nanomolar 
concentration range were investigated. Initially, it was hypothesised that the residual amounts of 
solvent in the reagents might exert a general cytotoxic effect on PMN, masking the pro survival 
effect of PGE2.  
Therefore, highly purified PMN were incubated with increasing amounts of the solvent 
dimethyl sulfoxide (DMSO), and the effects of DMSO on PMN apoptosis were investigated. 
Solvent concentrations lower than or equal to 0.1 % DMSO did not increase apoptosis (Fig. 9). 
A small, but significant increase in PMN apoptosis (2.5 %) was induced by the highest 
concentration tested (1 % DMSO). The highest concentration of solvent used in any PMN assay 
did not exceed 0.02 %, indicating that the hypothesized interference by DMSO is negligible in 
this study.  
3.1.1.1. Effect of Metabolic Degradation of PGE2 on PMN Survival.  
There is also a theoretical possibility that PGE2 might be degraded to PGF2α or 15-keto PGE2 
in the cell culture medium (Fig. 3; Polet, Levine, 1975), comparable to its breakdown in vivo 
(Hamberg, Samuelssen, 1971). The key metabolic enzymes regulating PGE2 concentrations are 
Carbonyl reductases (CBR) and Hydroxyprostaglandin dehydrogenase 15-(NAD) (15-PGDH), 
which respectively mediate the reduction and oxidation of PGE2 to PGF2α and 15-keto PGE2 
(Cho et al., 2006; Nishigaki et al., 1996).  
PGF2α was previously shown to delay PMN apoptosis at 10 μM in PMN (Ward et al., 2002). 
While PGF2α shows affinity for various PGE2 receptors (Table 5), 15-keto PGE2 was long 
thought to be biologically inactive, since it has high Ki values for EP2 and EP4 receptors only 
(Table 5; Nishigaki et al., 1996). However, 15-keto PGE2 was recently shown to act as an 
intracellular PPARγ ligand (Lu et al., 2013) and it induced low levels of human macrophage 
apoptosis in vitro (Chinetti et al., 1998).  
Therefore, it was theorized that the need for high concentrations of PGE2 to mediate PMN 
survival may be due to PGE2 degradation in cell culture medium and through the additional 
engagement of the FP receptor subtype. Degradation of PGE2 to 15-keto PGE2 might activate 
pro-apoptotic PPARγ signalling, and thus further mask the pro-survival effect of PGE2. 
Initially, the focus of this investigation was PGF2α, because of its high affinity towards 
prostaglandin receptors. Here, it was aimed to determine, whether PGF2α would be able to 
affect early PMN survival in a concentration-dependent manner. Therefore, highly pure PMN  
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Figure 9: Influence of the Solvent DMSO on PMN Apoptosis. Percoll purified PMN were 
further refined by negative magnetic selection with a custom antibody cocktail (purity > 97 %). 
PMN were incubated with varying concentrations of DMSO (0.00001 – 1 %). 0.00001 – 0.1 % 
DMSO did not significantly increase apoptosis, while the highest concentration used (1 %) 
significantly increased PMN apoptosis by a small amount. Statistical analysis was performed 
through One Way RM ANOVA with Dunnett’s posttest. Data shown are mean ± SEM of 4 
independent experiments, as described in chapter 2.5. Cellular morphology was assessed by 
light microscopy. * denote significant differences to the untreated control. Results were 
considered to be statistically significant for p<0.05 (*). 
 
 
 
Table 5: Affinity (Ki) of PGE2 Metabolic Products for Human Prostanoid Receptors.  
Ki values (nM) 
Ligands which displaced over 50% of their respective radioligand at 10 μM 
Ligands DP IP TP FP EP1 EP2 EP3 EP4 Reference 
PGE2 *  *  *  100 
(73  - 
140) 
20 
(15 - 26) 
12 
(9.2 - 15) 
0.85 
(0.69 - 
1.1) 
1.9 
(1.5 - 
2.5) 
Kiriyama et 
al., 1997 
PGF2 α * * * 3.4  
(2.8 - 
4.2) 
1300 * 75  
(53 – 
110) 
* Kiriyama et 
al., 1997 
dmPGE
2 
*  *  *  350 
(250 
– 
480) 
* 17 (13-
23) 
1.9  
(1.5 – 
2.5) 
43  
(32 – 
58) 
Kiriyama et 
al., 1997 
15-keto 
PGE2 
N/
K  
N/
K  
N/
K 
N/K * 2600 * 1500
0 
Nishigaki 
et al., 1996 
Ligands that did not displace over 50 % of their respective radioligand at 10 μM (*). 
Abbreviations: DP – DP receptor; IP – IP receptor; TP – TP receptor; FP – FP receptor; N/K – 
not known.  
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were incubated with increasing concentrations of PGF2α and PGE2 for comparison, for 4 hours 
following which PMN apoptosis was assessed. In a non-sigmoidal dose response for 
concentrations up to 1 μM, PGF2α increased PMN apoptosis hyperbolically, to then steeply 
drop off at 10 μM to induce comparable levels of PMN survival to 10 μM PGE2 (Fig. 10A).  
PGF2α shows a high affinity for the FP receptor, which is its main receptor (Table 5). 
Therefore, a partial degradation of PGE2 to PGF2α might exert their action through the high 
affinity FP receptor. To determine the effect of FP receptor inhibition on PMN survival, highly 
pure PMN were preincubated for 15 minutes with the irreversible FP receptor antagonist AL 
8810, before the addition of varying concentrations of PGE2 for 4 hours. In a control assay, AL 
8810 alone did not significantly increase PMN apoptosis, even at the highest concentration used 
(10 μM; Fig. 10B). However, treatment with AL 8810 blocked PGE2 induced PMN survival 
(Fig. 10B, C). At an agonist concentration of 0.1 μM, PGE2 induced survival was significantly 
blocked by treatment with 10 μM AL 8810 (Fig. 10C). 
Due to the reasons outlined above, it was hypothesised that degradation of PGE2 by 15-PGDH 
might target nuclear PPARγ in PMN, and could thus induce alterations in PMN survival. To test 
this hypothesis, highly pure PMN were incubated with increasing concentrations of the selective 
PPARγ agonist rosiglitazone or PGE2 for 4 hours. Conversely, rosiglitazone initially increased 
PMN apoptosis at concentrations well below its EC50 for PPARγ (EC50= 60 nM). This 
increase was dose-dependently reversed by higher agonist concentrations (0.1 – 10 μM;  
Fig. 11A), and thereby mirrored PGE2-incuded survival for these concentrations. To further 
elucidate the role of PPARγ on PMN survival, the competitive PPARγ antagonist GW 9662 was 
used. GW 9662 alone did not significantly alter PMN survival at any of the concentrations used 
(Fig. 11B). Thereafter, highly pure PMN were preincubated with GW 9662 for 15 minutes and 
subsequently cultured in presence of varying concentrations of PGE2 for 4 hours. Interestingly, 
PGE2-induced survival at 0.1 μM was significantly blocked by treatment with  
1 μM GW 9662 (Fig. 11C), while GW 9662 did not significantly block PGE2 survival induced 
at higher concentrations of the agonist. 
Thereafter, the hypothesis was further explored that the efficacy of PGE2 at supra-Ki 
concentrations only was due to a decrease in biologically active PGE2 concentrations caused by 
PGE2 metabolism. 16,16 dimethyl PGE2 (dmPGE2) is a PGE2 analogue with increased 
resistance towards PGDH metabolism. It competitively inhibits 15-PGDH, without agonistic 
properties (Ohno et al., 1978). In fact, the half-life of dmPGE2 is prolonged in vivo (Ohno et al., 
1978). Comparable to PGE2, dmPGE2 acts as an agonist on most PGE2 receptors (Table 5; 
Kiriyama et al., 1997). Furthermore, the reagent was shown to mediate physiological PGE2 
responses with increased potency in comparison to PGE2 (Robert et al., 1976). 
To assess the influence of PGE2 stability on PMN survival, highly pure PMN were incubated 
with the metabolically stable PGE2 analogue dmPGE2 in the presence of varying concentrations  
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Figure 10: PMN Survival Induced by High PGE2 Concentrations is not Triggered by PGE2 
Metabolism to PGF2α. Percoll purified PMN were further refined by negative magnetic 
selection with a custom antibody cocktail (purity > 97 %). Ultrapure PMN were cultured with 
0.01 – 10 μM PGE2 (Panel A, C) or PGF2α (Panel A). In some experiments, PMN were 
additionally preincubated with the FP receptor antagonist AL 8810 for 15 minutes (Panels B, 
C). PGE2 induced PMN survival dose dependently (Panel A), while PGF2α significantly 
increased PMN apoptosis at concentrations ≤ 1 μM, but induced PMN survival at 10 μM (Panel 
A). Statistical analysis was performed through Two Way RM ANOVA with Sidak’s post tests 
(Panels A, C), or One Way RM ANOVA with Dunnett’s posttests (Panel B). Data shown are 
mean ± SEM of 3 (Panels A, B) or 5 (Panel C) independent experiments with cells isolated from 
distinct healthy volunteers, as described in chapter 2.5. Cellular morphology was assessed by 
light microscopy. * denote differences to control conditions. # indicate differences to the PGE2 
control curve. Results were considered to be statistically significant for p<0.05 (*/#), p<0.01 
(**/##), p<0.001 (***/###) and p<0.0001 (****/####). 
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Figure 11: Off Target Activity of High PGE2 Concentrations Prompts PMN Survival 
Extension Through Engagement of the PPARγ Receptor. Percoll purified PMN were further 
refined by negative magnetic selection with a custom antibody cocktail (purity > 97 %). 
Ultrapure PMN were preincubated for 15 minutes in presence or absence of the PPARγ 
antagonist GW 9662 (Panels C, D). Thereafter, 0.001 - 10 μM PGE2 (Panel B, C; as indicated), 
the PPARγ agonist rosiglitazone (Panel A) or the antagonist alone (Panel B) were added for 4 
hours. Rosiglitazone increased PMN apoptosis until a concentration of 0.01 μM, but then 
mirrored the PGE2 survival curve at higher concentrations (Panel A). GW 9662 alone did not 
significantly increase PGE2 induced PMN survival (Panel B), although GW 9662 showed a 
tendency towards increased apoptosis at 10 μM. However, GW 9662 specifically increased 
PGE2 induced survival at 0.1 μM agonist concentration, consistent with a potential off target 
effect of PGE2 at the PPARγ receptor. Statistical analysis was performed through Two Way 
ANOVA with Sidak’s posttest (Panels A, C) or One-Way ANOVA with Dunnett’s posttest 
(Panel B). Data shown are mean ± SEM of 3 (Panel B), 4 (Panel A) or 5 (Panel C) independent 
experiments with cells isolated from distinct healthy volunteers, as described in chapter 2.5. * 
denote differences to control conditions. # indicate differences to the PGE2 control curve. 
Cellular morphology was assessed by light microscopy. Results were considered to be 
statistically significant for p<0.05 (*/#), p<0.01 (**/##) and p<0.001 (***/###). 
  
B C 
A 
0 
          CHAPTER 3 
- 79 - 
of PGE2 or dmPGE2 (as indicated) for 4 hours (Fig. 12A, B) and 20 hours (Fig. 12B). It was 
found that the efficacy of dmPGE2 at inducing PMN survival was mostly similar to PGE2, 
where dmPGE2 reached statistical significance at 1 μM and PGE2 at 0.1 μM at 4 hours  
(Fig. 12A). In a separate assay on the temporal effect of the agonists, there was no difference 
between PMN survival induced by 1 μM PGE2 and 1 μM dmPGE2 at 4 hours (Fig. 12B). 
However, at 20 hours, PGE2 was unable to sustain PMN survival, whereas dmPGE2 
significantly decreased PMN apoptosis at 20 hours. 
3.1.2. PGE2 Receptors: Involvement of the EP2 and EP4 Receptor Subtypes in 
PGE2 Signalling. 
3.1.2.1. Expression of EP Receptor mRNA in PMN. 
Prostaglandin receptors can be classified based on their respective PGE2 affinity: EP1 and EP2 
have a low affinity to PGE2, whereas EP3 and EP4 are classified as high-affinity receptors due 
to their respective Ki values (Table 6). The aim of this chapter was to identify the receptor 
subtypes that mediate the pro-survival effects of PGE2. Firstly, the mRNA expression of the 
PGE2 receptor subtypes in PMN was investigated by RT-PCR. For this, total RNA was 
extracted from highly pure PMN and reverse transcribed, as per chapter 2.3. Sequence-verified 
RT-PCR primers (kind gift of Dr. Linda Kay) were previously used by Kay et al. (2013). 
Densitometric RT-PCR analysis, as described in chapter 2.3.3., revealed that EP4 receptors and 
low levels of mRNA for EP2 are expressed in PMN (Fig. 13A, B). mRNA expression of EP1 
and EP3 receptors was not detected. 
3.1.2.2. Effect of EP Receptor Agonism on PMN Survival. 
To demonstrate the involvement of specific EP receptor subtypes in PMN survival, highly pure 
PMN were incubated with increasing concentrations (0.1 μM – 10 μM) of PGE2 or four distinct 
PGE2 receptor agonists: the EP1 receptor agonist 17-phenyl trinor PGE2, the EP2 receptor 
agonist butaprost, the EP3 receptor agonist sulprostone and the EP4 receptor agonist L-902,688. 
In this context, receptor expression of both EP2 and EP4 were previously demonstrated  
(Fig. 13), whereas EP1 and EP3 receptor expression was not detected on the mRNA level. 
However, EP1 and EP3 might possess high protein stability, and might still be expressed on the 
protein level. 
Here, incubation with the EP1 agonist 17-phenyl-trinor-PGE2 significantly reduced PMN 
survival at an agonist concentration of 1 μM, where the agonist reached its maximum efficiency 
(Fig. 14A). The EP1 agonist only induced a small amount of PMN survival for 1 concentration 
tested (1 μM), whereas the PGE2 control curve dose-dependently induced survival in PMN at 
the three highest concentrations (1-10 μM). 
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Figure 12: Early Effect of PGE2 is not Dependent on Low Metabolic Stability. Percoll 
purified PMN were further refined by negative magnetic selection with a custom antibody 
cocktail (purity > 97 %). Ultrapure PMN were incubated for 4 hours (Panels A, B) or 20 hours 
(Panel B) with varying concentrations (as indicated) of PGE2, or its analogue dmPGE2. PGE2 
and dmPGE2 significantly and dose-dependently enhanced PMN survival at 4 hours (Panel A). 
However, dmPGE2 was significantly less effective at inducing PMN survival at 0.001 μM of 
the agonist, compared to PGE2. Moreover, with 1 μM PGE2 or dmPGE2, there was no 
significant difference between the agonists at 4 hours, but dmPGE2 retained its influence on 
PMN survival at 20 hours (Panel B). Statistical analysis was performed through Two Way RM 
ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 3 independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular 
morphology was assessed by light microscopy. * denote differences to control conditions. # 
indicate differences to the PGE2 control curve. Results were considered to be statistically 
significant for p<0.05 (*/#), p<0.01 (**/##) and p<0.001 (***/###). 
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Table 6: Affinity (Ki) of PGE2, Agonists and Antagonists for Human Prostanoid Receptors. 
Ki values (nM) 
Ligands which displaced over 50% of their respective radioligand at 10 μM 
Ligands DP IP TP FP EP1 EP2 EP3 EP4 Reference 
PGE2 *  *  *  100 
(73 - 
140) 
20 
(15 - 
26) 
12 
(9.2 - 
15) 
0.85 
(0.69 - 
1.1) 
1.9 
(1.5 - 
2.5) 
Kiriyama et 
al., 1997 
17 phenyl 
trinor 
PGE2 
*  *  *  60 
(47 - 
77) 
14 
(11 - 
18) 
*  3.7 
(2.8 - 
4.9) 
1000 Kiriyama et 
al., 1997 
(R)-
Butaprost 
(free acid) 
*  *  *  *  *  110 
(83 - 
140) 
*  *  Kiriyama et 
al., 1997 
Sulproston
e 
*  *  *  580 
(360 - 
930) 
21 
(17 - 
25) 
*  0.60 
(0.44 - 
0.81) 
*  Kiriyama et 
al., 1997 
L 902,688 N/
K 
N/
K 
N/K N/K >1500 >1500 >1500 0.38 Young et 
al., 2004 
PF 
04418948 
N/
K  
N/
K  
N/K  N/K  N/K 1.3 
(KB) 
N/K N/K Birrell et 
al., 2013; 
Af Forselles 
et al., 2011 
GW627368
X 
>50
00 
>50
00 
158 >5000 >5000 >5000 >5000 100 Wilson et 
al.,2006 
Ligands that did not displace over 50 % of their respective radioligand at 10 μM (*). 
Abbreviations: DP – DP receptor; IP – IP receptor; TP – TP receptor; FP – FP receptor; N/K – 
not known.  
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Figure 13: Constitutive Expression of Prostaglandin Receptors in PMN. Percoll purified 
PMN were further refined by negative magnetic selection with a custom antibody cocktail 
(purity > 97 %). mRNA was isolated from PMN by TRI extraction (as described in chapter 
2.3.1.). PTGER2 (EP2) and PTGER4 (EP4), but not PTGER1 (EP1) and PTGER3 (EP3) were 
transcribed in ultrapure PMN through RT-PCR (Panel A, B). Expected band sizes for PCR 
amplification products (Panel A) of the PCR primers (described in Appendix 4) were as follows: 
PTGER1 (EP1) – 149 bp, PTGER2 (EP2) – 419 bp, PTGER3 (EP3) – 837 bp, PTGER4 (EP4) – 
434 bp. Data shown are mean ± SEM of 4 independent experiments (Panel B), as described in 
chapter 2.5. Densitometry was performed using the ImageJ software. 
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Figure 14: Agonism of Prostaglandin Receptors EP2, EP3 and EP4 Induces PMN Survival. 
Percoll purified PMN were further refined by negative magnetic selection with a custom 
antibody cocktail (purity > 97 %). Ultrapure PMN were incubated with 0.1 – 10 μM PGE2, the 
EP1 agonist 17-phenyl trinor PGE2 (Panel A), the EP2 agonist butaprost (Panel B), the EP3 
agonist sulprostone (Panel C) or the EP4 agonist L-902,688 (Panel D). 17-phenyl trinor PGE2 
moderately delayed PMN survival with a maximal biological response below 1 μM (Panel A). 
Butaprost enhanced PMN survival in a dose-dependent manner, comparable to PGE2 survival 
(Panel B). Sulprostone induced moderate PMN survival (Panel C). L-902,688 acted as a partial 
agonist at concentrations below 1 μM (Panel D). Statistical analysis was performed through 
Two Way ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 4 independent 
experiments, as described in chapter 2.5. Cellular morphology was assessed by light 
microscopy. * denote significant differences to untreated controls and # indicate differences 
between PGE2 and treatment with the respective agonist. Results were considered to be 
statistically significant for p<0.05 (*/#), p<0.01 (**/##), p<0.001 (***/###) and p<0.0001 
(****/####).  
A 
D C 
B 
0 
          CHAPTER 3 
- 84 - 
The EP2 receptor agonist butaprost (free acid) enhanced PMN survival dose-dependently for 
concentrations up to 3 μM, and had a slightly decreased, but significant effect on PMN survival 
at 10 μM (Fig. 14B). It thereby mirrored the effect of PGE2, which significantly induced 
survival for concentrations of 1-10 μM. 
In the initial phase of the curve, treatment with the EP3 agonist sulprostone shifted the dose 
response curve on PMN survival to the left, compared to the PGE2 dose-response curve. 
Sulprostone significantly inhibited neutrophil apoptosis at 300 nM, but was without further 
effect on apoptosis at concentrations greater than 1 μM (Fig. 14C).  
The EP4 agonist L-902,688 was extremely potent and resulted in a strong left-shift compared to 
the PGE2 curve (Fig. 14D). L-902,688 significantly increased PMN survival at 0.1 – 3 μM and 
its maximal biological response was observed at the lowest agonist concentration used  
(0.1 μM). Interestingly, the efficacy of L-902,688 deteriorated with increasing agonist 
concentrations from 1 – 10 μM. A comparable increase with high concentrations was observed 
for all agonists (Fig. 14B-D), apart from 17-phenyl trinor PGE2 (Fig. 14A). 
3.1.2.3. Effect of EP2 and EP4 Receptor Antagonism on PMN Survival. 
Antagonism of EP3 receptors in human PMN has previously been characterised and a non-
apoptotic form of cell death was found (Liu et al., 2005; Liu et al., 2007). Therefore, it was 
chosen to further investigate the involvement of EP2 and EP4 receptors in PGE2 survival. Here, 
it was aimed to confirm the findings of the agonist studies presented above; by using selective 
receptor antagonists to block PGE2 induced survival. 
For this end, the EP2-selective antagonist PF-04418948 and the EP4-selective antagonist  
GW 627368X were incubated with highly pure PMN for 4 hours. Incubation with 3 – 300 nM 
of either antagonist alone or in combination did not significantly increase constitutive PMN 
apoptosis (Fig. 15). 
To determine whether PGE2-induced survival was mediated through the EP2 receptor, highly 
pure PMN were pre-incubated for 15 minutes with the indicated amount of PF-04418948. 
Thereafter, a range of PGE2 concentrations (3 nM – 10 μM; as indicated; Fig. 16A, B) or a 
range of butaprost concentrations (3 nM – 10 μM; Fig. 16C) was added, and incubated for  
4 hours. As expected, PGE2 significantly induced PMN survival at 3 μM and 10 μM at 4 hours 
(Fig. 16A). PF-04418948 alone was without effect on constitutive apoptosis. However, 300 nM 
of the EP2 antagonist blocked PGE2-induced PMN survival (at concentrations of 30 nM to  
3 μM PGE2) and increased apoptosis by a mean of 8.3 % (± 0.2 SEM) in comparison to the 
PGE2 curve. Similarly, a higher concentration of PF-04418948 (10 μM) increased PMN 
apoptosis by 8.0 % (± 0.5 SEM). However, statistical significance was only achieved for  
1 μM PGE2 (Fig. 16B). PF-04418948 [0.3 μM] significantly blocked survival induced by the 
EP2 agonist butaprost at 3 μM (Fig. 16C). 
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Figure 15: Effect of EP2 Receptor Antagonist PF-04418948 and EP4-Receptor Antagonist  
GW 627368X on Basal PMN Survival. Percoll purified PMN were further refined by negative 
magnetic selection with a custom antibody cocktail (purity > 97 %). Ultrapure PMN were 
incubated in presence or absence of 3 – 300 nM PF-04418948, GW 627368X or both for 4 
hours. Incubation with PF-04418948 and GW 627368X alone or in combination did not 
significantly influence PMN survival at any of the concentrations tested. Statistical analysis was 
performed through Two Way RM ANOVA with Sidak’s posttests. Data shown are mean ± SEM 
of 4 independent experiments with cells isolated from distinct healthy volunteers, as described 
in chapter 2.5. Cellular morphology was assessed by light microscopy. * denote significant 
differences to untreated conditions and # indicate differences between treatments with different 
antagonists. Results were considered to be statistically significant for p<0.05 (*/#), p<0.01 
(**/##), p<0.001 (***/###) and p<0.0001 (****/####). 
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Figure 16: EP2 Receptor Antagonist PF-04418948 Blocks Agonist Induced PMN Survival. 
Percoll purified PMN were further refined by negative magnetic selection with a custom 
antibody cocktail (purity > 97 %). Ultrapure PMN were preincubated for 15 minutes in presence 
or absence of 300 nM (Panels A, C) or 10 μM (Panel B) of the EP2 antagonist PF-04418948. 
Thereafter, varying concentrations of PGE2 (Panels A, B) or the EP2 agonist (R)-Butaprost 
(Panel C) were added to treatment conditions for a further 4 hours. PGE2 significantly delayed 
PMN survival. 0.3 μM PF-04418948 partially, but irreversibly, decreased PGE2 survival 
additional to constitutively increased PMN survival with PF-04418948 alone (Panel A). 
Incubation with PF-04418948 resulted in a complete and non-competitive inhibition of the 
effects of low PGE2 levels (< 1 μM). Treatment with PF-04418948 for high PGE2 
concentrations (> 1 μM) only partially inhibits the survival effects of PGE2 (Panel A). The 
extent of PGE2 inhibition was not further increased by treatment with 10 μM PF-04418948 
(Panel B). PF-04418948 enhanced PMN apoptosis, but only blocked (R)-Butaprost induced 
survival at 3 μM (R)-Butaprost (Panel C). Statistical analysis was performed through Two Way 
RM ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 3 independent 
experiments (Panels A, C) or 4 independent experiments (Panels B) with cells isolated from 
distinct healthy volunteers, as described in chapter 2.5. Cellular morphology was assessed by 
light microscopy. * denote significant differences to untreated conditions and # indicate 
differences to the agonist control curve. Results were considered to be statistically significant 
for p<0.05 (*/#), p<0.01 (**/##), p<0.001 (***/###) and p<0.0001 (****/####). 
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To determine, whether PGE2 induced survival was mediated through the EP4 receptor subtype, 
highly pure PMN were pre-incubated for 15 minutes with the indicated amount of GW 
627368X. Thereafter, a range of PGE2 concentrations (3 nM – 10 μM; as indicated; Fig. 17A, 
B) or a range of L-902,688 concentrations (3 nM – 10 μM; Fig. 17C) was added, and incubated 
for 4 hours. 
The EP4 antagonist GW 627368X alone did not significantly increase constitutive survival  
(Fig. 17A). However, only one concentration of PGE2 induced survival (0.1 μM) was 
significantly antagonised by 300 nM GW 627368X, which only increased PMN apoptosis by 
less 6.7 %. However, also by using a higher antagonist concentration of 1 μM, only PGE2 
induced survival at 100 nM was significantly blocked, with a mean percentage difference at 
higher concentrations of only 2.52 % ± 0.98 (Fig. 17B). L-902,688 at concentrations of between 
10 nM and 1 μM significantly induced PMN survival, which was not blocked by treatment with 
0.3 μM GW 627368X (Fig. 17C).  
Co-treatment of both the EP2 and EP4 antagonists for 4 hours did not significantly increase 
PMN apoptosis for the antagonists alone in highly pure PMN (Fig. 15). However, treatment 
with both antagonists significantly protected PMN from PGE2 induced survival at all tested 
concentrations (0.1 – 10 μM PGE2) and increased PMN apoptosis by 10.4 % (± 1.5 SEM) in 
comparison to PGE2 (Fig. 18A). A comparison between the effect of 10 μM PF-04418948 and 
10 μM of both antagonists on PGE2 induced survival revealed only a very small difference, 
which was not significant (Fig. 18B). 
3.2. Evaluating the Influence of LPS on PGE2 Receptor Expression in the 
Context of COPD. 
There is increasing evidence that LPS and PGE2 induced signalling pathways are interrelated, 
and may have synergistic effects on the mediation of cellular responses in inflammation. An 
autoregulatory loop for PGE2 has previously been reported in macrophages, where PGE2 
treatment downregulated EP4 mRNA expression, but not EP2 mRNA (Ikegami et al., 2001). 
Moreover, LPS treatment transiently increased EP2 mRNA expression, but downregulated 
mRNA for EP4 (Ikegami et al., 2001). In the macrophage cell line RAW 264.7, LPS also 
upregulated mRNA for EP2, but not EP4, while PGE2 downregulated mRNA for both and 
constitutive expression of EP4 was higher than EP2 (Hubbard et al., 2001). Moreover, LPS-
induced Cox2 expression was found to be mediated by the EP4 receptor in macrophages 
(Pavlovic et al., 2006). Therefore, it was hypothesised that the inflammatory stimuli LPS and 
PGE2 can modulate EP receptor expression as autoregulatory responses in the control of 
inflammatory PMN survival. 
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Figure 17: Effect of EP4 Receptor Antagonist GW 627368X on Agonist Induced PMN 
Survival. Percoll purified PMN were further refined by negative magnetic selection with a 
custom antibody cocktail (purity > 97 %). Ultrapure PMN were preincubated for 15 minutes in 
presence or absence of 300 nM (Panels A, C) or 10 μM (Panel B) of the EP4 antagonist GW 
627368X. Thereafter, varying concentrations of PGE2 (Panels A, B) or the EP4 agonist L-
902,688 (Panel C) were added to treatment conditions for a further 4 hours. PGE2 significantly 
delayed PMN survival. Reversal of PGE2 induced PMN survival was observed for 
concentrations <1 μM PGE2 by incubation with 0.3 μM GW 627368X (Panel A). Treatment 
with GW 627368X for high PGE2 concentrations (> 1 μM) only partially inhibited the survival 
effects of PGE2. GW 627368X induced blocking of PGE2 survival was not further increased by 
a higher antagonist concentration of 10 μM (Panel B). GW 627368X showed weak intrinsic 
agonist activity and a potentially partial blockage of L-902,688 induced survival (Panel C). 
Statistical analysis was performed through Two Way RM ANOVA with Sidak’s posttests. Data 
shown are mean ± SEM of 3 independent experiments (Panels A, C) or 5 independent 
experiments (Panels B) with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Cellular morphology was assessed by light microscopy. * denote significant 
differences to untreated conditions and # indicate differences to the agonist control curve. 
Results were considered to be statistically significant for p<0.05 (*/#), p<0.01 (**/##), p<0.001 
(***/###) and p<0.0001 (****/####).  
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Figure 18: Antagonism of the EP2 Receptor is Sufficient to Block PGE2 induced Survival. 
Percoll purified PMN were further refined by negative magnetic selection with a custom 
antibody cocktail (purity > 97 %). Ultrapure PMN were preincubated for 15 minutes in presence 
or absence of 10 μM of the EP2 antagonist PF-04418948 and the EP4 antagonist GW 627368X. 
Thereafter, 0.1 – 10 μM PGE2 were added to treatment conditions for a further 4 hours. 
Incubation with PF-04418948 and GW 627368X in combination significantly blocked PGE2 
induced survival (Panel A). However, no significant differences were observed between PGE2 
survival blocked with PF-04418948 only and both antagonists (Panel B). Statistical analysis was 
performed through Two Way RM ANOVA with Sidak’s posttests. Data shown are mean ± SEM 
of 4 independent experiments with cells isolated from distinct healthy volunteers, as described 
in chapter 2.5. Cellular morphology was assessed by light microscopy. * denote significant 
differences to untreated conditions and # indicate differences to the PGE2 control curve. Results 
were considered to be statistically significant for p<0.05 (*/#), p<0.01 (**/##), p<0.001 
(***/###) and p<0.0001 (****/####). 
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3.2.1. Induction of EP2 and EP4 Receptor Expression by LPS. 
Initially, the effect of LPS on PGE2 signalling and PGE2 receptor expression in PMN was 
examined. For this, highly pure PMN were incubated with 1 ng/ml LPS, 10 μM PGE2 or both 
for 4 hours and receptor mRNA transcript levels were examined by RT-PCR (as described in 
chapter 2.3.). Constitutive mRNA expression for both EP1 and EP3 were undetectable (Fig. 13). 
Moreover, neither EP1, nor EP3 mRNA expression was induced by LPS or PGE2 (Fig. 19). In 
contrast, treatment with LPS induced the expression of EP2 mRNA, from a very low 
constitutive level at 4 hours in PMN (Fig. 20A, B). Similarly, EP4 mRNA was also upregulated 
at 4 hours by LPS (Fig. 20A, C). Neither EP2 nor EP4 were significantly regulated by PGE2, 
whereas EP4 expression was non-significantly decreased in response to PGE2 (Fig. 20C). 
Moreover, treatment with both LPS and PGE2 increased EP2 and EP4 mRNA transcript levels 
in comparison to the control (Fig. 20A-C). 
These findings were confirmed by qPCR, which is a more quantitative assessment of gene 
expression. The constitutive expression of EP4 was 16.23 ± 8.40 (S.E.M.) times greater than the 
basal levels of EP2 mRNA (Fig. 21A). LPS significantly upregulated EP2 expression over 5 
fold (Fig. 21B), and over 12 fold in EP4 mRNA expression (Fig. 21C). Interestingly, incubation 
with PGE2 significantly decreased EP4, but not EP2 mRNA expression. Remarkably, LPS 
induced expression of both EP2 and EP4 mRNA was attenuated by PGE2 treatment. 
3.2.2. Functional Consequences of EP2 and EP4 mRNA Regulation in the Context 
of COPD. 
In this chapter, the mRNA expression of EP2 and EP4 in response to LPS was examined in the 
context of COPD. For this, Percoll pure PMN from healthy control and COPD patients 
(recruited through the COPD MAP Initiative; Fig. 8C) were incubated in the presence of  
10 ng/ml LPS for up to 2 hours. mRNA expression for EP2 and EP4 were analysed by qPCR. 
LPS induced EP2 mRNA expression in a temporal manner up to 2 hours (Fig. 22B). At 2 hours, 
EP2 mRNA expression was significantly enhanced in COPD patient PMN in contrast to healthy 
control PMN. Similarly, EP4 mRNA expression was increased over 2 hours of LPS treatment, 
although this was not significant (Fig. 23B). However, there was no detectable difference 
between mRNA expression in COPD and healthy control PMN, as evidenced by the 
upregulation of EP expression in responsive donors only, independent of patient classification 
as healthy control or COPD patient (Fig. 22D; Fig. 23D). 
In a separate assay, Percoll pure PMN from healthy control and COPD patients were incubated 
in the presence of 10 ng/ml LPS, 10 μM PGE2 or both for 4 hours. mRNA expression for EP2 
and EP4 were analysed by qPCR. In this assay, LPS non-significantly increased mRNA 
expression of EP2 to comparable levels in both COPD and healthy control PMN (Fig. 22C). 
The increased rate of EP2 upregulation by LPS in COPD PMN (Fig. 22B) appeared to be  
          CHAPTER 3 
- 91 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: LPS Induced PTGER1 and PTGER3 Expression is Attenuated by PGE2. Percoll 
purified PMN were further refined by negative magnetic selection with a custom antibody 
cocktail (purity > 97 %). mRNA was extracted from PMN directly following the PMN 
preparation using the TRI method (as described in chapter 2.3.). Total cellular RNA was reverse 
transcribed into cDNA using random primers. Resulting cDNA was then analysed through 
densitometry by RT-PCR using primers for PTGER1 (Panels B), PTGER3 (Panels C) and 
GAPDH as a normalisation control. PMN were incubated for 4 hours with LPS (1 ng/ml), PGE2 
(10 μM) or both. Neither EP1, nor EP3 were significantly regulated by treatment with LPS or 
PGE2. Statistical analysis was performed through One Way RM ANOVA with Dunnett’s 
posttests on normalised Ct values (∆CT), and displayed on graphs for 2∆CT, where applicable. 
Data shown are mean ± SEM of 3 independent experiments with cells isolated from distinct 
healthy volunteers, as described in chapter 2.5. Cellular morphology was assessed by light 
microscopy. Results were considered to be statistically significant for p<0.05 (*/#).   
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Figure 20: Effect of PGE2 and LPS on EP2 and EP4 Expression in PMN. Percoll purified 
PMN were further refined by negative magnetic selection with a custom antibody cocktail 
(purity > 97 %). mRNA was extracted from PMN directly following the PMN preparation using 
the TRI method (as described in chapter 2.3.). Total cellular RNA was reverse transcribed into 
cDNA using random primers. Resulting cDNA was then analysed densitometry through RTPCR 
using primers for PTGER2 (EP2; Panel B), PTGER4 (EP4; Panel C) and GAPDH as a 
normalisation control. PMN were incubated for 4 hours with LPS (1 ng/ml), PGE2 (10 μM) or 
both. LPS non-significantly increased EP2 mRNA and EP4 mRNA expression at 4 hours in 
PMN (Panels B, C). PGE2 alone had little effect on expression levels, but potentially reduced 
LPS-induced EP2 (Panels B) mRNA expression levels by RT-PCR. Statistical analysis was 
performed through One Way RM ANOVA with Dunnett’s posttests on normalised Ct values 
(∆CT), and displayed on graphs for 2∆CT, where applicable. Data shown are mean ± SEM of 3 
independent experiments with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Results were considered to be statistically significant for p<0.05 (*/#).  
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Figure 21: qPCR Confirms that LPS Induced PTGER2 and PTGER4 Expression is 
Attenuated by PGE2. Percoll purified PMN were further refined by negative magnetic selection 
with a custom antibody cocktail (purity > 97 %). mRNA was extracted from PMN directly 
following the PMN preparation using the TRI method (as described in chapter 2.3.). Total 
cellular RNA was reverse transcribed into cDNA using random primers. Resulting cDNA was 
then analysed by qPCR using primers for PTGER2 (EP2; Panels A, B), PTGER4 (EP4; Panels 
A, C) and GAPDH as a normalisation control. PMN were incubated for 4 hours with LPS (1 
ng/ml), PGE2 (10 μM) or both. Basal expression of EP4 mRNA was greater than basal EP2 
mRNA expression (Panel A). LPS upregulated EP2 and EP4 mRNA expression at 4 hours in 
PMN (Panels B, C). PGE2 alone reduced EP4 expression at 4 hours, and likewise reduced LPS-
induced EP2 (Panel B) and EP4 (Panel C) mRNA expression levels by qPCR. Statistical 
analysis was performed through t-tests (Panel A) or One Way RM ANOVA with Dunnett’s 
posttests (Panels B, C) on normalised Ct values (∆CT), and displayed on graphs for 2-∆∆CT, 
where applicable. Data shown are mean ± SEM of 3 independent experiments with cells isolated 
from distinct healthy volunteers, as described in chapter 2.5. * denote differences to untreated 
conditions. # indicate differences to LPS treatment conditions. Results were considered to be 
statistically significant for p<0.05 (*/#) and p<0.01 (**/##).   
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Figure 22: Enhanced PTGER2 Gene Transcription in LPS Primed PMN. Ultrapure PMN 
from healthy volunteers or COPD patients were incubated for 0 hours (Panel A), 0 - 2 hours 
with 10 ng/ml LPS (Panels B, D) or incubated for 4 hours (Panel A) with either 10 ng/ml LPS, 
10 μM PGE2 or both (Panel C). mRNA was extracted from PMN using the TRI method (as 
described in chapter 2.3.). Total cellular RNA was reverse transcribed into cDNA using random 
primers. Resulting cDNA was then analysed by qPCR using primers for PTGER2 and GAPDH 
as a normalisation control. EP2 mRNA expression for cells cultured in plain medium was not 
significantly different between healthy control and COPD patient PMN (Panel A). PTGER2 
expression was upregulated in COPD patient PMN at 2 hours in presence of 10 ng/ml LPS 
(Panels B, D). Individual data points for the assay in Panel B showed that 2 of 4 COPD patient 
PMN samples had upregulated EP2 mRNA expression at 120 minutes (Panel D).There were no 
statistically significant changes in PTGER2 expression between healthy control and COPD 
patient PMN at 4 hours. Statistical analysis was performed through Two Way RM ANOVA 
with Sidak’s posttest on normalised Ct values (∆CT), and displayed on graphs for 2-∆∆CT, where 
applicable. Data shown are mean ± SEM of 4 (Panels B, D) or 3 independent experiments 
(Panels A, C) with cells isolated from distinct volunteers, as described in chapter 2.5. * denote 
significant differences to untreated conditions and # indicate differences between corresponding 
treatments for healthy volunteers and COPD patients. Results were considered to be statistically 
significant for p<0.05 (*/#). Abbreviations: HC – healthy control. 
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Figure 23: Enhanced PTGER4 Gene Transcription in LPS Primed PMN. Ultrapure PMN 
from healthy volunteers or COPD patients were incubated for 0 hours (Panel A), 0 - 2 hours 
with 10 ng/ml LPS (Panels B, D) or incubated for 4 hours (Panel A) with either 10 ng/ml LPS, 
10 μM PGE2 or both (Panel C). mRNA was extracted from PMN using the TRI method (as 
described in chapter 2.3.). Total cellular RNA was reverse transcribed into cDNA using random 
primers. Resulting cDNA was then analysed by qPCR using primers for PTGER4 and GAPDH 
as a normalisation control. EP4 mRNA expression for cells cultured in plain medium was not 
significantly different between healthy control and COPD patient PMN (Panel A). PTGER4 
expression was non-significantly upregulated in healthy control and COPD patient PMN at 2 
hours in presence of 10 ng/ml LPS (Panels B, D). Individual data points for the assay in Panel B 
showed that one PMN sample for each patient group had upregulated EP4 mRNA expression at 
120 minutes (Panel D). Statistically significant differences in PTGER4 expression were detected 
between healthy control and COPD patient PMN at 4 hours in presence of LPS (Panel C). 
Statistical analysis was performed through Two Way RM ANOVA with Sidak’s posttest on 
normalised Ct values (∆CT), and displayed on graphs for 2-∆∆CT, where applicable. Data shown 
are mean ± SEM of 4 (Panels A) or 3-4 independent experiments (Panels B, D) with cells 
isolated from distinct volunteers, as described in chapter 2.5. * denote significant differences to 
untreated conditions and # indicate differences between corresponding treatments for healthy 
volunteers and COPD patients. Results were considered to be statistically significant for p<0.05 
(*/#), p<0.01 (**/##). Abbreviations: HC – healthy control.  
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transient, as the difference between COPD and healthy control PMN was lost at 4 hours in a 
subsequent experiment (Fig. 22C). mRNA expression for EP4 was increased in healthy control 
PMN and significantly upregulated in COPD PMN (Fig. 23C). After 4 hours of LPS treatment, 
EP4 expression was significantly enhanced in COPD PMN. Treatment with PGE2 did not 
regulate EP2 or EP4 mRNA expression levels in COPD or healthy control PMN. However, in 
COPD PMN only, PGE2 blocked LPS-induced upregulation of EP2. 
The functional relevance of increased prostaglandin receptor mRNA expression on extracellular 
PGE2 signalling depends on the translation of the receptor mRNA into protein. Therefore, 
Percoll pure PMN were treated with 1-10 ng/ml LPS for 4 and 20 hours. Whole cell lysates 
were made as described in chapter 2, and subjected to SDS PAGE. Membranes were incubated 
with primary antibodies for EP2 (1:200), EP4 (1:100), or β actin (1:10000) and 
chemiluminescent images were analysed by densitometry. At 4 hours, LPS treatment did not 
modulate EP2 and EP4 protein expression (Fig. 24A, B), whereas at 20 hours, EP2 and EP4 
receptor protein was dose-dependently, but not significantly increased (Fig. 24C, D).  
It was recently proposed that neutrophils from COPD patients may be primed due to the 
previous exposure to cigarette smoke (Koethe et al., 2000). Likewise, the ability of LPS to 
induce a primed state in PMN, and thus to enhance the secondary responses to inflammatory 
reagents has long been recognised (Condliffe et al., 1996; Condliffe et al., 1998). Consequently, 
I investigated, whether pretreatment with LPS could enhance PGE2 induced survival in PMN. 
For this, Percoll pure PMN from healthy control volunteers were incubated in presence of 10 
ng/ml LPS for 20 hours. Subsequently, LPS-primed and unprimed PMN were incubated in the 
presence and absence of 10 μM PGE2 for a further 4 hours. At 24 hours, 94.0 % (± 5.1 SEM) of 
untreated PMN were apoptotic, and unresponsive to treatment with PGE2 (Fig. 25A). LPS 
treatment significantly enhanced PMN survival in presence and absence of PGE2. Remarkably, 
there was a significant 12.9 % (± 3.6 SEM) fold change difference in LPS-primed PMN at 24 
hours, between PMN incubated in presence or absence of PGE2  
(Fig. 25B, C). 
3.3. Discussion 
This chapter discusses influences that may affect the efficacy PGE2 in PMN survival, the 
involvement of a specific receptor subtype on PMN survival and the interactions of LPS on 
PGE2 signalling. 
3.3.1. Influences on the Efficacy of PGE2 on PMN Survival. 
PGE2 displays pro-survival effects in PMN (Fig. 8A), with an increased potency in PMN from 
COPD patients (Fig. 8B). PGE2-induced survival increases dose-dependently, with a maximal 
biological response observed for 10 μM, which is 500-fold to 10000-fold in excess of its Ki  
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Figure 24: Modulation of Late EP2 and EP4 Protein Expressio n in Presence of LPS in 
PMN. Percoll pure PMN from healthy volunteers were incubated for 4 hours (Panels A, B) or 
20 hours (Panels C, D) with LPS (1 - 10 ng/ml). Proteins were extracted from PMN with 
neutrophil lysis buffer (as described in chapter 2). Protein from 1 x 10
6
 PMN/lane were loaded 
onto a 10 % SDS PAGE gel and transferred to nitrocellulose membranes, which were incubated 
with primary antibodies for EP2 (1:200), EP4 (1:100), or β actin (1:10000). Treatment with 10 
ng/ml LPS non-significantly increased EP2 and EP4 protein expression at 20 hours in PMN 
(Panels C, D), but not at 4 hours (Panels A, B). Densitometry was undertaken using the ImageJ 
software. Statistical analysis was performed through two-tailed t-tests compared to the media 
control. Data shown are representative images (Panel A), or mean ± SEM (Panels B, D) of 3 
independent experiments with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Results were considered to be statistically significant for p<0.05 (*). 
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Samples (n=3) Mean ± SEM Mean difference 
± SEM 
t-test 
LPS-primed PMN untreated 58.1 ± 14.0  
-12.9 ± 3.6 
 
0.0130 (*) 
10 μM PGE2 51.6 ± 13.9 
 
 
Figure 25: LPS Pretreatment Enhances PGE2 Survival in PMN. Percoll pure PMN from 
healthy volunteers were pre-incubated for 20 hours with LPS (10 ng/ml). Subsequently, PMN 
were incubated in presence or absence of 10 μM PGE2 for a further 4 hours. PGE2 treatment 
alone did not significantly extend PMN survival at 24 hours (Panel A); however, PGE2 
significantly downregulated apoptosis in LPS-primed PMN at the same timepoint (Panel B, C). 
Statistical analysis was performed through Two Way RM Way ANOVA with Sidak’s posttests 
(Panel A), or paired (two-tailed) t-test (Panels B, C). Data shown are mean ± SEM of 3 
independent experiments (Panels A, B) with cells isolated from distinct healthy volunteers, as 
described in chapter 2.5. Cellular morphology was assessed by light microscopy. * denote 
significant differences to control conditions. Results were considered to be statistically 
significant for p<0.05 (*/#), p<0.01 (**/##), p<0.001 (***/###) and p<0.0001 (****/####). 
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(0.85 – 20 nM) towards the receptors EP1, EP2, EP3 and EP4 (Table 5). It was postulated that 
the lower than expected efficacy of PGE2 was caused by a cytotoxic effect induced by the 
solvent dimethyl sulfoxide (DMSO). However, DMSO did not induce apoptosis in PMN at the 
concentrations used in this study (Fig. 9). Agonism of FP receptors increased PMN survival and 
FP receptor antagonism likewise blocked PGE2-induced survival to a low extent (Fig. 10), as 
did PPARγ antagonism (Fig. 11). The stable PGE2 analogue dmPGE2 induced PMN survival 
comparable to PGE2, but while PGE2 survival was lost at 20 hours, dmPGE2 sustained its 
effect on survival at the late time point (Fig. 12). 
3.3.1.1. Influences of Solvent and Serum on PMN Apoptosis. 
Several authors have recently described the pro-apoptotic effect of the common solvent DMSO 
(Hanslick et al., 2009; Banic et al., 2011; Galvao et al., 2014) in the central nervous system of 
mice (Hanslick et al., 2010) and through the interference with Casp-9-mediated apoptosis in 
hepatocytes (Banic et al., 2011). 
Here, only 1 % DMSO induced a low increase in PMN apoptosis (Fig. 9). As the highest 
concentration of DMSO used in the following assays of this study was lower than 0.1 %, it was 
therefore concluded that the effect of the solvent on PMN apoptosis is negligible. It is 
conventional to supplement culture medium with 10 % FCS. To reduce potential secondary 
variability induced by FCS, a single batch of heat-inactivated FCS (# C-37372) was used 
throughout this study. The heat-induced inactivation of trypsin was verified by the supplier, and 
the functionality of further enzymes was greatly reduced (informal communication). 
However, the introduction of FCS in the cell culture medium encompasses the risk of allowing 
plasma protein to bind to PGE2 or its cell surface receptors. PGE2 binds readily to human 
serum albumin at 37 °C (Romanovsky et al., 1999). Binding of plasma proteins has previously 
been proposed to explain a lack of efficiency of ligands at the receptor level (Coleman et al., 
1985c), which might lead to a reduced potency of PGE2 in reducing apoptosis. The normal level 
of albuminin blood is 3.4 – 5.4 g per decilitre, and with a high association constant of  
2.4 x 10
4
 (unitless) for PGE2 with human serum albumin (Raz, 1972), this might indicate that a 
considerable proportion of PGE2 could be bound in a physiological setting. Therefore, the 
addition of FCS might model in vivo conditions, as a lack of growth factors might otherwise 
induce the development of a withdrawal phenotype with increased levels of PMN apoptosis. 
Nevertheless, the effect on FCS binding free PGE2 in the culture medium is likely of only 
minor importance for this study. In support, the affinity of bovine serum albumin to human 
PGE2 is thought to be considerably decreased compared to its affinity for bovine PGE2 (Raz, 
1972). In a serum free environment, PGE2 moreover significantly affected PMN function at 100 
nM (Armstrong, 1995; Talpain et al., 1995), which is only 10 fold lower than the concentration 
that significantly reduced PMN apoptosis in this study (1 μM). Future work to substantiate this 
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hypothesis may involve supplementing the PMN culture medium with varying concentrations of 
FCS, or BSA.  
3.3.1.2. Pro-Survival Effects of PGE2 at Ultra-Ki Concentrations. 
The need for relatively high (micromolar) PGE2 concentrations might also reflect a 
physiologically relevant effect. Biphasic and dose dependent actions of PGE2 signalling have 
been reported in various cell types (Coleman, Kennedy, 1980; Eglen, Whiting, 1988; Sergeeva 
et al., 1997; Tang et al., 2000; Zhang, Wang, 2014). In a study on the bronchoconstrictory 
effects of prostaglandins, the investigated prostaglandins were used at low micromolar 
concentrations, and the inefficacy of the PGs at lower concentrations was attributed to the 
involvement of the TP receptor, which had high Ki values for the prostaglandins in question 
(Coleman et al., 1989). Moreover, biphasic effects of PGE2 in the guinea pig trachea, where 
only the initial proportion of the contractile curve was antagonised by an EP receptor antagonist, 
were attributed to the involvement of an additional receptor subtype (Eglen, Whiting, 1988). In 
this study, PGE2 induced a delayed dose-dependent survival in a potentially biphasic sigmoidal 
manner (i.e. Fig. 10-12), suggesting that PGE2-induced survival involves the action of 
additional receptor subtypes to the classical PGE2 receptors EP1, EP2, EP3 and EP4. 
Therefore, a potential loss of specificity through the engagement of an additional receptor 
subtype for micromolar PGE2 concentrations was examined. With respect to the published 
receptor affinities of PGE2 (Table 6), the agonist has a Ki value of 100 nM for the FP receptor 
subtype. However, by using a FP receptor specific antagonist, only a modest inhibitory effect on 
PGE2 induced survival for 0.1 μM PGE2 was determined (Fig. 10C). This indicated that the 
engagement of the FP receptor subtype through PGE2 is possible and might influence the pro-
survival effect of PGE2 in PMN. However, the effects of FP receptors on PGE2 induced 
survival are very limited, and at an antagonist concentration that matched the highest 
concentration of PGE2 used (10 μM), it is unlikely that PGE2 with its comparatively low 
affinity towards FP displaced AL 8810 from its receptor at concentrations below 10 μM. 
However, in some (Fig. 10C), but not all assays (Fig. 10B), AL 8810 increased constitutive 
PMN survival, which hinders the interpretation of the impact of FP receptors on PMN survival. 
This may be caused by variability in the basal protein expression of FP receptors.  
3.3.1.3. Possible metabolism of PGE2 to PGF2α. 
The dual effects of the prostaglandin PGD2 on inflammation have previously been reviewed 
(Sandig et al., 2007). It was argued that PGD2 was rapidly metabolised and was able to exert 
further functions through its metabolic products. Interestingly, PGE2 shows similar dual roles in 
many cell types (Nishigaki et al., 1996) and is also considered as metabolically unstable. 
Moreover, the prostaglandin receptors EP2 and EP4 have shown different sensitivity to 
metabolic degradation products of PGE2, with EP4 being more susceptible to desensitization 
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and PGE2 metabolism. Therefore, poor lipid stability has to be taken into account, when 
investigating PGE2 induced survival in vitro, while high local PGE2 concentrations might be 
able to sustain PMN survival responses in vivo, irrespective of PGE2 degradation. 
It was therefore investigated, whether products of a potential protein-based catabolism of PGE2 
may exert an influence on PMN lifespan, or were responsible for reducing the efficacy of PGE2 
in inducing PMN survival. Intriguingly, the PGE2 metabolite PGF2α only decreased PMN 
apoptosis at 10 μM, to a similar extent as PGE2 at the same concentration (Fig. 10A). While 
these results corroborate the finding of Ward et al. (2002) for 10 μM PGF2α at a 4 hour 
timepoint, an additional, more complex role for PGF2α in the regulation of PMN survival was 
found. As micromolar concentrations of PGF2α were required to induce PMN survival, it is 
unlikely that PGE2 metabolism is responsible for the hypothetical engagement of the  
FP receptor. 
An alternative hypothesis to a potential interference of PGE2 metabolism, PGF2α had a pro-
apoptotic effect on PMN survival at low agonist concentrations. Therefore, it is possible that the 
non-specific engagement of the FP receptor at pharmacological concentrations of PGE2 masks 
the pro-survival effect of PGE2. However, PGE2 had a very low effect on PMN survival at sub-
Ki concentrations for the FP receptor. Hence, the impact of this effect on PMN survival is likely 
to be minute.  
3.3.1.4. Non-specific action through metabolism to 15-keto PGE2. 
The 15-PGDH mediated degradation of PGE2 to its metabolite 15-keto PGE2 (Fig. 3; Polet, 
Levine, 1975; Hamberg, Samuelssen, 1971; Nishigaki et al., 1996) may allow for inflammatory 
gene expression and side-effects on PMN survival induced by the targeting of PPARγ. 
Consistently, there is increasing evidence for a physiological role of PPARγ in inflammation 
(Rigamonti et al., 2008). In fact, targeting of PPARγ has recently been proposed as a strategy in 
the regulation of neutrophilic inflammation in airway diseases, as PPARγ agonism blocked 
neutrophilia induced by inflammatory stimuli in vivo (Birrell et al., 2004). In contrast to PGF2α, 
15-keto PGE2 possesses a considerably attenuated affinity towards prostaglandin receptors, and 
is thought to have reduced physiological activity in comparison to PGE2 (Table 5; Nishigaki et 
al., 1996; Hansen, 1976; Chi et al., 1996), because of which the effect of its downstream 
effector PPARγ on PMN survival was tested here.  
The PPARγ agonist rosiglitazone dose-dependently decreased PMN apoptosis for 
concentrations above 10 nM (Fig 11A), which might be consistent with its reported Ki of  
6.92 nM for PPARγ receptors (Liu et al., 2001). However, at sub-Ki concentrations (1-10 nM), 
rosiglitazone profoundly increased PMN apoptosis (Fig. 11A). This might indicate that a 
threshold level of receptor activation is required to show an effect for PPARγ agonism. 
However, it is also possible that rosiglitazone acts as an agonist on a second target at pre-Ki 
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concentrations. In fact, rosiglitazone also activates AMP-activated protein kinase (AMPK; 
Fryer, Parbu-Patel, Carling, 2002), which has been shown to be involved in the regulation of 
apoptosis. The increase in PMN apoptosis at low rosiglitazone concentrations was thus possibly 
mediated by a non-specific effect of the reagent only. Taken together, rosiglitazone did not 
significantly alter PMN survival at high reagent concentrations in respect to constitutive 
apoptosis. This is consistent with the findings of Ward et al. (2002), who were unable to alter 
apoptosis even with high PPARγ agonist concentrations. 
To further define the role of PPARγ in PMN survival, the irreversible, selective PPARγ 
antagonist GW 9662 was employed. GW 9662 alone did not significantly increase PMN 
apoptosis, indicating that PPARγ is not constitutively expressed, or its signalling not 
constitutively active. However, GW 9662 blocked PGE2 induced survival at 100 nM agonist 
concentration, indicating that PPARγ might have a small pro-survival role in PGE2-induced 
survival. However, PGE2 survival at concentrations higher than 0.1 μM was not significantly 
decreased by GW 9662 treatment, suggesting that the antagonist might be displaced from the 
PPARγ receptor. 
However, Lea et al. (2014) were unable to show the expression of PPARγ in human lung 
sputum neutrophils, questioning the relevance of the data obtained with the pharmaceuticals 
used to target PPARγ activity in this study. Nevertheless, PPARγ expression might be regulated 
through the induction of pro-survival gene expression, or in a temporal manner. 
Therefore, a distinct approach was used to determine the specific involvement of the PPARγ 
receptor with the 15-PGDH inhibitor dmPGE2. The PGE2 analogue decreased apoptosis to a 
similar extent as PGE2 at 10 μM (Fig. 12A); however, its efficiency at the lowest concentration 
range tested was significantly reduced, resulting in a right shift in comparison to the PGE2 
survival curve. It is well-known that the extent of dmPGE2 efficiency in comparison to PGE2 
varies in distinct cell types (Coleman et al., 1987; Eglen, Whiting, 1988), potentially dependent 
on the constitutive activity of PGDH metabolism in the corresponding cell type. 
However, the lower efficiency of dmPGE2 at low concentrations may also be attributable to the 
differences in receptor affinities between dmPGE2 and PGE2. dmPGE2 agonizes EP2 and EP3 
receptors at a comparable scale as PGE2 (Table 5), but possesses a lower affinity to EP4 and  
FP receptors, and does not target the EP1 receptor subtype. Judging by its lack of affinity 
towards the EP4 subtype at very low concentrations (Ki 43 nM); whereas PGE2 has a Ki of  
1.9 nM towards EP4 receptors, it is likely that its low efficiency may be grounded in the 
involvement of the EP4 receptor subtype in PMN survival. This hypothesis was further 
examined in chapter 3.1.2. 
Interestingly, dmPGE2 significantly sustained survival at early and late timepoints by roughly 
10 % (Fig. 12B), whereas PGE2 had lost its efficiency at the 20 hours timepoint, suggesting that 
the temporally short lived effects of PGE2 on PMN survival are indeed dependent on protein 
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degradation by 15-PGDH. Likewise, the low difference between both agonists at 4 hours 
indicate that protein degradation induced by 15-PGDH, and thus the agonism of PPARγ, is 
unlikely to affect assays on PMN survival at this timepoint. The low efficiency of dmPGE2 at 
the sustenance of PMN survival is not surprising, not only as the constitutive activity of PGDH 
in the culture medium is unknown, but as their effect on survival might also be limited by the 
cellular uptake of PGE2 (Nomura et al., 2004).  
3.3.1.5. Uptake of PGE2 into the perinuclear space. 
The physiological regulation of exogenous PGE2 levels is achieved by several mechanisms 
additional to PGE2 degradation. A prostaglandin transporter (PGT) mediating the cellular 
uptake of cell surface PGE2 has been reported (Kanai et al., 1995). Thus, PGT is able to 
regulate PGE2 bioavailability and potentially increases PGE2 concentrations in the perinuclear 
space (Spencer et al., 1998). PGE2 uptake would allow for the (partial) intracellular degradation 
of PGE2, accompanied with a loss of efficiency at the induction of PMN survival. This might 
help to explain the low efficiency of both PGE2 and dmPGE2 in PMN survival (Fig. 12A). 
PGE2 uptake, combined with degradation by 15-PGDH might therefore explain the efficiency 
of dmPGE2 at late timepoints only. As PGE2 uptake is thought to be a slow and energy-
consuming process, this will be most relevant for late timepoints in PMN survival.  
Decreased availability of PGE2 at the cell surface might thereby control PGE2 signalling. 
However, perinuclear localisation of functional EP receptors has also been reported 
(Bhattacharya et al., 1999; Konger et al., 2005), and will be discussed in more detail the next 
subchapters. 
In conclusion, the influences of the solvent DMSO and the serum used in this study are thought 
to be negligible. The activity of the enzymes CBR and 15-PGDH is likely to be reduced, but 
residual activity may induce PGE2 protein degradation to PGF2α and 15-keto PGE2. PGF2α 
and FP receptor engagement had a dual role on PMN survival, with pro-apoptotic effects in the 
nanomolar concentration range. Therefore, the pro-apoptotic effect of the FP receptors at low 
agonist concentrations may mask PGE2 induced survival, resulting in a lower efficacy of the 
reagent on PMN survival. On the other hand, engagement of PPARγ may have pro-survival 
roles, but its effects may be more relevant for the sustenance of late prostaglandin signalling. 
Therefore, it was postulated that PGE2 mediates PMN survival in a potentially biphasic manner 
through the involvement of distinct PGE2 receptor subsets, which will be further discussed in 
the next subchapter. 
3.3.2. EP2 Phenotype in the induction of PGE2 survival in PMN 
A molecular mechanism for biphasic effects of PGE2 was proposed as early as 1979 by Kather 
& Simon in human fat cells, who demonstrated that 0.1 – 10 nM PGE2 inhibited AC-mediated 
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cAMP release, whereas the cAMP release drastically increased for concentrations of  
10 nM – 1000 μM. This correlates well with the reported Ki values for low- and high-affinity 
prostaglandin receptors at different concentrations and their cellular functions. Therefore, the 
specific involvement of the distinct PGE2 receptor subtypes was examined, to determine 
whether the inhibitory effect on PGE2 survival might be caused by the engagement of a distinct 
PGE2 receptor subtype. 
Constitutive expression of EP2 and EP4, but not EP1 or EP3 was found (Fig. 13), with 
predominant expression of the EP4 receptor subtype. Agonists of EP2, EP3 and EP4 induced 
significant reductions in PMN apoptosis (Fig. 14). Antagonism of EP2 (Fig. 16) and EP4 
receptors (Fig. 17) blocked PGE2-induced survival, with a rank order of potency EP2>EP4. 
Similarly, antagonism of both EP2 and EP4 blocked PMN survival that was not significantly 
different from antagonism of EP2 alone (Fig. 18). 
3.3.2.1. Basal Prostaglandin Receptor Expression in PMN. 
RT-PCR analysis detected mRNA expression for EP2 and EP4 receptors (Fig. 13A, B). 
Consistently, basal expression of EP2 and EP4 mRNA was found in murine peritoneal 
neutrophils (Yamane et al., 2000) and murine RAW 264.7 macrophages (Arakawa et al., 1996; 
Hubbard et al., 2001), J774.1 macrophages (Katsuyama et al., 1998), and EP4 expression only 
in murine peritoneal macrophages (Ikegami et al., 2001). Constitutive expression of EP4 mRNA 
was highest, compared to the expression of the other PGE2 receptors in PMN and a low level of 
EP2 expression was detected (Fig. 13A, B). This is consistent with the constitutive expression 
of EP2 and EP4 in RAW 264.7 macrophages (Hubbard et al., 2001). 
In this assay, expression for EP1 and EP3 was not detected, consistent with the lack of RT-PCR 
expression of EP1 and EP3 in murine peritoneal neutrophils (Yamane et al., 2000). In contrast, 
low levels of EP3 were found in RAW 264.7 macrophages (Hubbard et al., 2001). However, 
EP1 and EP3 receptors have been proposed to possess higher protein stability and lower 
receptor turnover rates. Therefore, EP1 and EP3 receptors might be present on the cell surface 
despite lacking mRNA expression. This is consistent with the findings of Yamane et al. (2000), 
who detected EP1 and EP3 on the protein level, but not expressed as mRNA. Consequently, the 
functional relevance of EP2 and EP4 mRNA expression was likewise confirmed by western 
blotting (Fig. 24). 
3.3.2.2. Influence of Prostaglandin Receptor Agonism on PMN Survival. 
Selective agonists for the PGE2 receptors EP1, EP2, EP3 and EP4 were used to determine 
which PGE2 receptor subtype mediated PGE2 effects on PMN survival. The concentration 
ranges of the selective agonists correspond to the range of PGE2 concentrations where 
significant differences on PMN survival were previously detected (Fig. 7A). Notably, all 
agonists possess comparable or lower affinity towards their respective receptors than PGE2 
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(Table 6). The EP1 agonist 17-phenyl trinor PGE2 induced only a very low level of apoptosis at 
a concentration of 1 μM (Fig. 14A), which correlates with its inability to specifically distinguish 
between the EP1/EP3 and EP4 receptor subtype, because of its gain in EP4 affinity (Table 6). 
This indicates that either EP1 receptor agonism possesses a lower efficacy in mediating PMN 
survival, or that it is not expressed by human PMN.  
The EP2 agonist butaprost mirrored the PGE2 curve and was equally efficacious in prolonging 
PMN lifespan (Fig. 14B). However, butaprost possesses a more than 9 fold lower affinity 
towards the EP2 receptors than PGE2 (Table 6), indicating that the EP2 receptor subtype 
binding is involved in the transmission of PGE2 survival effects in PMN. 
With the EP3 agonist sulprostone, the initial proportion of the dose-response curve was shifted 
to the left from the PGE2 curve (Fig. 14C). This shift might be in keeping with the 1.4 fold 
higher affinity of the agonist towards the EP3 receptor in comparison to PGE2 (Table 6). This 
suggests an equipotent influence of the agonist on PMN survival with PGE2. A steep increase in 
sulprostone induced PMN survival followed for agonist concentrations above 1 μM, suggesting 
the engagement of an additional receptor subtype by the agonist. In the last part of the curve, 
sulprostone loses its specificity and targets FP receptors at a Ki of 580 nM (Table 6), coinciding 
with the increased levels of apoptosis observed for the respective concentration.  
The EP4 agonist L-902,688 was extremely potent and the tested concentration range was 
insufficient to capture its Ki (Fig. 14D). This was surprising, even when considering the 
approximately 7 fold higher affinity of the compound towards EP4 receptors when compared to 
PGE2. However, L-902,688 displayed a lower maximal efficacy than PGE2 at inducing PMN 
survival. Therefore, the agonist might have acted as a partial agonist on the receptor for 
concentrations below 1 μM, or its influences on PMN survival are limited. In conclusion, this 
finding warrants further investigation. In particular, because EP4 has been shown to be 
internalised and remain functional (Bhattacharya et al., 1999). Thus, PGE2 might mediate 
further effects on survival signalling once it has become imported into the cell. 
A steep increase in PMN apoptosis was observed for agonist concentrations of 3 μM to 10 μM 
for all agonists apart from the EP1 agonist. However, this is unlikely to be a non-specific effect 
of the solvent, as the solvent DMSO previously did not affect the extent of PMN lifespan in the 
concentrations used in this study (Fig. 8). This indicates that high agonist concentrations might 
induce cytotoxic effects, potentially through a loss of specificity towards their respective 
receptor subtype. As previously investigated, this might be mediated by the engagement of the 
FP receptor, as FP agonism was previously shown to induce apoptosis (Fig. 10). 
3.3.2.3. EP2 and EP4 Receptor Antagonism Blocks PGE2 Induced Survival in PMN. 
Due to the poor selectivity of the available receptor agonists, the use of selective receptor 
antagonists is commonly advisable in order to assign a functional role to individual receptors. 
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As previously elaborated, antagonism of EP3 in the context of PMN apoptosis has been 
previously examined elsewhere (Liu et al., 2005; Liu et al., 2007) and no functional role of EP3 
in apoptosis was found. Furthermore, EP3 mRNA was not detected in this current study and 
therefore, antagonism of the EP3 receptor was not examined here.  
The EP2 and EP4 selective antagonists PF-04418948 and GW 627368X were employed to 
confirm the preliminary findings of the agonist studies. Treatment of PMN with either 
antagonist alone, or a combination of both did not affect rates of constitutive PMN apoptosis 
(Fig. 15). However, PGE2 induced PMN survival was significantly delayed by both  
PF-04418948 and GW 627368X (Fig. 16A, B; Fig. 17A, B), as well as a combination of the 
antagonists (Fig. 18A), indicating that both receptors are involved in the mediation of pro-
survival responses to PGE2. For both 300 nM and 1 μM PF-04418948, the PGE2 survival curve 
was shifted to a similar extent, overall inducing a higher level of apoptosis. However, at the 
highest concentration used, PF-04418948 was unable to block PGE2-induced survival, 
potentially suggesting that the agonist might displace the antagonist from the receptor, whereas 
the involvement of an additional PGE2 target at low micromolar concentrations is also a 
possibility.  
The relative potencies of the agonists indicate that the EP2 receptor is the predominant receptor 
in PGE2 induced survival, in particular, when considering the higher constitutive expression of 
EP4 (Fig. 13). Consistently, butaprost-induced survival (3 μM) was significantly blocked by 
PF-04418948, suggesting that EP2 receptors are involved in the induction of PGE2 survival. 
Interestingly, treatment with 0.3 μM GW 627368X more prominently delayed PGE2 induced 
survival at an agonist concentration of 0.1 μM (Fig. 17A). This may suggest that the antagonist 
is displaced from the receptor by excessive PGE2 concentrations. However, a similar trend was 
observed with an increased GW 627368X concentration (1 μM; Fig. 17B). As the high-affinity 
receptor EP4 is preferentially targeted by low PGE2 concentrations, this infers that EP4 is 
involved in the transduction of the survival response at low PGE2 concentrations. Therefore, it 
is likely that high-affinity receptors mediate the actions of low PGE2 concentrations and vice 
versa. This corresponds well with the data in Fig. 12A, where dmPGE2 was less effective than 
PGE2 at low concentrations, and consistently has a significantly lower affinity towards EP4. 
Moreover, dmPGE2 previously displayed a lower efficiency at the induction of PMN survival 
than PGE2 (Fig. 12), which may be explained by its lower affinity towards EP4 receptors 
(Table 5). Consequently, EP2 may therefore predominantly induce PGE2 survival at high PGE2 
concentrations. 
A combination of PF-04418948 and GW 627368X was highly effective at blocking PGE2-
induced survival, where only the highest PGE2 concentration (10 μM) was able to induce 
significant amounts of PMN survival (Fig. 18A). Nevertheless, 10 μM PGE2 was still 
significantly blocked by EP2 and EP4 antagonism. However, there was no significant difference 
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to PGE2-survival blocked with PF-04418948 alone, indicating that the activity of EP2 alone is 
sufficient to induce PGE2 survival. This suggests that EP2, and not EP4 is the main receptor in 
the transduction of early PGE2 survival in PMN, while both may show additive effects on PMN 
survival. 
This suggests that even though both AC-coupled receptors EP2 and EP4 have previously been 
shown to increase intracellular cAMP, this highlights further non-redundant functions of the 
receptors in PMN survival. Interestingly, it was previously shown that PGE2-induced cAMP 
increases were not blocked by EP4 receptor antagonism (Armstrong, Talpain, 1994). However, 
the possibility was not excluded that a loss of EP2 might be partially compensated for by the 
EP4 receptor. Moreover, the detailed investigation of the involvement of the specific receptor 
subtypes involved in PGE2 survival is limited due to the insufficient specificity of the available 
pharmaceuticals. Antagonist specificity was compromised at concentrations that were required 
to prevent PGE2-induced competitive displacement of the receptor antagonists from their 
receptors. However, high PGE2 concentrations were needed to significantly influence PMN 
survival.  
In particular, a further investigation of the role of the EP4 subtype is warranted, because it has 
previously been shown that the EP4, but not EP2 receptors lose their sensitivity upon ligand 
binding (Nishigaki et al. 1996) and become internalised (Bhattacharya et al., 1999; Desai, 
Ashby, 2001). Functional EP3 and EP4 (Bhattacharya et al., 1999), as well as functional EP1 
and EP2 (Konger et al., 2005) have been observed in the perinuclear space. Moreover, PGT-
mediated PGE2 uptake (Kanai et al., 1995) may regulate PGE2 signalling through decreased 
availability of PGE2 in the extracellular matrix (Chi et al., 2014). This might represent an 
autoregulatory mechanism on PGE2 signalling through a negative feedback loop in PGE2 
signalling. However, as PGT-mediated PGE2 uptake and Cox-2 initiated PGE2 expression may 
overall increase intracellular PGE2 levels under certain conditions, this may also indicate that 
functional perinuclear EP4 receptors (Bhattacharya et al., 1999) might still be involved in the 
mediation of late PGE2-induced survival. Unfortunately, the permeability of the agonists and 
antagonists, and their potential interaction with intracellular (PGT-imported or LPS/Cox2 
derived) PGE2 signalling, are unknown. Therefore, the influence of PGE2 and/or PMN 
activation in this scenario on the regulation of EP receptor expression was examined.  
3.3.3. LPS induces EP2 and EP4 receptor expression and enhances late PGE2 
survival. 
In COPD, the presence of the pro-survival mediator PGE2 is increased (Ottonello et al., 1998; 
Montuschi et al., 2003; Dick et al., 2009; Profita et al., 2010), as is PMN survival (Perng et al., 
2004). LPS is a well-known inducer of COPD (Kobayashi et al., 2013; Korsgren et al., 2012), 
and it was thus hypothesized that both may cooperate in the induction of PMN survival. 
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EP1 and EP3 receptor mRNA expression could not be induced by treatment with LPS or PGE2 
(Fig. 19). LPS non-significantly induced the expression of both EP2 and EP4, which was 
reduced by PGE2 in a RT-PCR (Fig. 20). This finding was confirmed by qPCR, where LPS 
induced expression of both receptors, blocked by PGE2 treatment (Fig. 21). In PMN from 
COPD patients, the expression of EP2 was already increased after 2 hours of LPS treatment 
(Fig. 22). Comparable amounts of LPS-induced EP4 expression were observed (Fig. 23B); 
however, EP4 expression was non-significantly upregulated in one PMN sample for healthy 
controls, as well as COPD patients, potentially indicating that upregulation of EP expression is 
not a defining feature of COPD. On the contrary, it may be a typical host-response to previous 
exposure to infections that might lead to upregulation of TLR receptor expression. EP4 
expression was significantly increased by LPS in COPD PMN at 4 hours (Fig. 23C). mRNA 
expression was translated into protein by 20 hours, but not 4 hours of LPS treatment (Fig. 24). 
Late PMN-survival, sustained by LPS was furthermore enhanced by treatment with PGE2 (Fig. 
25). 
3.3.3.1. Regulation of Prostaglandin Receptor Expression by PGE2 and TLR4 Signalling. 
Prostaglandin receptor expression was investigated as described (chapter 3.2.1.). Treatment with 
PGE2 did not significantly regulate EP1, EP2, EP3 and EP4 receptor expression (Fig. 19,  
Fig. 20) by RT-PCR. Interestingly, incubation with PGE2 significantly decreased EP4, but not 
EP2 mRNA expression by qPCR, consistent with the data by Ikegami et al. (2001), who 
proposed that EP4 expression is regulated by PGE2 through a negative feedback loop. 
Similarly, PGE2-mediated EP2 and EP4 downregulation was observed by Nishigaki et al. 
(1996) and Hubbard et al. (2001). Both Hubbard et al. (2001) and Ikegami et al. (2001) found 
that downregulation of EP mRNA was mediated through the activity of PKA in macrophages.  
Here, LPS induced the expression of both EP2 and EP4 mRNA (Fig. 21B, C) and was 
attenuated by PGE2 treatment. This is consistent with Arakawa et al. (1996) and Pavlovic et al. 
(2006), who showed EP2 and EP4 upregulation upon LPS-stimulation in macrophages. LPS 
induced marked EP2 expression, and low levels of EP4 expression in J774.1 (Katsuyama et al., 
1998). EP2 upregulation in RAW 264.7 macrophages was thought to be mediated through the 
engagement of the p38/MAPK pathway (Hubbard et al., 2001). Conversely, EP2 was potently 
induced by LPS treatment, whereas EP4 mRNA was downregulated in murine peritoneal 
macrophages (Ikegami et al., 2001). LPS-induced suppression of EP4 expression was mimicked 
by PKA agonism, thus the LPS-induced decrease in EP4 mRNA was attributed to the action of 
LPS-induced PGE2 expression, which acted as a negative feedback loop (Ikegami et al., 2001). 
This may be consistent with the findings from this study, as macrophages are thought to be the 
main source of LPS-derived PGE2 (Hubbard et al., 2001). Therefore, the lacking presence of 
LPS-induced PGE2 may fail to control prostaglandin expression levels in PMN. Thus, these 
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findings suggest that a functional link between PGE2 and TLR4 signalling exists in the 
regulation of PGE2 induced PMN survival, potentially serving to prime PMN survival and/or 
inflammatory gene expression upon encounter of bacterial LPS. 
3.3.3.2. Regulation of Prostaglandin Receptor Expression by TLR4 Signalling in COPD 
PMN. 
It was investigated, whether LPS treatment can enhance PGE2 induced survival in the context 
of COPD through alterations in PGE2 receptor expression. LPS significantly enhanced EP2 
mRNA expression at 2 hours in COPD PMN (Fig. 22B), where two out of 4 donor samples 
displayed a response (Fig. 22D). This may be consistent with the data by Ikegami et al. (2001), 
where EP2 mRNA was transiently upregulated by LPS, with a maximum biological response at 
3 hours in macrophages. At 4 hours, COPD PMN were slightly more susceptible to PGE2 
induced blocking of LPS-elicited EP2 upregulation (Fig. 22C), potentially through the early 
upregulation of EP2 receptor expression at 2 hours. This may be consistent with the increased 
IL-6 production through the PGE2/EP2 axis (Yamane et al., 2000), and the highly increased 
levels of IL-6 in COPD PMN (Bucchioni et al., 2003). All assays were performed with matched 
COPD and healthy control samples. However, the samples were not age matched, so it may be 
possible that the age of the participants may further contribute to the variability of the data. 
Interestingly, alterations in PKA signalling were previously observed for physiological cues, 
such as nutritional status and age (Pérez-Sieira et al., 2014). 
Interestingly, EP4 expression was not significantly increased in both COPD PMN and healthy 
control PMN at 2 hours (Fig. 23B). Consistently, PGE2 had a lower effect on LPS-induced EP4 
expression at 4 hours (Fig. 23C). EP4 expression was strongly increased by LPS in COPD 
PMN, correlating with the strongly increased levels of TNFα in acute exacerbations in COPD 
(Daldegan et al., 2005). This potentially suggests that COPD patient PMN may be more prone 
to display increased levels of PGE2 induced survival and a difference in the responsiveness to 
the induction of survival by PGE2 induced survival in LPS primed PMN may exist. This 
hypothesis was tested hereafter. 
3.3.3.3. Expression Changes in EP2 and EP4 Receptor mRNA are Translated into Protein 
Expression. 
A potential effect of mRNA upregulation onto functional outcomes for the cell firstly depend on 
the translation of prostaglandin receptor mRNA to protein. EP2 and EP4 protein expression in 
response to LPS was determined by western blotting at 4 hours and 20 hours as described 
(chapter 3.2.2.). At 4 hours, no significant changes in protein expression were observed  
(Fig. 24A, B). In contrast, the expression of EP2 and EP4 was increased at 20 hours, whereby 
only treatment with 10 ng/ml LPS significantly enhanced EP4 levels (Fig. 24C, D). This 
suggests that mRNA for EP2 and EP4 may potentially be translated into protein. However, if a 
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higher increase in EP receptor translation takes place, it may be observed at an intermediate 
timepoint and a further detailed investigation of the temporal regulation of EP2 and EP4 protein 
translation in healthy control and COPD PMN would be required to further substantiate this 
claim. Taken together, there is insufficient evidence to support a functional role of LPS in the 
regulation of the PGE2 survival response through EP receptor upregulation. 
3.3.3.4. Functional Consequences of LPS-mediated EP2 and EP4 Receptor Upregulation. 
To determine the functional relevance of EP receptor upregulation on PMN survival, PMN were 
pretreated with or without LPS for 20 hours, and then exposed to PGE2 for 4 hours. As 
previously observed (Fig. 12B), PGE2 had lost its effect on PMN survival at 20 hours  
(Fig. 25A). As EP2 and EP4 receptor expression was observed by western blotting, this effect 
may be linked to EP receptor desensitisation, and/ or internalisation. However, as untreated 
PMN are highly apoptotic at 20 hours, the general responsiveness to PKA activation may be 
reduced. Interestingly, pretreatment with LPS for 20 hours increased general PMN survival at 
24 hours, and significantly increased the response to late PGE2 treatment (Fig. 25B, C). This 
effect may be a functional consequence of LPS-enhanced EP receptor expression (Fig. 24C, D), 
and may thus be even greater in COPD PMN, potentially contributing to the neutrophilia 
observed in the condition. However, the possibility cannot be excluded that the overall reduced 
levels of apoptosis in LPS-treated PMN contributes to their increased responsiveness to PGE2, 
but a further investigation may be required to further substantiate this hypothesis. Interestingly, 
Ikegami et al. (2001) proposed a functional switch from EP4 to EP2 in macrophage activation, 
which may induce differential cytokine expression, and exert an altered effect on functional 
responses. As this chapter showed a greater influence of EP2 on PMN survival, this may be 
consistent with Birrell et al. (2015), who conversely observed highly increased neutrophil 
numbers in EP4 KO mice in response to treatment with LPS or cigarette smoke. However not 
on a constitutive level, suggesting that the negative feedback loop exerted by PGE2 signalling is 
required for the maintenance of appropriate cell numbers in inflammation. Moreover, it was 
observed that PGE2 mediated its anti-inflammatory effects in the lung through the activation of 
the EP4 receptor subtype. Moreover, EP2 KO mice decreased neutrophilia. This is in contrast to 
Ikegami et al. (2001), who proposed a functional switch from EP4 to EP2 in macrophage 
activation, whereas EP4 was thought to be dominant in non-activated cells. 
A more detailed investigation of the events involved in LPS-induced survival are required to 
shed light on the potential functional relevance of LPS priming in PMN on PGE2 induced PMN 
survival. Therefore, it was concluded that LPS may interact with PGE2 signalling events in 
PMN by enhancing PGE2 pro-survival receptor expression. However, a further investigation of 
the exact mechanisms of the potential functional relevance of this finding is warranted. 
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3.4. Summary 
It was determined here that PGE2 exerts a possibly biphasic pro-survival effect in PMN, with a 
higher influence at low micromolar concentrations. The high amounts of PGE2 required to 
delay apoptosis were not affected by the influence of DMSO, or protein degradation at 4 hours. 
A potential non-specific targeting of PGE2 at FP receptors was observed and this might mask 
the pro-survival effect of PGE2 in PMN. Moreover, it was concluded that protein binding by 
serum might diminish the amount of free, extracellular PGE2 concentrations. 
The engagement of the EP2 and EP4 receptor subtypes might both contribute to the pro-survival 
effect of PGE2 in PMN, as both are coupled to the stimulation of adenylyl cyclase (AC) and 
thus cAMP production (Sugimoto, Narumiya, 2007). However, the extent of EP2-induced 
survival was by far greater, which supports an EP2 phenotype in the extension of PMN survival. 
EP2 and EP4 receptor expression was induced by LPS treatment, and downregulated 
through PGE2, indicating that a negative feedback loop may regulate PMN survival through 
LPS-induced PGE2 expression. Therefore, these findings propose a mechanism to the finding of 
the Sabroe/Whyte research groups, who observed that LPS-stimulation of neutrophils only 
transiently increased their survival via TLR4 and NF-κB activation. However, factors released 
by monocytes further prolonged neutrophil survival after the neutrophil TLR4 receptors lost 
responsiveness to LPS stimulation (Sabroe et al., 2002a), which was attributed to factors 
secreted by macrophages. Here, it is proposed that LPS modulates prostaglandin receptor 
expression in PMN, and may PKA-dependently extend PMN survival through enhanced Cox2-
derived PGE2 secretion in macrophages. 
Moreover, this is the first study to show that COPD PMN are hyperresponsive to LPS-induced 
EP2 mRNA expression at 2 hours, and to EP4 mRNA expression at 4 hours in PMN. EP2 and 
EP4 protein expression was induced by a low extent at a late timepoint by LPS, and this 
coincided with increased responsiveness to PGE2 induced survival in PMN. 
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CHAPTER 4. PKA IS A PRINCIPAL MEDIATOR OF PGE2 
INDUCED PMN SURVIVAL. 
PKA signalling is invariably linked to PMN survival. The first comprehensive study to show the 
importance of raising cAMP to prolong PMN survival was by Rossi et al. (1995), where the 
cAMP analogue dbcAMP and the adenylate cyclase inhibitor forskolin potently inhibited PMN 
apoptosis at a late timepoint. Ottonello et al. (1998) added to this by demonstrating the PKA-
dependence of the cAMP elevating agent PGE2 and likewise of an inhibitor of cAMP 
degradation (i.e. PDE4). 
In inflammation, neutrophil survival can be prolonged through the exposure to cAMP-elevating 
agents, such as extracellular ATP, acting through P2Y11 receptors (Vaughan et al., 2007). 
Inhibition of PKA-mediated survival of PMN in inflammation is thought to be an attractive 
strategy to achieve resolution of inflammation. PKA signalling is involved in many cellular 
functions and signalling pathways, including the regulation of lipid metabolism, epinephrine, 
glucagon, dopamine, and adrenergic signalling. However, the mechanisms involved in the 
transduction of the cAMP signal in PMN survival are less well characterised. In chapter 3, the 
particular involvement of the EP2 receptor subtype in PMN survival was found. EP2 is thought 
to increase intracellular cAMP levels, which is a strong activator of PKA in PMN, leading to the 
inhibition of apoptosis (Krakstad et al 2004). Hence, this chapter aims to elucidate the molecular 
mechanism of PGE2 mediated PMN survival and to investigate the role of the putative PKA 
secondary effectors nuclear receptor subfamily 4, group A, members 2 and 3 (NR4A2, NR4A3) 
to understand the molecular mechanisms in PGE2-induced survival in PMN, which may 
potentially contribute to the development of novel therapeutic strategies to combat neutrophilia 
in inflammatory diseases, such as COPD.  
4.1. Limitations and Opportunities in the Exploration of PKA Signalling. 
The investigation of PGE2-mediated survival signalling is hindered due to several reasons. In 
particular, the inability to differentiate between non-specific toxicity and targeted effects on 
survival signalling, the lack of specificity of pharmaceutical modulators at increasing reagent 
concentrations, influences of residual cell impurities in the cell preparation, and potential 
autocrine signalling that alters constitutive survival, are all able to mask the effect of specific 
inflammatory mediators with effects accumulating in the same readout. 
Here, it was aimed to substantiate the central role of PKA in cAMP mediated survival by using 
selective agonists and antagonists and to determine the paracrine and autocrine influences on 
PMN survival. 
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4.1.1. PKA: Constitutive PMN Survival is Mediated by PKA. 
Physiological stimulation of PKA is mainly achieved through the regulation of the second 
messenger cAMP, although different strategies can be employed to raise intracellular cAMP for 
PKA activation in vitro (Fig. 26). Firstly, this can be achieved by activation of adenylyl cyclase 
(AC), which synthesises cAMP from ATP (Taussig, Gillman, 1995; Scott, Mercer, 1995) and 
thus relies on the presence of intracellular ATP stocks. Secondly, cAMP levels can be raised by 
inhibiting its metabolism to 5’ AMP, mediated by Phosphodiesterases (PDE; Scott, Mercer, 
1995). However, since the discovery of the exchange protein directly activated by cAMP (Epac; 
Rooij et al., 1998), reagents that mediate non-specific elevations of cAMP can no longer be 
regarded as specific PKA activators. Thus, in addition to exploring the effect of constitutive 
PDE4 inhibition by using the PDE4 inhibitor rolipram, the PKA selective agonist dbcAMP, and 
the site-selective PKA agonists N6-MB-cAMP and 8-AHA-cAMP were used to explore PKA-
dependent survival in PMN. 
4.1.1.1. Influence of PDE4 Inhibition on PMN Survival. 
To evaluate the effect of constitutive PDE4 inhibition, ultrapure PMN were incubated with 
0.001 – 10 μM of the PDE4 inhibitor rolipram. Rolipram did not significantly alter PMN 
survival at any of the concentrations tested (Fig. 27). However, at the two highest 
concentrations tested, there was a modest, non-significant decrease in PMN apoptosis. 
4.1.1.2. Influence of PKA Agonism on PMN Survival. 
cAMP analogues are often employed in scientific research to mimic physiological cAMP 
responses in cAMP responsive cell lines and probe for the relevance of PKA signalling for the 
functional output; here: PMN survival. PMN were incubated with 50 μM and/or 100 μM of the 
well-established, membrane-permeable cAMP analogue dbcAMP (Fig. 28A) for 4 and 20 hours. 
dbcAMP significantly delayed PMN apoptosis at both timepoints (Fig. 28B, C). However, the 
highest level of PMN apoptosis inhibition achieved with 100 μM dbcAMP was merely 7.6 %  
(± 7.4 SEM) at 4 hours and 13.1 % (± 5.6 SEM) at 20 hours. To account for secondary effects 
induced by the degradation of dbcAMP to BTA through esterases in the cell culture serum  
(Fig. 26), the use of metabolically stable PKA agonists is required to substantiate the effect of 
cAMP-mediated PMN survival. 
The site-selective PKA agonist pair N6-MB-cAMP (Fig. 29A) and 8-AHA-cAMP (Fig. 29B) 
with affinity for site A (PKAR1A) and site B (PRKAR1B) of PKA type I (Table 7), 
respectively prolonged PMN survival in a dose and time dependent manner, reaching statistical 
significance at 6 hours (50 μM; Fig. 29C, D). In comparison to dbcAMP, treatment with 100 
μM N6/8-AHA reduced PMN apoptosis by 22.2 % (± 3.1 SEM) at 6 hours and 36.7 %  
(± 3.3 SEM) at 20 hours.  
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Figure 26: Diversity in the Activation of PKA Signalling. The release of the activated catalytic 
subunits from the PKA holoenzyme is achieved by the binding of two cAMP molecules to the A 
and B site of both regulatory subunits. Intracellualr cAMP stocks are replenished by the 
adenylyl cyclase (AC)-mediated conversion of ATP to cAMP. cAMP is degraded to the inactive 
compound 5’ AMP by the Rolipram-inhibitable Phosphodiesterase 4 (PDE4). The activity of 
AC can be engaged by the activation of various receptors: the ATP-receptor P2Y11, the 
Adenosine-receptor A2A, the PGE2 receptors EP2 and EP4. dbcAMP can be degraded in the 
culture medium to the side-product butyrate and cAMP, which can be imported into the cell. 
Butyrate is implicated in apoptosis signalling and neutrophil activation through the action of 
GPR43. Abbreviations: C – PKA catalytic subunit; RI – PKA regulatory subunit I; 8-AHA – 8-
AHA-cAMP; Rp-8 – Rp-8-Br-cAMPS; N6 – N6-AHA-cAMP; AC – adenylyl cyclase; Ado – 
Adenosine; P2Y – P2Y11 receptor; GPR43 – G-protein coupled receptor 43. 
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Table 7: Affinity (Ki) of PKA Agonists and Antagonists for PKA Subunits. 
Ligands Regulatory Type I Regulatory Type II References 
 Α 
(PRKAR1A) 
Β 
(PRKAR1B) 
Α 
(PRKAR2A) 
Β 
(PRKAR2B) 
 
cAMP High (Ki 
N/K) 
High (Ki 
N/K) 
Low (Ki 
N/K) 
Low (Ki 
N/K) 
Pink, 
Dell’Acqua, 
2003 
N6-MB-
cAMP 
(relative to 
cAMP) 
3.60 0.093 0.74 0.041 Christensen 
et al., 2003 
8-AHA-
cAMP 
(relative to 
cAMP) 
0.055 4.1 0.010 0.39 Christensen 
et al., 2003 
8-Br-cAMP >10000 N/K >10000 426 ± 63 Griffin et al., 
1999 
Rp-cAMPS 0.0013 0.0028 0.0021 0.022 Christensen 
et al., 2003 
Rp-8-Br-
cAMPS 
0.0008 0.00071 0.00048 0.094 Christensen 
et al., 2003 
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Figure 27: PDE4 inhibitor Rolipram does not Significantly Affect PMN Survival. PMN were 
separated from whole blood through Percoll density gradient centrifugation and negative 
magnetic selection. Following isolation, PMN were cultured at 1.67 × 10
6
/ml in RPMI and 10% 
FCS with increasing concentrations of the PDE4 inhibitor rolipram (0.001 – 10 μM). Rolipram 
did not significantly influence PMN apoptosis at 4 hours. Data shown are mean ± SEM of 3 
independent experiments with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Cellular morphology was assessed by light microscopy. Statistical analysis was 
performed through One Way RM ANOVA with Sidak’s posttest. Results were considered to be 
not statistically significant for p>0.05. 
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Figure 28: cAMP Analogue dbcAMP Prolongs PMN Survival Concentration and Time 
Dependently. PMN were separated from whole blood through Percoll density gradient 
centrifugation and negative magnetic selection. Following isolation, PMN were cultured at 1.67 
× 10
6
/ml in RPMI and 10% FCS. White bars are control conditions, while blue bars indicate 
incubation in the presence of 50 μM of the cell permeable cAMP analogue dbcAMP. Apoptosis 
was quantified by light microscopy of Wright/Giemsa stained cells. dbcAMP (Panel A) 
significantly delayed PMN survival in a dose dependent manner at 20 hours post-purification 
(Panel B) and time dependently with 50 μM dbcAMP (Panel C). Data shown are mean ± SEM 
of 3 independent experiments with cells isolated from distinct healthy volunteers, as described 
in chapter 2.5. Cellular morphology was assessed by light microscopy. Statistical analysis was 
performed through One Way RM ANOVA with Sidak’s posttest (Panel B) or Two Way RM 
ANOVA with Sidak’s posttest (Panel C). Asterisks (*) indicate differences to control 
conditions. Results were considered to be statistically significant for p<0.05 (*) and p<0.01 
(**).  
A 
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Figure 29: Selective PKA Type I Activation Enhances PMN Survival in a Concentration and 
Time Dependent Manner. PMN were separated from whole blood through Percoll density 
gradient centrifugation. Following isolation, PMN were cultured at 1.67 × 10
6
/ml in RPMI and 
10% FCS. White bars are control conditions, while blue bars indicate incubation in the presence 
of 50 μM or 100 μM of the PKA Type I site selective agonist pair N6-MB-cAMP and 8-AHA-
cAMP. Apoptosis was quantified by light microscopy of Wright/Giemsa stained cells. cAMP 
analogues N6-MB-cAMP (Panel A) and 8-AHA-cAMP (Panel B) significantly delayed PMN 
survival in a dose dependent manner at 20 hours post-purification (Panel C) and time 
dependently with 50 μM N6/8-AHA (Panel D). Data shown are mean ± SEM of 4 independent 
experiments with cells isolated from distinct healthy volunteers, as described in chapter  
2.5. Cellular morphology was assessed by light microscopy. Statistical analysis was performed 
through One Way ANOVA with Dunnet’s posttest (Panel C) or Two Way RM ANOVA with 
Bonferroni’s posttest (Panel D). Asterisks (*) indicate differences to control conditions. Results 
were considered to be statistically significant for p<0.05 (*), p<0.001 (***) and p<0.0001 
(****). 
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4.1.1.3. Influence of PKA Antagonism on PMN Survival. 
The PKA inhibitor Rp-8-Br-cAMPS (Fig. 30A) prevents the activation of the enzyme by 
blocking cAMP binding sites. Highly pure PMN were incubated for 4 hours in the presence or 
absence of Rp-8-Br-cAMPS. It was found here that 0.7 mM Rp-8-Br-cAMPS increased 
constitutive PMN apoptosis by 12.8 % (± 2.7 SEM.) at 4 hours (Fig. 30B). The efficacy of Rp-
8-Br-cAMPS was significantly greater in a proportion of assays, with a cut-off line at > 10 % 
mean difference between apoptosis in presence and absence of Rp-8-Br-cAMPS. In half of the 
assays, Rp-8-Br-cAMPS had a low efficacy and induced a mean percentage apoptosis increase 
of only 4.6 % apoptosis (± 1.2 SEM). In contrast, Rp-8-Br-cAMPS increased apoptosis with a 
high efficacy by a mean of 22.2 % (± 2.6 SEM; Fig. 30C) in the other moiety. This difference 
was not correlated with the level of constitutive apoptosis in PMN or the origin of the donation 
(data not shown). In summary, these data indicate that a low constitutive level of PKA 
signalling may be active in PMN. 
4.1.2. Paracrine and Autocrine Regulation of PMN Survival. 
Previously, low levels of PBMC were shown to prolong PMN survival (Sabroe et al., 2003). 
Additionally, macrophages were shown to be a potent source of PGE2, reaching a constant level 
that is maintained at approximately 90 ng/10
6
 cells (Sergeeva et al., 1997). To investigate 
whether the observed donor-independent fluctuations in constitutive PKA dependence might be 
accounted for by variability in the culture conditions, such as the varying presence of residual 
PBMC in the preparation, or autocrine PMN secretions, it was investigated, whether these 
factors could protect PMN from apoptosis through the action of PKA.  
Previously, it was shown that culturing PMN at higher densities or total cell numbers 
significantly lowered apoptosis rates (Hannah et al., 1998), independent of cell adhesion (i.e. 
β2-Integrin receptors) and cell-matrix interactions. This sort of variation might be introduced 
due to small changes in the PMN concentration. 
4.1.2.1. Influence of Paracrine and Autocrine Signalling on PMN Survival. 
Therefore, highly pure PMN were incubated with or without 2 % PBMC for 4 hours and the 
effect on PKA-dependent PMN survival was examined by the addition of 0.7 mM Rp-8-Br-
cAMPS. The presence of PBMC alone led to a low, non-significant increase in PMN survival 
(Fig. 31A). However, the high increase in PMN apoptosis induced by 0.7 mM Rp-8-Br-cAMPS 
in ultrapure PMN was significantly reduced in presence of 2% PBMC. 
Thereafter, the influence of a putative autocrine signal was examined, which might be altered by 
fluctuations in cell culture density. In a supernatant transfer assay, PMN were stimulated with or 
without dbcAMP for 1 hour, and supernatants were collected, as described in chapter 2. PMN 
from the same donor were thereafter treated with media or PMN supernatant and  
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Figure 30: Competitive Inhibition of PKA Type I by Rp-8-Br-cAMPs Accelerates Constitutive 
PMN Survival. PMN were separated from whole blood through Percoll density gradient 
centrifugation and negative magnetic selection. Following isolation, PMN were cultured at 1.67 
× 10
6
/ml in RPMI and 10% FCS. Incubation in presence of 0.7 mM of the PKA Type I site 
selective antagonist Rp-8-Br-cAMPS (red squares) significantly increased PMN apoptosis at 4 
hours post-purification (Panel A). In a proportion of experiments, a significantly higher 
responsiveness to PKA-inhibition by Rp-8-Br-cAMPS was observed in comparison to low 
responsive assays (Panel C). Data shown are individual datapoints and means ± SEM pooled 
from 16 independent experiments, as described in chapter 2.5. morphology was assessed by 
light microscopy. Statistical analysis was performed through a paired t-test. Asterisks (*) 
indicate differences to the control condition, whereas octothorpes (#) denote differences 
between low and high responsiveness to Rp-8-Br-cAMPS treatment. Results were considered to 
be statistically significant for p<0.001 (***) and p<0.0001 (####).  
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Figure 31: Paracrine and Autocrine Regulation of Basal PKA Survival in PMN. Ultrapure 
PMN with (Panel A) or without (Panel B) addition of 2 % PBMC were cultured for 4 hours in 
presence (Panel A) or absence (Panel A, B) of the competitive PKA Type I inhibitor Rp-8-Br-
cAMPS (0.7 mM). For the PMN supernatant assay (Panel B), complete media was incubated for 
1 hour in presence or absence of PMN, until supernatants were collected. PMN from the same 
donor were cultured with supernatants (1:3) for 3 hours (Panel B) in presence or absence of 
dbcAMP (50 μM). Basal PKA dependent PMN survival is largely independent of PBMC 
presence (Panel A). PMN supernatant treatment prolonged basal PKA survival through an 
autocrine stimulus (Panel B). Data shown are mean ± SEM of 4 independent experiments with 
cells isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular morphology 
was assessed by light microscopy. Statistical analysis was performed through Two Way RM 
ANOVA with Sidak’s posttest. Asterisks (*) denote significant differences to untreated 
conditions and octothorpes (#) indicate differences in Rp-8-Br-cAMPS-induced apoptosis in 
presence and absence of PBMC. Results were considered to be statistically significant for 
p<0.05 (*/#).  
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maintained in culture for a further 3 hours. Supernatant treatment significantly reduced PMN 
apoptosis by close to 50 % (Fig. 31B). Interestingly, supernatant reduced apoptosis to a similar 
extent as media, or supernatant with 50 μM dbcAMP, whereas there was no significant 
difference to supernatant treated PMN in presence of dbcAMP.  
4.1.2.2. Regulation of Constitutive PMN Survival by Adenosine. 
Adenosine is a well-known modulator of constitutive PMN survival (Yasui, et al., 2000), and 
metabolic products of adenosine previously delayed PMN apoptosis via A2A/PKA (Pliyev et 
al., 2014). To pursue the possibility that autocrine adenosine might enhance constitutive 
survival, the influence of adenosine and A2A receptors on PMN survival was examined. Highly 
pure PMN were incubated with increasing amounts of adenosine (0.1 -10 μM) for 4 hours. 
Adenosine significantly prolonged constitutive survival in a dose response curve at 1 μM and  
10 μM (Fig. 32A).  
Moreover, highly pure PMN were pretreated with or without the A2A receptor antagonist ZM 
241385 (1 μM), or the PKA antagonist Rp-8-Br-cAMPS (0.7 mM). PMN survival induced by 
10 μM adenosine was partially inhibited by A2A receptor antagonism by ZM 241385  
(Fig. 33A) and completely abolished by PKA inhibition with Rp-8-Br-cAMPS (Fig. 32B).  
When constitutive PMN survival was targeted by incubation with ZM 241385 alone, 
ZM 241385 dose-dependently accelerated PMN apoptosis (Fig. 33B). Addition of Rp-8-Br-
cAMPS significantly increased constitutive survival, but did not have additional effects on rates 
of apoptosis when compared with ZM 241385 alone (Fig. 33C).  
4.2. The Mechanisms of PGE2 Signalling in the Context of Inflammation. 
Having established the importance of the prostaglandin receptor EP2 in PGE2 mediated PMN 
survival in chapter 3, it was queried, whether PGE2 induced survival via EP2 is PKA 
dependent. It was hypothesised that stimulation of EP2 by PGE2 affects PMN survival through 
cAMP/PKA signalling, as the EP2 receptor is coupled to stimulation of AC. Pretreatment with 
LPS previously reduced PGE2 induced cAMP elevation by 50 % (Okonogi et al., 1991). 
Therefore, the effect of LPS presence on PKA mediated PMN survival and the influence of 
PBMC contamination in this setting was determined. 
In a neutrophil microarray performed by the Sabroe/Whyte group, PKA activation by the 
selective PKA agonist pair N6/8-AHA, but not stimulation with LPS, caused a marked 
upregulation of the mRNA coding for the transcription factors NR4A2 and NR4A3 
(unpublished data). NR4A receptors contribute to the regulation of survival in many cell types, 
and in fact, PGE2 was previously shown to induce NR4A gene expression through CREB 
(Holla et al., 2006). However, the role of NR4A nuclear receptors in the regulation of PMN  
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Figure 32: Adenosine Induced PMN Survival is Reversed by Rp8-Br-cAMPS and Partially 
Inhibited by A2A Receptor Inhibition. PMN were separated from whole blood through Percoll 
density gradient centrifugation and negative magnetic selection. Following isolation, PMN were 
cultured at 1.67 × 10
6
/ml in RPMI and 10% FCS. Ultrapure PMN were pretreated for 15 
minutes with either 1 μM of the A2A antagonist Zm 241385 or 0.7 mM of the PKA antagonist 
Rp8-Br-cAMPS (Panel B) and subsequently incubated for 4 hours in presence or absence of 10 
μM adenosine (Panels A, B). White bars are control conditions, while black bars indicate 
incubation in the presence of 10 μM of adenosine (Panel B). Adenosine significantly delayed 
PMN apoptosis (Panels A, B), which was reversed by treatment with the PKA inhibitor Rp-8-
Br-cAMPS and attenuated by the A2A antagonist Zm241385 (Panel B). Data shown are mean ± 
SEM of 3 (Panel B), or 4 (Panel A) independent experiments with cells isolated from distinct 
healthy volunteers, as described in chapter 2.5. Cellular morphology was assessed by light 
microscopy. Statistical analysis was performed through One Way RM ANOVA with Dunnet’s 
posttest (Panel A) or Two Way RM ANOVA with Sidak’s posttest (Panel B). Asterisks (*) 
indicate differences to control conditions, while octothorpes (#) denote differences in apoptosis 
between control and adenosine treated conditions. Results were considered to be statistically 
significant for p<0.05 (*) and p<0.01 (**/##).  
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Figure 33: Basal Autocrine Signalling is Governed by Adenosine Signalling in PMN. 
Ultrapure PMN were cultured for 4 hours in presence (Panel C) or absence (Panel B) of the 
competitive PKA Type I inhibitor Rp-8-Br-cAMPS (0.7 mM) and with or without 0.1 - 10 μM 
of the A2A receptor antagonist ZM241385 (Panels A-C). Treatment with ZM241385 
accelerated constitutive PMN apoptosis concentration dependently (Panel B, C). ZM 241385 
abrogated basal PKA dependence to a similar magnitude as Rp-8-Br-cAMPS (Panel C). Data 
shown are mean ± SEM of 3 independent experiments (Panel B) or 4 independent experiments 
(Panel C) with cells isolated from distinct healthy volunteers, as described in chapter 2.5. 
Cellular morphology was assessed by light microscopy. Statistical analysis was performed 
through One Way RM ANOVA with Dunnet’s posttest (Panel B) or Two Way RM ANOVA 
with Sidak’s posttest (Panel C). * denote significant differences to untreated conditions. Results 
were considered to be statistically significant for p<0.05 (*).  
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survival has not yet been determined, and thus the working hypothesis was here that PGE2/EP2 
signalling induces PMN survival through the involvement of NR4A2 and NR4A3. 
4.2.1. Regulation of PGE2 Survival through an EP2/PKA Signalling Axis.  
To further substantiate the role of PKA in PGE2 survival, the influence of the PDE4 inhibitor 
rolipram in combination with PGE2 was investigated. For this end, highly purified PMN were 
incubated in presence or absence of 1 - 10 μM PGE2, with or without addition of 50 - 100 nM 
rolipram for 4 hours. Constitutive PMN survival was not significantly enhanced by PDE4 
treatment in this assay (Fig. 34A). In the presence of PGE2, rolipram potentially decreased 
PMN apoptosis by a small, but non-significant extent, comparable to its influence on 
constitutive PMN apoptosis. 
In an additional assay, highly purified PMN were incubated in the presence or absence of 1 μM 
PGE2, with or without addition of 100 nM rolipram for 4 – 20 hours to identify late effects of 
PDE4 activity. As before (Fig. 34A), addition of rolipram did not have a significant effect on 
constitutive PMN survival. However, while survival induced by 1 μM PGE2 was not significant 
in this assay, addition of 100 nM rolipram shifted the non-significant survival for PGE2 to a 
significant level (Fig. 34B). At 20 hours, the effect of PGE2 and rolipram on PMN apoptosis 
was lost.  
Constitutive PKA signalling was active to a low degree in most PMN preparations, whereas 
PKA inhibition had a higher effect on PMN apoptosis in some assays (Fig. 30). PKA is known 
to play a role in PGE2 signalling and it was investigated whether PGE2-mediated survival is 
reversible by the PKA inhibitor Rp-8-Br-cAMPS. Highly pure PMN were simultaneously 
treated with increasing concentrations of PGE2 and the PKA antagonist Rp-8-Br-cAMPS to 
determine the level of PKA dependent PGE2 survival. In this set of experiments,  
10 nM – 10 μM PGE2 induced PMN survival at 4 hours (Fig. 35A, C). Rp-8-Br-cAMPS  
[0.7 mM] increased constitutive apoptosis (Fig. 35A) and furthermore entirely blocked PMN 
survival induced by 10 nM PGE2, reaching statistical significance at concentrations of 100 nM 
to 10 μM (Fig. 35A, C).  
Thereafter, it was aimed to verify the hypothesis of chapter 3; supporting a PKA-dependent EP2 
phenotype in PGE2 induced PMN survival. Accordingly, highly pure PMN were treated with 
100 nM and 1 μM of the EP2 agonist butaprost, with or without addition of 0.7 mM of the PKA 
antagonist Rp-8-Br-cAMPS. Butaprost alone induced PMN survival at 1 μM (Fig. 35B, D).  
Rp-8-Br-cAMPS not only increased constitutive apoptosis (Fig. 35B), but also significantly 
blocked butaprost-induced survival (Fig. 35D). 
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Figure 34: PMN Survival by High Concentrations of PGE2 is Enhanced by 
Phosphodiesterase Inhibition. Percoll purified PMN were further refined by negative magnetic 
selection with a custom antibody cocktail (purity > 97 %). Ultrapure PMN were preincubated 
for 15 minutes in presence or absence of 50 (Panel A), or 100 nM (Panel B) of the PDE4 
inhibitor rolipram before incubation of 1 – 10 μM PGE2 for 4 (Panel A) or 20 hours (Panel B). 
PGE2 treatment non-significantly decreased PMN apoptosis at 4 hours (Panels A, B). In 
presence of 1 μM PGE2, rolipram significantly extended PMN survival at 4 hours (Panel B). 
Statistical analysis was performed through Two Way ANOVA with Sidak’s posttests. Data 
shown are mean ± SEM of 3 (Panel B) or 4 (Panel A) independent experiments with cells 
isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular morphology was 
assessed by light microscopy. Asterisks (*) indicate differences to the control condition. Results 
were considered to be statistically significant for p<0.05 (*/#). 
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Figure 35: EP2 Receptor Agonist Butaprost Induces Rp8-Br-cAMPs Reversible PMN 
Survival. Percoll purified PMN were further refined by negative magnetic selection with a 
custom antibody cocktail (purity > 97 %). Ultrapure PMN were preincubated for 15 minutes in 
presence or absence of 0.7 mM of the PKA antagonist Rp-8-Br-cAMPS. Thereafter, 10 nM – 10 
μM PGE2 (Panels A, C) or 0.1 - 1 μM Butaprost (Panels B, D) were added for a further 4 hours. 
Rp-8-Br-cAMPS significantly increased basal survival (Panels A, B). Moreover, Rp-8-Br-
cAMPS significantly increased survival elicited by PGE2 (Panel C), or Butaprost (Panel D). 
Statistical analysis was performed through Two Way ANOVA with Sidak’s posttests. Data 
shown are mean ± SEM of 3 independent experiments with cells isolated from distinct healthy 
volunteers, as described in chapter 2.5. Cellular morphology was assessed by light microscopy. 
Asterisks (*) indicate differences to control conditions. Octothorpes (#) denote differences 
between treatments with and without Rp8-Br-cAMPS. Results were considered to be 
statistically significant for p<0.05 (*/#), p<0.01 (**/##), p<0.001 (***/###) and p<0.0001 
(****/####). 
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4.2.2. Influence of PBMC on PKA dependent PGE2 Survival. 
To investigate whether the presence of contaminating monocytes might account for the 
observed fluctuations in constitutive PKA dependence, highly purified PMN were treated with 
PGE2 and with or without Rp-8-Br-cAMPS for 4 and 20 hours. As previously shown  
(Fig. 31A), PMN survival was increased in the presence of PBMC (Fig. 36A, B). In both 
Percoll pure and highly pure PMN, PGE2 induced PKA dependent survival at 4 hours. As 
previously shown (Fig. 12), PGE2 survival was lost at 20 hours in ultrapure PMN  
(Fig. 36A, B). Similarly, PKA inhibition by Rp-8-Br-cAMPS did not significantly increase 
PMN apoptosis in highly pure PMN (Fig. 36B). Interestingly, in Percoll pure PMN, PGE2 
induced a non-significant reduction in late PMN apoptosis that was significantly blocked by Rp-
8-Br-cAMPS, which considerably increased PMN apoptosis at 20 hours (Fig. 36A). 
4.2.3. Interdependence of LPS and PGE2 Signalling in PKA Survival Pathways in 
PMN. 
In chapter 3.2, the effect of LPS-induced EP2 and EP4 receptor expression on PMN survival 
was examined. Moreover, it was shown in chapter 4.2.1 that EP2 mediated PMN survival is 
dependent on PKA activation. To further examine the molecular mechanisms involved in the 
potential synergy of LPS and PGE2 signalling, the PKA dependence of LPS and its potential 
effects on PGE2 survival was examined in Percoll pure and highly pure PMN. For this, highly 
pure or Percoll pure PMN were incubated with LPS, PGE2 or both for 4 hours. In both cell 
types, Rp-8-Br-cAMPS increased constitutive PMN apoptosis. LPS inhibited PMN apoptosis in 
highly pure PMN (Fig. 37B) and in Percoll pure PMN (Fig. 37A). In ultrapure (Fig. 37B), but 
not Percoll pure PMN (Fig. 37A), PGE2 significantly delayed apoptosis, which was reversed by 
Rp-8-Br-cAMPS treatment. Treatment with both LPS and PGE2 significantly reduced PMN 
apoptosis in both assays (Fig. 37A, B). Interestingly, in both Percoll pure and ultrapure PMN, 
Rp-8-Br-cAMP-induced apoptosis in presence of both PGE2 and LPS was comparable to the 
effect of the antagonist in presence of LPS alone. To further validate a role for PKA in LPS and 
PGE2-mediated PMN survival, highly pure PMN were incubated a range of LPS concentrations 
(10 pg/ml - 10 ng/ml) in the presence or absence of Rp-8-Br-cAMPS. LPS profoundly delayed 
PMN apoptosis, reaching statistical significance at 100 pg/ml (Fig. 38A, C). Interestingly,  
Rp-8-Br-cAMPS increased constitutive PMN apoptosis, but the effect of the antagonist was 
diminished with increasing LPS concentrations (Fig. 38A). Moreover, the normalisation of data 
in Fig. 38A revealed a PKA-independent effect of LPS on PMN survival (Fig. 38C). 
Thereafter, PMN were coincubated with increasing amounts of PGE2 (10 nM – 10 μM) and  
100 pg/ml LPS, in the presence or absence of Rp-8-Br-cAMPS. Simultaneous treatment with 
PGE2 (10 nM - 10 μM) and LPS [100 pg/ml] inhibited PMN apoptosis, reaching statistical 
significance at 1 μM (Fig. 38B, D). However, in contrast to PGE2 alone (Fig. 35A, C),  
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Figure 36: Temporal Regulation of PMN Apoptosis by PGE2-Initiated Engagement of PKA 
Signalling. Percoll purified PMN (Panel A) were further refined by negative magnetic selection 
with a custom antibody cocktail (purity > 97 %; Panel B). PMN were preincubated for 15 
minutes in presence or absence of 0.7 mM of the PKA antagonist Rp-8-Br-cAMPS. Thereafter, 
PMN were incubated for 4 or 20 hours in presence of 10 μM PGE2. Rp-8-Br-cAMPS 
significantly increased constitutive apoptosis in both Percoll pure (Panel A) and highly pure 
PMN (Panel B). In this assay, PGE2 did not significantly induce PMN survival. However, in 
Percoll pure PMN only, the effect of Rp-8-Br-cAMPS on apoptosis was maintained in presence 
of PGE2 at 20 hours (Panel A). Statistical analysis was performed through Two Way ANOVA 
with Sidak’s posttests. Data shown are mean ± SEM of 3 independent experiments with cells 
isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular morphology was 
assessed by light microscopy. Asterisks (*) denote differences to control. Octothorpes (#) 
indicate differences between treatments with and without Rp8-Br-cAMPS. Results were 
considered to be statistically significant for p<0.05 (*/#), p<0.01 (##) and p<0.001 (###). 
 
  
A B 
           CHAPTER 4 
- 130 - 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Regulation of PMN Survival by LPS and PGE2: Influence of Cell Purity. Percoll 
purified PMN (Panel A) were further refined by negative magnetic selection with a custom 
antibody cocktail (purity > 97 %; Panel B). PMN were preincubated for 15 minutes in presence 
or absence of 0.7 mM of the PKA antagonist Rp-8-Br-cAMPS. Thereafter, PMN were incubated 
for 4 or 20 hours in presence of 1 ng/ml LPS, 10 μM PGE2, or both. Rp-8-Br-cAMPS 
significantly increased constitutive apoptosis in both Percoll pure (Panel A) and highly pure 
PMN (Panel B). LPS increased PMN survival in a partially PKA-dependent manner in both 
assays. Here, PGE2 increased PMN survival in ultrapure (Panel B), but not Percoll pure PMN 
(Panel A). Interestingly, the effect of PGE2 on PMN survival was reduced in percoll pure PMN 
(Panel A). Statistical analysis was performed through Two Way ANOVA with Sidak’s 
posttests. Data shown are mean ± SEM of 4 (Panel A) or 5 (Panel B) independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular 
morphology was assessed by light microscopy. Asterisks (*) denote differences to control. 
Octothorpes (#) indicate differences between treatments with and without Rp-8-Br-cAMPS. 
Results were considered to be statistically significant for p<0.05 (*/#), p<0.01 (##), p<0.001 
(***/###) and p<0.0001 (####). 
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Figure 38: LPS Induces PKA-Independent PMN Survival in Absence of PGE2. Percoll 
purified PMN were further refined by negative magnetic selection with a custom antibody 
cocktail (purity > 97 %). PMN were pre-incubated for 15 minutes in presence (red lines) or 
absence (black lines) of the competitive PKA Type I inhibitor Rp8-Br-cAMPS. Thereafter, 
PMN were incubated with varying concentrations of PGE2 (0.01 - 10 μM) or LPS (0.01 - 10 
ng/ml), as indicated. LPS (Panels A, C) treatment dose-dependently decreased apoptosis rates at 
4 hours post inoculation. Rp-8-Br-cAMPS significantly delayed constitutive PMN survival, 
while Rp-8-Br-cAMPS induced apoptosis was dose-dependently abrogated in presence of LPS 
(Panels A, C). Incubation with both LPS and PGE2 increased PMN survival, which was 
increased to a constant level by Rp-8-Br-cAMPS treatment (Panels B, D). Data shown are mean 
± SEM of 3 independent experiments with cells isolated from distinct healthy volunteers, as 
described in chapter 2.5. Cellular morphology was assessed by light microscopy. Statistical 
analysis was performed through Two Way RM ANOVA with Sidak’s posttest. Asterisks (*) 
denote significant differences to untreated conditions and octothorpes (#) indicate differences 
between Rp-8-Br-cAMPs treatment conditions. Results were considered to be statistically 
significant for p<0.05 (*/#), p<0.01 (**), p<0.001 (***) and p<0.0001 (****). 
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Rp-8-Br-cAMPS did not block the effect of PGE2 at higher concentrations, but mirrored the 
treatment curve for PGE2 and LPS, with only non-significant increases in Rp-8-Br-cAMPS-
induced apoptosis with increasing PGE2 concentrations (Fig. 38D). 
4.2.4. NR4A: Mechanism of PKA dependent PMN Regulation through Nuclear 
Receptors. 
Therapeutic targeting of neutrophil survival is considered to be an attractive strategy in the 
regulation of neutrophillic inflammation in vivo. NR4A2 and NR4A3 are orphan transcription 
factors in the nuclear receptor family, and are implicated in cell survival pathways in various 
cell types including macrophages. NR4A2 and NR4A3 are well-established components of 
cAMP/PKA signalling in neurons (Hawk, Abel, 2011) and Th1 cells (Yao et al., 2012). 
Moreover, in gastrointestinal disorders, NR4A2 expression is induced by PGE2, in a PKA-
dependent manner (Holla et al., 2006; Han et al., 2012). However, their role in neutrophil 
survival in response to PGE2 and PKA activation is still largely unknown due to the short 
lifespan and genetic intractability of these immune cells. It was hypothesised that orphan 
nuclear receptor NR4A family members play a role in neutrophil cell survival.  
In a human neutrophil microarray study previously conducted by Sabroe group members, 
expression of NR4A2 and NR4A3 was rapidly induced by the PKA agonist N6/8-AHA-cAMP 
(unpublished work). To validate this, highly pure PMN were incubated with or without 
dbcAMP (50 – 100 μM) for the indicated amount of time (Fig. 39). NR4A2 and NR4A3 mRNA 
expression dramatically decreased at an equal rate over the course of 20 hours of culture  
(Fig. 39A, B). Treatment with dbcAMP dose-dependently increased NR4A2/NR4A3 expression 
levels at 4 hours (Fig. 39C) and 20 hours (Fig. 39D). In the same assay, 100 μM dbcAMP 
restored NR4A3 expression to levels comparable to constitutive expression (Fig. 39B).  
Highly pure PMN were incubated with the cAMP-elevating agent adenosine, the A2A 
antagonist Zm 241385 and Rp-8-Br-cAMPS. Similar to Fig. 39, NR4A2 and NR4A3 mRNA 
expression increased by qPCR upon adenosine treatment, and was inhibited by 0.7 mM Rp-8-
Br-cAMPS at 4 hours (Fig. 40A, B). Zm 241385 attenuated adenosine-induced NR4A2  
(Fig. 40A), but not NR4A3 (Fig. 40B) expression in the same assay.  
Thereafter, highly pure PMN were pretreated for 15 minutes with 0.7 mM Rp-8-Br-cAMPS, and 
subsequently incubated with or without PGE2 for the indicated amount of time. NR4A2 and 
NR4A3 mRNA expression was examined. Treatment of highly pure PMN with PGE2 resulted in 
upregulation of NR4A2 (Fig. 41A) and NR4A3 (Fig. 41B) at 8 hours, the latter of which was 
inhibited by Rp-8-Br-cAMPS. LPS did not significantly alter NR4A2 and NR4A3 mRNA 
expression (Fig. 42A, B). Interestingly, treatment with both LPS and PGE2 further potentiated 
NR4A2 and NR4A3 expression (Fig. 42A, B), and was partially inhibited by Rp-8-Br-cAMPS  
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Figure 39: dbcAMP Induces NR4A2 and NR4A3 mRNA Expression in PMN. Ultrapure PMN 
were incubated for 0 – 20 hours (as indicated) in presence or absence of 50 – 100 μM of the 
PKA agonist dbcAMP. mRNA was extracted using the TRI method (as described in chapter 
2.3.1.). Total cellular RNA was reverse transcribed into cDNA using random primers. Resulting 
cDNA was then analysed by qPCR using primers for NR4A2, NR4A3 and GAPDH as a 
normalisation control. NR4A2 and NR4A3 mRNA expression was significantly reduced at 4 
hours compared to 1 hour (Panel A) or 0 hour (Panel B) timepoints. In the same assay as Panel 
B, treatment with dbcAMP dose-dependently increased NR4A expression levels at 4 hours 
(Panel C) and 20 hours (Panel D). 100 μM dbcAMP restored NR4A3 expression to levels 
comparable to constitutive expression (Panel B). Statistical analysis was performed through 
Two Way RM ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 3 independent 
experiments with cells isolated from distinct healthy volunteers, as described in chapter 2.5. 
qPCR expression levels were normalised by using a GAPDH standard curve. Asterisks (*) 
denote differences to 1 hour (Panel A), 0 hour (Panel B) or untreated conditions (Panel C and 
D). Octothorpes (#) indicate differences between NR4A2 and NR4A3 mRNA expression. Results 
were considered to be statistically significant for p<0.05 (*/#), p<0.01 (**/##) and p<0.0001 
(****).  
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Figure 40: Adenosine Induces PKA-Dependent NR4A2 and NR4A3 mRNA Expression. 
Ultrapure PMN were pretreated for 15 minutes with either 1 μM of the A2A antagonist Zm 
241385 or 0.7 mM of the PKA antagonist Rp8-Br-cAMPs and subsequently incubated for 4 
hours in presence or absence of 10 μM adenosine. mRNA was extracted using the TRI method 
(as described in chapter 2.3.1.). Total cellular RNA was reverse transcribed into cDNA using 
random primers. Resulting cDNA was then analysed by qPCR using primers for NR4A2 (Panel 
A), NR4A3 (Panel B) and GAPDH as a normalisation control. Adenosine increased NR4A2 and 
NR4A3 expression, which was abolished by Rp8-Br-cAMPs treatment. A2A antagonist Zm 
241385 attenuated Adenosine-induced NR4A2 (Panel A), but not NR4A3 (Panel B) expression. 
Statistical analysis was performed through Two Way RM ANOVA with Sidak’s posttests. Data 
shown are mean ± SEM of 4 independent experiments with cells isolated from distinct healthy 
volunteers, as described in chapter 2.5. qPCR expression levels were normalised by using a 
GAPDH standard curve. Asterisks (*) denote differences to control conditions. Octothorpes (#) 
indicate differences of NR4A mRNA expression in presence and absence of adenosine. Results 
were considered to be statistically significant for p<0.05 (*/#). 
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Figure 41: Temporal Regulation of NR4A2 and NR4A3 mRNA Expression by PGE2. 
Ultrapure PMN were incubated for 1 - 8 hours. PMN were pretreated for 15 minutes with or 
without 0.7 mM Rp-8-Br-cAMPS before addition of 10 μM PGE2 (Panels A, B). mRNA was 
extracted using the TRI method (as described in chapter 2.3.1.). Total cellular RNA was reverse 
transcribed into cDNA using random primers. Resulting cDNA was then analysed by qPCR 
using primers for NR4A2 (Panel A), NR4A3 (Panel B) and GAPDH as a normalisation control. 
PGE2 robustly increased NR4A2 and NR4A3 expression. Upregulation of NR4A3 at 8 hours 
was inhibited by Rp-8-Br-cAMPS (Panel B). Statistical analysis was performed through Two 
Way RM ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 3 independent 
experiments (Panels B) with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. qPCR expression levels were normalised by using a GAPDH standard curve. 
Asterisks (*) denote significant differences to 1 hour incubation. Octothorpes (#) indicate 
differences to the 8 hour media control. Results were considered to be statistically significant 
for p<0.05 (*/#) and p<0.01 (**/##).  
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Figure 42: Synergistic Induction of NR4A3 Expression by LPS and PGE2 is Inhibited by Rp-
8-Br-cAMPS. Ultrapure PMN were incubated for 4 hours. PMN were pretreated for 15 minutes 
with or without 0.7 mM of the PKA inhibitor Rp-8-Br-cAMPS before addition of 10 μM PGE2 
(Panels A, B), 1 ng/ml LPS (Panels A-C) or a combination of both (Panels A, B). mRNA was 
extracted using the TRI method (as described in chapter 2.3.1.). Total cellular RNA was reverse 
transcribed into cDNA using random primers. Resulting cDNA was then analysed by qPCR 
using primers for NR4A2, NR4A3 and GAPDH as a normalisation control. PGE2 and LPS 
synergistically increased NR4A2 and NR4A3 expression (Panels A, B), which was inhibited by 
Rp-8-Br-cAMPS treatment. Rp-8-Br-cAMPS significantly increased LPS-induced NR4A3 
expression (Panel C). The level of NR4A2 and NR4A3 expression was similar upon Rp-8-Br-
cAMPS treatment in PMN treated with LPS alone, or both PGE2 and LPS (Panels A, B). 
Moreover, inhibition of PKA signalling stabilised NR4A3 levels in presence of LPS (Panel A). 
Statistical analysis was performed through Two Way RM ANOVA with Sidak’s posttests 
(Panels A-C). Data shown are mean ± SEM of 5 independent experiments with cells isolated 
from distinct healthy volunteers (Panels A, B), as described in chapter 2.5. Panel C shows a 
comparison of LPS treated cells only. qPCR expression levels were normalised by using a 
GAPDH standard curve. Asterisks (*) denote significant differences to the media control. 
Octothorpes (#) indicate differences between control and Rp-8-Br-cAMPS treated conditions. 
Results were considered to be statistically significant for p<0.05 (#) and p<0.01 (**/##).  
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treatment. Moreover, in a direct comparison of NR4A expression in LPS-treated cells only,  
Rp-8-Br-cAMPS significantly increased NR4A3 expression in LPS-treated PMN with a similar 
tendency for NR4A2 (Fig. 42C). 
In chapter 3.1.2., a role for EP2 in mediating PGE2 survival was identified, therefore, the 
receptor involved in the upregulation of NR4A2 and NR4A3 by PGE2 was also examined. 
Highly pure PMN were incubated with 10 μM PGE2, the EP2 agonist butaprost, or the EP4 
agonist L-902,688 for 4 hours, and the respective mRNA expression of NR4A2 and NR4A3 was 
evaluated by qPCR. PGE2 increased NR4A2 expression 3.75 fold and NR4A3 expression  
17.86 fold (Fig. 43A, B). Similarly, butaprost partially induced NR4A2 and NR4A3 expression 
by a mean of 2.41 fold and 6.92 fold respectively. L-902,688 in contrast was inefficient at 
increasing NR4A2 expression, and only induced a non-significant 1.74 mean fold increase in 
NR4A3 expression.  
To investigate the influence of LPS and PGE2 synergy in the context of chronic lung 
inflammation, Percoll pure PMN from healthy controls and COPD patients were incubated in 
the presence of LPS for 0 – 120 minutes, and NR4A2 and NR4A3 expression was measured by 
qPCR. LPS induced the expression of NR4A3, but not NR4A2 in both healthy control and COPD 
patient PMN (Fig. 44A, Fig. 45A). Despite comparable mRNA expression at baseline of both 
NR4A2 and NR4A3 (data not shown), LPS mediated a comparatively high fold change of 
NR4A3 mRNA from baseline in healthy control PMN (7.37 mean fold induction) and COPD 
PMN (8.32 mean fold induction), whereas NR4A2 was only induced to a low fold extent by LPS 
at 2 hours in healthy control PMN (1.88 mean fold induction) and COPD PMN (2.51 mean fold 
induction). When incubating both types of PMN for 4 hours with or without LPS and PGE2, 
there were no detectable differences in NR4A expression between the cell types (Fig. 44B, Fig. 
45B). 
4.3. Discussion 
4.3.1. PKA Extends PMN Survival. 
PKA is a potent pro-survival mediator in PMN (Vaughan et al., 2007). PKA activation can be 
achieved through the activation of AC or the inhibition of cAMP metabolism by PDE. In this 
chapter, the modulation of PKA activation was examined using the PDE4 inhibitor rolipram, the 
PKA agonist dbcAMP and the agonist pair N6-MB-cAMP/8-AHA-cAMP (N6/8-AHA), as well 
as the PKA antagonist Rp-8-Br-cAMPS.  
In previous studies, the role of PGE2 in elevating intracellular cAMP levels and the connection 
to PKA-dependent PMN survival has already been established. Briefly, 10 μM PGE2 mediated 
a >50% increment in intracellular cAMP after 30 minutes incubation in PMN, as determined by 
a radioimmunoassay for intracellular cAMP accumulation (Ottonello et al., 1998). In the same 
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study, 10 μM PGE2 inhibited PMN apoptosis by >30 % at 18 hours. A range of cAMP-
elevating agents, including dbcAMP and forskolin, as well as various prostaglandin analogs, 
were found to significantly attenuate PMN apoptosis at 20 hours, assessed by CD16 expression 
(Rossi et al., 1995). Moreover, PMN survival induced by 200 μM dbcAMP was blocked by 
treatment with 100 μM of the PKA inhibitor H-89 at 20 hours, confirming the involvement of 
cAMP in PKA activation in PMN apoptosis.  
4.3.1.1. PDE4 Inhibition has a Limited Effect on PMN Survival. 
Forskolin is the best established and most widely used AC agonist, which efficiently elevates 
intracellular cAMP (Truss et al., 1996). However, its rather non-specific action, in particular 
towards glucose transporters, ion channels, further membrane transport proteins and the 
inhibition of Platelet activating factor (PAF) binding (Wong et al., 1993), make it unsuitable for 
the use in the research of specific signalling pathways. Therefore, the selective PDE4 antagonist 
rolipram was employed in this study due to the reasons outlined below. 
The efficiency of PDE inhibition likewise relies on intracellular cAMP stocks, as well as 
constitutive PDE activity. Agents that non-selectively inhibit PDE are IBMX and theophylline, 
both of which have been shown to inhibit adenosine receptors (Wu et al., 1982; Daly et al., 
1987), and might therefore interfere with other PKA responsive pathways.  
The predominant PDE subtype expressed in human leukocytes is PDE4 (Wang et al., 1999) and 
rolipram is a widely used tool in PDE4 inhibition. Rolipram is highly selective towards human 
PDE4 subtypes A, B, C and D with Ki values of 1.1 ± 0.3 nM, 0.9 ± 0.0 nM, 324.6 ± 27.4 nM 
and 61.1 ± 12.8 nM respectively (Wang et al., 1997). In human PMN, 50 nM rolipram inhibited 
the fMLP induced superoxide generation by 47 % (Talpain et al., 1995), PMN chemotaxis with 
an EC50 of 23.0 ± 2.3 nM and it potentiated inhibition of chemotaxis by PGE2 with  
57.2 ± 5.9 nM (Armstrong et al., 1995). Moreover, rolipram showed considerably higher  
IC50 values ranging from 200 nM to 3 μM in various other cell types and species (amongst 
others: Tenor et al., 1996; Souness et al., 1994). However, rolipram was inefficient at elevating 
cAMP levels in SMC (Truss et al., 1996). This might reflect inherent variations in the 
constitutive PDE4 activity in these cell types, which thus have to be empirically determined in 
every cell type. 
Consequently, PMN were treated with a range of rolipram concentrations (1 nM – 10 μM), but 
rolipram was unable to significantly prolong PMN survival at any concentration tested. The lack 
of effect of rolipram may be due to low effect of constitutive PDE4 activity on PMN survival in 
the assays of this study (Fig. 27). At the two highest concentrations a limited, non-significant 
increase in PMN survival was observed, which was only 3 fold above the Ki of rolipram 
towards the PDE4 subtype C (Wang et al., 1997), potentially suggesting a differential role for 
PDE4 subtypes in PMN survival. However, this finding might also be correlated with a   
           CHAPTER 4 
- 139 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: PGE2-Induced NR4A2 and NR4A3 Expression is Mimicked by EP2 Agonist 
Butaprost, but not EP4 Agonist L-902,688. Ultrapure PMN were incubated for 4 hours with 10 
μM PGE2, Butaprost or L-902,688 for 4 hours. mRNA was extracted using the TRI method (as 
described in chapter 2.3.1.). Total cellular RNA was reverse transcribed into cDNA using 
random primers. Resulting cDNA was then analysed by qPCR using primers for NR4A2 (Panel 
A), and NR4A3 (Panel B) and GAPDH as a normalisation control. PGE2 substantially increased 
NR4A2 and NR4A3 expression. Butaprost similarly increased NR4A2 and NR4A3 expression, 
while L-902,688 was ineffective at increasing NR4A expression levels. Statistical analysis was 
performed through paired t-tests. Data shown are mean ± SEM of 3 independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. qPCR 
expression levels were normalised by using a GAPDH standard curve. Asterisks (*) denote 
significant differences to the media control. Results were considered to be statistically 
significant for p<0.05 (*). 
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Figure 44: Effect of LPS and PGE2 on NR4A2 Expression in COPD PMN. Percoll pure PMN 
from healthy control and COPD patients were incubated for 0 – 120 minutes with 10 ng/ml LPS 
(Panel A), or 4 hours with 10 ng/ml LPS, 10 μM PGE2, or both for 4 hours (Panel B). mRNA 
was extracted using the TRI method (as described in chapter 2.3.1.). Total cellular RNA was 
reverse transcribed into cDNA using random primers. Resulting cDNA was then analysed by 
qPCR using primers for NR4A2 and GAPDH as a normalisation control. LPS non-significantly 
increased NR4A2 expression in both healthy control and COPD PMN at 120 minutes (Panel A). 
At 4 hours, no significant difference in NR4A2 expression between healthy control and COPD 
PMN was detected (Panel B). Statistical analysis was performed through Two Way RM 
ANOVA with Sidak’s posttests. Data shown are mean ± SEM of 3 independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. qPCR 
expression levels were normalised by using a GAPDH standard curve. Abbreviations: HC – 
healthy control. 
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Figure 45: Effect of LPS and PGE2 on NR4A3 Expression in COPD and Healthy Control 
PMN. Percoll pure PMN from healthy control and COPD patients were incubated for 0 – 120 
minutes with 10 ng/ml LPS (Panel A), or 4 hours with 10 ng/ml LPS, 10 μM PGE2, or both for 
4 hours (Panel B). mRNA was extracted using the TRI method (as described in chapter 2.3.1.). 
Total cellular RNA was reverse transcribed into cDNA using random primers. Resulting cDNA 
was then analysed by qPCR using primers for NR4A3 and GAPDH as a normalisation control. 
LPS significantly increased NR4A3 expression in both healthy control and COPD PMN at 120 
minutes (Panel A). At 4 hours, no significant differences between healthy control and COPD 
PMN were detected. Statistical analysis was performed through Two Way RM ANOVA with 
Sidak’s posttests. Data shown are mean ± SEM of 3 independent experiments with cells isolated 
from distinct healthy volunteers, as described in chapter 2.5. qPCR expression levels were 
normalised by using a GAPDH standard curve. Asterisks (*) denote differences to control 
conditions. Results were considered to be statistically significant for p<0.01 (**) and p<0.001 
(***). Abbreviations: HC – healthy control. 
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similarly low level of constitutive PKA signalling in the PMN in this assay, as PKA 
phosphorylates, and thereby activates PDE4 (MacKenzie et al., 2002). Therefore, the activation 
of PKA and their effect on PMN survival was further investigated. As selective PKA RI 
agonism, but not RII agonism was sufficient in the induction of cAMP-dependent PMN survival 
(Parvathenani et al., 2015), PKA RI specific agonists and antagonists were used. 
4.3.1.2. PKA Agonism Extends PMN Survival. 
A comparatively high agonist dose of 50 μM was required to induce significant PMN survival 
with dbcAMP (Fig. 28), consistent with the studies by Rossi et al. (1995) and Usher et al. 
(2002), where 2 mM or 100 μM dbcAMP induced PMN survival at 20 hours or 5 hours, 
respectively. The highest inhibition of PMN apoptosis by dbcAMP was well below the levels 
achieved for the agonist pair N6/8-AHA at 50 μM and 100 μM (Fig. 29B, C). This may in part 
relate to their specific induction of PKA RI activity, as Type I specific agonist pairs previously 
induced survival, in contrast to Type II specific pairs (Parvathenani et al., 1998). An explanation 
for the lower efficiency of dbcAMP at extending PMN survival might be the action of butyric 
acid (Stadl et al., 1987; Graham et al., 1988; Rivero et al., 1998; Cuisset et al., 1998; Sjöholm 
et al., 1997; Conway et al., 1998, Salminen et al., 1998; Soldatenkov et al., 1998). The activity 
of dbcAMP towards PKA is dependent on the enzymatic action of esterases, which catalyse the 
reaction of dbcAMP to monobutyryl cAMP and butyric acid (BTA). In vitro, the presence of 
esterases in the serum can allow this reaction to already occur in the culture medium (Köckritz-
Blickwede, Chow, Nizet, 2009). To minimise the variation introduced by serum, a single batch 
(Lot #07372381) of heat inactivated FCS was used in all assays. Nevertheless, heat inactivation 
was unable to inactivate some types of thermally stable esterases contained in serum (Köckritz-
Blickwede, Chow, Nizet, 2009), which allows for the possibility that action of esterases might 
affect dbcAMP survival effects. The released reaction products, namely monobutyryl cAMP, 
monobutyryl cGMP, cAMP and BTA can then have their own biological effects, which include 
the stimulation of gene expression in proliferation and apoptotic death (Schwede et al., 2000a). 
In this context, monobutyryl cAMP shows increased membrane permeability and stability 
towards PDE metabolism (Schwede et al., 2000b), which might potentially increase the effect of 
the drug on PMN survival. However, BTA induced apoptosis in various cell types, including 
PBMC (Kurita-Ochiai, Fukushima, Ochiai, 1999), which might mask the survival effect 
mediated by dbcAMP or monobutyryl cAMP. 
The active metabolite of dbcAMP is the PDE resistant cAMP analogue N6-MB-cAMP, which is 
highly effective in the distinction between PKA and Epac (Christensen 2003). However, cAMP 
and its analogues possess varying inherent binding affinities towards the two distinct cyclic 
nucleotide binding (CNB) domains on the regulatory PKA subunits (Christensen 2003). As 
previously elaborated, a requirement for the activation of PKA is the occupation of both CNB 
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domains. Hence, in this chapter, the synergistic pair N6-MB-cAMP and 8-AHA-cAMP with 
affinities towards the CNB domain sites A and B (Table 7; Christensen et al., 2003) were 
employed to synergistically activate PKA, as there is a lack of other 8-modified cAMP 
analogues with increased selectivity towards PKA over Epac. 
The effect on PMN survival induced by BTA was further defined by using N6/8-AHA, both of 
which are insensitive to esterase degradation (Christensen et al., 2003; Kopperud et al., 2003), 
due to their chemical structures. Moreover, both, N6-MB-cAMP and 8-AHA-cAMP are 
described by the manufacturer as possessing increased membrane permeability and stability 
towards PDE metabolism, whereas dbcAMP only possess a low, non-selective affinity towards 
PDE (Tilley al., 2002). Taken together, this is consistent with their increased efficacy at 
inducing PMN survival and the low pro-survival action of rolipram. 
It has been suggested that cAMP possesses a greater affinity for RI subunits than RII subunits 
(RIIβ<RIIα<RIα<RIβ; Edelman, 1987; Taylor et al., 1992; Pink, Dell’Acqua, 2003), and  
N6-MB-cAMP and 8-AHA-cAMP preferentially target PKA subunit I (Table 7). Previously, it 
has been suggested that the differential binding affinities of cAMP to the distinct PKA subunits 
may also mediate transient effects at low cAMP concentrations via RI subunits, whereas 
persistent effects of high cAMP concentrations may be more dominantly transmitted through the 
involvement of the RII subunits (Zippel, Baldassa, Sturani, 2004). This might indicate that the 
distinct regulatory PKA subunits may be involved in the sequential orchestration of the effects 
of cAMP at high or low agonist concentrations. Interestingly, this may be consistent with the 
finding that RIα has been shown to be regulated by the increased expression other PKA subunits 
and showed additional compensatory functions upon loss of other regulatory subunits (Amieux 
et al., 1997; Brandon et al., 1997), supporting a more complex interplay of PKA subunits in the 
regulation of PMN survival, which would need to be addressed in an additional study. 
4.3.1.3. PKA Antagonism increases PMN Apoptosis. 
In a previous publication, the Sabroe/Whyte research groups showed that PMN survival induced 
by 1 mM N6-MB-cAMP can be inhibited by 0.7 mM of the competitive PKA Type I inhibitor 
Rp-8-Br-cAMPS at a late timepoint in Percoll pure PMN (Vaughan et al., 2007).  
The mechanism through which Rp-8-Br-cAMPS inhibits PKA, is by targeting the regulatory 
subunits RIα, RIβ and RIIα and competing for binding to the substrate sites with cAMP 
(Christensen et al., 2003). Rp-8-Br-cAMPS preferentially targets the bound PKA RI subunits, 
but not the isolated RI subunits, which is thought to promote the stabilisation of the PKA 
holoenzyme with increased efficiency than 8-Br-cAMP (Gjersten et al., 1995). Due to its 
chemical composition and structure, Rp-8-Br-cAMPS is also more lipophilic, and consequently, 
more membrane permeable than Rp-cAMPS (Gjertsen et al., 1995), and shows increased 
resistance to PDE metabolism (Gjersten et al., 1995; Butt, 2015). Moreover, Rp-8-Br-cAMPS 
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has a lower affinity towards Epac than comparable other PKA antagonists. This was 
demonstrated by Krakstad et al. (2004), who showed that the effect of the Epac negative control 
N6-MB-cAMP was completely blocked by Rp-8-Br-cAMPS (Krakstad et al., 2004). Hence,  
Rp-8-Br-cAMPS would be thought to highly efficiently inhibit PKA signalling.  
The relatively high levels of Rp-8-Br-cAMPS required to affect PMN survival are not 
surprising, considering that 8-Br-cAMP similarly displayed a low affinity towards PKA 
(Gjertsen et al., 1995). However, the chosen concentration of 0.7 mM Rp-8-Br-cAMPS has 
previously been reported to induce a complete reversal of N6-MB-cAMP induced PMN survival 
(Krakstad et al., 2004), demonstrating the value of Rp-8-Br-cAMPS in the investigation of PKA 
dependent PMN death. Moreover, no general cytotoxicity of 0.7 mM of the compound was 
observed by Krakstad et al. (2004), further highlighting the biological significance of the 
obtained results. This led us to conclude that the results obtained with Rp-8-Br-cAMPS are 
valid and biologically significant. 
In a previous study, Rp-8-Br-cAMPS treatment did not influence constitutive survival of Percoll 
pure PMN at 16 hours (Vaughan et al., 2007), suggesting that PKA signalling can be readily 
engaged, but is not constitutively active at a late timepoint following the separation from the 
blood. In addition, it was found here that 0.7 mM Rp-8-Br-cAMPS moderately increased 
constitutive PMN apoptosis at an early timepoint (Fig. 30), suggesting a transient survival effect 
induced by PKA signalling in PMN. Nevertheless, Rp-8-Br-cAMPS was only moderately 
efficacious at retarding constitutive PMN survival in one half of the donations (mean fold 
difference 4.6 % PMN apoptosis ± 1.2 SEM), while it profoundly increased apoptosis by a mean 
of 22.2 % (± 2.6 SEM) in the other moiety (Fig. 6). This difference was not correlated with the 
level of constitutive apoptosis in PMN, but might be grounded on constitutive differences in the 
basal cAMP levels. Various factors are able to influence intracellular cAMP levels (as 
previously discussed in chapter 1). Most relevantly, caffeine was shown to inhibit PKA 
signalling by blocking A2A receptors (Abo-Salem et al., 2004). Insulin lowered cAMP levels, 
which was inhibited by glucose, which in turn increased cAMP production and activated PKA 
signalling in pancreatic endocrine cells (Elliott et al., 2015). Thus, the difference between low 
responsive and high responsive PMN might be grounded in exogenous factors, such as natural 
variation induced by changes in the nutritional status (Oliveira et al., 2014b; Elliott et al., 2015; 
Zhao, Bruemmer, 2010), coffee consumption (Bassini-Cameron et al., 2007), or alterations in 
culture conditions (i.e. purity of PMN preparation, variations in culture density; Sabroe et al., 
2004; Hannah et al., 1998), whereas the difference is unlikely to be due to an inherent donor-
dependent variable with genetic origin. Interestingly, this is supported by the reported 
dependence of the PKA signalling mediator subfamily NR4A on physiological cues, such as 
nutritional status and age (Pérez-Sieira et al., 2014), and their induction by environmental 
stimuli (Zhao, Bruemmer, 2010; Martorell et al., 2006). In summary, it was concluded that PKA 
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signalling can be readily engaged in PMN and is constitutively active at a lower level in most 
subjects. 
4.3.2. The effect of autocrine and paracrine signals on PKA dependent neutrophil 
survival. 
4.3.2.1. Low Levels of PBMC Extend PMN Survival. 
Here, the influence of cell purity on constitutive PMN survival and PKA signalling was 
evaluated. Adding a small percentage (2 %) of PBMC into neutrophil cultures non-significantly 
delayed neutrophil survival at an early timepoint. Interestingly, Rp-8-Br-cAMPS induced a 
significantly lower amount of PMN apoptosis in the presence of PBMC. This indicates that the 
presence of PBMC might affect PKA survival signalling in PMN to a low extent, potentially 
through the secretion of pro-survival factors, as suggested by Sabroe et al. (2001). This 
underlines the importance of negative magnetic selection to obtain highly pure PMN in the 
investigation of PMN survival, as evidenced by Sabroe et al. (2004), and thereby reducing the 
variability in constitutive PKA dependence and constitutive levels of PMN survival (Fig. 30). 
4.3.2.2. Autocrine Adenosine Extends PMN Survival Through PMN Survival. 
The influence of a putative autocrine signal was examined, which has been suggested to be 
altered by fluctuations in cell culture density (Hannah et al., 1998). In a supernatant transfer 
assay, PMN supernatant treatment was unable to rescue PMN survival at 20 hours, which led 
the authors to conclude that PMN were unable to produce autocrine factors in sufficient 
amounts to affect their survival. In contrast here, in an adaptation of the supernatant transfer 
assay performed at 4 hours PMN survival was prolonged by supernatant treatment (Fig. 31B), 
possibly suggesting that the autocrine factor is either shortlived or that the diminished growth 
factor content at 20 hours may have a detrimental effect on PMN lifespan, rendering PMN 
unable to respond to the autocrine signal.  
This may well be reflected in the difference between the results of the two studies and further 
amplified by the ratio of supernatant to fresh media used. Here, we used supernatants in a  
1:3 ratio with fresh media, while Hannah et al., (1998) employed neat supernatants from a  
20 hour culture, which thus encompasses the risk of depriving PMN of crucial survival factors. 
Moreover, Hannah et al. (1998) cultured neutrophils at a high density to obtain supernatants, 
while subsequently culturing them with a low PMN density. In contrast, here we used a constant 
density of PMN at a considerably shorter timepoint, which all may contribute to maintaining a 
minimal required level of serum constituents in culture.  
Here, supernatant treatment increased PMN survival to a similar extent as PKA activation by 
dbcAMP at 4 hours (Fig. 31B), indicating that the survival factor might extend PMN survival 
through PKA activation. The PKA dependence and short-lived effects of the autocrine factor 
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may be consistent with the action of adenosine, which is rapidly taken up into the intracellular 
space due to the action of equilibrate nucleoside transporters and therefore often only exerts 
local effects by transient binding to the adenosine receptors A1, A2A, A2B, and A3 (Morote-
Garcia et al., 2013; Sitkovsky et al., 2004). It was suggested that baseline adenosine signalling 
modulates constitutive survival in PMN (Yasui, et al., 2000). Moreover, activated PMN were 
shown to release ATP, which is rapidly degraded to adenosine (Chen et al., 2006), which 
mediates an autocrine feedback mechanism, regulating PMN function through A2 receptors 
(Chen et al., 2004; Sitkovsky et al., 2004). In this context, A2A receptors positively regulate 
PKA signalling through activation of AC (Pliyev et al., 2014; Sitkovsky et al., 2004), which 
sets them apart from other adenosine receptors.  
To pursue the possibility that autocrine adenosine might enhance constitutive survival, the 
influence of adenosine and A2A receptors on PMN survival was examined. Increasing amounts 
of adenosine induced PKA-dependent PMN survival that was at least partially inhibited by  
A2A receptor antagonism (Fig. 32A, B), suggesting that adenosine induced PKA survival in 
PMN through the engagement of the A2A receptor. Moreover, antagonism of A2A receptors by 
ZM 241385 alone, increased constitutive PMN apoptosis; an effect that was mimicked by PKA 
inhibition through Rp-8-Br-cAMPS, indicating that PKA-dependent adenosine signalling is 
constitutively active through the involvement of A2A/PKA, consistent with the previous studies 
on the function of the receptor subtype (Pliyev et al., 2014; Sitkovsky et al., 2004). 
This led us to conclude that the basal autocrine signal is governed by purinergic signalling in 
PMN. Interestingly, caffeine has previously been shown to interfere with adenosine signalling 
by blocking A2A receptors (Abo-Salem et al., 2004). As caffeine levels following coffee 
consumption has been determined to be in the range of 10-50 μM in serum of healthy 
individuals (Baselt, 2011) and coffee consumption has previously been shown to influence 
neutrophil numbers (Bassini-Cameron et al., 2007), the influence of caffeine on experimental 
procedures may often be underestimated. Thus, a donor dependent variable, influencing the 
assay might be dietary intake of caffeinated beverages of the donors prior to the blood donation. 
On the other hand, a previous study in monocytes did not detect an effect of caffeine on 
monocyte-induced PGE2 expression in response to LPS (Ulcar et al., 2003) suggesting that if 
caffeine was to influence PMN survival, it would be unlikely to be an indirect PBMC-dependent 
mechanism. 
Moreover, Insulin-induced reduction in cAMP levels was inhibited by glucose, which itself is a 
potent PKA activator in pancreatic endocrine cells (Elliott et al., 2015). Thus, the difference 
between low responsive and high responsive PMN might also be grounded in exogenous 
factors, such as natural variation induced by changes in the nutritional status (Oliveira et al., 
2014b). 
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Taken together, these findings indicate that autocrine purinergic signalling constitutively 
activates cAMP/PKA signalling to a limited extend in PMN, but can be readily engaged, while 
the culture conditions and donor dependent variables might potentiate the influence of basal 
activity of PKA. 
4.3.3. Mechanism of PKA-dependent Regulation of PGE2 Survival. 
4.3.3.1. PGE2 Mediates PMN Survival via EP2. 
PGE2/EP2 signalling is known to increase intracellular cAMP in PMN through the action of AC 
(Armstrong, 1995) and elevations in cAMP increase PMN survival (Rossi et al., 1995). PDE4 is 
the main PDE subtype in PMN (Bäumer et al., 2007). Therefore, it was hypothesised that PDE4 
inhibition would enhance PGE2 induced survival by blocking cAMP degradation. In this study, 
rolipram alone showed little effect at concentrations up to 100 nM, and only slightly increased 
PMN survival thereafter (Fig. 27), indicating that there is a low constitutive activity of PDE4 
and/or low constitutive cAMP levels present in PMN. In contrast to this, Armstrong (1995) 
found that 100 nM rolipram was sufficient to inhibit PMN chemotaxis in fMLP-stimulated 
Percoll-pure PMN (84 % purity). The higher efficacy of the reagent in the study by Armstrong 
(1995) may be grounded in the influence of PBMC on PKA-dependent PMN survival. In 
support, it was shown here that ultrapure PMN had 4 fold higher levels of constitutive apoptosis 
than Percoll pure PMN (Fig. 36), and the pro-apoptotic effect of PKA-inhibition by  
Rp-8-Br-cAMPS was an increase of 1.9 fold in ultrapure PMN and 4 fold in Percoll pure PMN, 
suggesting that the pro-survival role of PBMC may be exerted through the secretion of  
PKA-activating pro-survival factors.  
Therefore, the role of PDE4 inhibition upon PGE2-mediated engagement of PKA signalling was 
investigated, to determine whether rolipram might potentiate the effect of the PKA activator. 
PGE2 was therefore incubated with PMN, at a concentration range that previously induced 
PMN survival (Fig. 7). The chosen concentrations of rolipram were based upon a study, where 
rolipram altered functional responses in PMN at these concentrations (Talpain et al., 1995; 
Armstrong, 1995). Constitutive PMN survival was not significantly enhanced by PDE4 
inhibition with 50 – 100 nM rolipram (Fig. 34A). This is consistent with a low constitutive 
activity of PDE4 in PMN that is not further activated through cAMP stimulation. Interestingly, 
1 μM PGE2 alone did not significantly increase PMN survival at 4 hours in this assay, whereas 
addition of 100 nM rolipram to the PGE2 sample significantly increased PMN survival  
(Fig. 34B), and consistent with Talpain et al. (1995) and Armstrong (1995), where the PGE2-
induced inhibition of superoxide generation and chemotaxis was respectively enhanced by co-
incubation with rolipram. These results may further support the low inherent activity of PDE4 in 
           CHAPTER 4 
- 148 - 
highly pure PMN and consequently their low influence on PGE2 survival. However, these data 
do not shed light on the intracellular availability of basal cAMP stocks in ultrapure PMN. 
To further substantiate the PKA dependence of PGE2-induced PMN survival, the  
PKA-inhibitor Rp-8-Br-cAMPS was used to block PGE2 survival. While Rp-8-Br-cAMPS 
constitutively increased apoptosis by only 6 % (Fig. 35A), PKA inhibition also shifted the dose 
response curve for PGE2 (Fig. 35C). These results are consistent with previous studies, which 
reported delays of PMN apoptosis by elevations in cAMP (Rossi et al., 1995), by PGE2 
treatment (Ottonello et al., 1998) and upon treatment with PKA RI-specific agonist pairs 
(Parvathenani et al., 1998). This is in contrast to the study by Martin et al. (2001), where the 
pro-survival effect of cAMP in PMN was suggested to be independent of PKA. In particular, 
they found that dbcAMP and PGE2 induced late PMN survival, whereby PMN survival induced 
by dbcAMP could not be blocked by PKA inhibition, from which it was concluded that cAMP 
does not mediate PKA survival in PMN. Unfortunately, it may not have been known at the time 
of publication that dbcAMP is close to inactive towards PKA, and needs to be metabolised to 
MB-cAMP, MB-cGMP and butyrate to show functional effects. The reaction product butyrate 
has been implicated in various cellular processes (Yusta et al., 1988), including the induction of 
gene expression, apoptosis and the interference with PKA signalling through the induction of 
PKC (Stadl et al., 1987; Graham et al., 1988; Rivero et al., 1998; Cuisset et al., 1998; Sjöholm 
et al., 1997; Conway et al., 1998, Salminen et al., 1998; Soldatenkov et al., 1998). Butyrate was 
furthermore shown to target the G-protein coupled receptor GPR43 (Le Poul et al., 2003), 
which in turn was implicated in apoptosis signalling by inducing caspase activity (Tang et al., 
2011). This makes it a crucial requirement to control for the effects of butyrate in the 
investigation of PKA survival. Thus, the inability to block dbcAMP-induced survival may have 
been in part derived from the action of butyrate on PMN survival. Here, we showed that Rp-8-
Br-cAMPS was in fact able to block survival induced by the cAMP-elevating agents adenosine 
(Fig. 32B) and PGE2 (Fig. 35A), indicating that the induced survival is PKA-dependent at an 
early timepoint, consistent with previous studies (Rossi et al., 1995; Ottonello et al., 1998; 
Parvathenani et al., 1998). Moreover, this fits well with the effect of dbcAMP and PGE2 on the 
rapid enhancement of constitutive PKA activity at 30 minutes of treatment (Martin et al., 2001), 
which is more relevant to the early PMN survival investigated here, in contrast to investigation 
of late PKA-dependent survival by Martin et al. (2001). However, these findings may also 
indicate that PKA-dependent survival is only transiently active, and more relevant at early 
timepoints after exposure to cAMP-elevating agents, as supported by Fig. 36, where PGE2 was 
ineffective at inducing late PMN survival.  
Rp-8-Br-cAMPS more efficiently blocked PGE2-induced survival at lower agonist 
concentrations. Due to the competitive nature of Rp-8-Br-cAMPS binding to PKA (Gjertsen et 
al., 1995), higher PGE2 concentrations and thus increased amounts of synthesized intracellular 
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cAMP, might be able to displace the competitive inhibitor from the cAMP binding sites. This 
may reduce the efficacy of the antagonist to bind the holoenzyme and to prevent its dissociation. 
Thus, it was concluded that PGE2-induced survival is PKA-dependent, and the relative loss of 
efficiency for higher PGE2 concentrations is due to the antagonist specificities, inducing a shift 
in the dose-response curve for PGE2.  
Moreover, in chapter 3, the effects of EP2 on survival were hypothesised to be mediated 
through the engagement of the EP2 receptor subtype. Therefore, it was here examined, whether 
survival specifically induced by EP2 agonism can be blocked by inhibition of PKA. 
Consistently with Fig. 35A, constitutive survival was PKA-dependent in this assay (Fig. 35B). 
Moreover, butaprost-induced survival was blocked by PKA inhibition (Fig. 35D), indicating 
that the PKA dependence of PGE2 survival may be at least partially mediated via the 
prostaglandin receptor subtype EP2. Nevertheless, it should be noted that the agonist butaprost 
has a 10x lower affinity towards EP2 than PGE2 (Table 6). Thus, the PKA-dependent effect of 
EP2 signalling induced by butaprost may be even greater than anticipated. A comparison of the 
extent of PKA dependence in PGE2 and butaprost treatment curves suggests that PGE2 survival 
at lower concentrations is most likely mainly mediated by EP2. Yet, a higher PKA-dependence 
and increased effect of PGE2 at higher agonist concentrations was observed, which is not 
consistent with the reported affinity profiles (Table 6). It is possible that PGE2 mediates further 
pro-survival effects at higher concentrations through the non-specific engagement of an 
additional prostaglandin receptor subtype, due to the limitations of the pharmaceuticals (i.e. low 
affinity, non-selectivity, competition for binding). However, the identity of this potential 
receptor subtype remains to be confirmed. 
4.3.3.2. Cell Purity Influences PGE2 Signalling in PMN. 
Previously, low levels of PBMC were shown to increase PMN survival (Sabroe et al., 2002a; 
Sabroe et al., 2003). Moreover, late PMN survival induced by LPS was dependent on the 
presence of monocytes (Sabroe et al., 2002a). In continuation of chapter 4.1.2., it was aimed 
here to examine the influence of PBMC on PGE2 induced PKA survival. 
In this assay, constitutive PMN apoptosis was increased in highly pure PMN, whereas cell 
purity did not influence the PKA-dependence of constitutive PMN survival, as Rp-8-Br-cAMPS 
increased apoptosis in both Percoll pure (Fig. 36A) and highly pure PMN (Fig. 36B). However, 
in this assay PGE2 did not induce a significant increase in PMN survival at 4 hours. 
Interestingly, PKA-dependence was lost at 20 hours in highly pure PMN, whereas,  
PKA-dependence was maintained in PGE2 treatment samples of Percoll pure PMN. 
Considering the low PDE4 activity in PMN (Fig. 27, Fig. 34), the loss of PGE2 induced 
survival at 20 hours in PMN might be due to PGE2 degradation or uptake, which may be 
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counteracted by monocyte-derived PGE2 in presence of PBMC. This finding is consistent with 
Sabroe et al. (2002a), where monocytes induced PKA-dependent survival in PMN. 
4.3.3.3. Early LPS–Induced Survival in PMN is Independent of PKA. 
Previously, the Sabroe/Whyte laboratories showed that LPS transiently increased PMN survival 
at early timepoints, while the presence of monocytes was required to sustain late PMN survival 
in response to LPS (Sabroe et al., 2002a). LPS treatment induced PGE2 expression via a  
Cox2 related mechanism in macrophages (Amann et al., 2001; Ikegami et al., 2001; Hofer et 
al., 2004), suggesting that LPS might sustain late PMN survival via PKA in presence of 
monocytes. Additionally, in chapter 3.2., it was demonstrated that LPS upregulated receptor 
expression for prostaglandin receptors EP2 and EP4 and may thus potentially increase the 
susceptibility of PMN to PGE2 signalling.  
As previously demonstrated (Fig. 36A, B), and corroborating the findings of Sabroe et al. 
(2002a), PMN survival was greater in the presence of PBMC (Fig. 37A, B). Moreover, LPS was 
more effective at increasing PMN survival in Percoll pure PMN, whereas PKA dependence was 
decreased by LPS treatment in both cell types (Fig. 37A, B). This may indicate that early LPS 
signalling induces the cessation of PKA signalling regardless of immune cell presence. 
Furthermore, PGE2 induced survival was PKA-dependent in both highly pure and ultrapure 
PMN. Strikingly, PKA dependence of LPS signalling was much more decreased in presence of 
monocytes, indicating that LPS acts through different PKA-dependent and independent 
pathways consistent with (Regenhard et al., 2001; Wall et al., 2009; Díaz-Muñoz et al., 2012; 
Sabroe et al., 2005), or that LPS reduced PKA dependent signalling, potentially through an 
indirect feedback mechanism involving EP receptor upregulation, as reported by (Ikegami et al., 
2001) in macrophages. Therefore, it was concluded that the presence of immune cells had a 
significant effect on LPS signalling; however, PKA dependence was influenced by the type of 
PMN stimulation, rather than immune cell presence. 
As LPS survival retained a residual level of PKA dependence (Fig. 37), the dose-dependent 
relationship of LPS and PKA-dependence was examined. LPS induced PMN survival, whereas 
the effect of PKA inhibition decreased with increasing LPS concentrations and was entirely 
abolished at 1-10 ng/ml LPS (Fig. 38A). This may indicate that LPS not only induces a PKA 
independent form of survival, but in fact also diverts constitutive PKA signalling pathways with 
increasing efficiency, correlated with the concentration of LPS. Incubation with LPS and 
increasing concentrations of PGE2 increased PMN survival (Fig. 38B). Interestingly,  
Rp-8-Br-cAMPS increased PMN apoptosis on a constitutive level, while the extent of  
Rp-8-Br-cAMPS induced apoptosis by increasing PGE2 concentrations was attenuated in 
presence of LPS. This indicates that LPS does not interfere with constitutive PKA signalling; 
however, may lead to the cessation of PGE2-induced PKA signalling, potentially through the 
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inhibition of a signalling component upstream of PKA. With increasing PGE2 concentrations, 
the LPS-induced abrogation of PKA-dependent survival was rescued by PGE2 (Fig. 38D). 
Therefore, LPS induced signalling may partially regulate PGE2-induced PKA survival, but LPS 
treatment is not sufficient to inhibit PGE2-induced survival.  
Since LPS induced monocytic PGE2 expression through Cyclooxygenase 2 (Cox2; Amann et 
al., 2001; Ikegami et al., 2001; Hofer et al., 2004), the greater effect of LPS on PMN survival 
observed in these assays, may partially be explained by the induction of the Cox2/PGE2 
pathways by LPS (Fig. 37A, B). However, in highly pure PMN, high concentrations of LPS 
induced a PMN survival that was independent of PKA signalling (Fig. 38A, C), indicating that 
LPS can induce PKA survival by the engagement of an additional signalling pathway. 
Interestingly, PGE2 was shown to increase intracellular cAMP in murine peritoneal 
macrophages, irrespective of LPS treatment, (Ikegami et al., 2001), indicating that LPS would 
not affect PKA signalling in this way. A potentially indirect effect of LPS on PGE2-induced 
PKA signalling may be mediated through LPS-induced upregulation of EP2 and EP4 receptors. 
Cox2-derived intracellular PGE2 has been proposed to be a significant source of PGE2 in 
leukocytes, such as macrophages (Amann et al., 2001; Ikegami et al., 2001; Hofer et al., 2004; 
Profita et al., 2010). Strikingly, cigarette smoke extract increased PGE2 and Cox2 levels in 
macrophages, and may therefore also be involved in the extension of neutrophil survival in 
COPD (Profita et al., 2010). Cox-2 derived PGE2 may further exert its action through the 
engagement of functional, perinuclear EP2 and EP4 receptors (Bhattacharya et al., 1999; 
Konger et al., 2005). Thus, the occurrence of prostaglandin receptor shuffling and 
internalisation may be the subject of a follow-up study. 
4.3.3.4. NR4A2 and NR4A3 are Downstream Regulators of PKA-Dependent PGE2 Survival. 
The mechanisms of PKA survival induced by PGE2 was investigated, and it was hypothesised 
that NR4A2 and NR4A3 may be critical parts of this pathway based on the upregulation of these 
nuclear receptors by a PKA agonist in a microarray (unpublished data). It was shown here that 
treatment with dbcAMP significantly increases expression of NR4A2 and NR4A3 at both 
investigated timepoints (Fig. 39B), indicating that NR4A2 and NR4A3 expression is activated 
through elevations of cAMP, and consistent with the reported induction of these molecules by 
PKA (Mohan et al., 2012). Moreover, it has been noted that NR4A2 and NR4A3 expression 
decreases following the PMN preparation (Fig. 39A, B). The highly increased levels of NR4A2 
and NR4A3 expression following the PMN isolation from the blood might constitute a cellular 
stress-response, as previously reported (Helbling et al., 2014; Mohan et al., 2012) or might 
actually reflect the constitutive levels of PMN in the blood. However, treatment with 100 μM 
dbcAMP entirely blocked the temporal decrease in NR4A3 expression following the cell 
preparation (Fig. 39B) and partially inhibited time-dependent NR4A2 decline, suggesting that 
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NR4A2 and NR4A3 expression may become decreased during the onset of cellular aging and 
engagement of apoptosis pathways. Interestingly, there is substantial evidence for a pro-survival 
role of NR4A2 and NR4A3 (Mullican et al., 2007), potentially supporting this hypothesis. 
In a separate assay, PMN were incubated with adenosine, which is a well-known 
activator of PKA signalling. As expected, adenosine increased the expression of both NR4A2 
and NR4A3 at an early timepoint (Fig. 40A, B), suggesting that both nuclear receptors are 
implicating in Adenosine/PKA signalling, as previously shown in monocytes (Crean et al., 
2015). A2A receptor antagonism prevented adenosine-induced upregulation of NR4A2, but not 
NR4A3, suggesting that NR4A3 is not engaged through the classical pro-survival receptor A2A, 
in contrast to NR4A2, consistent with Crean et al. (2015). In both cases, PKA antagonism 
efficiently blocked nuclear receptor upregulation by adenosine. This indicates that NR4A2 and 
NR4A3 mRNA expression can be increased by agonists that mediate elevations of intracellular 
cAMP, and that the upregulation of NR4A2 and NR4A3 is mediated through the activation of 
PKA. In line with the previous experiment, the increased NR4A2 expression by adenosine may 
suggest that the effectivity of dbcAMP may be decreased due to the agonist specifics (as 
outlined above).  
PGE2 treatment potently induced the expression of both NR4A2 (Fig. 41A) and NR4A3  
(Fig. 41B). NR4A3 upregulation was significantly blocked by PKA inhibition, indicating that at 
least NR4A3 is a downstream effector of PKA signalling. Moreover, the LPS-induced 
expression of NR4A3 was partially inhibited by constitutive PKA signalling, indicated by the 
significantly increased expression of NR4A3 upon Rp-8-Br-cAMPS treatment in presence of 
LPS (Fig. 42C), when comparing NR4A expression in response to stimulation by LPS only. 
This may be explained by an indirect effect of LPS on PKA signalling, such as prostaglandin 
receptor upregulation, or stimulation of Cox2-derived PGE2 expression (Amann et al., 2001; 
Ikegami et al., 2001; Hofer et al., 2004). More strikingly, LPS and PGE2 displayed synergy in 
the induction of NR4A2 and NR4A3 expression, and Rp-8-Br-cAMPS treatment only partially 
blocked the receptor upregulation, stabilising the receptor expression at a level observed for 
PKA inhibition in LPS-treated PMN (Fig. 42A, B). This indicates that LPS and PGE2 cooperate 
in the expression of both nuclear receptors and that PKA may be able to block the pathway 
involved in the LPS-induced NR4A2 and NR4A3 expression. Only recently, the induction of 
NR4A receptors through an Adenosine/A2A pathway and its further enhancement by TLR4 
stimulation was demonstrated (Crean et al., 2015), indicating that both LPS and PGE2 can 
cooperatively induce NR4A expression. Here, it was added to this by showing that PKA 
signalling may regulate the LPS-induced NR4A upregulation. Interestingly, both PKA and 
LPS/TLR4/MAPK cascades can activate the cAMP-responsive element binding protein (CREB; 
Roberson et al., 1999), whereby the control of MAPK signalling by PKA is a well described 
occurrence (Stork, Schmitt, 2002). CREB regulates gene transcription upstream of NR4A2 and 
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NR4A3 (Mohan et al., 2012), and thereby, NR4A2 and NR4A3 may be involved in the 
transcriptional regulation of congruent outcomes of PGE2 and LPS-initiated signalling, such as 
their pro-survival effect in PMN, or the observed synergy in the production of IL-6, IL-10 or  
G-CSF (Strassmann et al., 1994; Yamane et al., 2000; Sugimoto et al., 2005). Most 
interestingly, Crean et al. (2015) showed that the role of NR4A2 in inflammation was through 
the limitation of the effects of NFκB, and the control of an excessive inflammatory response. 
These results are in line with the low level of PKA-dependent survival induced by LPS for 
PMN survival, and may suggest a specific involvement of the nuclear receptors in PMN 
survival. As both, LPS and PGE2 are involved in PKA signalling and NR4A2 and NR4A3 
mRNA is induced by dbcAMP, both nuclear receptors may be linked to the mediation of PKA-
dependent pro-survival effects in PMN. This is supported by their involvement in PKA/CREB 
signalling (Mohan et al., 2012) and the roles of the highly homologous (Zhao, Bruemmer, 
2009), and partially redundant receptor NR4A1 in cell survival and proliferation (Nomiyama et 
al., 2006; Park et al., 2013; Hanna et al., 2011; Mohan et al. 2012).  
In chapter 3.1.2., an EP2 mediated phenotype of PGE2 survival was proposed. Here, it was 
shown that NR4A2 and NR4A3 are upregulated by PGE2 and EP2 agonism, but not EP4 
agonism (Fig. 43A, B), supporting the findings of chapter 3 and placing NR4A2 and NR4A3 as 
downstream components of PGE2/EP2/PKA signalling, with a potential involvement in PMN 
survival. Previous research suggested that NR4A receptors are upregulated through 
Adenosine/A2A signalling in macrophages (Crean et al., 2015), which shows congruency in the 
LPS and PGE2 mediated cellular effects (as discussed above). 
Ultimately, the involvement of nuclear receptors NR4A2 and NR4A3 in COPD patient PMN 
was examined, to substantiate the clinical relevance of these findings. NR4A3 was significantly 
increased through LPS treatment at 2 hours in both healthy control and COPD PMN (Fig. 44A), 
and a similar, but non-significant tendency was observed for NR4A2 expression (Fig. 45A). This 
correlates well with the reported function of PMN as effector cells in COPD that are not 
inherently altered, but predominantly engaged by the unique alterations in the inflammatory 
environment in COPD. Due to their localisation downstream of PKA and CREB (Mohan et al., 
2012) and their synergistic expression by LPS and PGE2, they may be promising novel 
therapeutic targets for the treatment of neutrophilia in COPD. Interestingly, NR4A receptor 
targeting has previously been proposed as a therapeutical strategy in cancer, inflammation and 
metabolic disease (Mohan et al., 2012; Deutsch et al., 2012; Hsu et al., 2004; Zhao, Bruemmer, 
2010). However, the development of NR4A specific pharmaceuticals is hindered by the lack of 
an active site (Roshan-Moniri et al., 2014).  
Conclusively, to evaluate the applicability of NR4A2 and NR4A3 as therapeutic targets in 
PGE2-induced PMN survival in COPD, it was aimed to determine the specific role of both 
nuclear receptors in PMN survival. Although the number of publications on NR4A receptor has 
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been on the rise for the last year years, a lack of well-established agonists (Roshan-Moniri et al., 
2014) hinders the detailed investigation of the specific role of these nuclear receptors in PMN 
survival. In particular, a pharmacological activator or inhibitor of NR4A3 would prove to be of 
immense value in the investigation of PGE2 survival in PMN, as NR4A3 was highly upregulated 
by dbcAMP and PGE2 treatment. To further address the role of NR4A2 and NR4A3 in PMN 
survival, an additional neutrophil model was employed in chapter 5 to modulate NR4A2 and 
NR4A3 expression levels. 
4.4. Summary 
In summary, we suggest here that PKA is a major pro-survival mediator in cAMP-mediated 
PMN survival, supported by the increased PMN survival in presence of dbcAMP and  
N6/8-AHA (Fig. 28-29), as well as the inhibition of constitutive survival by the PKA inhibitor 
Rp-8-Br-cAMPS (Fig. 30). However, the extent of constitutive cAMP-dependent survival 
varies, supported by the data achieved with Rolipram and Rp-8-Br-cAMPS (Fig. 27; Fig. 30). 
Even though most cell preparations showed close to 0 % apoptosis at 0 hours, the amount of 
constitutive cell survival at 4 hours varies considerably. Therefore, potential influences on the 
rate of apoptosis were investigated; in particular, autocrine and paracrine influences were 
investigated. It was found that constitutive PMN apoptosis was delayed by a small degree 
through variations in PBMC presence, as well as autocrine adenosine, acting through  
A2A receptors (Fig. 31-33). 
PGE2 is a pro-survival mediator in PMN, acting via the EP2 receptor subtype and through 
activation of PKA. This was shown in Fig. 35, where effects of PGE2 on survival were thought 
to be mediated by EP2 at low agonist concentrations. However, higher PGE2 concentrations 
showed an additive effect, which was not attributable to EP2, but potentially to the engagement 
of another unknown receptor or signalling pathway. Here, it was proposed that this receptor is 
unlikely to be the EP4 receptor.  
In Fig. 36, it was confirmed that the presence of contaminating cells (i.e. Percoll pure PMN), 
enhances the PKA-dependent pro-survival response of PMN at a late timepoint. Moreover, 
increased susceptibility to LPS-induced survival was observed in Percoll pure PMN in contrast 
to ultrapure PMN. This coincided with an increased rate of PKA-dependence in highly pure 
PMN, suggesting that LPS-induced survival is largely independent of PKA, whereas the mean 
overall survival was greater in Percoll pure PMN. A dose-response of LPS for PKA inhibition 
further confirmed that LPS induces a PKA-independent form of survival, and moreover dose-
dependently terminates constitutive PKA-dependent survival signalling (Fig. 38A, C). The 
effect of LPS on PKA signalling was lost upon simultaneous treatment with PGE2, suggesting 
that LPS does not inhibit PKA, but may be involved in the regulation of PKA signalling 
upstream of PKA through an indirect mechanism (Fig. 38B, D). 
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Moreover, these data suggest that NR4A2 and NR4A3 nuclear receptors are downstream 
effectors of PKA signalling, as they become expressed by dbcAMP (Fig. 39), adenosine  
(Fig. 40) and PGE2 (Fig. 41-43). Expression induced by both Adenosine and PGE2 can be 
blocked by PKA-inhibition (Fig. 40; Fig. 41C; Fig. 42). Additionally, the EP2 agonist 
Butaprost non-significantly increased the expression of both NR4A2 and NR4A3 (Fig. 43). 
Butaprost was less efficient than PGE2, which might be explained by the different relative 
receptor affinities of the agonists (Table 6). LPS induced the expression of and NR4A3 (Fig. 
45A), correlating with the increase of EP2 and EP4 receptor expression induced by LPS (Fig. 
20-21; Fig. 22-23).  
In summary, here a novel mechanism in LPS enhanced PGE2 survival was proposed. In 
addition, the PKA-dependent effects of PGE2 on PMN survival are exerted via the EP2 receptor 
subtype. However, due to the limitations of the available pharmaceuticals (i.e. low affinity, non-
selectivity, competition for binding), a further investigation of the mechanisms of the role of 
PKA-dependent survival in PMN is warranted. Therefore, cell type specific knockdown of PKA 
signalling partners might be useful in determining the exact role of PKA in PGE2 signalling. 
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CHAPTER 5. RNA INTERFERENCE MODULATES NR4A 
EXPRESSION IN MNØ. 
Neutrophils are notoriously short-lived and post-mitotic cells and therefore they are genetically 
intractable. This obstacle can be overcome by the use of neutrophil precursor cell lines, which 
allows the genetic modification and subsequent differentiation of the cells into modified 
neutrophils. This allows the detailed investigation of the role of survival pathway components in 
neutrophils. In 1979, Gallagher et al. described the HL60 cell line, which are neutrophil 
progenitors derived from an acute promyelocytic leukaemia patient. HL-60 cells may be 
unsuitable as a model for primary human PMN for various reasons. Firstly, genetic variations 
have been described to increase the susceptibility for the development of leukaemia, which 
might indicate that HL60 cells are inherently different from healthy control PMN. Secondly, 
defects in the (malignant) proliferation of promyelocytes and their differentiation to neutrophils 
are well described in leukaemia. Moreover, the high passage numbers of available HL60 cells 
introduces the risk that genomic instability and chromosomal irregularities, potentially further 
altering neutrophil responses. Differentiation of HL60 cells is achieved by foreign reagents with 
largely unknown molecular mechanisms, such as DMSO. Taken together, the source of the 
precursors, their high passage numbers and the mechanism of their differentiation therefore are 
major limitations for the comparison between HL60 derived neutrophils and primary human 
neutrophils from healthy volunteers. This limits the usefulness of HL60 cells in the 
investigation of neutrophil survival pathways. 
More recently, a novel approach for the generation of large quantities of genetically modified 
neutrophils from knockout mice has been described (Wang et al., 2006). This approach is based 
on the discovery that Class I Homeobox (Hox) Transcription Factors are highly expressed in 
CD34
-
 Haematopoietic stem cells (HSC) and myeloid lineage committed progenitors (LCP). 
Progressing differentiation is marked by increasing CD34 expression, coinciding with 
downregulation of Hox gene expression (Lawrence et al., 1997, Pineault et al., 2002). 
Moreover, expression of Hoxb8 has also been shown to directly arrest the differentiation of 
myeloid progenitors (Fujino et al., 2001, Knoepfler et al., 2001), and thereby allows the 
expansion of myeloid progenitors via expression of Hox oncoproteins. 
For this end, lineage-negative progenitors (MacI
-
, B220
-
, Thy1.2
-
, lin
-
) were derived from the 
bone marrow of BALB/c mice and prestimulated with SCF, IL-3 and IL-6 by Wang et al. 
(2006). Subsequently, progenitors were infected with a retrovirus of a MMLV-derived retroviral 
vector (MSCV) encoding an estrogen-dependent (ER-binding domain fusion) Hoxb8 
transcription factor. Expression of conditional Hoxb8 thus resulted in the factor-dependent 
immortalisation of the transfected progenitors. Upon inactivation of the conditional Hoxb8 and 
supplementation with neutrophil lineage specific growth factors, murine common myeloid 
           CHAPTER 5 
- 157 - 
progenitor line (mCMP) terminally differentiated into neutrophils (mNØ; Wang et al., 2006; 
McDonald et al., 2011) that resembled mature murine neutrophils.  
A modification of the protocol described by Wang et al. (2006) was published by McDonald et 
al. (2011), allowing the direct modification of gene expression in the lineage committed 
progenitors. Thereby, mature mutant neutrophils were directly derived from knockout (KO) 
progenitors, circumventing the cost- and time-consuming step of generating KO mouse models. 
Therefore, in this chapter, I examined the suitability of mCMP to model primary neutrophil 
apoptosis and PKA survival pathways. Thereafter, the feasibility of RNAi mediated transient 
gene expression knockdown of the nuclear receptors NR4A2 and NR4A3 was evaluated, and it 
was explored whether modification of NR4A signalling alters cell survival during mNØ 
differentiation. 
5.1. mNØ: A Model for the Exploration of PMN Survival.  
A conditionally immortalised mCMP (kind gift of Prof. P. R. Taylor) was cultured and 
differentiated into mature neutrophils (mNØ) in a 4-day protocol with daily media 
replenishment. The aim of this chapter was to assess mNØ apoptosis and survival to determine 
the applicability of the model for this study. 
5.1.1 mCMP Differentiate into Highly Pure Populations of mNØ with High 
Morphological Resemblance to Murine Neutrophils. 
mCMP were maintained as conditionally immortalised progenitors in the presence of estrogen 
and SCF in long-term culture as described in chapter 2.1.1. Morphologically, mCMP exhibited a 
myeloid phenotype. Estrogen withdrawal resulted in increased cell death, but also enabled 
spontaneous differentiation of the mCMP into diverse cells, amongst which macrophages and 
eosinophils were most abundant at light microscopic observation (data not shown). 
Supplementation with neutrophil-specific growth factors drives differentiation into 
morphological mature primary murine neutrophils (Wang et al., 2006). Through estrogen 
withdrawal and supplementation with SCF and G-CSF, mCMP were differentiated into mature 
mNØ in a 4-day protocol (Fig. 46A, B). On day 2 of differentiation, the first significant 
increases in mNØ and decreases in mCMP were observed. The amount of differentiation into 
other cell types was negligibly low. On day 4, differentiation cultures routinely contained  
20-40 x 10
6
 of ≥ 95 % mNØ. On average, Day 4 cultures were composed of 80-90% mature 
lobulated mNØ (Fig. 46C) and 5-15% band-like mNØ, while the numbers of mCMP and 
intermediate differentiation stages was negligibly low. 
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Figure 46: Differentiation of mCMP into Highly Pure, Morphologically Mature Neutrophil-
like Cells (mNØ). mCMP were differentiated into mNØ in a 4 day timecourse, as described in 
2.1.2. Apoptosis was quantified by light microscopy of Wright/Giemsa stained cells. Bars 
represent 10 μm (Panel A). Red line and blue line indicate percentage of mCMP or mNØ, 
respectively. Relative percentage of mNØ increased on days 0 – 4 post Estrogen withdrawal, 
with corresponding decreases in mCMP percentage (Panels A, B). Average purity of mature 
mNØ on day 4 post differentiation was above 80 % (Panel C). Cell maturity was assessed based 
on the presence of lobulated nuclei of mNØ (see Fig. 4). Data shown are mean ± SEM of 7 
independent experiments (Panel A, B) or 13 independent experiments (Panel C) with cells 
isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular morphology was 
assessed by light microscopy. Statistical analysis was performed through Two Way ANOVA 
with Sidak’s posttest (Panel B). Asterisks (*) indicate significant differences to the maintenance 
control and octothorpes (#) denote differences between mCMP and mNØ in the differentiation 
culture. Results were considered to be statistically significant for p<0.01 (**) and p<0.0001 
(****/####). 
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5.1.2. mNØ Lifespan Is Regulated Through Spontaneous Cell Death. 
Like human PMN, murine neutrophils undergo apoptosis shortly following their release from 
the bone marrow in vivo (Pillay et al., 2010) and during aging in culture. It was therefore 
examined whether mNØ displayed similarly high rates of spontaneous cell death. Spontaneous 
cell death was examined in media, supplemented with the full amount of growth factors. 
Additionally, growth factor deprived media was used to model the release of neutrophils from 
the bone marrow into the blood stream.  
Morphologically mature mNØ populations were obtained on day 4 of differentiation cultures, 
and maintained in culture for a further 12 – 48 hours. Apoptosis was examined by two different 
measures. Firstly, relative abundance of cells with apoptotic morphology was measured by light 
microscopy, as described in chapter 2. Secondly, cell suspensions were stained with Annexin V-
PE. Annexin V binds to cell surface phosphatidyl serine (PS), a receptor that is known to be 
redistributed to the outer membrane of apoptotic cells from the internal plasma membranes (Van 
Engeland et al., 1998; Fadeel et al., 1998; Fadok et al., 2001; Hampton et al., 2002). 
Additionally, cells were stained with the vital dye, Topro3, to measure necrotic like cell death 
(Van Hooijdonk et al., 1994). Gating was based on both Topro3 and PE-annexin V staining. 
Position of gates was determined by a freeze/thaw control to model membrane permeability and 
the use of the calcium chelator EDTA to inhibit the calcium-dependent binding of Annexin V to 
PS. Furthermore, cell loss was measured via relative abundance of healthy cells remaining in 
culture compared to a predefined amount of flow cytometric beads. In growth factor deprived 
media, significantly increased levels of morphological apoptosis were first present after  
36 hours (Fig. 47A, C). Likewise, the mean percentage of FL2
+
/FL4
-
 mNØ was significantly 
greater at 24 hours, compared to the 0 hours control (Fig. 48A, D).  
Cell loss was determined by measurements of remaining viable cells through haemocytometer 
counts and CountBright beads. Viable cell numbers were significantly decreased after 12 hours 
measured by either haemocytometer counts (Fig. 47B) or CountBright beads (Fig. 48). Notably, 
only 25 x 10
4
 viable cells were detected at the beginning of the timecourse through CountBright 
beads, compared to 50 x 10
4
 viable cells by haemocytometer counts.  
The growth factors SCF and G-CSF are implicated in neutrophil haematopoiesis and with 
known pro-survival functions in PMN (Hoffmann et al., 1993; Duarte, Frank, 2002; Roberts, 
2005; van Raam et al., 2008). Since SCF and G-CSF are used in the differentiation of mCMP to 
mNØ, the influence of the growth factors on mNØ lifespan was investigated. mNØ were 
cultured in the presence and absence of SCF and G-CSF for 12 and 24 hours, before samples 
were collected for further analysis. In both growth factor deprived and supplemented media, 
mNØ exhibited increasing amounts of PS exposure in membrane impermeable cells (FL2
+
/FL4
-
; 
Fig. 49A, D). Likewise, the overall amount of viable cells remaining in the culture significantly 
decreased over time at a similar rate for both conditions (Fig. 49B). However, at 24 hours  
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Figure 47: mNØ display Morphological Hallmarks of Apoptosis Constitutively and in a Time 
Dependent Manner. mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml 
apoptosis medium, as described in chapter 2.1.2. mNØ were cultured for 0 – 48 hours before 
apoptosis was quantified by light microscopy of Wright/Giemsa stained cells (Panel A, C) and 
total cell numbers determined by Haemocytometer counts (Panel B). Relative percentage of 
morphologically apoptotic cells increased (Panel A, C) to a similar extent as means of viable 
cells decreased over time (Panel B). Data shown are mean ± SEM of 3 independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. Cellular 
morphology was assessed by light microscopy. Bars represent 10 μm. Statistical analysis was 
performed through One Way RM ANOVA with Sidak’s posttest. Results were considered to be 
statistically significant for p<0.05 (*) and p<0.0001 (****). 
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Figure 48: FACS Analysis of Time Dependent Phophatidylserine Exposure and Membrane 
Integrity in mNØ. mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml 
apoptosis medium, as described in chapter 2.1.2. mNØ were cultured for 0 – 48 hours before 
apoptosis was quantified by FACS through PE-annexin V (FL2) and Topro-3 (FL4; Panels A, 
D) and total cell numbers determined through FACS analysis of CountBright beads (Panel B). 
Mean percentage of FL2
+
/FL4
-
 mNØ (Panel A) significantly increased over time, while means 
of viable cells/bead decreased (Panel B). Representative images show SSC/FSC graphs (Panel 
C) and FL4/FL2 dotplots (Panel D) of PE-annexin V/ToPro-3 stained mNØ at time points 0, 12, 
24, 36 and 48 hours respectively. Data shown are mean ± SEM of 3 independent experiments 
with cells isolated from distinct healthy volunteers, as described in chapter 2.5. Gates were 
established by EDTA, Freeze Thaw and unstained controls. Statistical analysis was performed 
through One Way ANOVA with Sidak’s posttest. Results were considered to be statistically 
significant for p<0.05 (*), p<0.01 (**), p<0.001 (***) and p>0.0001 (****).  
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significant differences between FL2
+
/FL4
-
 cells (< 10%) and viable cells (< 2 x 10
4
) were 
observed between growth factor deprived and SCF/G-CSF treated cells.  
5.1.3. mNØ Undergo Caspase-Dependent Apoptosis. 
Apoptosis is a well-known mechanism of cell death in primary neutrophils. Moreover, there is 
considerable evidence to support the involvement of caspases in neutrophil apoptosis (Fadeel et 
al., 1998). Q-VD-OPh (QVD) is a pan-caspase inhibitor, which has been shown to block 
apoptosis in human neutrophils (Wardle et al., 2011). In contrast to other caspase inhibitors,  
Q-VD-OPh is highly effective, even at low concentrations. This was attributed to its high cell 
permeability and irreversible binding to activated caspases.  
To investigate caspase-dependent apoptosis in this model system, morphologically mature mNØ 
populations were obtained on day 4 of differentiation cultures. Cells were cultured in presence 
and absence of Q-VD-OPh in full and growth factor deprived medium for 30 hours. Apoptosis 
was assessed through PE-annexin V/ToPro-3 staining and flow cytometric analysis. Cell loss 
was measured via relative abundance of viable cells remaining in culture compared to a constant 
amount of flow cytometric beads. Q-VD-OPh significantly reduced the levels of FL2
+
/FL4
-
 cells 
irrespective of growth factor presence (Fig. 50A, D). Q-VD-OPh and growth factor treatment 
both increased survival (Fig. 50B, C). Interestingly, cell survival induced by Q-VD-OPh 
treatment could not be further extended in the presence of growth factors. 
5.2. PKA Survival Pathways Can Be Readily Engaged in mNØ. 
The aim of this chapter was to assess the relevance of PKA signalling in the induction of mNØ 
survival, and thereby to determine their applicability as a model for the pathways in question. 
5.2.1. mNØ Are Sensitive to Kinase Inhibition. 
Staurosporine (STS) is a pan kinase inhibitor with a high affinity for the catalytic subtype β of 
PKA. Additionally to, or possibly as a consequence of its action on kinases, it has also been 
shown to activate caspase-dependent cell death (Belmokhtar et al., 2001). 
To determine, whether mNØ are sensitive to kinase inhibition, morphologically mature mNØ 
from a 4 day differentiation culture were cultured in the presence and absence of STS in full and 
growth factor deprived medium for 30 hours. STS modestly, yet significantly accelerated PMN 
apoptosis (FL2
+
/FL4
-
) at 30 hours compared to the untreated control (Fig. 51A, C - D). There 
was no significant loss of viable cells in presence of STS, but STS treatment resulted in a 
pronounced trend towards decreased viable cell numbers at 6 hours and 30 hours (Fig. 51B). 
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Figure 49: Spontaneous mNØ Apoptosis is Accelerated through Growth Factor Deprivation. 
mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml apoptosis medium, as 
described in chapter 2.1.2. mNØ were cultured for 0 – 48 hours with or without 20 ng/ml 
SCF/G-CSF before apoptosis was quantified by FACS through PE-annexin V (FL2) and Topro-
3 (FL4; Panels A, D). Total cell numbers were determined through FACS analysis of 
CountBright beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ (Panel A) significantly 
increased through growth factor deprivation, while retaining constitutive levels of apoptosis 
(Panel A). Means of viable cells/bead likewise increased at late timepoints in presence of 
growth factors (Panel B). Representative images show cellular morphology of mNØ (Panel C) 
and FL-4/FL-2 graphs of PE-annexin V/ToPro-3 stained mNØ (Panel D) at time points 12 hours 
and 24 hours, cultured with and without growth factors respectively. Data shown are mean ± 
SEM of 5 independent experiments with cells isolated from distinct healthy volunteers, as 
described in chapter 2.5. Gates were established by EDTA, Freeze Thaw and unstained controls. 
Bars represent 10 μm. Statistical analysis was performed through Two Way RM ANOVA with 
Sidak’s posttest. Asterisks (*) represent differences to the 0 hour control, while octothorpes (#) 
denote differences between growth factor treatment conditions. Results were considered to be 
statistically significant for p<0.05 (*/#), p<0.01 (##), p<0.001 (***) and p<0.0001 (****).  
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Figure 50: Evidence for Inhibition of Apoptosis by Caspase Inhibitor Q-VD-OPh in mNØ. 
mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml apoptosis medium, as 
described in chapter 2.1.2. mNØ were cultured cultured in presence and absence of the Pan-
Caspase Inhibitor Q-VD-OPh (0.1 μM) and with or without addition of 20 ng/ml SCF/G-CSF. 
mNØ were maintained for 30 hours before apoptosis was quantified by FACS through PE-
annexin V (FL2) and Topro-3 (FL4; Panel A - D). Total cell numbers were determined through 
FACS analysis of CountBright beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ (Panel A) 
significantly decreased through treatment with 0.1 μM Q-VD-OPh independent of growth factor 
presence (Panel A). Relative abundance of viable cells compared to Countbright Beads similarly 
decreased in presence of Q-VD-OPh in starvation and fully supplemented media (Panel B). 
Representative images show cellular morphology of mNØ (Panel C) and FL-4/FL-2 graphs of 
PE-annexin V/ToPro-3 stained mNØ (Panel D) at 30 hours, cultured in presence or absence of 
QVD with or without growth factors. Data shown are mean ± SEM of 3 independent 
experiments with cells isolated from distinct healthy volunteers, as described in chapter 2.5. 
Gates were established by EDTA, Freeze Thaw and unstained controls. Bars represent 10 μm. 
Statistical analysis was performed through Two Way RM ANOVA with Sidak’s posttest. 
Asterisks (*) mark differences to an untreated control, while octothorpes (#) denote differences 
to Q-VD-OPh treatment conditions. Results were considered to be statistically significant for 
p<0.05 (*), p<0.01 (##) and p<0.001 (###).  
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re 52: mNØ Apoptosis is Accelerated by Treatment with the Broad Spectrum Kinase Inhibitor 
Staurosporine.  
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Figure 51: mNØ Apoptosis is Accelerated by Treatment with the Broad Spectrum Kinase 
Inhibitor Staurosporine. mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml 
apoptosis medium, as described in chapter 2.1.2. mNØ were cultured in presence and absence of 
the broad spectrum kinase inhibitor STS (500 μM) for 6 and 30 hours before apoptosis was 
quantified by FACS through PE-annexin V (FL2) and Topro-3 (FL4; Panels A, B, D). Total cell 
numbers were determined through FACS analysis of CountBright beads (Panel B). Mean 
percentage of FL2
+
/FL4
-
 mNØ (Panel A) significantly increased at late timepoints through 
treatment with 500 μM STS (Panel A). Relative abundance of viable cells compared to 
Countbright Beads increased in presence of STS at early timepoints (Panel B). Representative 
images show cellular morphology of mNØ (Panel C) and FL-4/FL-2 graphs of PE-annexin 
V/ToPro-3 stained mNØ (Panel D) at 0-30 hours, cultured in presence or absence of STS. Data 
shown are mean ± SEM of 3 independent experiments with cells isolated from distinct healthy 
volunteers, as described in chapter 2.5. Gates were established by EDTA, Freeze Thaw and 
unstained controls. Bars represent 10 μm. Statistical analysis was performed through Two Way 
ANOVA with Sidak’s posttest. Asterisks (*) indicate differences to 0 hour control, while 
octothorpes (#) denote differences between STS treatment. Results were considered to be 
statistically significant for p<0.05 (#), p<0.01 (**) and p<0.0001 (****).  
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5.2.2. PKA Survival Pathways Can Be Engaged in mNØ. 
In chapter 4, PKA was found to be an important mediator of PMN survival. Here, the validity of 
mNØ as a model system in the study of PKA survival was examined. The PKA activator 
dbcAMP and the analogue pair N6-MB-cAMP/8-AHA-cAMP were employed as PKA 
activators. Briefly, mNØ from Day 4 differentiation cultures were seeded at a density of 0.5 x 
10
6
 cells/well (96-well plates) in apoptosis medium. Stimuli were inoculated at a final 
concentration of 100 μM for dbcAMP or N6/8-AHA. A temporal increase of FL2+/FL4-cells 
(Fig. 52A, D; Fig. 53A, D) was significantly attenuated at 30 hours by incubation with dbcAMP 
(Fig. 52A, D), but not N6/8-AHA (Fig. 53A, D). The mean percentage of FL2
+
/FL4
-
 fluorescent 
cells was reduced by 30.8 % with dbcAMP and by 17.3 % with N6/8-AHA at 30 hours. For 
both assays, the number of viable cells in culture was increased at 6 hours of agonist treatment 
(Fig. 52B, Fig. 53B). Increases were significant for N6/8-AHA treatment only. However, for 
both assays, the effect on cell numbers was lost at 30 hours.  
To substantiate the involvement of PKA signalling in mNØ survival, mNØ were incubated for 
24 hours with Rp-8-Br-cAMPS. At 24 hours of treatment with 0.7 mM Rp-8-Br-cAMPS the 
mean percentage of FL2
+
/FL4
- 
mNØ was modestly yet significantly increased by 2.9 %  
(Fig. 54A). There was no significant change in mean viable cell numbers in Rp-8-Br-cAMPS 
treated conditions (Fig. 54B). Similarly, Rp-8-Br-cAMPS was unable to block the dbcAMP-
induced reduction in FL2
+
/FL4
- 
cells (Fig. 55A). Viable cell numbers were not significantly 
affected by dbcAMP and Rp-8-Br-cAMPS (Fig. 55B).  
5.2.3. Engagement of PKA Survival Through Inflammatory Stimuli in mNØ. 
The effect of LPS and PGE2 on mNØ apoptosis and survival was then investigated and  
Rp-8-Br-cAMPS was used to substantiate the differential PKA-dependence of the survival 
mediators in mNØ. Therefore, mNØ from a 4 day differentiation culture were incubated with 
LPS, PGE2 or both, in the presence or absence of Rp-8-Br-cAMPS. LPS and PGE2 alone did 
not result in significant changes to numbers of FL2
+
/FL4
-
 or viable cells (Fig. 56A, B).  
Co-incubation with LPS and PGE2 induced a statistically significant increase in viable cell 
numbers that was significantly blocked by PKA inhibition with Rp-8-Br-cAMPS (Fig. 56B). 
5.3. Transient RNAi Mediated Knockdown in mCMP Alters Gene 
Expression Levels in mNØ. 
In this chapter, the ability to genetically modify mCMP and the resulting mNØ by siRNA 
transfection techniques was examined. Here, mRNA expression of several pro- and anti-survival 
molecules was modulated to determine their involvement in the regulation of mNØ lifespan. 
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Figure 52: mNØ Survival is Activated by dbcAMP. mNØ from a 4-day differentiation culture 
were seeded at 3.3 x 10
6
/ml apoptosis medium, as described in chapter 2.1.2. mNØ were 
cultured in presence and absence of 100 μM of the cAMP analogue dibutyryl cyclic AMP 
(dbcAMP) for 6 and 30 hours before apoptosis was quantified by FACS through PE-annexin V 
(FL2) and Topro-3 (FL4; Panel A - D). Total cell numbers were determined through FACS 
analysis of CountBright beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ was significantly 
lower for dbcAMP treated conditions (Panel A). Relative abundance of viable cells compared to 
Countbright Beads was enhanced in presence of dbcAMP (Panel B). Representative images 
show cellular morphology of mNØ (Panel C) and FL-4/FL-2 graphs of PE-annexin V/ToPro-3 
stained mNØ (Panel D) of treatment conditions at 30 hours. Data shown are mean ± SEM of  
3 independent experiments with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Gates were established by EDTA, Freeze Thaw and unstained controls. Bars 
represent 10 μm. Statistical analysis was performed through Two Way ANOVA with Sidak’s 
posttest. Asterisks (*) indicate differences to 0 hour control, while octothorpes (#) denote 
differences between dbcAMP treatment. Results were considered to be statistically significant 
for p<0.05 (*), p<0.01 (**/##) and p<0.001 (***).  
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Figure 53: mNØ Survival is Activated by N6/8-AHA. mNØ from a 4-day differentiation culture 
were seeded at 3.3 x 10
6
/ml apoptosis medium, as described in chapter 2.1.2. mNØ were 
cultured in presence and absence of 100 μM of the dbcAMP analogue-pair N6-MB-cAMP and 
8-AHA-cAMP (N6/8-AHA) for 6 and 30 hours before apoptosis was quantified by FACS 
through PE-annexin V (FL2) and Topro-3 (FL4; Panel A, D). Total cell numbers were 
determined through FACS analysis of CountBright beads (Panel B). Mean percentage of 
FL2
+
/FL4
-
 mNØ was significantly lower for N6/8-AHA treated conditions at 30 hours (Panel 
A). Relative abundance of viable cells compared to Countbright Beads was significantly 
enhanced in presence of N6/8-AHA at 6 hours (Panel B). Representative images show cellular 
morphology of mNØ (Panel C) and FL-4/FL-2 graphs of PE-annexin V/ToPro-3 stained mNØ 
(Panel D) of treatment conditions at 30 hours. Data shown are mean ± SEM of 3 independent 
experiments with cells isolated from distinct healthy volunteers, as described in chapter 2.5. 
Gates were established by EDTA, Freeze Thaw and unstained controls. Bars represent 10 μm. 
Statistical analysis was performed through Two Way ANOVA with Sidak’s posttest. Asterisks 
(*) indicate differences to 0 hour control, while octothorpes (#) denote differences between 
N6/8-AHA treatment. Results were considered to be statistically significant for p<0.05 (*) and 
p<0.01 (**/##).  
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Figure 54: PKA Inhibitor Rp-8-Br-cAMPS Significantly Increases Constitutive mNØ 
Apoptosis. mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml apoptosis 
medium, as described in chapter 2.1.2. mNØ were cultured in presence and absence of 0.7 mM 
of the PKA antagonist Rp-8-Br-cAMPS for 24 hours before apoptosis was quantified by FACS 
through PE-annexin V (FL2) and Topro-3 (FL4; Panel A). Total cell numbers were determined 
through FACS analysis of CountBright beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ 
was significantly higher for Rp-8-Br-cAMPS treated conditions at 24 hours (Panel A). Relative 
abundance of viable cells compared to Countbright Beads was lower in presence of  
Rp-8-Br-cAMPS at 24 hours (Panel B). Data shown are single data points and mean ± SEM of  
4 independent experiments with cells isolated from distinct healthy volunteers, as described in 
chapter 2.5. Gates were established by EDTA, Freeze Thaw and unstained controls. Statistical 
analysis was performed through paired t tests. Significant differences between Rp-8-Br-cAMPS 
treated and control conditions were indicated by octothorpes (#). Results were considered to be 
statistically significant for p<0.05 (#). 
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Figure 55: PKA Inhibitor Rp-8-Br-cAMPS does not Significantly Increase mNØ Apoptosis in 
Presence of the PKA Agonist dbcAMP. mNØ from a 4-day differentiation culture were seeded 
at 3.3 x 10
6
/ml apoptosis medium, as described in chapter 2.1.2. mNØ were cultured in presence 
and absence of 100 μM of dbcAMP and 0.7 mM of the PKA inhibitor Rp-8-Br-cAMPS for 24 
hours before apoptosis was quantified by FACS through PE-annexin V (FL2) and Topro-3 
(FL4; Panel A). Total cell numbers were determined through FACS analysis of CountBright 
beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ was lower for dbcAMP treated 
conditions at 24 hours (Panel A). Relative abundance of viable cells compared to Countbright 
Beads was not significantly regulated by dbcAMP or Rp-8-Br-cAMPS treatment at 24 hours 
(Panel B). Data shown are mean ± SEM of 4 independent experiments with cells isolated from 
distinct healthy volunteers, as described in chapter 2.5. Gates were established by EDTA, 
Freeze Thaw and unstained controls. Statistical analysis was performed through Two Way 
ANOVA with Sidak’s posttest. Asterisks (*) indicate differences to the untreated control. 
Results were considered to be statistically significant for p<0.05 (*).  
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Figure 56: LPS and PGE2 Cooperate in the Induction of PKA-Dependent Prevention of Cell 
Loss in mNØ. mNØ from a 4-day differentiation culture were seeded at 3.3 x 10
6
/ml apoptosis 
medium, as described in chapter 2.1.2. mNØ were preincubated for 15 minutes with 0.7 mM 
Rp-8-Br-cAMPS. Thereafter, mNØ were cultured in presence or absence of 1ng/ml LPS, 10 μM 
PGE2, or both for 30 hours before apoptosis was quantified by FACS through PE-annexin V 
(FL2) and Topro-3 (FL4; Panel A). Total cell numbers were determined through FACS analysis 
of CountBright beads (Panel B). Mean percentage of FL2
+
/FL4
-
 mNØ was significantly lower 
for treatment with both LPS and PGE2 (Panel A). Relative abundance of viable cells compared 
to Countbright Beads was significantly enhanced in presence of both LPS and PGE2, and 
treatment-induced increase in viable cells was blocked by Rp-8-Br-cAMPS-treatment (Panel B). 
Data shown are mean ± SEM of 3 independent experiments with cells isolated from distinct 
healthy volunteers, as described in chapter 2.5. Gates were established by EDTA, Freeze Thaw 
and unstained controls. Statistical analysis was performed through Two Way ANOVA with 
Sidak’s posttest. Asterisks (*) indicate differences to control conditions, while octothorpes (#) 
denote differences in Rp-8-Br-cAMPS treatment conditions. Results were considered to be 
statistically significant for p<0.05 (#) and p<0.01 (**).  
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5.3.1. Optimisation of the RNAi Strategy. 
Small interference RNAs (siRNA) were delivered into mCMP by nucleofection with an Amaxa 
Nucleofector, as previously described in chapter 2.3.6. To optimise the transfection efficiency, 
conditionally-immortalised mCMP were transfected with a non-targeting (siScrbl) and a CypB 
(siCypB) targeting siRNA pool and subsequently incubated for 48 to 96 hours. Transfection 
efficiency was assessed through the measurement of gene expression changes by RT PCR. 
CypB gene expression was reduced following transfection with CypB siRNA (Fig. 57). There 
was no change in gene expression at 24 hours post-transfection (data not shown). Gene 
knockdown was most efficient at 48 hours post-transfection (85 % compared to scrambled; Fig. 
57A, B) and gene transcripts typically increased over time until 96 hours at which time only  
12 % reduction in CypB mRNA was observed (Fig. 57A, B). Nucleofection reduced overall cell 
numbers (data not shown); however, numbers of viable cells recovered over the course of the 
next 72 hours (Fig. 57C). Moreover, there were no significant differences in viable cell numbers 
in siScbrl and siCypB transfected cultures (Fig. 57C). 
Since transfection efficiency was sub-optimal at 96 hours posttransfection, siRNA transfection 
during the differentiation process of mCMP to mNØ is necessary to obtain newly matured 
neutrophils with the greatest gene knockdown. To optimise the transfection strategy, mCMP 
were transfected with an siRNA pool for siScrbl at D0 to D3 of differentiation (n=1). 
Transfection at D0 considerably reduced viable cell numbers during the differentiation which 
continued through to D4 posttransfection (Fig. 58A). Transfection at D1 of mCMP 
differentiation initially reduced viable cell numbers, while cell numbers recovered considerably 
over the following two days. Transfection on D2 on the other hand noticeably reduced cell 
numbers with a decreased recovery rate, and an overall reduced number of viable cells on D4. 
Transfection at D3 did not impair the recovery of cells and yielded the highest number of viable 
mNØ at D4 (Fig. 58A).  
Transfection on D1 of the differentiation process was chosen as a suitable timepoint for mCMP 
transfection, due to acceptable numbers of viable cells (Fig. 58A), as well as gene knockdown 
efficiency at 72 hours post-transfection (Fig. 57A, B). Consequently, cells were transfected with 
the siRNA pools siScrbl and siCypB on D1 post estrogen withdrawal, and cultured in the 
presence of SCF and G-CSF for a further 3 days. There was no difference in viable cell numbers 
between siScrbl and siCypB transfected cultures (Fig. 58B). On D4, mCypB levels were reduced 
by 67.8 % (± 18.8 SEM) in siCypB transfected cells in comparison to the non-targeting control 
(Fig. 58C, D). This indicates that gene product knockdown is retained throughout the 
differentiation procedure by transfection of mCMP at D1 of differentiation. 
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Figure 57: mRNA Expression of CypB in mCMP is Transiently Modulated by RNAi. mCMP 
were transfected with a siRNA pool for mCypB (siCypB) or a non-targeting control pool 
(siScrbl) with the Amaxa Nucleofector (as described in chapter 2.3.6.). mRNA was extracted 
from mNØ 48 -96 hours post transfection using the TRI method (as described in chapter 2.3.1.). 
Total cellular RNA was reverse transcribed into cDNA using random primers and reverse 
transcribed RT-PCR products (as described in chapter 2.) were visualised by ethidium bromide 
staining on a 1.2 % Agarose TAE gel (Panel A). mCypB levels were reduced by 85 % at 48 
hours posttransfection (n=1), 52.5 % ± 13.6 SEM (n=3) at 72 hours p.t. and 12 % at 96 hours 
p.t. (n=1) compared to a non-targeting control and normalised to GAPDH (Panel A, B). Viable 
cell numbers for siScrbl and siCypB transfected cells were measured by haemocytometer 
counts. Viable cell numbers significantly increased for both siScrbl and siCypB transfected cells 
(n=3), whereas no differences in viability could be detected between the cultures (Panel C). The 
molecular weight standard HyperladderIV was used to approximate the band size of mCypB 
(343 bases) and mGAPDH (233 bases). Reductions in band intensity were quantified by 
densitometry with the ImageJ software. Statistical analysis was performed through Two Way 
RM ANOVA with Sidak’s posttests and significant differences to the 0 hour control were 
indicated by asterisks (*). Results were considered to be statistically significant for p<0.05 (*). 
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Figure 58: Transfection with siRNA for CypB in mCMP Modulates Gene Expression in 
mNØ. mCMP were incubated in differentiation medium for 4 days after estrogen withdrawal (as 
described in chapter 2.1.2.). mCMP were transfected on Day 0 (Panel A), Day 1 (Panel A, B), 
Day 2 (Panel A) or Day 3 (Panel A) with a siRNA pool for mCypB (Panel B) or the non-
targeting control pool siScrbl (Panel A, B) using the Amaxa Nucleofector. mRNA was extracted 
from mNØ on D4 using the TRI and reverse transcribed into cDNA using random primers, 
where indicated. RT-PCR products (as described in chapter 2) were visualised by ethidium 
bromide staining on a 1.2 % Agarose TAE gel (Panel C). Transfection with siScrbl (Panel A) 
reduced viable cell numbers to a greater extent by transfection of D2, in contrast to D1 (n=1). 
Transfection of differentiation cultures on D1 of differentiation allowed the further expansion of 
the growth culture (Panel B), with no significant differences in viable cell numbers between 
siScrbl and siCypB transfected cells. On D4, mCypB levels were reduced by 67.8 %  
(± 18.8 SEM) in siCypB transfected cells in comparison to the non-targeting control (Panels C, 
D). Molecular weight standard HyperladderIV was used to approximate the band size of mCypB 
(343 bases) and mGAPDH (233 bases). Images were analysed with ImageJ. Statistical analysis 
was performed through Two Way RM ANOVA with Sidak’s posttests. Unless otherwise 
indicated, data shown are representative for three independent experiments. Significant 
differences to D0 were indicated by asterisks (*). Results were considered to be statistically 
significant for p<0.05 (*), p<0.01 (**) and p<0.0001 (****). 
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5.3.2. Modulation of Mcl-1 and Casp-3 Levels in mNØ and Assessment of 
Functional Consequences. 
Following the successful knockdown of CypB, it was aimed to modify the expression of key 
genes in neutrophil survival and apoptosis, and to study the functional consequences on cell 
death. In this context, caspase 3 (Casp-3) was chosen as a target, as it is a well-established 
component of spontaneous apoptosis (Pongracz et al., 1999; Porter, Jänicke, 1999). In addition, 
the anti-apoptotic Bcl-2 family member Mcl-1 has been shown to be essential for neutrophil 
survival and therefore an ideal candidate for this experiment (Wardle et al., 2011; Murphy, 
Caraher, 2015). Consequently, mCMP were transfected on D1 of differentiation with siRNA 
pools for the pro-apoptotic Casp-3 or Mcl-1. On D4, mMcl-1 levels were reduced by 63.2 %  
(± 16.6 SEM) and mCasp-3 levels by 57.5 % (± 11.7 SEM) in comparison to the non-targeting 
control (Fig. 59A, B). Viable cell numbers significantly increased in a time dependent manner 
in all transfection cultures during their differentiation (Fig. 59C). However, siMcl-1 transfected 
cultures had significantly lower viable cell numbers in comparison to the non-targeting control, 
indicating that Mcl-1 knockdown cultures had a growth disadvantage. Transfection cultures 
showed a fully mature morphology on D4 (Fig. 59D), indicating that the reduction in mature 
mNØ numbers was not caused by a delay in differentiation. Therefore, it was hypothesised that 
changes in constitutive apoptosis in the Mcl-1 knockdown culture decreased viable cell numbers 
during mNØ differentiation. 
Consequently, fully mature mNØ from a 4 day differentiation culture were examined for 
baseline apoptosis. Transfected mNØ were cultured in basal medium for 6 or 30 hours. Viable 
cell numbers and apoptosis were examined by flow cytometry. At 0 hours, the mean percentage 
of FL2
+
/FL4
-
 cells in the Mcl-1 knockdown culture was increased by 40.3 % ± 50.3 SEM in 
comparison to the non-targeting control (Fig. 60A), while FL2
+
/FL4
-
 cells in the Casp-3 
knockdown culture was decreased by 16.5 % ± 7.2 SEM, indicating that Mcl-1 and Casp-3 
knockdown altered mNØ apoptosis. For all, siScrbl, siMcl-1 and siCasp-3 mNØ, the mean 
percentage of FL2
+
/FL4
-
 was significantly increased at 6 hour and 30 hours (Fig. 60B). At  
30 hours, siCasp-3 transfected cells showed a significantly lower mean percentage of FL2
+
/FL4
-
 
cells in comparison to siScrbl cultures. Viable cell numbers decreased over time for siScrbl 
transfected cultures (Fig. 60C). An increased number of viable cells were present in the Casp-3 
knockdown cultures compared to Mcl-1 cultures, but this was not significant. Taken together, 
siMcl-1 and siCasp-3 mNØ displayed functional alterations in the regulation of their lifespan, 
and the increased apoptosis in siMcl-1 cultures might account for the decrease in viable cell 
numbers during differentiation. 
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Figure 59: RNAi in mCMP Reduces Mcl-1 and Casp-3 mRNA Expression in Mature mNØ. 
mCMP were incubated in differentiation medium for 4 days after estrogen withdrawal (as 
described in chapter 2.3.6.). mCMP were transfected on Day 1 post estrogen withdrawal (Panel 
A, B) with a siRNA pool for mMcl-1, mCasp-3 or the non-targeting control siScrbl with the 
Amaxa Nucleofector. mRNA was extracted from mNØ on D4 using TRI reagent and reverse 
transcribed into cDNA with random primers. RT-PCR products (as described in chapter 2) were 
visualised by ethidium bromide staining on a 1.2 % Agarose TAE gel (Panel A). On D4, mMcl-
1 levels were reduced by 63.1 % (± 16.6 SEM) and mCasp-3 levels by 57.5 % (± 11.7 SEM) in 
comparison to the non-targeting control (Panels A, B). Viable cell numbers of transfection 
cultures significantly increased in a time dependent manner during their differentiation (Panel 
C). siMcl-1 transfected cultures had significantly lower viable cell numbers in comparison to 
the non-targeting control. Transfection cultures showed a fully mature morphology on D4 
(Panel D). Molecular weight standard HyperladderIV was used to approximate the band size of 
mMcl-1 (265 bases), mCasp-3 (379 bases) and mGAPDH (233 bases). Images were analysed 
with ImageJ. Statistical analysis was performed through Two Way RM ANOVA with Sidak’s 
posttests. Data shown are representative for three independent experiments. Significant 
differences to D0 were indicated by asterisks (*), while changes to the siScrbl transfected 
culture were denoted by octothorpes (#). Results were considered to be statistically significant 
for p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.0001 (****).  
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Figure 60: Modulation of Mcl-1 and Casp-3 mRNA Expression Induces Functional Changes 
in mNØ Apoptosis and Survival. mCMP were incubated in differentiation medium for 4 days 
after estrogen withdrawal (as described in chapter 2.3.6.). mCMP were transfected on Day 1 
post estrogen withdrawal (Panel A, B) with a siRNA pool for mMcl-1, mCasp-3 or the non-
targeting control siScrbl with the Amaxa Nucleofector. Modified mNØ from a 4-day 
differentiation culture were seeded at 3.3 x 10
6
/ml apoptosis medium, as described in chapter 
2.1.2. mNØ were cultured for 0 – 30 hours before apoptosis was quantified by FACS through 
PE-annexin V (FL2) and Topro-3 (FL4; Panel B) and total cell numbers determined through 
FACS analysis of CountBright beads (Panel C). At 0 hours, the mean percentage of FL2
+
/FL4
-
 
cells in the Mcl-1 knockdown culture was increased by 40.3 % ± 50.3 SEM in comparison to 
the non-targeting control (Panel A), while FL2
+
/FL4
-
 cells in the Casp-3 knockdown culture was 
decreased by 16.5 % ± 7.2 SEM. Mean percentage of FL2
+
/FL4
-
 siScrbl, siMcl-1 and Casp-3 
mNØ (Panel B) was significantly increased at 6 hour and 30 hours. At 30 hours, siCasp-3 
transfected cells showed a significantly lower mean percentage of FL2
+
/FL4
-
 cells in 
comparison to siScrbl cultures. Viable cell numbers decreased over time for siScrbl transfected 
cultures (Panel C). Viable cell numbers of Casp-3 knockdown cultures were non-significantly 
increased. Data shown are mean ± SEM of 4 independent experiments. Statistical analysis was 
performed through Two Way ANOVA with Sidak’s posttest. Significant differences to 0 hours 
were indicated by asterisks (*), while changes to the siScrbl transfected culture were denoted by 
octothorpes (#). Results were considered to be statistically significant for p<0.05 (*), p<0.01 
(**/##) and p<0.0001 (****).  
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5.3.3. Modulation of NR4A2 and NR4A3 Levels in mNØ. 
To examine the influence of nuclear receptors on mNØ lifespan, mCMP were transfected with a 
siRNA pool for mNR4A2, mNR4A3 and a non-targeting control on D1 of differentiation. In 
mNØ, mNR4A2 and mNR4A3 levels were reduced at D4 by a mean of 91.2 % ± 3.4 SEM and 
75.1 % ± 14.5 SEM in comparison to siScrbl mNØ respectively (Fig. 61A, B). Transfection 
with siNR4A2 in mCMP significantly reduced total viable cell numbers of mNØ at D4  
(Fig. 61C), indicating a potential role of NR4A2 in mNØ development. Reasons for this include 
decreased differentiation, delayed proliferation or increased apoptosis, overall resulting in a 
growth disadvantage in contrast to siScrbl mNØ. Interestingly, an increased amount of 
FL2
+
/FL4
-
 mNØ was observed in NR4A2 KD mNØ at D4 of differentiation (n=1; Fig. 61D). 
5.4. Discussion 
5.4.1. Choice of Apoptosis Assay. 
The main aim of this chapter was to validate mNØ as a tool to investigate apoptosis and survival 
pathways and to be able to relate the findings to PMN survival pathways. For this end, the 
choice of an appropriate apoptosis assay is crucial to accurately distinguish distinct forms of cell 
death. Complicating their distinction is the fact that apoptotic cells are rapidly phagocytosed in 
vivo, while the lack of macrophages in vitro allows apoptosis to proceed to secondary necrosis 
(Haslett, 1999). Hence, in a neutrophil cell line with prolonged time in culture, this full cellular 
disintegration can lead to the culmination of extensive amounts of cellular debris.  
Morphological assessment of apoptosis is often referred to as the most accurate measure of 
apoptosis and often described as the gold standard. This technique is based on microscopic 
observation of visible apoptotic hallmarks, such as chromatin condensation and cleavage, cell 
shrinkage and formation of membrane protrusions (Saraste, 1999). Murine neutrophils possess a 
nuclear shape distinct to that of human neutrophils, which can be observed by light microscopy 
(Thompson et al., 2014). Good practice for the assessment of apoptosis in murine neutrophils 
encompasses the use of flow cytometry to validate findings for morphological apoptosis. 
Assessing apoptosis solely based on their morphological features can be misleading, as mNØ 
displayed the first pre-apoptotic changes (i.e. localised spots of chromatin condensation) shortly 
after their differentiation (Fig. 46A), while they still possessed full membrane integrity, no PS 
exposure, or reductions in their forward and side scatter (FSC, SSC; Fig. 48).  
However, the percentage of morphologically apoptotic mNØ was considerably lower (20 %,  
36 hours; Fig. 47A) than mean mNØ apoptosis based on membrane integrity and PS exposure 
(40 %, 36 hours; Fig. 48A). Expression of PS on the outer membrane is an early apoptotic 
feature (Fadeel et al., 1998; Fadok et al., 2001; Hampton et al., 2002), and thus may account for 
the higher levels of FL2
+
/FL4
-
 mNØ as compared to morphologically apoptotic cells. Moreover,   
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Figure 61: NR4A2, but not NR4A3 Knockdown in mCMP Reduces Cell Numbers During the 
Differentiation to mNØ. mCMP differentiation cultures were transfected one day post-estrogen 
withdrawal using the Amaxa Nucleofector. Cells were transfected with siRNA for mNR4A2, 
mNR4A3 or a non-targeting control (siScrbl) on day 1, and subsequently incubated in 
differentiation medium for further 3 days with daily media replenishment. mRNA was extracted 
on day 4 using the TRI method (as described in chapter 2.3.1.). Total cellular RNA was reverse 
transcribed into cDNA using random primers. RT-PCR products (as described in chapter 2) 
were visualised by ethidium bromide staining of a 1.2 % Agarose TAE gel (Panel A). Total cell 
numbers were determined through haemocytometer counts (Panel C). mNR4A2 and mNR4A3 
levels were reduced by 91.2 % ± 3.4 SEM and 75.1 % ± 14.5 SEM respectively (Panel A, B) at 
day 4 in mNØ. Representative blots are shown in Panel A. Transfection with siNR4A2 in 
mCMP significantly reduced total cell numbers of mNØ at D4 (Panel C). Molecular weight 
standard HyperladderIV was used to approximate the band size of mNR4A2 (990 bases), 
mNR4A3 (328 bases) and mGAPDH (233 bases). cDNA band intensity was quantified by 
densitometry using the ImageJ software. Data shown are mean ± SEM (Panels B-D), or 
representative images (Panel A) of 1(Panel D) or 3 (Panels A-C) independent experiments. 
Statistical analysis was performed through Two-Way ANOVA with Sidak’s post-tests. 
Significant differences to D1 were indicated by asterisks (*), while changes to the siScrbl 
transfected culture were denoted by octothorpes (#). Results were considered to be statistically 
significant for p<0.01 (**), p<0.001 (***/###) and p<0.0001 (****). 
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neutrophils undergo secondary necrosis upon failure of efferocytosis in vitro (Haslett, 1999). 
This may lead to the underestimation of apoptosis in cultured cells, when relying on 
morphology alone (Fig. 47; Fig. 48). The gating used for this study relied on the use of negative 
controls for PS/Annexin V binding and membrane integrity (as described in chapter 2.2.2.). 
Interestingly, the negative control for membrane integrity was not only highly FL4
+
, but also 
FL2
+
, indicating that necrotic cells may expose PS residues and thus bind to Annexin V. This is 
supported by studies, where primary necrotic cells displayed PS/Annexin V binding and, albeit 
less efficiently than apoptotic cells, were phagocytosed by macrophages (Fadeel et al., 1998; 
Fadok et al., 2001; Hampton et al., 2002; Broukaert et al., 2004; Appelt et al., 2005). Since PS 
is typically present on the internal plasma membrane leaflet, the increased membrane 
permeability may thus allow for the internalisation and binding of Annexin V to PS. In this 
study, dual positive cells with high levels of FL4
+
 were excluded to allow the distinction 
between apoptotic and necrotic cells. A potential overlap of primary and secondary necrotic 
mNØ does not hinder the investigation of mNØ cell death in this study and is in fact comparable 
to the occurrence of secondary necrosis in human PMN. 
It has been reported that membrane permeabilisation is not a unique feature of necrotic cells, but 
also occurs at late apoptotic/secondary necrotic stages (Dive et al., 1992; Ni et al., 1993; 
Ormerod et al., 1993), and apoptotic cells allow increased leakage of viability dyes (Ormerod et 
al., 1993; Schmid et al., 1994; Idziorek et al., 1995). This is consistent with the typically 
moderately increased FL4 fluorescence of FL2
+
 cells in comparison to viable cells (FL2
-
/FL4
-
; 
Fig. 48E), suggesting that loss of membrane integrity encompasses later stages of apoptosis in 
mNØ. Hence, quantitatively more accurate means to determine actual amounts of neutrophils 
committed to an apoptotic pathway in vitro may incorporate the flow cytometric assessment of 
apoptotic features, where on average 30x more individual cells are routinely assessed per 
sample. It was therefore determined that for the purpose of this project, the quantification of 
murine apoptotic neutrophils can be more representatively undertaken through flow cytometric 
analysis. 
Additionally, the quantification of cell loss in culture was used to provide another distinction 
between cell death mechanisms specifically modulating apoptosis or general cell survival. In 
this context, cell loss is an accumulative measurement, while apoptosis reflects more accurately 
apoptotic cells at a given time due to secondary necrotic loss of apoptotic cells. In vitro 
secondary necrotic cell loss furthermore results in variability if assessing cell loss based on total 
cell counts. Thus, cell loss can be more accurately reflected when based on the amount of viable 
cells remaining in culture (Fig. 48C). Viable cells can either be counted in a haemocytometer, 
or based on the relative abundance of flow cytometric beads in a sample. Hodge et al. (2004) 
previously demonstrated that neutrophil numbers determined by manual counting or flow 
cytometric assessment were comparable. In this context, the use of CountBright beads has the 
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convenience of linking the apoptotic cells in one sample directly to the cell counts. This 
measurement is independent from loss of culture volume due to evaporation. Therefore, viable 
cells were assessed by CountBright beads in this study, as this was perceived to be highly 
accurate and the most reproducible measure. 
5.4.2. mNØ Apoptosis Displays Vital Similarities to PMN Apoptosis. 
The similarity of mNØ to primary neutrophils was demonstrated by the occurrence of 
spontaneous apoptosis in a time-dependent manner (Fig. 47, Fig. 48). The apparent difference 
between morphological apoptosis and FL2
+
/FL4
-
 cells (Fig. 47A, D; Fig. 48A, D) may be 
explained by the longer preparation time and exposure to potentially cytotoxic reagents in the 
flow cytometry staining protocol. However, the previous assay found only a small difference 
between FL2
+
/FL4
-
 and all FL2
+
 cells, indicating that necrotic cell death in itself is not a 
common occurrence. In fact, the lack of constitutive necrosis may also indicate the occurrence 
of secondary necrosis of apoptotic cells, and further limitations of the distinct assays were 
discussed in the previous subchapter. Briefly, a comparison between the apoptosis 
measurements for 36 hours showed over 40 % of cells were positive for PS exposure, while 
only 20 % of cells displayed apoptotic morphology at the same timepoint (Fig. 47A, D;  
Fig. 48A, D). The difference between the measurements is not unexpected, as PS exposure has 
been described as a hallmark of early apoptosis (Savill, 1997b), and therefore the measurement 
of PS exposure might be higher than morphological apoptosis at comparable timepoints. In a 
previous publication (Kirschnek et al., 2011; Gautam et al., 2013), considerably higher 
percentages of Annexin V/PI positive mNØ were observed at basal levels (20-40 %) and  
24 hours (80-90 %), indicating that the occurrence of necrosis and PS exposure may vary 
considerably in different studies.  
Moreover, the relative decrease in cell numbers from 0 hours to 12 hours was comparable for 
both assay types (Fig. 47B, Fig. 48B). Therefore, the most likely explanation is that basal levels 
of cell loss occurred due to the washing steps during preparation and their analysis in the flow 
cytometer, which is a common limitation of flow cytometric analysis (Dux et al., 1994).  
mNØ apoptosis was modulated by addition of growth factors (Fig. 49), corresponding to the 
findings in primary human neutrophils (van Raam et al., 2008). At 24 hours, a third of mNØ 
were apoptotic in growth-factor deprived media, whereas a quarter was apoptotic in presence of 
SCF and G-CSF (Fig. 49A). This correlates well with the apoptosis rates in bone-marrow 
derived murine neutrophils with 70 % survival in growth factor deprived media, and 80 % 
survival in supplemented medium at the same timepoint (Villunger et al., 2003) and mNØ 
apoptosis of 53.2 % in absence of SCF and 16.9 % in presence of the growth factor at 24 hours 
(Koedel et al., 2009). In human PMN, 45 % (Percoll-purified PMN) to 70 % (Optiprep- highly 
purified PMN) apoptosis would be expected at a comparable (20 h) time point (Wardle et al., 
           CHAPTER 5 
- 182 - 
2011). Apart from species-dependent variations in neutrophil lifespan, these differences in 
constitutive apoptosis rates might also depend on the initial neutrophil maturity and cell age at 
start of the experiments. Thereby, bone-marrow derived murine neutrophils resemble mNØ 
closely. This is interesting, as it has not only been shown that the occurrence of band neutrophils 
is more common in murine blood, but also that Percoll gradients can be utilised to separate 
different types of neutrophil precursors according to their increasing densities in maturation 
(Cowland, Borregaard, 1999). Potentially this might also account for differences between 
Percoll and Optiprep-purified neutrophils.  
However, it cannot be disregarded that the occurrence of uncommitted mCMP by the end of the 
differentiation process might account for the presence of functional macrophages and thus 
reduced numbers of apoptotic neutrophils in samples; the importance of this factor was 
previously demonstrated (Sabroe et al., 2001; Sabroe et al., 2004). Based on the low presence of 
mCMP, macrophages, and band neutrophils in light microscopic examination of differentiation 
cultures (Fig. 46), the effect of this phenomenon is likely to be rather limited. Additionally, the 
further purification of differentiation cultures by a modified Percoll column (data not shown), 
which would remove contaminating mononuclear cells, did not result in substantial increases in 
cell purity and constitutive apoptosis. 
Kirschnek et al. (2011) observed that ER-Hoxb8 mNØ show typical high rates of constitutive 
apoptosis (80% at 24 hours) in culture. This is surprising, as murine neutrophils typically 
display lower rates of apoptosis than human neutrophils (Villunger et al., 2003). In our study, 
we have found rates of 30% apoptosis at 24 hours (Fig. 49), comparable to the rates previously 
observed for murine bone-marrow neutrophils (Villunger et al., 2003), and consistent with the 
results of Kirschnek et al. (2011) for bone marrow derived mNØ. In summary, differences in 
apoptosis rates found in this study were only subtle in comparison to primary murine 
neutrophils, while differences to human PMN were more pronounced. Culturing conditions of 
differentiated neutrophils were aimed at modelling physiological conditions, where a majority 
of lobulated neutrophils are released into the blood stream following their maturation in the 
bone marrow (Metcalf, 2008). Taken together, it was concluded that SCF and G-CSF suppress 
mNØ apoptosis and prolong their lifespan to a limited extend at late timepoints. However, mNØ 
retained their ability for constitutive apoptosis even in presence of growth factors. Moreover, 
the residual amount of growth factors in the culture after consecutive washes is likely to be 
extremely low. Hence, the influence of SCF and G-CSF in this setting is thought to be 
negligibly low. 
Apoptotic cells in vitro undergo secondary necrosis, which is thought to be due to the lack of 
macrophage phagocytosis (Haslett, 1999). Here, the observed cell loss in Fig. 47 correlated well 
with the apoptosis levels and it was thus concluded that apoptosis constitutes the major form of 
cell death occurring in this model system (Fig. 47). Both, intrinsic and extrinsic apoptosis 
           CHAPTER 5 
- 183 - 
essentially rely on the action of initiator and executioner caspases. Hence, the pan-caspase 
inhibitor Q-VD-OPh (QVD) was utilised to show the relevance of caspases in mNØ apoptosis. 
Consistent with the reported effect of Q-VD-OPh on primary human neutrophils (Wardle et al., 
2011) and a previous study in mNØ (Kirschnek et al., 2011), apoptosis was significantly 
delayed by QVD, demonstrating the caspase dependence of mNØ apoptosis (Fig. 50). However, 
QVD more effectively induced apoptosis in a comparable study with human PMN (Wardle et 
al., 2011). This may indicate that affinity of QVD for murine caspase domains may be reduced. 
Interestingly, mice lack the initiator caspase 10 (Lamkanfi et al., 2002), which may account for 
the difference in efficacy. However, in human cells, QVD was equally effective at targeting the 
different caspase domains (Caserta et al., 2003). On the other hand, QVD might also cause 
nonspecific effects, as demonstrated by its (limited) cellular toxicity in high concentrations with 
human neutrophils (Caserta et al., 2003). This would not be surprising, as various other caspase-
inhibitors are poorly selective and show wide-ranging toxic effects (McStay et al., 2008). 
Interestingly, there are a large number of caspases, with partially redundant functions involved 
in human apoptosis pathways (McStay et al., 2008). In murine neutrophils, homologues for 
most human caspases exist; however, existing differences between two species (reviewed by: 
Mestas et al., 2004; Degterev et al., 2003) may account for discrepancies in the responses to 
QVD. Due to the high divergence in human caspases, the question of partial functional 
abundance might become relevant, as apoptosis can be engaged in a similar manner in both 
systems.  
Treatment of mNØ with the broad-spectrum protein kinase inhibitor staurosporine resulted in a 
significant increase in late apoptosis (Fig. 51). The low efficiency of STS is not surprising, as 
the molecular action of staurosporine in apoptosis is not well understood, but may only partially 
be derived by the activation of caspases (Belmokhtar et al., 2001), furthermore supporting the 
caspase-dependence of mNØ apoptosis. Besides its action on caspases, staurosporine competes 
for ATP-binding and thereby acts as a pan-kinase inhibitor, which might indicate that 
staurosporine shows a lower efficacy in mNØ, because important pro-survival kinases, such as 
PKA, are not constitutively active. Taken together, STS increased apoptosis, indicating that 
either constitutive kinase activity or caspase dependent apoptosis are involved in the regulation 
of mNØ lifespan. 
5.4.3. The Relevance of PKA Signalling in mNØ Survival. 
The relevance of PKA survival pathways in mNØ was evaluated. Thereby, the cAMP agonist 
dbcAMP and the PKA agonist pair N6-MB-cAMP and 8-AHA-cAMP were shown to reduce 
apoptosis (Fig. 52, Fig. 53). Reduction in apoptosis for dbcAMP in mNØ at 30 hours was 
comparable to percentages observed at 20 hours for human PMN (Fig. 36; Martin et al., 2001). 
This might indicate that human PMN are more prone to undergo apoptosis, potentially due to 
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their mixed age profile at the start of the experimental setup in vitro. Use of N6/8-AHA  
(Fig. 53) more efficiently reduced apoptosis than dbcAMP (Fig. 52), consistent with the earlier 
finding in PMN (Fig. 28-29; discussed in chapter 4.3.). Briefly, an explanation for the lower 
efficacy of dbcAMP may be due to its poor cell permeability, the potential side-effects of 
second signalling chains induced by butyrate (Yusta et al., 1988). Interestingly, dbcAMP shows 
a low activity towards PKA in its inactive form (Yusta et al., 1988), which may reduce its 
activity in mNØ survival pathways. Interestingly, viable cell numbers of dbcAMP treated cells 
were increased at 6 hours of treatment (Fig. 52B). As mNØ are postmitotic and the number of 
progenitors in the cell preparations was negligibly low, a possible explanation may be that 
dbcAMP could exert an effect on cell numbers at the 0 hours timepoint already during the time 
required to prepare cells for their flow cytometric assessment. 
The PKA antagonist Rp-8-Br-cAMPS only increased basal mNØ apoptosis by a small extent 
and had no effect on viable cell numbers (Fig. 54), indicating that only a low level of 
constitutive PKA signalling might be active in mNØ. A technical reason for the low efficiency 
of Rp-8-Br-cAMPS in the induction of mNØ apoptosis might involve a potentially decreased 
affinity of Rp-8-Br-cAMPS to murine PKA isoforms. However, as mNØ are not directly 
derived from an in vivo system, and thereby potentially show but a low level of constitutive 
PKA-dependent survival due to a lack of previous cell activation. In fig. 52, PKA survival was 
readily engaged by dbcAMP, and cell numbers were increased at 6 hours (Fig. 53B), and late 
mNØ apoptosis was increased by Rp-8-Br-cAMPS treatment (Fig. 54A). In fig. 55B, dbcAMP 
did not induce significant amounts of mNØ survival, which consequently could not be blocked 
by PKA antagonism. Despite the inefficacy of inducing survival, dbcAMP had a low effect on 
reducing apoptosis (Fig. 55A), which was not prevented by Rp-8-Br-cAMPS treatment. This 
apparent inconsistency with previous data on PKA inhibition in mNØ may very well indicate 
that other cAMP-responsive pathways, such as Epac-signalling, have a greater influence on 
survival signalling in mNØ than in human PMN. Moreover, the rather low constitutive activity 
of PKA signalling (Fig. 54) may also differ between distinct batches of cells, which consistently 
also possess varying levels of constitutive apoptosis. Nevertheless, a near significant p-value of 
p=0.0569 was achieved by t-test, when comparing the media control to Rp-8-Br-cAMPS 
treatment samples. A comparison of Rp-8-Br-cAMPS treatment of dbcAMP treated samples 
only achieved a p-value of p=0.1596, which may further support the involvement of further 
cAMP-dependent signalling pathways that may alter apoptosis levels. The decreased efficiency 
of LPS and PGE2 in rescuing mNØ from apoptosis (Fig. 56) may be due to a decreased affinity 
of the agonists towards the murine receptor isoforms. Moreover, it is possible that the 
expression of the relevant pro-survival receptors in mNØ (i.e. EP receptors, TLR4) is 
diminished, and a minimum threshold level of receptor binding needs to be achieved before 
PKA activation is achieved. In support, B cells and macrophages from BALB/c mice exhibit 
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reduced functional responses to LPS stimulation caused by their attenuated TLR4 receptor 
expression (Tsukamoto et al., 2013; Oliveira et al., 2014a), caused by a single nucleotide 
polymorphism in the receptor gene. Additionally, the responsiveness of mice to LPS is greatly 
attenuated in comparison to humans (Warren et al., 2010). In Balb/c mice, no constitutive 
expression of EP receptors EP1, EP2, EP3 and EP4 was detected (Akaogi et al., 2004), while 
their expression could be induced. This may help to explain the reduced efficacy of PKA 
survival in mNØ. 
As PKA survival can be engaged in mNØ (Fig. 52-53), it was concluded that the reduced 
efficacy of PKA antagonism in mNØ may be caused by 1) the low constitutive activity of PKA 
signalling, 2) the specific involvement of a PKA subtype, or 3) the unknown affinity of the 
antagonist towards PKA homologs in mice. However, this does not necessarily reflect upon the 
physiological relevance of the model in the research of PKA survival. Taken together, only 
limited evidence for the relevance of PKA-mediated survival in mNØ was determined, while 
this may be comparable to the signalling events in Balb/c mice and may be overcome by the use 
of a different background strain used in the production of mCMP. A failure to achieve 
significant changes in constitutive apoptosis through PKA antagonist treatment further indicate 
that only a negligibly low constitutive PKA activity might be present in mNØ.  
5.4.4. Optimisation of Gene Expression Knockdown in mNØ. 
Artificially synthesised siRNAs, targeting specific gene products can be used to specifically 
modulate gene expression of desired mRNAs and knock down gene expression in dividing cells 
(Tuschl et al., 2002). These siRNAs are 19 base pairs double-stranded RNA molecules with an 
overhang of two bases. Hydrophobic bilayer membranes contain many hydrophobic pore 
openings, which can be converted into hydrophilic pores through an electric pulse, leading to 
rearrangements of the lipids in the pore composition, so that highly charged RNA is enabled to 
pass through (Tarek, 2005). According to the manufacturer, electroporation is ~10x more 
effective than chemical transformation, it can however also result in increased cell death. As 
mNØ are terminally differentiated and quiescent cells (Bainton et al., 1971; Klausen et al., 
2004; Theilgaard-Monch et al., 2005), the efficacy of RNAi needs to be empirically determined 
and optimised to achieve gene product knockdown in the course of the differentiation of mCMP 
to mNØ. 
CypB is a non-essential housekeeping gene that is not involved in the maintenance of cell 
survival (Pachot et al., 2004). Transfection of mCMP with a validated siRNA CypB control pool 
most efficiently reduced gene knockdown at 2 days post-transfection (Fig. 57), where siRNA 
transfected mCMP retain their viability and potential for growth. However, gene knockdown 
before the start of the differentiation of mCMP to mNØ (here: D0), resulted in a low number of 
viable neutrophils at day 2 post-estrogen withdrawal (Fig. 58A). In mCMP, a reasonable 
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reduction of mCypB levels (40 %) was observed 3 days post-transfection (Fig. 57). Therefore, 
mCMP were transfected on day 1 of the differentiation protocol, overall yielding a greater level 
of mNØ numbers on day 4 post-estrogen withdrawal (Fig. 58). Viable cell numbers were not 
significantly different from a control transfection with non-targeting siRNA (Fig. 58B), and 
mCypB levels were reduced by a considerable amount (67.8 % ± 18.8 SEM; Fig. 58 C, D). This 
adds to a study, where CypB was proposed as a general housekeeping gene in peripheral blood 
cells (Pachot et al., 2004). 
5.4.5. Modulation of the Expression of Mcl-1 and Casp3 mRNA. 
To determine the applicability of mNØ as a model system for the modulation of survival and 
apoptosis pathway components, the pro-survival mediator Mcl-1 (Wardle et al., 2011) and the 
pro-apoptotic caspase 3 (Pongracz et al., 1999) were chosen as targets for gene expression 
knockdown in mNØ. siRNA transfection reduced mMcl-1 mRNA by 63.2 % (± 16.6 SEM) and 
mCasp-3 levels by 57.5 % (± 11.7 SEM), respectively (Fig. 59), with no apparent changes in the 
morphological phenotype of mature mNØ. In fact, gene knockdown increased constitutive 
apoptosis by 40.3 % (± 50.3 SEM) in mMcl-1 KD mNØ and reduced basal apoptosis by 16.5 % 
(± 7.2 SEM) in mCasp-3 KD mNØ at 0 hours (Fig. 60A), consistent with the expected function 
of the molecules in the regulation of mNØ lifespan. Interestingly, in the course of the next  
6 – 30 hours, apoptosis in mMcl-1 KD mNØ was not significantly different to the non-targeting 
control. This indicates that Mcl-1 is not modulating mNØ survival following the activation of 
constitutive apoptosis pathways. This is in line with the observations of Wardle et al., (2011), 
who showed that Mcl-1 levels in human PMN decline in a temporal manner. Moreover, Mcl-1 
can be cleaved following caspase activation, and caspase-inhibitable decreases in Mcl-1 
expression were observed in late stages of apoptosis (Wardle et al., 2011).  
Consistently, at 30 hours, the mean levels of apoptosis in mCasp-3 KD mNØ were significantly 
decreased in comparison to the non-targeting control by close to 20 % (Fig. 60B). This suggests 
a role for caspase 3 in mNØ apoptosis, but a lower influence of the molecule in basal 
conditions. This is consistent with the reported involvement of Casp-3 in Noxa-dependent 
apoptosis in mNØ (Kirschnek et al., 2011). Apoptosis was not completely prevented in Casp-3 
KD mNØ, indicating that Casp-3 may be essential, but not sufficient to induce apoptosis. 
Consistently, the non-redundant roles of the effector caspases in the induction of apoptosis were 
previously demonstrated (Slee et al., 2001). Interestingly, Casp-3 knockdown could not prevent 
the occurrence of apoptosis, but resulted in defects of nuclear fragmentation (Degterev et al., 
2003), consistent with the reported requirement for Casp-3 in apoptosis (Woo et al., 1998). 
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5.4.6. Role of NR4A2 mRNA during mNØ Differentiation. 
In chapter 4.2.4, a role for the nuclear receptors NR4A2 and NR4A3 in PKA-dependent survival 
of PMN was observed. Therefore, the effect of NR4A2 and NR4A3 mRNA reduction by RNAi 
was investigated here. An effective knockdown of NR4A2 and NR4A3 levels by 91.2 %  
(± 3.4 SEM) and 75.1 % (± 14.5 SEM), respectively, was achieved at day 4 post estrogen 
withdrawal (Fig. 61A, B). The NR4A2 KD mNØ culture showed significantly decreased cell 
numbers at the end of the differentiation process (D4; Fig. 61C), indicating that NR4A2 has 
important roles during mNØ differentiation. Consistently, specific roles for NR4A2 in cell 
development and differentiation have previously been reported (Yao et al., 2012; Hawk, Abel, 
2011; Sekiya et al., 2013). Thus, NR4A2 may also be employed as an anti-neutrophilic strategy 
in COPD by reducing the numbers of pre-mature neutrophils in the blood during the immune 
response (Gossett and Macwilliams, 1982, Yokose et al, 1998; Seebach et al., 1997). 
Interestingly, apoptosis of NR4A2 KD mNØ, but not NR4A3 KD mNØ cultures at Day 4 of 
differentiation was ~20% higher than in siScrbl-transfected mNØ (n=1; Fig. 61D). This 
indicates that the decreased cell numbers during NR4A2 KD mNØ differentiation may also be 
grounded in the increased rate of cellular apoptosis, as supported by a recent study on the role of 
NR4A2 in survival (Crean et al., 2015).  
5.5. Summary 
In conclusion, the use of murine Hoxb8 conditionally immortalised progenitors and derived 
mNØ is a physiologically relevant model for research into neutrophil survival pathways and 
offers the potential to genetically manipulate and alter gene expression levels by siRNA 
interference in mCMP prior to their differentiation into mNØ. Murine models were used for 
several decades in granulocyte research, and a substantial amount of knowledge has been 
accumulated for the peculiarities of murine neutrophils and their conformities with human 
neutrophils. Furthermore, the model provides the unique opportunity to modulate gene 
expression levels by siRNA interference in neutrophils, which opens near unrestricted 
possibilities to investigate pathways underpinning neutrophil apoptosis and survival.  
Despite the lack of PKA–mediated survival in mNØ, these cells showed responses similar to 
those observed in peripheral blood neutrophils, while being susceptible to manipulation of gene 
expression levels by non-viral RNAi techniques. While a proof-of-principle for the use of this 
technique has been provided here, the optimisation of the nucleofection strategy might enhance 
the gene expression level changes in differentiated neutrophils.  
Moreover, a role for the nuclear receptor NR4A2 in mNØ development and potentially mNØ 
survival was uncovered. The use of a different mouse strain in the expression of ER-Hoxb8 in 
mCMP may thus be useful to further explore the role of NR4A2 in PKA-mediated survival. 
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CHAPTER 6. DISCUSSION 
6.1. Major Findings of this Thesis 
This thesis describes detailed examination of the receptors and molecular mechanisms of PGE2 
survival in PMN in the context of COPD. The pro-survival effect of the prostaglandin PGE2 on 
PMN was shown to be exerted by the EP2 receptor subtype and through the activation of PKA, 
with only a minor for the EP4 receptor subtype on PMN survival. Despite a high affinity of 
PGE2 towards all prostaglandin receptors, PGE2 concentrations in the micromolar range were 
required to induce PMN survival. Possible explanations included the affinity of PGE2 on  
FP receptors, masking the pro-survival effect of PGE2, or that the amount of unbound PGE2 
might be reduced by the presence of serum in the cell culture medium. Moreover, variations in 
the efficacy of PGE2-induced PMN survival may be introduced by the constitutive activity of 
PKA in PMN, which was in turn influenced by both, the presence of macrophages, as well as an 
autocrine survival signal. 
Here, a novel mechanism for the connection of LPS and PGE2 signalling in PMN survival was 
uncovered. It was demonstrated for the first time that LPS modulates the expression of the AC-
coupled prostaglandin receptors EP2 and EP4 in PMN (Fig. 62), which may sensitize PMN to 
the PGE2-mediated survival. Consistently, LPS induced the PKA-inhibitable expression of the 
PKA downstream targets NR4A2 and NR4A3, correlating with LPS-induced survival.  
However, in co-treatment experiments, PGE2 prevented LPS-induced prostaglandin receptor 
upregulation, suggesting a negative feedback loop in the regulation of PMN survival. The  
pro-survival influence of monocytes on PMN survival (Sabroe et al., 2002a) and the greater 
influence of LPS on PMN survival in this context were substantiated. Thus, a crucial step in the 
sustenance of the inflammatory process and increased PMN survival may be through monocyte-
derived PGE2 secretion, induced by LPS.  
Prostaglandin receptor expression of EP2 and EP4 was comparable in PMN from healthy 
control and COPD patients. This furthermore substantiated current models, where neutrophils 
are considered the inflammatory mediators, but not initiator cells in COPD (Sabroe et al., 
2002b). The understanding of the causes of PGE2 secretion by other immune cells implicated in 
the pathology of COPD may thus be beneficial towards the understanding of the complex 
mechanisms of the inflammatory network in COPD. 
Moreover, it was determined that the nuclear receptors NR4A2 and NR4A3 are downstream 
effectors of PKA signalling, and are induced by the EP2/PGE2 signalling axis, thus potentially 
coupling to PMN survival. In a murine neutrophil model, gene expression knockdown 
uncovered a functional role of NR4A2 in neutrophil development, potentially through a  
pro-survival role in neutrophils. 
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Figure 62: Proposed Interactions of LPS and PGE2 Signalling in the Induction of 
Neutrophil Survival in Inflammation in COPD. LPS prolongs PMN survival through several 
mechanisms: indirectly, through the induction of Cox-2 expression in macrophages, leading to 
the release of PGE2 into the inflammatory environment. Secondly, LPS increases the expression 
of EP receptor mRNA, which enhances the late response of PMN to PGE2, thus prolonging 
their survival. Thirdly, LPS-induced increases in NR4A2 expression were inhibited by PKA, 
which may present a switch from early to late survival pathways and/or to the resolution of 
inflammation. PGE2 in itself acts through PKA to induce NR4A2 mRNA expression, overall 
prolonging neutrophil survival, potentially through the induction of pro-survival gene 
expression. Abbreviations: LPS – lipopolysaccharide, TLR4 – toll-like receptor 4, Cox-2 – 
cyclooxygenase 2, PGE2 – prostaglandin E2, EP2 – e-prostanoid receptor 2, AC – adenylyl 
cyclase, cAMP – cyclic AMP, PKA – protein kinase A, PMN – polymorphonuclear cell. 
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6.2. Implications for the Regulation of PMN Survival Through PKA in 
Inflammation. 
Current therapeutic strategies neglect and underestimate the harmful effect of neutrophils in 
inflammatory conditions. Neutrophils are considered to exert a protective role in inflammation 
due to anti-inflammatory cytokine expression (Tecchio et al., 2014), whereas mounting 
scientific evidence of a pathogenic role for neutrophils in chronic inflammation likewise exists 
(Peleman et al., 1999; Yoshioka et al., 1995; Nadel, 1991; Qiu et al., 2003; O’Donnell et al., 
2004; Baraldo et al., 2004), and neutrophils are also known to express a range of  
pro-inflammatory cytokines (Tecchio et al., 2014). In this context, neutrophilia is well known to 
contribute to the deterioration observed in acute exacerbations in chronic inflammatory 
conditions, such as COPD (Qiu et al., 2003). Due to the fact that neutrophils are the main 
leukocyte associated with COPD, the regulation of neutrophil survival may be crucial towards 
the clinical outcome of COPD patients. Thus, the increased neutrophil presence may be a 
beneficial host-response at the early stages of infection and inflammation, but a failure in 
neutrophil clearance at later stages of the inflammatory response may contribute to the 
persistence of chronic inflammation.  
Here, it was proposed for the first time that LPS may indirectly enhance PMN survival through 
the increased mRNA expression coding for EP2 and EP4 receptors, while the direct functional 
relevance through increased protein expression could not be demonstrated at the timepoints in 
question. Whereas basal expression of EP4 was greater in the neutrophil, PGE2 survival was 
mainly transduced by the action of EP2. Consistently, it was previously described in 
macrophages that a functional switch from EP4 to EP2 takes place in macrophage activation by 
LPS (Ikegami et al., 2001). Simultaneously, increasing levels of LPS incapacitated constitutive 
PKA signalling, as PMN lost responsiveness to PKA inhibition. This may indicate that in the 
primary stages of acute inflammation, PMN become functionally prepared for the later stages of 
the inflammatory response, and their late survival may be enhanced through a PKA-independent 
mechanism. Moreover, macrophages are able to produce large quantities of PGE2 (Arakawa et 
al., 1996). Interestingly, LPS previously induced the secretion of PGE2 in a Cox-2 dependent 
manner in monocytes at near-pharmacological levels (Amann et al., 2001; Ikegami et al., 2001; 
Hofer et al., 2004); and the presence of PBMC also induced PMN survival (Sabroe et al., 
2002a). Increased levels of PGE2 may then potently enhance PMN survival through the LPS-
induced EP2 and EP4 receptor protein expression, making them more responsive to the 
conditions present in inflammatory lesions. The subsequent recruitment of macrophages into the 
tissue and LPS-induced PGE2 secretion may further enhance PMN survival. Similarly, PGE2 
regulates EP receptor expression by a potential negative feedback loop, ultimately predisposing 
the cells for increased apoptosis. In COPD PMN, LPS was more effective at the induction of 
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EP2 receptor expression, and the following hyperresponsiveness may enable neutrophils to 
linger at inflammatory sites. 
To control the effect of PGE2, Cox-2 inhibitors were proposed as a pharmaceutical strategy in 
COPD (as discussed in chapter 1.2.2.4.). Despite showing potent anti-inflammatory potential, 
their use was linked to an increased risk of myocardial side-effects. This may argue for both a 
damaging, but also beneficial effect of PGE2 in inflammation. Consistently, the non-specific 
anti-inflammatory drug (NSAIDS) Ibuprofen, also acts as a Cox-2 inhibitor (Rose et al., 2014). 
The results from this study may indicate that the effect of Cox-2 inhibition may partly be 
derived from the inhibition of PGE2-induced PMN survival. Interestingly, LPS and cigarette 
smoke highly increased cell numbers of neutrophils in EP4 knockout mice (Birrell et al., 2015). 
This suggests that in addition to the stimulatory effect of PGE2 on PMN survival, it exerts a 
negative feedback effect, which serves to control unnecessary increases in PMN in neutrophilia. 
Thus, a therapeutic strategy may aim at the discovery of a survival-specific target of PGE2/PKA 
signalling in neutrophils. 
In summary, neutrophil survival can be engaged by various stimuli, present in the context of 
inflammation, such as LPS and PGE2. Both stimuli can engage PMN survival through divergent 
pathways, with a common denominator being PKA signalling. This study showed a novel link 
between LPS and PGE2-induced PMN survival, which is an important step towards the 
understanding of the role of PKA-mediated PMN survival and neutrophilia in inflammatory 
diseases. A potential therapeutic strategy involving the targeting of the nuclear receptors 
NR4A2 and NR4A3 for the resolution of persistent neutrophilia in COPD will be discussed in 
the following chapter.  
6.3. Therapeutic Strategies by Targeting Nuclear Receptors NR4A2 and 
NR4A3. 
Targeting neutrophil apoptosis has often been proposed as a strategy to enable the resolution of 
inflammation (Heasman et al., 2003; Kennedy, DeLeo, 2009; Sousa et al., 2010). The value of 
neutrophils during the acute inflammatory response in the lung (i.e. anti-inflammatory cytokine 
expression, host defence; Tecchio et al., 2014; Parker et al., 2005) may be outweighed by the 
pathogenic/deleterious consequences of their persistence during the chronic inflammatory 
response (i.e. cytokine expression; tissue damage; elastase secretion; Tecchio et al., 2014; 
O’Donnell et al., 2004; Yoshioka et al., 1995; Nadel, 1991) and a delay in their apoptosis, 
which increased the severity of COPD (Zhang et al., 2012). Current therapeutic strategies are 
inadequate, as they may alleviate some of the symptoms, such as bronchoconstriction, but they 
cannot effectively reverse the disease progression. One particularly neglected characteristic of 
COPD is the excessive presence of neutrophils in the lung, although there is compelling 
evidence for their detrimental effects (as elaborated in section 1.1.).  
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A commonly employed non-invasive treatment options in COPD are bronchodilators to 
decrease the airflow resistance in the airways and steroids to reduce the swelling in the airways. 
β2-adrenoreceptor agonists are bronchodilators that moderately relieved bronchoconstriction, 
but did not significantly improve other characteristics of the disease (Appleton et al., 2000).  
β2-adrenoreceptor agonists increase intracellular cAMP levels and thus activate PKA in SMC, 
resulting in airway relaxation. However, it was also shown that treatment with  
β2-adrenoreceptor agonists inhibited SMC proliferation (Stewart et al., 1997), consistent with 
the reported effect of cAMP on cell proliferation in other cell types. Their selective effect on 
bronchoconstriction in SMC might be outweighed by adverse effects of the drugs on other 
immune cells, such as neutrophils, where the activation of PKA increases survival.  
Glucocorticoids are a type of steroids that reduce swelling, and may be used in conjunction with 
mucolytics to reduce the build-up of mucus. However, inflammation was not suppressed by 
treatment with corticosteroids (Brown, 2007) perhaps because glucocorticoids are known to 
disrupt apoptotic signalling in neutrophils and thus prolong their survival (Liles et al., 1995; 
Meagher et al., 1996). Additionally, the involvement of glucocorticoid-regulated  
kinase 1 in the extension of neutrophil survival was demonstrated (Burgon et al., 2014), which 
may additionally contribute to the occurrence of neutrophilia.  
Selective PDE4 inhibitors were proposed as a novel therapeutical strategy in COPD, as they 
previously increased anti-inflammatory gene expression (Vignola, 2004; Wang, Cui, 2006; 
Brown, 2007; Crilly et al., 2011). However, neutrophils secrete a wide range of cytokines, with 
pro-inflammatory mediators in addition to anti-inflammatory effectors (Tecchio et al., 2014). 
The gastrointestinal side-effects of PDE4 inhibitors limited the dosing, and thus the efficacy of 
the drug (Brown, 2007). Likewise, low rolipram concentrations were unable to extend PMN 
survival to a great extent in the present study. However, as PDE4 inhibitors are also used to 
increase cAMP levels, they may contribute to neutrophilic inflammation by modulating 
neutrophil lifespan. Taken together most current therapeutic options may increase neutrophil 
presence through the prolongation of their survival, which may be disastrous in regards to the 
undesirable effects of neutrophil accumulation in the COPD lung, and novel survival specific 
targets in neutrophils are required to complement the current treatments. Taken together, this 
indicates that current treatments in COPD may be inadequate or even counteractive in the 
treatment of neutrophilia, as both corticosteroids and PDE inhibitors increase PMN survival 
(Bjornson et al., 1985; Parkkonen et al., 2008). 
In regards to the findings of this thesis, it is proposed here that agents that increase cAMP may 
have beneficial effects on other parts of the disease, such as bronchoconstriction and potentially 
inflammatory gene expression. However, they may also exert detrimental effects by delaying 
neutrophil apoptosis. Therefore, it is proposed here that a targeted therapy to complement the 
current treatments may be necessary to control the detrimental effects induced by neutrophilia 
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and could involve increasing neutrophil apoptosis. This may be achieved by selective inhibitors 
of NR4A2, as the evidence of this study points towards a pro-survival effect of this molecule 
subtype. Moreover, we showed here that NR4A2 expression becomes increased by elevations in 
cAMP, as well as treatment with the inflammatory stimuli LPS and PGE2, suggesting that 
NR4A2 expression in the COPD lung may be greatly increased and may thus contribute to 
increased neutrophil survival and neutrophilia. Thus, the use of selective NR4A2 inhibitors may 
be useful in the treatment of excessive neutrophilia in chronic inflammation of COPD. Overall, 
NR4A2 might be a useful therapeutic strategy in the treatment of neutrophilia, as it appears to 
be invariably linked to PKA survival and can also be engaged by PGE2/EP2 signalling (Holla et 
al., 2006; Shigeishi et al., 2011). This might thus provide a target to compensate for the lack of 
neutrophil specific treatments in COPD, and complement the existing therapeutical strategies. 
6.4. Limitations of the Model Systems. 
Neutrophil lifespan is controlled by constitutive apoptosis. This element of neutrophil biology 
poses a great difficulty and can induce variability into the results obtained with neutrophils. 
Rates of basal apoptosis may vary in PMN, possibly depending on their age at extraction from 
whole blood, the general effect of a potential cytokine-withdrawal phenotype after the 
extraction from the blood and sensitivity to reagents used in the extraction procedure. Therefore, 
the culturing medium contains a percentage of serum, aiming to replicate the physiological 
conditions in whole blood and to minimise variation. Whereas differences in cell death rates are 
not a major obstacle for the research into many cellular functions, it represents a great difficulty 
for the investigation of cell survival signalling, as it hampers the distinction between relevant 
effects and random variation. Thus, a great amount of consistency is required in the scientific 
method used to minimise random variation. 
Pharmacological modulators are widely used in research, but may introduce artefactual 
cytotoxicity that may be misinterpreted for physiologically relevant, reagent-specific effects. In 
this study, the usefulness of the pharmacological modulators was limited by various factors, as 
follows: 1) the specificity of selective agonists and antagonists was lost at increasing reagent 
concentrations, 2) high antagonist concentrations were required to prevent competitive 
replacement by the agonist, 3) comparisons between reagents were hampered by differences in 
their specific stability towards metabolism and 4) cell permeability. 
Modulating gene expression levels by RNAi is therefore a common strategy used to circumvent 
the limitations listed above. However, PMN are genetically intractable, which requires the use 
of an alternative neutrophil model. In this study, mNØ were used here for this purpose. 
However, the investigation of mNØ survival pathways through selective gene expression 
knockdown was complicated by the lag-period between knockdown and cell differentiation, as 
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the proposed survival mediator was found to be also crucial to cell survival during the course of 
the differentiation.  
6.5 Future Work  
Here, it was demonstrated that PGE2 enhances survival through the action of PKA. PGE2-
induced survival in PMN was slightly improved through pretreatment with LPS, which 
correlated with the upregulation of EP2 and EP4 receptor mRNA (and protein) expression. If 
the effect of LPS on PGE2 survival in PMN is a direct consequence of enhanced EP receptor 
expression, the influence of LPS may thus be even greater in COPD patient PMN, as LPS 
induced a higher level of EP2 receptor expression. Taken together with the reported increase of 
PGE2 expression in the COPD lung, this may potentially contribute to the neutrophilia observed 
in the condition. However, PGE2 furthermore controlled EP2 and EP4 expression levels by a 
negative feedback loop, which may serve as a regulatory mechanism of LPS-induced PKA 
survival in vivo. However, the relevance of this finding in an inflammatory setting in vivo would 
still need to be further elucidated. 
Moreover, a further detailed investigation of the temporal regulation of EP2 and EP4 protein 
translation in healthy control and COPD PMN is warranted to substantiate the influence of LPS 
on PKA-dependent neutrophil survival, and the time point of the maximal biological response. 
Additionally, the molecular mechanisms involved in EP receptor expression regulation by LPS 
may elucidate the complex interplay of LPS and PGE2 PMN survival regulation. 
The pro-survival influence of monocytes on PMN survival (Sabroe et al., 2002a) was 
substantiated in this study, and it was suggested that monocyte-derived PGE2 secretion may 
induce PKA-dependent survival in PMN, as a crucial step in the sustenance of the inflammatory 
process. In particular, it needs to be tested, whether the enhanced survival in presence of PBMC 
may dependent on increases in PGE2 expression, potentially through previous exposure to 
inflammatory stimuli in the host. Interestingly, LPS is known to induce Cox-2 derived PGE2 
secretion by monocytes, which might furthermore enhance neutrophil survival in an 
inflammatory setting. Thus, the basal presence of extracellular PGE2 in the culture medium and 
its influence on variability of basal PKA-dependence needs to be further elucidated. 
Additionally, monocyte-derived PGE2 secretion in healthy control or COPD blood may differ 
and thus influence constitutive rates of PMN survival and the sensitivity of their functional 
responses. In this context, no difference in EP2 and EP4 receptor expression was observed in 
PMN from healthy control and COPD patients. This furthermore substantiated current models in 
COPD, where neutrophils are considered as inflammatory mediators with no genetic 
abnormalities that are responsive to alterations in cytokine secretion by other immune cells. 
Here, NR4A2 expression was PKA-dependently induced by PGE2. Although the tools 
for pharmacological modulation of NR4A2 are limited, an experimental agonist induced 
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survival, and similarly, NR4A2 knockdown was associated with reduced cell numbers during 
differentiation and increased apoptosis in mature mNØ. Pro-survival effects of PGE2/PKA-
mediated NR4A2 expression have previously been described in the context of cancer (Shigeishi 
et al., 2011). To substantiate the impact of PGE2-induced NR4A2 expression in inflammation, 
the overexpressing of the nuclear receptor in the context of inflammation would be 
advantageous to be able to examine potential changes in cytokine expression or ROS secretion 
and explore, whether the effects of NR4A2 are selective towards PMN survival. This would 
enable the exploration of novel NR4A2 agonists in drug-development to complement the 
existing therapies.  
Previously, a negative feedback loop of PGE2 on the regulation of its receptor expression was 
proposed. The role of NR4A2 in the regulation of EP2 and EP4 receptor expression by PGE2 
would shed further light on the downstream effects of PGE2. In particular, to elucidate the 
complex interplay of LPS and PGE2 signalling, a detailed assay of the temporal events in LPS-
induced survival upon PKA-inhibition, and the influence of EP receptor upregulation and 
NR4A2 expression would be beneficial. 
This may be complemented by a study on EP2 and EP4 localisation, as EP4 receptors have been 
found to be internalised, thus regulating PGE2 signalling (Chi et al., 2014) and were functional, 
when found in the perinuclear space (Bhattacharya et al, 1999). Their granular appearance 
indicated that they may have localised effects, and thus the regulation of PKA localisation and 
function by AKAPs and their involvement in PMN survival would be interesting in this context. 
Moreover, NR4A2 and NR4A3 have previously been observed localised to the mitochondria, 
which might there exert an effect on local Cox-2 derived PGE2 expression. 
In this study, PGE2 induced transient survival that was lost at 20 hours, which may be due to a 
loss of receptor responsiveness, may also depend on the metabolic degradation of PGE2. 
Interestingly, a substantial amount of research on the effect of PGE2 in neutrophils has been 
undertaken at late time points. Therefore, the degradation of PGE2 to metabolic products, such 
as 15-keto PGE2, and their involvement in late PMN survival may be of interest for the 
investigation of neutrophil survival in vitro, as the effects that were previously attributed to 
PGE2 at late time points, might not be specific to PGE2, but its metabolic products. PGE2 is 
expected to be continuously produced in inflammation in vivo, and may indicate that the short 
PMN lifespan in vitro is induced by a cytokine-withdrawal phenotype through the isolation of 
the cells from the blood. Thus, future work following from this observation may involve a meta-
analysis of previous studies on PMN function.  
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6.6 Summary 
In the course of this research project, the following specific questions were addressed: 
1) Does PGE2 induce PKA dependent survival in PMN? 
2) Does the selective stimulation of prostaglandin receptors attenuate neutrophil survival? 
3) Do inflammatory mediators present in the context of COPD perpetuate PGE2-induced 
survival? 
4) Are nuclear receptors NR4A2 and NR4A3 molecular targets that may be used to 
specifically block PGE2-induced PKA survival in neutrophils? 
 
Thus, the scope of this dissertation was to investigate the interplay of PGE2 and cAMP/PKA 
signalling in the context of COPD and their influence of neutrophil survival, as well as to 
elucidate potential roles for NR4A2 and NR4A3 as novel pathway components in PKA 
signalling and neutrophil survival, respectively. The answers to the questions outlined above are 
of major clinical importance, as neutrophilia is an aspect of COPD pathology that is often 
dismissed, as having a minor impact on inflammation. Partially, this is due to the historic 
development of the area, because neutrophils typically have a very short lifespan, and thus it 
was often theorised that they can only exert a minimal impact on inflammation. However, it is 
now well established that neutrophil lifespan largely exceeds the initially reported one and can 
also be further prolonged at inflammatory sites. In this study it was thus determined that: 
1) PKA is a potent pro-survival agent in PGE2-induced survival in PMN. 
2) An EP2 receptor phenotype was determined for the pro-survival effects of PGE2 in 
PMN. 
3) The COPD-phenotype inducing agent LPS can increase EP2 and EP4 receptor 
expression, augmenting the functional influence of PGE2 on PMN survival. 
4) NR4A2 and NR4A3 nuclear receptors are implicated in PKA-dependent PGE2 
signalling. Moreover, NR4A2 has crucial roles in neutrophil development, potentially 
through its pro-survival effect. 
 
To conclude, it was demonstrated here that PKA has an essential role in neutrophil survival and 
that the increased presence of PGE2 and LPS in the COPD lung may contribute to the 
phenotype of neutrophilia. Thus, the selective targeting of PKA pathway components, such as 
NR4A2, may be explored as a therapeutic strategy to relieve the detrimental symptoms induced 
by neutrophil accumulation in inflammatory diseases, such as COPD. 
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CHAPTER 8. APPENDICES 
Appendix 1. Materials 
Table 8: Table of reagents used in this study. 
Description Reagent Supplier Location 
Receptor Agonists/Antagonists 
EP1/2/3/4 agonist PGE2 Cayman Chemical Ann Arbor, MI 
EP1/2/3/4 agonist 16,16-dimethyl PGE2 Cayman Chemical Ann Arbor, MI 
EP1/3 agonist 17 phenyl trinor PGE2 Cayman Chemical Ann Arbor, MI 
EP2 agonist ®-Butaprost (free acid) Sigma St. Louis, MO 
EP2 antagonist PF-04418948 Cayman Chemical Ann Arbor, MI 
EP3 agonist Sulprostone Cayman Chemical Ann Arbor, MI 
EP4 agonist L-902,688 Cayman Chemical Ann Arbor, MI 
EP4 antagonist GW 627368X Cayman Chemical Ann Arbor, MI 
FP agonist PGF2α Cayman Chemical Ann Arbor, MI 
FP antagonist AL-8810 Cayman Chemical Ann Arbor, MI 
PPARγ agonist Rosiglitazone Cayman Chemical Ann Arbor, MI 
PPARγ antagonist GW9662 Cayman Chemical Ann Arbor, MI 
A1/A2/A3 
agonist 
Adenosine Sigma St. Louis, MO 
A2A antagonist ZM 241385 Sigma St. Louis, MO 
TLR4 agonist LPS Enzo Life Sciences Exeter, UK 
Pharmacological Modulators of Neutrophil Apoptosis 
cAMP analogue  dbcAMP Sigma St. Louis, MO 
Site-selective 
PKA agonist (Site 
A of RIα) 
N6-MB-cAMP Sigma St. Louis, MO 
Site-selective 
PKA agonist 
(Site B of RIα) 
8-AHA-cAMP Sigma or Calbiochem/CN 
Biosciences 
St. Louis, MO or 
Beeston, UK 
PKA antagonist 
(Site A & B of 
RIα, Site A of 
RIIα) 
Rp-8-Br-cAMPS Biolog Hayward, CA 
Protein Kinase 
Inhibitor 
Staurosporine Sigma St. Louis, MO 
Selective PDE4 
inhibitor 
Rolipram Cayman Chemical Ann Arbor, MI 
Adenylyl cyclase 
inhibitor 
SQ 22,536 Cayman Chemical Ann Arbor, MI 
Cytokines 
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Recombinant 
cytokine 
Murine GM-CSF Peprotech Rocky Hill, NJ 
Recombinant 
cytokine 
Murine SCF Peprotech Rocky Hill, NJ 
Cell Culture 
Cell medium RPMI Medium 1640 Gibco Waltham, MA 
Cell medium OptiMEM Invitrogen Paisley, UK 
Serum Heat Inactivated FCS 
(Catalogue #C-37372; Lot 
#07372381) 
Promocell Heidelberg, 
Germany 
Estrogen β-estradiol Sigma St. Louis, MO 
Flexiwell plates 96 well Flexiwell plates Costar (corning inc.) Amsterdam, The 
Netherlands 
Amino Acid L-Glutamine Invitrogen Paisley, UK 
Cell Dissociation Non-enzymatic cell 
dissociation solution 
Sigma St. Louis, MO 
Antioxidant β-mercaptoethanol Sigma St. Louis, MO 
Antibiotics Penicillin/Streptomycin Invitrogen/Life 
Technologies 
Paisley, UK 
Culture flask T25 cm²/ T75 cm² flasks Nunc(lon) Roskilde, 
Denmark 
Solvent DMSO Sigma St. Louis, MO 
Neutrophil isolation 
Anticoagulant Sodium citrate BP Martindale Brentwood, UK 
Sedimentation Dextran Sigma St. Louis, MO 
Density 
Separation 
Percoll Sigma St. Louis, MO 
Density 
Separation 
Histopaque Sigma St. Louis, MO 
Buffer 1x HBSS without Ca2+/Mg2+ Gibco Waltham, MA 
Base 7.5%  
sodium bicarbonate  
Gibco Waltham, MA 
Antibody cocktail Human StemSep Negative 
Human Granulocyte 
Cocktail Lot 12H45799 
StemCell Technologies Vancouver, 
Canada 
Cell separation 
reagent 
StemSep magnetic colloid  StemCell Technologies Vancouver, 
Canada 
Cell separation 
column 
LS Columns Miltenyi Biotech Bisley, UK 
Apoptosis Assay 
Cell stain Diff-Quik stains Reagena Toivala, Finland 
Centrifuge Cytospin centrifuge  Shandon Inc. Pittsburgh, PA 
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Mounting 
Medium 
DPX Fisher Chemical Loughborough, 
UK 
Microscope Light Microscope Nikon Surrey, UK 
Flow Cytometry Reagents 
Buffer Annexin Binding Buffer BD Pharmigen San Diego, CA 
Calcium chelator 0.5M EDTA, pH 8.0 Invitrogen/Life 
Technologies 
Paisley, UK 
Fluorescent beads CountBright Absolute Beads Invitrogen Paisley, UK 
Flow cytometer FACSCalibur Becton Dickinson San Jose, CA 
PS stain PE-annexin V  BD Pharmigen San Diego, CA 
Viability stain ToPro-3 Molecular Probes Paisley, UK 
Software CellQuest Pro BD Biosciences San Jose, CA 
Software FlowJo  FlowJo, LLC Ashland, OR 
Transfection Reagents 
Electroporator Amaxa Nucleofector Kit V Lonza Basel, 
Switzerland 
siRNA pool ON-TARGET plus 
cyclophilin B control siRNA 
Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
siRNA pool ON-TARGET plus non-
targeting pool siRNA 
Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
Mcl-1 siRNA 
pool 
L-062229-00-0005 Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
Casp3 siRNA 
pool 
L-043042-00-0005 Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
NR4A2 siRNA 
pool 
L-048281-01-0005 Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
NR4A3 siRNA 
pool 
L-043983-01-0005 Dharmacon (Thermo 
Fisher Scientific) 
Lafayette, CO 
RNA Extraction 
RNA isolation 
reagent 
TRI reagent LS Sigma St. Louis, MO 
Phase separation 
reagent 
1-bromo-3 chloropropane Santa Cruz Chemical Dallas, TX 
DNAse treatment 
kit 
DNA-free DNAse Treatment 
& Removal Kit  
Ambion (Life 
Technologies) 
Carlsbad, CA 
RT kit High-Capacity cDNA 
Reverse Transcription Kit 
Applied Biosciences Carlsbad, CA 
Alcohol Isopropanol (BDH) VWR 
International or Fisher-
Chemical 
Poole, UK  or 
Loughborough, 
UK 
Alcohol Methanol (BDH) VWR 
International 
Poole, UK 
qPCR Reagents 
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qPCR Buffer Mix qPCR MasterMix Plus Eurogentec Seraing, Belgium 
GAPDH plasmid IRAU24E08 Source BioScience Rochdale, UK 
EP4 plasmid IRATp970E11120D Source BioScience Nottingham, UK 
GAPDH 
Primer/Probe Set 
Hs02758991_g1 Applied Biosystems Foster City, CA 
NR4A2 
Primer/Probe Set 
Hs00428691_m1 Applied Biosystems Foster City, CA 
NR4A3 
Primer/Probe Set 
Hs00545009_g1 Applied Biosystems Foster City, CA 
PTGER2 (EP2) 
Primer/Probe Set 
Hs04183523_m1 Applied Biosystems Foster City, CA 
PTGER4 (EP4) 
Primer/Probe Set 
Hs00168761_m1 Applied Biosystems Foster City, CA 
RT-PCR Reagents 
PCR reagent 25 mM MgCl2 Promega Southampton, 
UK 
dNTP dATPs, dTTPs, dGTPs, 
dCTPs, 
Promega Southampton, 
UK 
Polymerase GoTaq DNA polymerase Promega Southampton, 
UK 
Buffer Green GoTaq Flexi Buffer Promega Southampton, 
UK 
Marker HyperLadder I Bioline London, UK 
Marker HyperLadder IV Bioline London, UK 
Software ImageJ Public Domain N.A. 
PCR primer PCR Primer Sigma St. Louis, MO 
Marker PCR Ranger 100bp DNA 
Ladder 
Norgen Biotek 
Corporation 
Thorold, Canada 
Polysaccharide 
polymer 
Agarose Melford Suffolk, UK 
DNA 
intercalating 
agent 
Ethidium Bromide Sigma St. Louis, MO 
Chemiluminescen
ce imager 
Chemidoc XRS+ BioRad Hercules, CA 
Western Blotting Reagents 
Serine protease 
inhibitor 
DFP Sigma St. Louis, MO 
Serine protease 
inhibitor 
PMSF Sigma St. Louis, MO 
Protease inhibitor Protease Inhibitor Calbiochem St. Louis, MO 
Blocking agent BSA 100mg/ml Promega Southampton, 
UK 
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Blocking agent Milk Sainsbury’s London, UK 
Blotting 
membrane 
Nitrocellulose Biotrace Onehunga, New 
Zealand 
Marker Colour Protein Standard 
Broad Range 
New England BioLabs Ipswich, MA 
Primary antibody EP2 antibody (H-75) Santa Cruz 
Biotechnology 
Dallas, TX 
Primary antibody EP4 antibody (C-4) Santa Cruz 
Biotechnology 
Dallas, TX 
Primary antibody Actin primary (mouse) Dako Glostrup, 
Denmark 
Secondary 
antibody 
Polyclonal Anti-rabbit IgG-
HRP 
Dako Glostrup, 
Denmark 
Secondary 
antibody 
Polyclonal Anti-mouse IgG-
HRP 
Dako Glostrup, 
Denmark 
Protein stain Ponceau S Sigma St. Louis, MO 
Peroxidase 
substrate 
Clarity Western ECL 
substrate 
BioRad Hercules, CA 
Various Reagents 
Buffer 10x DPBS Invitrogen Paisley, UK 
 
Pharmaceuticals were dissolved in PBS or dimethyl sulfoxide (DMSO) and further diluted in 
PBS to obtain a final concentration of DMSO < 0.1 %.  
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Appendix 2. Buffer Recipes 
 Gel Electrophoresis 
 
Recipe for 50x TAE Buffer 
Reagent Concentration 
TRIS base 242 g 
Glacial acetic acid 57.1 ml 
EDTA (0.5 M, pH 8.0) 100 ml 
 
Recipe for 1x TAE Buffer 
20 ml 50x TAE Buffer + 980 ml ddH20 
 
Recipe for 1 % Agarose Gel 
Reagent Amount 
Agarose powder 1.5 g 
1x TAE 100 ml 
Ethidium Bromide (μl) 0.8 μl 
 
 Western Blotting Buffers 
 
Recipe for PMN lysis buffer  
Reagent Concentration 
Diisopropylfluorophosphate 
(DFP) 
1 mM (1:100 of 100 mM stock) 
Phenylmethanesulfonylfluoride 
(PMSF) 
1 mM (1:100 of 100 mM stock) 
PI (protease inhibitor set) 1 mM (1:100 of 100 mM stock) 
H20 485 μl 
 
Recipe for 2x SDS loading dye 
Reagent Concentration 
TRIS-Cl (pH 6.8) 100 mM 
SDS 4 % (w/v) 
Bromophenol Blue 0.2 % (w/v) 
Glycerol 20 % (w/v) 
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β-mercaptoethanol   200 mM 
 
Recipe for 10x Running Buffer 
Reagent Concentration 
TRIS base 30.3 g  
Glycine 190 g 
20 % SDS 50 ml 
ddH20 to 1 L 
 
Recipe for 1x Running Buffer 
100 ml 10x Running Buffer + 900 ml ddH20 
 
Recipe for 1x Transfer Buffer 
Reagent Concentration 
TRIS base 5.8 g  
Glycine 2.9 g 
20 % SDS 1.85 ml 
MeOH 200 ml 
ddH20 to 1 L 
 
Recipe for 1x Blocking Buffer 
Reagent Concentration 
Skimmed milk powder 1.5 g  
1x TBS 30 ml 
 
Recipe for 10x TBS-Tween 
Reagent Concentration 
Tris HCl (1M, pH 8.0) 100 ml 
NaCl (1M) 97.3 g 
Tween 20 2.5 ml 
ddH20 to 1 L 
 
Recipe for 1x TBS-Tween 
100 ml 10x TBS-Tween + 900 ml ddH20 
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Recipe for 10% Resolving Gel (SDS-PAGE) 
Reagent Volume 
ddH20 3.2 ml 
30 % Acrylamide 2.67 ml 
1.5 M Tris (pH 8.8) 2 ml 
10 % SDS 80 μl  
10 % Ammonium 
Persulphate (APS) 
80 μl  
TEMED 8 μl  
Total Volume 8 ml 
 
Recipe for 6 % Stacking Gel (SDS-PAGE) 
Reagent Volume 
ddH20 2.6 ml 
30 % Acrylamide 1 ml 
0.5 M Tris (pH 6.8) 1.25 ml 
10 % SDS 50 μl  
10 % Ammonium 
Persulphate (APS) 
50 μl  
TEMED 5 μl  
Total Volume 5 ml 
 
  
           CHAPTER 8 
- 242 - 
  
           CHAPTER 8 
- 243 - 
Appendix 3. Vector Map 
 
 GAPDH Base vector pOTB7 (Source Bioscience)/IRAU24E08 
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 EP2/EP4 Base vector MAM pCR4-TOPO (Source Bioscience)/ IRATp970E11120D 
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Appendix 3. DNA Sequences 
 GAPDH sequence and location of primer targeting sequences (yellow). 
GGGGTGGGCCCGGGCGGCCTCCGCATTGCAGGGGCGGGCGGAGGACGTGA
TGCGGCGCGGGCTGGGCATGGAGGCCTGGTGGGGGAGGGGAGGGGAGGCG
TGTGTGTCGGCCGGGGCCACTAGGCGCTCACTGTTCTCTCCCTCCGCGCAGC
CGAGCCACATCGCTCAGACACCATGGGGAAGGTGAAGGTCGGAGTCAACG
GATTTGGTCGTATTGGGCGCCTGGTCACCAGGGCTGCTTTTAACTCTGGTAA
AGTGGATATTGTTGCCATCAATGACCCCTTCATTGACCTCAACTACATGGTT
TACATGTTCCAATATGATTCCACCCATGGCAAATTCCATGGCACCGTCAAGG
CTGAGAACGGGAAGCTTGTCATCAATGGAAATCCCATCACCATCTTCCAGG
AGCGAGATCCCTCCAAAATCAAGTGGGGCGATGCTGGCGCTGAGTACGTCG
TGGAGTCCACTGGCGTCTTCACCACCATGGAGAAGGCTGGGGCTCATTTGC
AGGGGGGAGCCAAAAGGGTCATCATCTCTGCCCCCTCTGCTGATGCCCCCA
TGTTCGTCATGGGTGTGAACCATGAGAAGTATGACAACAGCCTCAAGATCA
TCAGCAATGCCTCCTGCACCACCAACTGCTTAGCACCCCTGGCCAAGGTCAT
CCATGACAACTTTGGTATCGTGGAAGGACTCATGACCACAGTCCATGCCAT
CACTGCCACCCAGAAGACTGTGGATGGCCCCTCCGGGAAACTGTGGCGTGA
TGGCCGCGGGGCTCTCCAGAACATCATCCCTGCCTCTACTGGCGCTGCCAAG
GCTGTGGGCAAGGTCATCCCTGAGCTGAACGGGAAGCTCACTGGCATGGCC
TTCCGTGTCCCCACTGCCAACGTGTCAGTGGTGGACCTGACCTGCCGTCTAG
AAAAACCTGCCAAATATGATGACATCAAGAAGGTGGTGAAGCAGGCGTCG
GAGGGCCCCCTCAAGGGCATCCTGGGCTACACTGAGCACCAGGTGGTCTCC
TCTGACTTCAACAGCGACACCCACTCCTCCACCTTTGACGCTGGGGCTGGCA
TTGCCCTCAACGACCACTTTGTCAAGCTCATTTCCTGGTATGACAACGAATT
TGGCTACAGCAACAGGGTGGTGGACCTCATGGCCCACATGGCCTCCAAGGA
GTAAGACCCCTGGACCACCAGCCCCAGCAAGAGCACAAGAGGAAGAGAGA
GACCCTCACTGCTGGGGAGTCCCTGCCACACTCAGTCCCCCACCACACTGA
ATCTCCCCTCCTCACAGTTGCCATGTAGACCCCTTGAAGAGGGGAGGGGCC
TAGGGAGCCGCACCTTGTCATGTACCATCAATAAAGTACCCTGTGCTCAACC
AGTTAAAAAAAAAAAAAAAAAAAAA 
 
 EP2 protein sequence and location of targeting sequence (yellow). 
MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRWRGD
VGCSAGRRSSLSLFHVLVTELFTDLLGTCLISPVVLASYARNQTLVALAPESRAC
TYFAFAMTFFSLATMLMLFAMALERYLSIGHPYFYQRRVSRSGGLAVLPVIYA
VSLLFCSLPLLDYGQYVQYCPGTWCFIRHGRTAYLQLYATLLLLLIVSVLACNF
SVILNLIRMHRRSRRSRCGPSLGSGRGGPGARRRGERVSMAEETDHLILLAIMTI
TFAVCSLPFTIFAYMNETSSRKEKWDLQALRFLSINSIIDPWVFAILRPPVLRLMR
SVLCCRISLRTQDATQTSCSTQSDASKQADL 
 
 EP4 protein sequence and location of targeting sequence (yellow). 
MSTPGVNSSASLSPDRLNSPVTIPAVMFIFGVVGNLVAIVVLCKSRKEQKETTFY
TLVCGLAVTDLLGTLLVSPVTIATYMKGQWPGGQPLCEYSTFILLFFSLSGLSIIC
AMSVERYLAINHAYFYSHYVDKRLAGLTLFAVYASNVLFCALPNMGLGSSRL
QYPDTWCFIDWTTNVTAHAAYSYMYAGFSSFLILATVLCNVLVCGALLRMHR
QFMRRTSLGTEQHHAAAAASVASRGHPAASPALPRLSDFRRRRSFRRIAGAEIQ
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MVILLIATSLVVLICSIPLVVRVFVNQLYQPSLEREVSKNPDLQAIRIASVNPILDP
WIYILLRKTVLSKAIEKIKCLFCRIGGSRRERSGQHCSDSQRTSSAMSGHSRSFIS
RELKEISSTSQTLLPDLSLPDLSENGLGGRNLLPGVPGMGLAQEDTTSLRTLRISE
TSDSSQGQDSESVLLVDEAGGSGRAGPAPKGSSLQVTFPSETLNLSEKCI 
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Appendix 4. Primer Sequences 
Table 9: Nucleotide sequences and specifications of conventional PCR primers by Sigma.  
Primer Sequence (5’ -> 3’) Length Tm (°C) GC% Product Anneal 
(°C) 
Murine GAPDH 
(Fwd) 
GGTGAAGGTCG
GTGTGAACG 
20 61.22 60 233 (transcript 
variants 1, 2, 
X1, X2, X3) 
56 
Murine GAPDH 
(Rev) 
CTCGCTCCTGG
AAGATGGTG 
20 60.18 60 
Murine CypB 
(Fwd) 
TCGGAGCGCAA
TATGAAGGTGC 
22 63.54 54.55 343 58 
Murine CypB 
(Rev) 
AGATGCTCTTTC
CTCCTGTGCCA 
23 63.81 52.17 
Murine Casp3 
(Fwd) 
CTCGCTCTGGTA
CGGATGTG 
20 65.8 60 379 (transcript 
variants 1, 2) 
61 
Murine Casp3 
(Rev) 
ACCGGTATCTTC
TGGCAAGC 
20 65.3 55 
Murine Mcl-1 
(Fwd) 
TGTAAGGACGA
AACGGGACT 
20 63.4 50 265 59 
Murine Mcl-1 
(Rev) 
AAATCCTGGGC
AGCTTCAAGT 
21 65.9 47.6 
Murine NR4A2 
(Fwd) 
GACGGGCTGGA
TTCCCAATA 
20 68 55 990 (transcript 
variants 1, 2, 
X1, X2) 
62 
Murine NR4A2 
(Rev) 
GCACCGTGCGC
TTAAAGAAA 
20 67.2 50 
Murine NR4A3 
(Fwd) 
TTCTGACGGCCT
CCATTGAC 
20 67.5 55 328 62 
Murine NR4A3 
(Rev) 
AACCCATGTCG
CTCTGTGAT 
20 64.6 50 
Human GAPDH 
(Fwd) 
GGTGAAGGTCG
GAGTCAACG 
20 61.22 60 233 (transcript 
variants 1, 3, 4) 
56 
Human GAPDH 
(Rev) 
CTCGCTCCTGG
AAGATGGTG 
20 60.18 60 
Human 
PTGER1 (Fwd) 
ATCATGGTGGT
GTCGTGCAT 
20 60.04 50 149 56 
Human 
PTGER1 (Rev) 
TACACCCAAGG
GTCCAGGAT 
20 59.88 55 
Human 
PTGER2 (Fwd) 
CAACCTCATCCG
CATGCAC 
19 59.57 57.89 419 55 
Human 
PTGER2 (Rev) 
CTCAAAGGTCA
GCCTG 
16 50.92 56.25 
Human 
PTGER3 (Fwd) 
CGCCTCAACCA
CTCCTACACA 
21 62.04 57.14 837 (transcript 
variants 4, 5, 6, 
7, 8, 9, 11) 
61 
Human 
PTGER3 (Rev) 
GCAGACCGACA
GCACGCACAT 
21 66.07 61.9 
Human 
PTGER4 (Fwd) 
TGGTATGTGGG
CTGGCTG 
18 59.32 61.11 434 (transcript 
variants 1, X1, 
X2) 
55 
Human 
PTGER4 (Rev) 
GAGGACGGTGG
CGAGAAT 
18 59.11 61.11 
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Appendix 5. siRNA Sequences 
Table 10: Nucleotide sequences of ON-TARGETplus SMARTpool siRNA by Thermo 
Scientific. 
Primer  Sequence (5’ -> 3’) 
Mcl1 J-062229-05 UUUCAAAGAUGGCGUAACA 
J-062229-06 AAACGAAGGCGAUGUUAAA 
J-062229-07 CCGAAAGGCGGCUGCAUAA 
J-062229-08 GAUCAUCUCGCGCUACUUG 
CypB Mix of 4 proprietary siRNAs 
Casp3 J-043042-05 GAAAUGGGCAUAUGCAUAA 
J-043042-06 CAACGGAAUUCGAGUCCUU 
J-043042-07 GGAUAGUGUUUCUAAGGAA 
J-043042-08 CGCACAAGCUAGAAUUUAU 
NR4A2 J-048281-09 CGUCAGAGCCCACGUCGAU 
J-048281-10 CCACACAGCGGGUCGGUUU 
J-048281-11 AGGCAAACCCUGACUAUCA 
J-048281-12 CAGAAUAUGAACAUCGACA 
NR4A3 J-043983-09 AGACUUAUGGCUCGGAAUA 
J-043983-10 CAAGAGACGCCGAAACCGA 
J-043983-11 GGUUAAGGAAGUUGUGCGU 
J-043983-12 GAUGAAUGCCCUUGUCCGA 
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Appendix 6. Meetings  
 
 Powerpoint Presentation at the Infection and Immunity Research Day, Sheffield 
(2015). 
Lipopolysaccharide Upregulates Prostaglandin Receptor EP2 mRNA 
Expression in Human Peripheral Blood Neutrophils from COPD Patients and 
Healthy Controls. Authors: Svenja Dannewitz, Lynne Prince, Ian Sabroe, David 
Sammut, Richard Budd, David Dockrell, Moira Whyte. 
 Powerpoint Presentation at the Yorkshire Immunology Group Meeting, Leeds 
(2014). 
Prostaglandin E2 Regulates NR4A2 and NR4A3 through cAMP/PKA 
Signalling in Human Peripheral Blood Neutrophils. Authors: Svenja Dannewitz, 
Elizabeth Jones, Lynne Prince, Ian Sabroe, Moira Whyte. 
 Poster Presentation at the University of Sheffield Medical School 10th Annual 
Research Meeting, Sheffield (2014). 
The role of orphan nuclear receptors NR4A2 and NR4A3 in neutrophil cell 
death. Authors: Svenja Dannewitz, Lynne Prince, Ian Sabroe, Moira Whyte. 
 Poster Presentation at the Department of Infection and Immunity Annual Research 
Day, Sheffield (2013). 
Targeting PKA pathways: A potential strategy in inflammatory disease. 
Authors: Svenja Dannewitz, Lynne Prince, Ian Sabroe, Moira Whyte. 
 Poster Presentation at the University of Sheffield Medical School 8th Annual 
Research Meeting, Sheffield (2012). 
Murine Haematopoietic Stem Cells: A Model to Investigate Pathways 
Underpinning Neutrophil Apoptosis and Survival. Authors: Svenja Dannewitz, 
Lynne Prince, Ian Sabroe, Moira Whyte. 
